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It is well established that free radical mediated oxidative stress plays a critical role in aging and 
age-related diseases. Among the post-translational protein modifications, carbonylation has 
attracted a great deal of attention due to its irreversible and irreparable nature. Despite the fact 
that protein carbonylation is associated with a series of physiological and pathological processes, 
there are still issues to be clarified such as why certain proteins are more vulnerable to 
modification, what are the locations of the protein modifications, and how does the nature of the 
oxidant affect the preferred site of modification. In this study, we will seek an answer to these 
questions and examine the global effect of oxidative stress on protein abundance.  The study 
embraces three distinct specific aims.  In the first, methods are developed for identifying sites of 
protein carbonylation.  In the second specific aim, these methods are used to identify 
carbonylaytion sites in model proteins subjected to chemical oxidants.  In the third aim, the focus 
is on a model organism, C. elegans, subjected to paraquat-induced oxidative stress.  This is 









































Among the post translational protein modifications carbonylation has attracted a great 
deal of attention due to its correlation with aging and age-related diseases. It is well established 
that free radical mediated oxidative stress plays a critical role in many diseases including 
preeclampsia (PE), Alzheimer disease (AD), Parkinson disease (PD), diabetes, liver disease, 
heart disease,	 atherosclerosis (inflammatory disease),stroke,	 rheumatoid arthritis (RA),	
inflammatory bowel disease,	asthma, chronic obstructive pulmonary disease (COPD), obstructive 
sleep apnea (OSAS), cancer and aging.1-49 Despite the fact that protein carbonylation is 
associated with a series of physiological and pathological processes, there are still issues to be 
clarified. In our present study we will seek answers to the following questions: why certain 
proteins are more vulnerable to modification, what are the locations of the protein modifications, 
and how does the nature of the oxidant affect the preferred site of modification. Bridging this 
knowledge gap will not only help us understand how disease and aging alter protein structure 
and protein function, but also open the door to finding interventions to oxidative damage. 
The objective of our work is to identify the carbonylation sites in the proteins which have 
been subjected to reactive oxygen species (ROS) and reactive carbonyl species (RCS). We 
propose that modification sites are controlled by characteristics of the protein and nature of the 
oxidant rather than a random process. In addition, we believe that carbonylation is localized on 
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specific sites of the protein with susceptible structural motifs such as metal binding, substrate 
binding or other active sites in the protein. By finding the specific carbonylation sites in proteins, 
we will understand better how oxidative damage changes protein structure and function. In 
addition, we can determine the structural motifs that are prone to carbonylation. Oxidation motifs 
in turn can act as biomarkers for disease states because they provide information about the nature 
of the oxidative stress in the system.  
Our goals are the following: (1) We will find an efficient labeling strategy to determine 
modification sites. Our working hypothesis is that the structure of a hyrazide labeling agent will 
affect the efficiency of detection. (2) We will identify carbonylation pattern in human serum 
albumin (HSA) and ubiqutin treated with reactive oxygen species. Our working hypothesis is 
that oxidative modifications are localized at sites that are vulnerable to oxidation and that they 
will depend on the nature of the oxidant. Fulfilling these aims will provide an efficient way of 
detecting modification sites and also provide maps of modification sites for protein treated with 
reactive oxygen species. These studies will establish a strong foundation for the next goals. (3) 
We will examine the carbonylated proteins and the effect of imposed oxidative stress on the 
relative levels of mitochondrial proteins in C. elegans. Our hypothesis is that the some proteins 
are more prone to oxidation and the model system will respond to oxidative stress by altering the 




In 1928 Raymond Pearl reported that the life span of living species depends on metabolic 
rate. His observation was that life span is limited by vital cell components that were decreased or 
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damaged more rapidly in animals with a faster metabolism. He formulated his observation into a 
hypothesis that the higher the metabolic rate of the animal, the shorter the life span. He did not 
have any mechanistic explanation about the link between rate and longevity.50 After 28 years, 
Denham Harman brought forward the free radical theory of aging. The theory basically states 
that endogenous oxygen radicals were generated in cells, and this results in collective oxidative 
damage.51 It supports Pearl’s metabolic rate hypothesis. As the metabolic rate increases, 
production of reactive oxygen species increases, and life span decreases. At first, the endogenous 
oxidants theory was controversial, but later it was understood that oxygen metabolism produces a 
small percentage of semi-reduced oxygen species. Endogenous and exogenous oxidants also 
generate reactive oxygen species. There is a subtle balance between production of these oxidants 
and their consumption by enzymatic and non-enzymatic antioxidant cascades as shown in Figure 









































Figure 1: Sources and cellular response to reactive oxygen species52. 
 
Generation of ROS to some extent is crucial for maintaining homeostasis.52 Under 
normal conditions ROS function as signaling molecules. ROS generation by phagocytic cells is a 
component of host defense mechanism and essential for fighting against the infection. ROS 
generation stimulated by growth factors also play a role in regulating proliferative response. 
Generation of ROS potentially has two impacts: (1) damaging some cell components (2) taking 
part in specific signaling pathways. Both of these factors might have an influence on aging and 
age-related disease.53, 54 
Oxygen metabolism takes place in mitochondria, which are the main source of oxygen 
free radicals. It is essential for normal functioning of all cells and absolutely critical for the 
tissues dependent on aerobic metabolism such as muscle and brain.55-57 Approximately 1-2 % of 
the total oxygen consumed in mitochondria lead to formation of superoxide radicals. 58 
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Production of these superoxide radicals takes place mainly at two points in the electron transport 
chain. These two points are complex I (NADH dehydrogenase) and complex III (ubiquinine- 
cytochrome c reductase).59Complex III is responsible for the majority of ROS production. In 
Complex III, free radical semiquinone anion species (•Q-) are formed as an intermediate in the 
regeneration of coenzyme Q. Once (•Q-) is formed, it easily transfers electrons to molecular 
oxygen to generate superoxide radicals as shown in Figure 2. Since superoxide generation is 




























Mitochondria are not the only endogenous source of oxygen free radicals and some other 
biochemical reactions also result in oxygen free radicals such as peroxisomal β-oxidation of fatty 
acids, the glyoxylic acid cycle in glyoxysomes, microsomal cytochrome P450, metabolism of 
xenobiotic compounds, stimulation of phagocytosis by pathogens or lipopolysaccharides, and 
arginine metabolism.61-66 Environmental pollutants, cigarette smoke, heavy alcohol consumption, 
estrogen administration, forced exercises, ischemia-reperfusion, exposure to hypoxia, ultraviolet 
(UV) radiation, chemotherapeutic agents, and hyperthermia, are also considered as exogenous 
sources of ROS. Reactive oxygen species generated by endogenous and exogenous sources are 
superoxide anion, peroxyl radical, hypochlorous acid (HOCl), hydrogen peroxide, hydroxyl 
radical, and singlet oxygen. Superoxide and hydroxyl radicals are very unstable and have short 
half-lives whereas hydrogen peroxide is very diffusible and relatively long-lived.67-82 ROS are 
eliminated by antioxidants namely, enzymatic or non enzymatic free radical scavengers. 
Enzymatic anti-oxidants are superoxide dismutase (SOD), catalase (CAT), and glutathione 
peroxidase (GPx). SOD converts superoxides into hydrogen peroxide. CAT and GPx convert 
hydrogen peroxide to water. Non-enzymatic antioxidants are glutathione, ascorbate (vitamin C), 
alpha-tocopherol (vitamin E), carotenoids (vitamin A), flavonoids (vitamin P), and pyruvate. 
Most of the anti-oxidants are electron donors and react with free radicals to form harmless end 
products such as water. The balance between ROS generation and their neutralization by anti-
oxidants determine the degree of oxidative stress.83-91 
In the case of oxidative stress, ROS react with a number of different cell components 
such as lipids, proteins and DNA.92-98 This reaction between ROS and cell components lead to 
mitochondrial malfunction, activation of oncogenes and transcription factors, stimulation of 
inflammatory processes, DNA damage, cell membrane damage and ultimately apoptosis (cell 
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death).99-102 Protein oxidation is a good biomarker for oxidative damage and has been shown in 
many diseases including Alzheimer’s disease, Parkinson’s disease, inflammatory disease, liver 
disease, heart disease and aging.103-108 
Since proteins have many biological functions, oxidative stress causes a variety of 
impacts. For example, oxidative stress results in inhibitory effects on a wide array of enzymes 
such as glutamine synthetase, mitochondrial aconitase, adenine nucleotide translocase, and 
carbonic anhydrase. Oxidative modifications of protein also lead to loss of function. For 
example, once the plasma protein fibrinogen is oxidized, it loses its function and no longer forms 
solid clots, and oxidation of synovial fluid immunoglobins result in aggregation. Studies have 
shown that oxidative modification of proteins makes them vulnerable to proteolysis. In other 
words, cells preferentially degrade oxidized proteins. Oxidative modification of the primary 
structure of bovine serum albumin results in changes in the secondary and tertiary structure. This 
conformational change may expose the previously embedded peptides to protease attack. Studies 
with E. coli have shown that proteases have a preference towards hydrophobic or aromatic amino 
acid residues. This specificity may lead to detoxification of oxidized proteins.109-111 Living 
organisms are continuously under attack by reactive oxygen species and other secondary 
oxidizers leading to modification of protein. These modifications are cleavage of the polypeptide 
chain, formation of inter and intra–molecular cross linkages, and carbonylation of side chains.112-
121 Production of ROS such as H2O2 is the inevitable result of oxygen metabolism, but may not 
be too damaging when held at baseline physiological concentrations. However, in the presence 
of weakly ligated  iron species, they lead to catalytic production of very reactive hydroxyl 
radicals. Metal catalyzed oxidation (MCO) is one of the major contributors to oxidative damage 
to proteins. The mechanism of the MCO system, as explained in Scheme 1, follows the Fenton 
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type of oxidation mechanism. In the presence of transition metal ions such as iron and copper, 
hydrogen peroxide results in hydroxyl radicals. 119,122,123Among the ROS, hydroxyl radicals are 
the most reactive oxygen radicals. These oxygen radicals can lead to chain reactions, polymer 
breakage and lipid peroxidation. Lipid peroxidation products act as secondary oxidation products 
and include α,β-unsaturated aldehyes. Acrolein (2-propanal) is a lipid peroxidation-derived 
active aldehyde that can readily modify the surrounding biomolecules via Michael addition.124-125 
 
 
Once superoxide radicals are formed by one electron reduction of molecular oxygen, super oxide 
dismutase catalyzed reaction leads to the formation of hydrogen peroxide. Interaction of super 
oxide molecules and H2O2 may result in hydroxyl radicals as shown in equation 1 and 2 
O2 + O2 H2O2 + O2
O2 H2O2+ OH + OH + O2
(1)
(2)  
The reaction in Equation 2 is known as the Haber-Weiss reaction. Under physiological 
conditions, the Haber-Weiss reaction is too slow to account for any significant level of hydroxyl 
radicals. However, the presence of trace amount of transition metals catalyzes the reaction and 
rate of the reaction drastically increases. The metal catalyzed Hyber-Weiss reaction is also called 
the Fenton reaction, as shown in equation 3-5. 
10 
 
Fe(II) + H2O2 Fe(III) + OH + OH
Fe(III) + O2 Fe(II) + O2






Scheme 1: Fenton Reaction (Metal catalyzed Haber-Weiss reaction). 
 
Proteins are a major target of ROS.126 Proteins can be modified by a variety of reactions 
involving reactive oxygen species as shown in Table 1. Oxidative protein modifications can be 
divided into two main categories, reversible and irreversible modifications.127 Cysteine and 
methionine oxidation are the most common reversible modifications. Cysteinyl residue thiolate 
side chains can be oxidized to disulfides and can be reduced back to thiols by glutathione 
reductase or thioredoxin reductase enzymes. Methionine residues can be oxidized to methionine 
sulfoxide and reduced back to methionine by methionine sulfoxide reductase. On the other hand, 
irreversible modifications are non-enzymatic and lead to protein-protein cross linking, protein 
fragmentation or side-chain oxidation. Among these irreversible and irreparable modification, 
carbonylation is a focal point because of its association with number of age-related disorders 
including Alzheimer’s disease34-37, Parkinson’s disease139 and cancer.49 The proposed reason is 
that carbonylation marks proteins for proteolysis and Lon protease.128 However, some of these 
proteins may not be degraded and form high molecular weight aggregates that accumulate with 
age. These aggregates are cytotoxic and can cause disease. It is well established that the amount 
of protein carbonyls exponentially increases with age and age-related disease.129 This has been 
observed in different organisms such as insects78, rodents254, and humans.245 Protein carbonyl 
level is much higher in patients with Werner syndrome or Progeria77, ischemia-reperfusion 
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injury72, diabetes13, Alzheimer’s disease,34-37 amyotrophic lateral sclerosis,23 cataractogenesis145, 
atherosclerosis24, and many others.146 Protein carbonyl level increases in skin fibroblasts and 
brain as a function of the age of the donor.245 It is very difficult to identify factors behind the 
increase in age-dependant carbonylation. However, the overall increase can be explained by one 
or a combination of the following reasons: (1). An increased production of ROS (2). A decrease 
in anti-oxidant defense system. (3). A decline in protease capacity to remove carbonylated 






Table 1: Amino acid residues that are oxidized and their modifications 
Amino Acids Oxidative Modifications 
Cys disulfide, glutathiolation, lipid peroxidation 
adducts, amino acid oxidation adducts 
Met Methionine sulfoxide 
Lys carbonyls, lipid peroxidation adducts, amino 
acid oxidation adducts, chloramines, 
deamination, glycoxidation adducts 
Arg, Pro, Thr carbonyls 
His oxo-histidine, lipid peroxidation adducts, 
amino acid oxidation adducts 
Tyr dityrosine, chlorotyrosine, nitrotyrosine, 
hydro(pero)xy derivatives 
Trp trytophanyl modifications, (N-formyl) 
kynurenine, hydro(pero)xy derivatives 
Val, Leu 
Others 
Hydro(pero)xy derivatives  





Protein carbonyls originate from direct oxidation of proteins by ROS, formation of 
advanced lipoxidation end-products (ALEs), and formation of advanced glycation end-products 
(AGEs).130,131 Direct oxidation of Lys, Arg, Pro, and Thr side chains, especially by metal 
catalyzed oxidation, results in α-aminoadipic semialdehyde from lysyl residues, glutamic 
semialdehyde from arginyl and prolyl residues, 2-pyrrolidone from prolyl residues, and 2-amino-
3-ketobutyric acid from threonyl residues (Figure 3). ROS induced direct oxidation of proteins 
can result in cleavage of peptide bonds via an α-amidation pathway which also generates protein 


































Pro     glutamic semialdehyde 























Figure 4: Protein carbonyl formation by an α-amidation pathway 
 
Lipid peroxidation is a series of reactions that result in fragmentation of polyunsaturated 
fatty acids and the production of highly reactive α-β-unsaturated aldehydes such as 4-hydroxy-2-
(E)-nonenal (HNE), acrolein, and malondialdehyde (MDA). HNE and acrolein are α-β-
unsaturated aldehydes that alkylate cellular nucleophilic groups on proteins. They undergo 
Michael-addition reactions between their electrophilic C=C double bond and the sulfhydryl 
group of Cys, the ε-amino group of Lys or the imidazole group of His residues. The chemical 
modification of protein by reactive carbonyl compounds derived from lipid peroxidation 
reactions results in the formation of advanced lipoxidation end-products (ALEs) (Figure 5). 
AGE formation is complex and there are several mechanisms by which AGEs can form. 
One explanation is reducing sugars such as glucose form Schiff bases with primary amino 
groups. This adduct can undergo Amadori rearrangement to give Amadori products. These 
Amadori products under oxidizing conditions result in Maillard reaction products. The second 
path is oxidation of the sugar by transition metal resulting in the formation of glyoxal, 


















































































































Figure 6: Protein carbonyl formation by non-enzymatic glycation 
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The discovery that oxidative damage results in carbonyl formation pushed researchers to 
develop tools for detection and quantification of the protein carbonyls.132-147 Since protein 
carbonyls have no distinguishable UV-visible spectrophotometric absorbance or fluorescence 
properties, they cannot be directly determined. Instead detection and quantification of protein 
carbonyls is achieved by taking advantage of the electrophilicity of the carbonyl groups to label 
them. A number of labels have been developed for analysis of protein carbonyls, including 2,4-
dinitrophenylhydrazine (DNPH), tritiated sodium borohydride, biotin containing labels and 
fluorescence labels. Except for tritiated sodium borohydride, a common part of all labels is a 
hydrazine-like moiety that can react with carbonyl groups.  
A spectrophotometric measurement of protein carbonyls with DNPH was first developed 
by the Levine group.148 This method employs DNPH to form protein bound hydrazone that gives 
an absorbance at 370 nm. In a gel-based analysis, proteins treated with DNPH can be separated 
by SDS-PAGE, and carbonylation associated with specific bands can be detected on Western 
blots using commercially available anti-DNPH antibodies.149,150 Oxyblot is one of the common 
commercially available kits on the market for analysis of protein carbonyls.151 
Immunofluorescent imaging of carbonylated proteins can be done using anti-DNP antibodies and 
fluorescent secondary antibodies. Protein carbonyls labeled with DNPH can also be visualized 
via in situ immunofluorescent imaging.152 In addition, protein carbonyl content can be measured 
using an enzyme-linked immunosorbent assay (ELISA).153 The assay utilizes biotin linked anti-
DNP antibodies that not only bind to the coated DNP-derivatized proteins, but also facilitate 
detection with streptavidin. In analysis of protein carbonyls with tritiated sodium borohydride 
(NaBT4), protein carbonyls are reduced to the corresponding alcohol group. After that, 
radioactivity can be measured using a scintillation counter.154 There are two basic biotins 
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commonly used for the analysis of protein carbonyls, biotin hydrazide and N’-
aminooxymethylcarbonylhydrazino-d-biotin (ARP). Biotinylated proteins can be affinity 
captured using avidin or streptavidin based materials. The Regnier group has extensively studied 
the biotin hydrazides.155 They used biotin hydrazide as an affinity tag and mass spectroscopic 
marker so that carbonylated proteins could be enriched and identified in different experimental 
systems. Reaction of the carbonyl group with biotin hydrazide results in a Schiff base, which is 
further reduced to a more stable hydrazone. There are many different types of biotin hydrazide 
labels that are commercially available and differ in the linker between the biotin and the hyrazide 
group. ARP was introduced by Maier’s group.156 The advantage of this label is that removal of 
excess ARP is not necessary if the biotinylated samples are to be subjected to gel-based analysis, 
because the bond formed between ARP and the carbonyl group is stable. Biotinylated protein 
carbonyls can be quantified using 4’-hydroxyazobenzene-2-carboxylic acid (HABA).157 When 
complexes with avidin, HABA has a strong absorbance at 500 nm, whereas free HABA has an 
absorbance at 348 nm. Since the biotin-avidin binding affinity (Kd =1×10−15) is stronger than the 
HABA-avidin binding affinity (Kd =5.8×10−6), HABA bound to avidin can be easily replaced by 
biotin resulting in a decrease in absorbance of the mixture at 500 nm. Hence, the amount of 
HABA released from the HABA-avidin complex is proportional to the biotin in the biotinylated 
proteins. Fluorescein-5-thiosemicarbazide (FTC) and Alexa 488 fluorescence hydroxylamine 
(FHA) are the two visible wavelength fluorescence labels reported in the literature that react with 
protein carbonyls.158,159 Both of them are commercially available.  N-aminoperylene-3,4,9,10-
tetracarboxylic-bismides (APTB) is exceptional in that the label itself is not fluorescent but 





PROTEOMICS AND MASS SPECTROMETRY  
 
Proteomics by definition is the study of identification, quantification, and function of all 
expressed proteins. Proteomics is composed of not only identification and quantification of 
proteins but also includes the study of their structure, modification, interactions, and functions. 
In general, proteomics deals with the large-scale determination of gene and cellular function 
directly at the protein level. 161 The “proteome” term was first introduced by Mach Wilkins and 
Keith William in 1995.162 Since then, a great deal of effort has been spent to characterize a 
healthy or a diseased proteome. However, it has emerged that the proteome is much more 
complex and dynamic then initially assumed. The wide array of protein abundances, dynamics, 
and space/time distribution of the proteome resulted in the development of new fields such as 
phospho-, glyco-, sub-cellular and membrane proteomics, etc.163 In the post-genomics era, we 
now know that gene-based expression analysis is not sufficient to comprehend biological 
processes at the molecular level because there is no direct correlation between gene and protein 
expressions.164 This protein diversity can be explained by different stability and turnover of 
mRNA and proteins, alternative mRNA splicing resulting in a variety of protein products, and 
post-translational modifications. It became clear that these processes occurring at the RNA and 
protein levels play an important role in expanding protein diversity and might be responsible for 
the apparent difference in gene number and complexity of human cells.165 It is likely that 
development took place by increasing the complexity of regulation processes at the RNA and 
protein level instead of a simple increase in gene number, so investigation of proteins and protein 
complexes became important field in the post-genomic era.166 Instead of the looking at a static 
genome, we would rather look at the entire dynamic proteome to understand the biological 
20 
 
complexity of a cell. The diversity of different covalent forms of proteins is much greater than 
the number of proteins predicted by DNA coding capacities because of post-translational 
modifications. Understanding the extent and the motif of the many post translational 
modifications in cells will shed a light on the function and dynamics of proteome 
compositions.167 Typically such studies are hampered by the high degree of complexity of 
cellular proteomes and the low abundance of many of the proteins, which requires highly 
sensitive analytical techniques. High pressure liquid chromatography (HPLC) coupled to mass 
spectrometry is one of the most powerful techniques in proteomics and allows high throughput 
identification of proteins in complex protein mixtures.168 In addition to high sample throughput, 
sensitivity is one of the big advantages of this technology. One requirement for sensitive analysis 
is chromatography with a very low flow rate, in the nanoliter per minute range. High pressure 
liquid chromatography and high resolution gels combined with sensitive mass spectrometry can 
identify almost all the proteins for which genome sequence is known. Mass spectrometry has 
become a central tool in the analysis of complex protein samples.169  
Mass spectrometers are composed of three basic components; an ion source, a mass 
analyzer, and an  ion detector. Mass spectrometry measurements are done on ionized analytes in 
the gas phase. It is critical to transfer molecules from solution or solid phase to the gas phase. 
Discovery of soft ionization techniques such as electrospray ionization (ESI) and matrix-assisted 
laser desorption ionization (MALDI) has opened a new era in proteomics research.170,171 These 
are the most commonly used ionization techniques. Both MALDI and ESI are soft ionization 
techniques and ions are formed with very low internal energies and undergo little fragmentation. 
After ionization, the samples reach the mass analyzer, which separates ions by their mass-to 
charge (m/z) ratios. Ion motion can be manipulated by electric or magnetic fields in the mass 
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analyzer to direct ions to a detector, which detects the number of ions at each individual m/z 
value. There are five different types of mass analyzers that are being used in proteomics 
research:  time-of-flight (TOF), ion trap (quadrupole ion trap QIT; linear ion trap, LIT), 
quadrupole (Q), Orbitrap and Fourier transform ion cyclotron resonance (FTICR) analyzers. All 
five are considerably different in sensitivity, resolution, mass accuracy and the ability to 
fragment peptide ions. Depending on the application, different combinations of ion sources, mass 
analyzers and detectors can be utilized. ESI is most commonly coupled with ion traps. (Three-
dimensional, linear) and hybrid instruments like quadrupole time-of-flight (Q/TOF).  
Depending on the application, different combinations of ion sources, mass analyzers and 
detectors can be utilized. ESI is most commonly coupled with ion traps (three-dimensional or 
linear) and hybrid instruments like quadrupole time-of-flight (Q/TOF). Linear ion traps are 
quickly finding new applications in many areas of proteomics. Figure 5 shows a linear ion trap 
configuration.172 Typical pressures and operational settings are shown.  Ionized analyte ions are 
be guided through the multipole field and ions in the oscillating electric field will move to 
regions of lower electric potential. Analyte ions are confined radially by a two-dimensional (2D) 
radio frequency (RF) field and axially by stopping potentials applied to end electrodes. The ions 
with stable trajectories are first held in the center of the device for a certain time interval and 
then scanned from the ion trap to a detector. Ions with specific m/z ratios can be captured in the 
trap for fragmentation, induced by the application of a resonant excitation pulse leading to 
energetic collisions of the ion with the helium in the ion trap. This process is called collision-





Figure 7: Linear ion trap instrument configuration is shown.172 
 CID has been the most commonly used MS/MS technique in proteomics research.174 The kinetic 
energy of the peptides are converted into internal energy which fragments the peptides at 
different points, usually at the peptide bond, and produces b and y ions as shown in the Figure 7. 
The McLafferty group introduced a fragmentation technique, electron capture dissociation 
(ECD) in 1998.175 In ECD, capture of a thermal electron by a multiply protonated peptide or 
protein induces fragmentation and generates c and z ions. As compared to CID, ECD gives more 
extensive fragmentation resulting in more MS/MS spectra and better sequence coverage.176 
However, it requires very expensive and complicated FTICR instruments. In order to avoid that 
limitation, the Hunt group has developed a very similar technique, electron transfer 
dissociation.177 It provides extensive fragmentation like ECD and is applicable to more common 
bench top mass spectrometers. In the ETD technique, electrons are transferred from radical 
anions with low electron affinities to multiply-protonated peptides resulting in fragmentation. 
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ETD produces mainly c and z ions as in ECD. ETD gives superior sequence coverage and can be 
a good complement to traditional CID.178 
 
Figure 8: Peptide fragmentation patterns. 
 
The recorded product ions represent the tandem mass spectrum (MS/MS or MS2 
spectrum) and contain information on the amino acid sequence. Despite the fact that three-
dimensional ion traps show low mass accuracy, they are sensitive, robust, and relatively 
inexpensive.179 On the other hand, two dimensional ion traps have a considerably larger volume, 
which allows increased sensitivity, resolution and mass accuracy.180,181 Alexander Makarov 
invented a new type of mass analyzer, the Orbitrap, in 1995 and the Hu group employed it as a 
tool for proteomics in 2005.182,183 In the orbitrap, ions are trapped and circle around a central 
electrode. Harmonically oscillating ions create an image current in the outer electrode. The 
frequency of these oscillations is independent of the velocity of ions and inversely proportional 
to the mass-to-charge ratio. The image current is Fourier transformed into the time domain 
producing mass spectra. Based on this development, Thermo Fisher Scientific made a new 
hybrid mass spectrometer (LTQ-Orbitrap) that is now commercially available. LTQ-Orbitrap 
combines robustness, sensitivity, and MS/MS capabilities of the LTQ linear ion trap with high 
mass accuracy and high resolution capabilities of the Orbitrap.184 
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Recently, a major focus of proteomics projects has been to quantify the constituents of a 
proteome. In order to solve biological problems, the changes and dynamics of the changes on the 
protein level must be monitored quantitatively.185 There are two main methodologies to quantify 
the proteome: Isotopic labeling techniques and label-free techniques.186 For accurate 
measurements, quantitative proteomics isotope labeling techniques have been introduced. Even 
though isotope dilution strategies were well known for the analysis of small molecules, drugs 
and metabolites, the Aebersold group was the first to bring this technique to proteomics.187 In the 
isotope coding affinity tag (ICAT) method, the cysteine residues are labeled with either a heavy 
or light biotin containing reagent. The labeled sample and control are combined. After digestion, 
only cysteine containing peptides carrying the label are isolated by affinity purification using 
streptavidin. Peptide separation and mass spectroscopic analysis of the mixture not only 
identifies the peptides but also gives the quantitative ratio of the peptides in the original 
proteome by comparing the signal intensity of the isotopic peptide pair. ICAT had been 
improved and the isotope coding protein label (ICPL) was developed. Having small amino group 
reactive reagents, ICPL gave better reaction yields and increased sequence coverage.188 
Introducing isotopic labels as early as possible reduces uncertainty in quantification results so, 
stable isotope labeling of amino acid in cell culture (SILAC) was developed.189 Culture media 
enriched with 15N isotopes of amino acids is used in cell culture or with microorganisms for 
quantification. The metabolic labeling technique is generally limited to cell culture experiments 
and not applicable to samples from higher organism. With enzymatic labeling, 18O atoms are 
incorporated into the C-terminus of every proteolytic peptide during or after digestion catalyzed 
by trypsin or other proteases in H218O. Samples are digested in H218O, whereas controls are 
digested in H216O resulting in 2-4 Da mass shifts from incorporation of one or two 18O atoms on 
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the carboxy terminus of each peptide. There are two main issues; incomplete labeling and 18O 
back exchange to 16O can occur in solvents contain natural water.190 One of the most common 
peptide based quantification methods is isobaric tag for relative and absolute quantitation 
(iTRAQ). iTRAQ is based on the use of a group of eight isobaric amino group reactive reagents. 
Since they all have identical masses, a certain peptide from control and sample will appear with 
identical masses. In MS/MS analysis, specific reporter ions from the different reagents will be 
formed and can be quantified.191Targeted quantification approaches using selected reaction 
monitoring or multiple reaction monitoring for accurate quantification are getting more and more 
popular because they overcome the limitation of global quantitative proteomics, such as missing 
data in individual analyses, false identifications, reproducibility issues, and computational 
challenges.192  
Mass spectroscopic proteomics methods can be divided into two categories: Top-down 
and bottom-up approaches. In the top-down approaches, intact proteins are cleaved in the gas 
phase rather than solution. The protein is fragmented in the mass spectrometer to generate series 
of ions indicative of the sequence. The position and the sequence of amino acids in the protein 
can be derived from the difference in m/z values of fragment ions.193 The approach requires 
extreme mass accuracy and often is unable to provide detailed information about large sequences 
of protein. In the bottom-up approach, complex protein mixtures are digested with specific 
proteases into complex peptide mixtures.194 Peptide mixtures are then fractionated before being 
subjected to tandem mass spectrometry. MS/MS spectra are recorded for as many peptides as 
possible, and the results used for searching databases to identify the proteins in the proteome 
under study. MS/MS spectra are analyzed with SEQUEST or MASCOT software programs, 
which search protein sequence databases.195,196 This is a very useful method for automation and 
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high sample throughput. The heart of bottom-up proteomics remains an LC-MS/MS instrument, 
in which high pressure liquid chromatography enriches and separates the peptides for mass 
analysis and sequencing.197 One of the most important recent developments is the creation of 
high-resolution mass spectrometers like the Orbitrap, which allows routine measurement of 
peptides with consistently high mass accuracy and higher quality ion selection in data-dependent 
experiments.183 Multidimensional protein identification technology (MudPIT) is widely used in 
bottom-up approaches and simplifies the analysis of complex protein mixtures at the peptide 
level.198 After enzymatic digestion of the proteins, peptides are separated by both HPLC and 
strong cation/anion exchange chromatography.199 
The development of new ion trap instruments, the availability of genome sequence 
databases and new bioinformatics tools has made mass spectrometry an indispensible tool for 
proteomics. Recent breakthroughs in stable isotope labeling techniques and chemical labeling 
allow mass spectrometry to quantify proteins, and newly established affinity procedures enable 










CHAPTER 2: Comparing the Efficiency of Hydrazide Labels in the Study of 




Among the post-translational protein modifications, carbonylation has attracted a great 
deal of attention due to its correlation with oxidative stress, aging and age-related diseases.201,202 
Protein carbonyls involve the introduction of an aldehyde group on the side-chain of an amino 
acid and have been identified as important biomarkers for disease and aging.203 These protein 
carbonyls are formed on amino acid side chains either via direct oxidation with reactive oxygen 
species (ROS), such as hydroxyl radicals, or by the addition of α,β–unsaturated aldehydes, which 
are the result of lipid peroxidation processes.204-206 A number of studies have reported that 
protein carbonylation is selective and only certain proteins are carbonylated in systems under 
oxidative stress.205-215 Identifying carbonylation sites has proven to be challenging with in vivo 
experiments and only a limited number of studies have reported specific modification sites.216-226. 
A key problem is the low concentration of modification sites in samples. For example, if one has 
a sample of roughly 200 proteins, each of which yields roughly 50 tryptic peptides, the 
concentration ratio of a specific modified peptide to the background in a bottom-up LC/MS/MS 
experiment is at best 1:10,000 (50 X 200), but likely much lower because only a fraction of any 
particular protein is expected to be carbonylated at any specific site. As a result, samples must 
generally be fractionated in some way before analysis to concentrate the modifications. The 
typical approach has been to take advantage of the unique reactivity of protein carbonyls 
(aldehydes) with hydrazine and hydrazide reagents as an entryway to an affinity tag.  The most 
common has been biotin and a variety of strategies have been employed for immobilizing and 
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isolating the biotin-tagged protein carbonyls.  Despite this activity, there has not been a 
systematic evaluation of the efficiency of hydrazide-based tags in isolating and identifying 
protein carbonyls.  However, Guo and Prokai have recently published a paper focused on the 
ability of a series of hydrazides to produce useable CID spectra from a collection of six 4-
hydroxynonenal-labeled peptides.  The work indicates that biotin hydrazide labeling can increase 
the quality of CID spectra (suppress neutral loss), but in 4 of 6 cases, labeling with biotin 
hydrazide failed to produce identifiable MS/MS spectra, potentially due to inefficient labeling.224 
In the present study, we test the effectiveness of five hydrazide-labeling agents for 
identifying protein carbonyls (Scheme 2). The first three are commercially-available biotin 
hydrazides with varying spacer groups between the two components. The last two are hydrazides 
of simple fatty acids.  They have been included because Muddiman and co-workers reported that 
hydrophobic tagging groups can substantially increase the electrospray ionization efficiency of 
some peptides.227 To stabilize the resulting hydrazones, they have been reduced with sodium 
cyanoborohydride to give hydrazine linkages as described by Yoo and Regnier.228 Scheme 3 
outlines the process with biotin hydrazide. As a model protein, we have chosen human serum 
albumin (HSA). It is readily available and been the subject of several studies of in vitro oxidative 
stress.222,229-231 We have found that the treatment of HSA with acrolein provides a convenient 
and reproducible source of protein carbonyls that can be used for testing various isolation 
strategies. Acrolein is an α, β-unsaturated aldehyde and can undergo Michael additions with 
histidine, lysine, and cysteine to produce protein carbonyls (Scheme 4) – it is also capable of a 
variety of other reactions including Schiff base formation with lysine as well as cross-linking 
processes. This reaction is akin to the condensation of proteins with α,β-unsaturated aldehydes 
derived from lipid peroxidation processes – a key source of protein carbonyls for systems under 
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oxidative stress.  In the present study, we simply use acrolein as a convenient means of 
generating protein carbonyls – no effort was made to assess the relative reactivity of the residues 
in HSA with acrolein (we have shown that more sophisticated quantitation schemes are needed 
for that task).232 Using MS/MS spectrum counts of modified peptides as a measure of a label’s 
effectiveness, we have done experiments with and without affinity chromatography of the tagged 
peptides. The results of this study indicate that the choice of label has a significant impact on the 
tagging efficiency and relative detectability of the modification sites. As a result, care must be 
taken in the choice of a tagging group and in the interpretation of data from pseudo-quantitative 


































































































































MATERIALS AND METHODS 
 
MATERIALS  
Human serum albumin (HSA), acrolein, biotin hydrazide, extended-chain biotin 
hydrazide, PEG4-linked biotin hydrazide, and sodium cyanoborohydride were purchased from 
Sigma (St. Louis, MO). Palmityl hydrazide and lauryl hydrazide were purchased from Alfa 
Aesar (Ward Hill, MA). Sequencing grade, modified trypsin used for the enzymatic digestion 
was obtained from Promega (Madison, WI). Immobilized monomeric avidin kits and BCA 
protein assay kits were purchased from Pierce (Rockford, IL). MCX columns were purchased 
from Waters (Milford, MA). All other chemicals and solvents were obtained from commercial 
sources and were of the highest purity available. 
MODIFICATION OF HSA 
HSA (1 mg/mL) was treated with acrolein in a 1:10 (HSA:acrolein) final molar ratio and 
then incubated at 25οC for 1 hour according to a method described by Dalle-Donne.233 Following 
the modification, excess acrolein was removed by filtering the solution through a Microcon YM-
30 filter (Millipore) with PBS (phosphate-buffered saline) buffer (pH 7.4). Filtration was 
accomplished by centrifugation of the Microcon assembly at 8000 rpm for about 4 min. The 
filtration/centrifugation process was repeated three times and subsequently the modified HSA 
sample was labeled. 
LABELING MODIFIED PROTEIN 
Labeling of the carbonyl groups of modified HSA was performed by reaction with the 
appropriate hydrazide using an approach based on the method of Yoo and Regnier. 228 In 
summary, the oxidized protein samples were treated with 50 mM hydrazide label stock solution 
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to a final 5 mM of the hydrazide concentration. The samples were reincubated at room 
temperature for 2 h with shaking and then cooled to 0 °C. An equal volume of 30 mM sodium 
cyanoborohydride in PBS buffer was subsequently added to stabilize the reaction products. 
Following the labeling, the HSA samples were precipitated with 20% trichloroacetic acid in an 
ice bath for 1 h, and the excess reagents were removed as a part of the supernatant. The pellets 
were washed three times with ethanol/ethyl acetate (1:1) and then dissolved in ammonium 
bicarbonate buffer in preparation for enzymatic digestion. 
 
ENZYMATIC DIGESTION 
The labeled HSA samples in 50 mM ammonium bicarbonate buffer at a concentration of 
1 mg/mL were reduced with 30 mM dithiothreitol at 50 °C for 20 min and alkylated with 55 mM 
iodoacetamide at room temperature for 30 min in the dark. The excess of dithiothreitol and 
iodoacetamide were removed using a Microcon YM-30 filter at 8000 g for 15 min. The proteins 
were redissolved in 50 mM ammonium bicarbonate, and subsequently digested with trypsin 
(substrate/enzyme ratio of 40/1, wt/wt) at 37 °C for 24 h. The digestion was terminated by 
adding 0.1% formic acid (120 L). 
ENRICHING MODIFIED PEPTIDES  
Modified peptides were enriched with a monomeric avidin kit as described by the 
manufacturer. After pre-conditioning the column, samples were loaded. Non-bound peptides 
were washed away with PBS buffer and bound ones were eluted with the biotin blocking and 










Figure 9: Enrichment of modified peptides with monomeric avidin kit. 
 
The resulting peptide solutions were pre-concentrated with a mixed-mode cation exchange 
(MCX) column as described by the manufacturer. The peptide solutions were dried with a Speed 
Vac concentrator and peptide concentrations were determined using a bicinchoninic acid  
 (BCA) assay kit as described by the manufacturer.  
QUANTIFICATION OF TOTAL CARBONYLATED PROTEIN LEVELS 
Quantification of carbonylated proteins was done as described by Levine.234 In this 
protocol, reactive carbonyl groups were converted to the corresponding hydrazone by reaction 
with 10 mM 2,4-dinitrophenyl hydrazine (2,4-DNPH) in 2 M HCl (1:500 protein to 2,4-DNPH 
ratio). The reaction mixture was incubated for 15 min with shaking and the protein mixtures 
were precipitated with trichloroacetic acid (final concentration 15% vol/vol ratio). After 
incubation in an ice bath for 45 min, the precipitate was centrifuged at 13400 rpm for 5 min. The 
supernatant was discarded and the precipitate was washed 3 times with an ethanol-ethyl acetate 
mixture (1:1 vol/vol ratio). The precipitate was resuspended in 6 M guanidine-HCl solution (pH 
2.3). The absorbance was measured at 370 nm and 276 nm. The former corresponds to the 
hydrazone maximum with an estimated molar absorptivity coefficient of 22,000 M-1 cm-1.234 We 
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have used commercial HSA as a control. It shows a significant background signal and there was 
concern that it may be partially carbonylated. To test this hypothesis, we pre-reduced the 
commercial HSA with sodium borohydride (NaBH4) and then used it as a control in the DNPH 
analysis. The calculations have been made based on Lambert-Beer Law shown in Equation 1 and 
Equation 2. A276 and A370 are absorbencies at 276 nm and 370 nm consequently. [HSA] and 
[HSAoxi] are concentration of HSA and oxidized HSA. εAbs@276 and εAbs@370 are molar absorption 
coefficients for HSA at 276 nm and 370 nm. ε [HSAoxi]@276nm and ε [HSAoxi]@370nm are molar 
absorption coefficients for oxidized HSA at 276 nm and 370 nm. l is the path length. 
A276=εAbs@276[HSA]l +εAbs@276[HSAoxi]l   Eq. 1 
A370= εAbs@370[HSA]l +εAbs@370[HSAoxi]l   Eq. 2 
ε [HSAoxi]@276nm=9460 M-1cm-1  ε [HSA]@276nm=45800 M-1cm-1 
ε [HSAoxi]@370nm=22000  M-1cm-1 ε [HSA]@370nm=900 M-1cm-1 
 
Figure 10 shows the UV spectra of the DNPH analysis. We have measured the 
absorbances at 276 nm and 370 nm.The latter wavelength is the λmax for the DNPH analysis. 
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Figure 10: UV spectra of the DNPH analysis of two control and oxidized HSA 
 
The DNPH analysis has shown that the ratio of active carbonyls per protein molecule,and 
background signal, is approximately 2.7, and suggests 2-3 carbonyl modifications per HSA 
molecule.(Table 2) Given the 10:1 ratio of acrolein to HSA, it also suggests that 70% of the 
acrolein did not result in protein carbonyl modifications under our reaction conditions.  
Table 2: DNPH analysis of native, prereduced, and modified HSA samples. 
 Abs at  276 
nm 





0.455  0.053  9.52 10-6 2.03 10-6 0.21 ±0.01 
HSA  
(Modified)  













BIOTIN QUANTIFICATION ASSAY: 
The extent of HSA biotinylation was measured with a HABA-biotin quantitation assay 
kit as described by the manufacturer (Pierce Biotechnology). In short, 100 µl of biotinylated 
HSA was added to 900 µl of the HABA-avidin solution and then the absorbance of the mixture 
was measured at 500 nm.  The ratio of biotin to protein was calculated based on the difference in 
absorbance before and after addition of biotinylated HSA using a HABA-avidin extinction 
coefficient of 34,000 M-1cm-1at 500 nm.235 HABA bound to avidin can be easily replaced by 
biotin resulting decrease in absorbance of the mixture at 500 nm. Hence, the amount of HABA 
released from HABA-avidin complex is proportional to the biotin in the biotinylated proteins 
(Figure 10). The assay was repeated three times, each with three technical replicates, for the 
biotin labels, 1, 2 and 3. As a positive control, commercial, biotinylated BSA (Sigma, St. Louis, 
MO) was used.  The manufacturer reports an average of 9 biotinylation sites per protein for this 
sample. 
 





Liquid chromatography/electrospray ionization-tandem mass spectrometry (LC/ESI-
MS/MS) analysis of digested HSA samples (300 pmol/injection) was performed using a capillary 
HPLC system (Thermo Finnigan, San Jose, CA) connected to an LTQ ion trap mass 
spectrometer (Thermo Finnigan, San Jose, CA) with a nanospray source. Tryptic peptides were 
separated by reverse-phase chromatography on a C18 column (C18 Thermo, 5μm particle size, 
300Å, 100x0.18 mm;) with a split flow system. The split is approximately 100:1 with a master 
flow rate of 50 μl/min (~0.5 μl/min in the analytical column). The digested peptides were eluted 
from the column using two mobile phases, A (0.1% formic acid in water) and B (0.1% formic 
acid in methanol). The gradient started from 2% B, then increased to 15% B over 15 min, then 
increased to 80% B over 70 min, and finally increased to 95% B over 25 min. The eluted 
peptides (singly, doubly, or triply-charged ions) were analyzed using a data-dependent scan 
procedure. To exclude the redundant processing of a few dominant ions in the MS/MS analyses, 
a dynamic exclusion feature was used that only allows a particular m/z value to be processed 
twice in a 2 min time window. The acquired MS/MS spectra were then searched against the 
NCBI non-redundant protein database (GI: 4502027) using the Finnigan Bioworks v.3.2 
(Sequest) software. The database searching was set to only consider peptides within the mass 
range 500–4000 Da. Up to two missed cleavage sites were allowed, and cysteines were defined 
as modified with carbamidomethylation. To search for labeled peptides, differential 
modifications of cysteine, histidine, lysine, and arginine were set to, and +298.4, +411.5, +545.3, 
+254.3, and +310.4 Da, respectively, for 1 – 5. In order to filter the search results, the Yates 
Rule236 was applied and the Xcorr threshold was set to 1.9, 2.2 and 3.75 for +1, +2 and +3 




RESULTS AND DISCUSSION 
 
HSA was modified with acrolein and labeled with five different hydrazide compounds to 
compare their effectiveness in LC/MS/MS analysis. The sample preparations were repeated at 
least three times to establish reproducibility and the data are derived from multiple LC/MS/MS 
runs on each sample. Using tryptic digests, average sequence coverage was over 85% with our 
experimental arrangement.  
MS/MS Spectra 
A key issue with a label’s efficiency in LC/MS/MS experiments is its impact on the 
production of useful fragments, b and y ions, with our CID protocol.  If the label diverts signal 
intensity into unproductive side-chain losses (i.e., breakdown of the label group), the quality of 
the MS/MS spectra will be degraded and the identification efficiency will potentially be reduced. 
For comparison, sample MS/MS spectra for peptides with and without modifications at His170 are 
shown in Figures 11 through 16 (+2 charge state). The spectra for the biotin-containing tags (1 – 
3) exhibit a similar number of identified b and y ions, and share the pattern of strong y12, but 
weak y8 ions for the expected proline-directed cleavages.  There is a bias towards cleavage near 
the N-terminus (modification site) with strong signals for b2, b3, y11, y12 and y13 ions. A 
dehydrated b3 ion is particularly intense in the parent as well as the biotinylated spectra, but the 
b2 ion is only intense in the biotinylated system. This bias is charge state dependent and more 
evenly distributed cleavages are seen in the corresponding triply-charged peptides (Figures 17 
through 22). In these spectra, no intense peaks were identified for fragmentation on the biotin 
label groups themselves (some unlabeled peaks in the spectra are for multiply-charged b and y 
ions with either H2O or NH3 loss).  The lack of label breakdown with the biotin hydrazides is 
consistent with Prokai’s recent observations.224 With the fatty acid derived tags, typical 
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fragmentation spectra are observed, but there are some differences compared to those seen for 
the biotin hydrazides. A key difference is that the fatty acid tags suppress tryptic cleavage at 
Arg169 and lead to peptides extended by one residue at the N-terminus – tryptic cleavage occurs 
at Lys168. The added arginine at the N-terminus provides a minor bias towards b ions with the 
most intense b ion being about 2-fold more intense than the most intense y ion. In addition, it 
appears that there are fewer ions from dehydration and ammonia loss with the fatty acid labels. 
Finally, each of them gives an intense peak for the loss of the label with the remnants of the 
acrolein group – this leads to the full-length peptide, but with no modifications (doubly-charged, 
m/z 950.2). Some label group breakdown is also evident in spectra for other peptides with the 
fatty acid hydrazides (Appendix A).  Overall, each of the tagging agents leads to useful data 












H    P    Y    F    Y    A    P    E    L    L    F    F    A    K
b3* b9 b10 b11 b12 b13
y3y4y5y8y11y12y13 y9  
 
Figure 12: MS/MS spectrum of peptide containing residues 170-183 in the +2 charge state, m/z 
872.21.Blue peaks are y ions and red peaks are b ions. Orange ones represent either loss of water 
or loss of ammonia from b and y ions. b˚ and y˚ represent loss of water and b* or y* represent loss 
of ammonia from b and y ions (doubly-charged ammonia and water loss peaks are not assigned). 
Black peaks were not identified as b or as y ions. 
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Figure 13: MS/MS spectrum of peptide containing residues 170-183 in the +2 charge state, m/z 
1022.02. Modification of His-170 with acrolein and label 1. Blue peaks are y ions and red peaks 
are b ions. Orange ones show either loss of water or loss of ammonia from b and y ions. b˚ and y˚ 
represent loss of water and b* or y* represent loss of ammonia from b and y ions (doubly-charged 
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Figure 14: MS/MS spectrum of peptide containing residues 170-183 in the +2 charge state, m/z 
1077.94. Modification of His-170 with acrolein and label 2. Blue peaks are y ions and red peaks 
are b ions. Orange ones show either loss of water or loss of ammonia from b and y ions. b˚ and y˚ 
represent loss of water and b* or y* represent loss of ammonia from b and y ions (doubly-charged 
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Figure 15: MS/MS spectrum of peptide containing residues 170-183 in the +2 charge state, 
1145.35.  Modification of His-170 with acrolein and label 3. Blue peaks are y ions and red peaks 
are b ions. Orange ones show either loss of water or loss of ammonia from b and y ions. b˚ and y˚ 
represent loss of water and b* or y* represent loss of ammonia from b and y ions (doubly-charged 
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Figure 16: MS/MS spectrum of peptide containing residues 169-183 in the +2 charge state, m/z 
1078.01.  Modification of His-170 with acrolein and label 4.  Blue peaks are y ions and red peaks 
are b ions. Orange ones show either loss of water or loss of ammonia from b and y ions. b˚ and y˚ 
represent loss of water and b* or y* represent loss of ammonia from b and y ions (doubly-charged 
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Figure 17: MS/MS spectrum of peptide containing residues 169-183 in the +2 charge state, m/z 
1104.85. Modification of His-170 with acrolein and label 5. Blue peaks are y ions and red peaks 
are b ions. Orange ones represent either loss of water or loss of ammonia from b and y ions. b˚ 
and y˚ represent loss of water and b* or y* represent loss of ammonia from b and y ions (doubly-
charged ammonia and water loss peaks are not assigned). Black peaks were not identified as b or 
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Figure 18: MS/MS spectrum of peptide containing residues 170-183 in the +3 charge state. Blue 
peaks are y ions and red peaks are b ions. Orange ones represent either loss of water or loss of 
ammonia from b and y ions. b* and y* represent loss of water and bo or yo represent loss of 
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Figure 19: MS/MS spectrum of peptide containing residues 170-183 in the +3 charge state. 
Modification of His-170 with acrolein and label 1. Blue peaks are y ions and red peaks are b 
ions. Orange ones show either loss of water or loss of ammonia from b and y ions. b* and y* 
represent loss of water and bo or yo represent loss of ammonia from b and y ions. Black peaks 
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Figure 20: MS/MS spectrum of peptide containing residues 170-183 in the +3 charge state. 
Modification of His-170 with acrolein and label 2. Blue peaks are y ions and red peaks are b 
ions. Orange ones show either loss of water or loss of ammonia from b and y ions. b* and y* 
represent loss of water and bo or yo represent loss of ammonia from b and y ions. Black peaks 
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Figure 21: MS/MS spectrum of peptide containing residues 170-183 in the +3 charge state. 
Modification of His-170 with acrolein and label 3. Blue peaks are y ions and red peaks are b 
ions. Orange ones show either loss of water or loss of ammonia from b and y ions. b* and y* 
represent loss of water and bo or yo represent loss of ammonia from b and y ions. Black peaks 
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Figure 22: MS/MS spectrum of peptide containing residues 169-183 in the +3 charge state. 
Modification of His-170 with acrolein and label 4. Blue peaks are y ions and red peaks are b 
ions. Orange ones show either loss of water or loss of ammonia from b and y ions. b* and y* 
represent loss of water and bo or yo represent loss of ammonia from b and y ions. Black peaks 
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Figure 23: MS/MS spectrum of peptide containing residues 169-183 in the +3 charge state. 
Modification of His-170 with acrolein and label 5. Blue peaks are y ions and red peaks are b 
ions. Orange ones represent either loss of water or loss of ammonia from b and y ions. b* and y* 
represent loss of water and bo or yo represent loss of ammonia from b and y ions. Black peaks 







MS/MS Spectrum Counts 
In bottom-up proteomics approaches, a reasonable measure of a labeling scheme’s 
effectiveness is the number of times a peptide with the label is targeted for an MS/MS scan and 
identified with acceptable confidence by a cross-correlation approach such as that found in 
SEQUEST. It is important to note that we are not correlating spectrum counts with peptide 
concentration, but instead, using them as a practical measure of the likelihood that a peptide 
would be detected in an LC/MS/MS experiment. The spectrum count total is based on multiple 
factors. (1) To be selected for an MS/MS scan, the labeled peptide must present sufficient signal 
intensity to be competitive with other signals in the full scan.  The intensity relates to the 
efficiency of the labeling reaction as well as to the ionization/detection efficiency of the labeled 
peptide. (2) To be identified, the labeled peptide must give an MS/MS spectrum with an 
adequate set of characteristic fragment ions. (3) The number of competing species in the sample 
with relatively similar retention times affects the probability of a peptide being chosen for an 
MS/MS scan. Because the impacts of these individual factors can be constant across samples, 
particularly in complex mixtures, it has been reported that peptide hits and spectrum counts can 
be used as measures of relative protein abundance and detectability.237-240 In the present context, 
MS/MS spectrum counts will be used to assess the ability of the labels to produce useful 
proteomic data. In these systems, each label is applied to the same protein sample and should 
produce analogous collections of modified peptides.  Because the majority of peptides are not 
modified in these samples, the background matrix is similar for each of the labeled mixtures. In 
Table 3, the effectiveness of each label can be assessed in terms of the fraction of MS/MS 
identifications that include the label. The fractions are roughly similar for the biotin-based labels 
(1 – 3), but rise for the fatty acid based labels (4 and 5). This is consistent with Muddiman’s 
observation that hydrophobic tags enhance the ionization properties of some peptides.227 As 
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noted in the Methods section, a standard 2,4-dinitrophenylhydrazine assay for the level of protein 
carbonylation in the acrolein-modified HSA indicates approximately 1.5 active carbonyls per 
protein molecule. Given that HSA yields roughly 75 tryptic peptides with identifiable MS/MS 
spectra, one expects that about 4% of the peptides in the tryptic digest to be labeled (2.7/75). 
Based on this crude estimate, it appears that all of the labels are enhancing the detectability of the 
peptides. The effect is most dramatic in label 4 where over a 2-fold enhancement is seen. 
Table 3: Fraction of MS/MS Spectra Identified for Labeled Peptides from Modified/Labeled 
HSA. 
Label Fraction Labeled Standard Deviation 
1 0.041  ± 17% 
2 0.044  ± 33% 
3 0.037  ± 14% 
4 0.095  ± 12% 
5 0.068  ± 7% 
 
Number of MS/MS spectra for labeled peptides divided by total number of MS/MS 
spectra obtained for HSA samples (labeled + unlabeled).  Uncertainties are projected from 
standard deviations in the log of the ratios from three preparations. 
An important question in interpreting the data is whether the labels were equally 
successful in modifying the protein carbonyls in the sample.  To address this issue, we have 
turned to an established biotinylation assay.  As noted in the Methods section, a DNPH analysis 
of the acrolein-treated HSA indicated that the protein, on average, carried 2.7 active carbonyl 
groups.  This is a measure of the number of DNPH molecules captured by the acrolein-treated 
HSA and therefore is sensitive to the efficiency of the reaction of the DNPH with the protein 
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carbonyls (the reported value assumes 100% efficiency).  Using a HABA-avidin assay for the 
biotin-based labels, we obtained the data in Figure 23.  As a control, we have included 
commercial, biotinylated BSA, which is reported to carry 9 biotinylation sites per protein.  This 
value is reproduced within experimental uncertainty in the HABA-avidin assay.  The data for 
labels 1, 2, and 3 suggest a marked variation in the efficiency of the hydrazide labeling reactions.  
Although there are significant uncertainties in the experimental values, the results indicate the 
following order of efficiency in the reactions with protein carbonyls: 3 > 2 > 1.  The absolute 
values are in the general range suggested by the DNPH results, but it appears that under our 
specific reaction conditions, 3 may be more effective than DNPH with protein carbonyls (given 
the uncertainties in absolute measurements with the two assays, this must be viewed as a 
tentative conclusion).  The low labeling efficiency, particularly with label 1, may partially 
explain the lack of MS/MS spectra for biotin hydrazides in Prokai’s study.224 The chemical basis 
for the variation in reactivity is likely linked to two factors, (1) interference, possibly steric, by 
the biotin/linker in the hydrazide reaction and (2) the hydrophobicity of the labeling reagent 
(which also impacts its solubility).  Label 3 benefits from having the most flexible linker and the 
greatest aqueous solubility.  These data offer a contrasting picture to the spectral counts in Table 
1 and suggest that the labeling groups impact the ionizability/detectability of the peptides in such 
a way that the concentration variations indicated in Figure 23 are nearly canceled in the spectral 
counts (i.e., ionizability/detectability follows the opposite trend, 1 > 2 > 3).  This is an intriguing 
result and indicates that label 3 would be superior in situations where detection of biotinylated 
peptides is not the primary goal (e.g., identification/isolation of proteins with carbonyl 





Figure 24: Quantification of biotin labels using HABA-avidin assay.  BSA standard is a 
commercially-available, biotinylated BSA sample. 
 
Data presented in Figure 24 show the number of MS/MS identifications at a set of 
common modification sites.  These are the sum of three separate preparations, each subjected to 
3 LC/MS/MS runs.  The results point to several conclusions.  First, there is substantial variability 
in the effectiveness of a labeling reagent depending on the nature of the labeled peptide.  Despite 
the fact that all of the biotin labels give roughly similar totals of labeled MS/MS spectra, there 
are multi-fold variations in relative effectiveness at a given modification site.  For example, 
although Lys186 and Lys375 exhibit relatively similar detectability with the three biotin hydrazides 
(a modest advantage for 2), Lys549 exhibits a nearly 4-fold preference for label 1 relative to label 
3.  Variability is also seen in the response of the labeled histidines with the biotin hydrazides, 
particularly in His312, where label 3 provides no MS/MS spectra with our search parameters, 
whereas the response is fairly similar with His170 for all the biotins.  With the fatty acid 
hydrazides, there is greater variability in the response.  For example, label 5 gives over five times 
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more spectra than label 1 for His312, but nearly 5 times fewer than label 1 for His170 – a 25 fold 
shift in response. There are many variables that impact these data and the number of spectral 
counts is low in some cases, so one can make only general rationalizations of the preferences.  
His170 is an interesting outlier in that it gives very few spectra with the hydrophobic alkyl labels 
(4 and 5).  The sequence is HPYFYAPELLFFAK and contains the highest percentage of 
hydrophobic residues of the set shown in Figure 8.  In addition, Lys549 (KQTALVELVK – 
modification leads to a missed cleavage) contains a high fraction of hydrophobic residues and the 
hydrophobic alkyl labels are also less effective relative to the biotin labels (specifically 1 and 2) 
with this peptide.  In contrast, His312 exhibits the strongest bias in favor of the hydrophobic alkyl 
labels and the peptide, SHCIAEVENDEMPADLPSLAADFVESK, is one of the richest in 
hydrophilic residues in the set.  Therefore, it appears that the alkyl labels can enhance the 
hydrophobicity of a relatively hydrophilic peptide giving a beneficial effect, but in some cases, 
such as His312, push the peptide to be too hydrophobic for efficient analysis.  The differences 
exhibited between the individual biotin hydrazides are too subtle to analyze with the limited data.   
Overall, the variability is somewhat surprising and indicates that label choice will have a 
significant effect on the modifications that are detected.  This will critically impact titration 
experiments where minimum detection level is used as a measure of the concentration of a 
modified peptide. Second, the data in the figure indicate that labels 1 and 2 provide the most 
consistent performance and gave at least a moderate number of MS/MS spectra (> 25 in this data 
set) for each of the modification sites. Third, the fatty acid labels provide the most variability in 
their performance. This is likely due to their ability to increase the peptide’s hydrophobicity, 




Figure 25: Spectrum counts for HSA peptides modified by acrolein and labeled with different 
hydrazide tags. 
 
Avidin Column Enrichment of Biotinylated Peptides 
The three biotin-based labels were also assessed in assays involving enrichment with a 
monomeric avidin column. Samples were prepared using the same protocol as above and then 
split. One fraction was analyzed directly and the other subjected to an affinity chromatography 
cycle before analysis. Table 4 shows the fraction of biotinylated peptides that were detected 
before and after enrichment. Combining the data from three runs, each of the labels leads to an 
enrichment of a factor of about 8-9 fold for the biotinylated peptides. Avidin enrichment leads to 
a reduction in the total number of identified MS/MS spectra of about 75%, but generally an 
increase in the MS/MS spectra for biotinylated peptides (Appendix A). The behavior of all of the 
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tags is roughly equivalent suggesting that there is no significant advantage between the tags in 
the enrichment phase – this is an expected result.  The level of enrichment in this system is 
potentially limited by the sample’s complexity because the small number of unique biotinylated 
peptides leaves large gaps in the chromatographic run and allows even low abundance non-
biotinylated peptides to be identified in those gaps.  Future work will concentrate on more 
complex biological samples where the potential level of enrichment can be more accurately 
assessed. 
Table 4: Fraction of Labeled Peptides Identified in MS/MS Spectra from Modified/Labeled HSA 
Before and After Enrichment. 
Label Before STD After STD 
1 0.041  ± 17% 0.39  ± 8% 
2 0.044  ± 33% 0.34  ± 27% 
3 0.037  ± 14% 0.33  ± 33% 
 





Carbonylation of human serum albumin with acrolein offers the opportunity to 
conveniently assess the labeling efficiency of various hydrazide compounds. Based on a HABA-
avidin assay, we find that the labeling efficiencies vary considerably among the biotin 
hydrazides, but this variation is effectively canceled by the impact of the label on the 
ionizability/detectability of the peptides in this data set.  For each of the modification sites tested, 
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the pattern of relative responses from the labeling groups, as measured by MS/MS spectrum 
counts, varied considerably, suggesting that features of the individual peptides had an impact on 
the label’s effectiveness in producing identifiable MS/MS spectra.  As a result, care must be 
taken in titration experiments that attempt to link the onset of identifiable MS/MS spectra with 
the reactivity of a particular modification site because the results will vary considerably with the 
choice of labeling group.  Although none of the labeling groups is markedly superior in terms of 
spectrum counts, label 3 is the most efficient of the biotin hydrazides in reacting with protein 
carbonyls.  At the peptide level, these data indicate that labels 1 and 2 give the most consistent 
response pattern and are best suited for identifying the maximum number of modification sites; 
however, other labeling groups can give much better response for particular modification sites. 
The three tested biotin hydrazides appeared to perform equally well during affinity 
chromatography and in our system, gave multi-fold enrichments in MS/MS counts (relative to 










CHAPTER 3: Identification of Specific Protein Carbonylation Sites in Model 




Oxidative damage by ROS is associated with aging and age-related disease. 241,242 The 
production of ROS is an inevitable result of aerobic metabolism.243 ROS can be highly reactive 
and can oxidatively modify a wide array of biomolecules such as proteins, nucleic acids, sugars, 
and lipids.244 Proteins are a major target for oxidations.245 Since most of the cellular work is done 
by proteins, oxidative modifications can result in serious damage to a living organism. Numerous 
reports support the notion that metal catalyzed oxidation (MCO) is the most important 
mechanism of protein oxidative damage and results in polypeptide backbone cleavage, cross 
linking, and modification of amino acid side chains, which in turn results in structural alteration 
and loss of protein functions.246-248 Proteins can undergo various types of oxidative 
modifications, but protein carbonylation is often used to monitor oxidative damage due to its 
irreversible and irreparable nature as well as the easy access to labeling techniques with this 
functional group. Protein carbonyls can be formed by direct MCO attack on the side chains of 
amino acids such as arginine (Arg), lysine (Lys), threonine (Thr) and proline (Pro). Protein 
carbonyls are also formed by adduction of reactive α, β-unsaturated aldehydes. These aldehydes 
are derived from oxidation of lipids or carbohydrates and add to nucleophilic residues such as 
Lys, Cys and His.249  
It has been reported that approximately 10% of the proteome is vulnerable to protein 
carbonylation.246 A number of studies have reported that protein oxidation is selective and only 
certain proteins are oxidized in the systems under oxidative stress. For example β-actin, β-
tubulin, creatine kinase BB are the only proteins oxidized in the brain of AD patients. 250-258 The 
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specificity is likely driven in part by the proximity of the oxidant to the protein because the most 
reactive oxidants have short half-lives in biological systems. However, the molecular basis for 
the observed specificity in not clear. Interestingly, carbonylation sites show a very strong 
tendency to cluster in the protein’s primary sequence suggesting some kind of distinguishable 
mechanism. Depending on the nature of the oxidant, different amino acids might be oxidized. 
Table 5 shows amino acid residues that are modified by a variety of different oxidizers.259  
 
Table 5: Amino acid residues that are modified by variety of different oxidizers 












MCO, x-ray, ozone 










Tyr-Tyr cross links 
S-S cross links 
 
Different physiological and non-physiological processes can generate ROS that result in 
protein oxidation. Various methods can be employed to generate ROS for experimental purposes 
such as X-ray or UV irradiation, or chemicals. However, living organisms are hardly ever 
exposed to this type of damage. The most physiologically relevant mechanism of protein 
carbonylation in living cells appears to be MCO. MCO generally happens when reduced metal 
ions such as Fe+2 and Cu+1 react with H2O2 in a Fenton reaction and generate extremely reactive 
hydroxyl radicals as shown in Equation 1. 
Fe(II) + H2O2 Fe(III) + OH + OH (Eq1)  
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Despite extensive research on protein carbonylation over several decades, an 
understanding of the carbonylation process is still lacking. Most studies have only identified 
carbonylated proteins, not the actual site of carbonylation.260-263 We believe that it is important to 
find the sites of protein carbonylation because it will provide insights about the molecular 
changes that occur during oxidative stress, which in turn helps us understand the role of protein 
carbonylation in altering cellular function during aging and age-related disease. A great deal of 
progress has been made in identifying the sites of other oxidative modifications in proteins such 
as histidine oxidation and tyrosine nitration; however, research towards determining 
carbonylation sites has fallen short.264-267 The high reactivity of aldehydes, especially in the 
presence of nucleophilic groups common in peptides, make them difficult to identify. We believe 
that the carbonylation is site specific and dependent on the nature of the oxidant, and will test 
this hypothesis in the following study.  
Figure 25 shows the proposed mechanism of site selective lysine oxidation with MCO. 
In this mechanism it has been proposed that Fe (II) binds the ε-amino group of the lysine residue 
(-CH2-NH2) and forms a Fe (II)-protein coordination complex. Reaction with H2O2 results in the 
formation of protein bound Fe (II), OH−, and •OH as a result of a Fenton reaction. The •OH 
radicals formed abstract a hydrogen from the carbon carrying the ε-amino group to give a 
carbon-centered radical. After that, transfer of an electron from the alkyl radical to Fe (III) 
results in the formation of an imine derivative (-CH=NH) of the lysine residue and reduced Fe 
(II). Hydrolysis of the imine group gives the aldehyde derivative of the lysine residue. Similar 
mechanisms are available for arginine and proline. The •OH generally damage protein at a site 




























Note: Fe+2   +   H2O2 Fe(OH)2
+2
(FeO)+2 + H2O
(FeOH)+3 + OH- Fe+3 + OH + OH-
 
Figure 26: H2O2 reacts with Fe (II) or Cu (I) ions that can also bind to specific metal binding 
sites on proteins and produce •OH. These highly reactive free radicals readily oxidize the 
neighboring amino acid side chains.268 
 
HOCl is another major endogenous source of oxidant. HOCl is introduced by neutrophils 
and monocytes in host defense reactions. HOCl is produced to kill bacteria and invading 
pathogens. In the case of oxidative stress, HOCl reacts with tyrosine, tryptophan, methionine, 
and lysine to give chloro amines, methionine sulfoxide and aldehydes. Lysine is the primary 
target for HOCl oxidation and it gives carbonyl modifications as shown in Figure 26.269 In this 
mechanism, lysine is in an equilibrium between the ammonium and free amine form. At first, the 
reaction of free amine with HOCl results in an unstable hydroxylamine intermediate. The 
hydroxylamine is subsequently converted to an imine adduct. Hydrolysis of the imine gives the 




















Figure 27: Mechanism of lysine oxidation with HOCl.269 
 
Human serum albumin (HSA) is the model protein in our studies. HSA is a 66 kDa 
protein that has been identified as a target protein for oxidative damage and it has been reported 
that albumin is selectively oxidized in various species such as cows, mice and insects. 270-273 This 
makes it a relevant model for oxidation studies. Since it is a model protein and protocols will be 
established, the commercial availability of HSA is important. A crystal structure of HSA is also 
available, which helps in structural analyses of the results. Ubiquitin is another model protein we 
have chosen. Ubiquitin is a small protein that has a molecular mass near 8.5 kDa. It functions as 
a label for proteasomal degradation. In addition to this function, ubiquitination controls the 
stability, function and intracellular localization of various proteins. Ubiquitin is commercially 
available and a NMR structure of ubiquitin is available. 
In this work, human serum albumin (HSA) and ubiquitin were oxidized in vitro with 
MCO and HOCl. To protect against further reactions of the protein carbonyl modifications, they 
have been converted to stable hydrazines via reaction with biotin hydrazide followed by 
reduction with sodium cyanoborohydride. One of the advantages of using biotin hydrazides is 
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that they offer an affinity tag for potentially enriching the modified proteins and resulting 
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Figure 28: Analysis of HSA with mass spectrometry. 
 
METHODS AND MATERIALS 
  
MATERIALS 
Human serum albumin (HSA), biotin hydrazide, and 2, 4-dinitrophenylhydrazine (2, 4-
DNPH) were purchased from Sigma (St. Louis, MO). Sodium cyanoborohydride (5 M solution 
in aqueous 1 M sodium hydroxide) was obtained from Sigma-Aldrich (St. Louis, MO). Sodium 
hypochlorite (4–6% NaOCl) was purchased from Fisher Scientific (Fair Lawn, NJ). Sequencing 
grade, modified trypsin used for the enzymatic digestion was obtained from Promega (Madison, 
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WI). All other chemicals and solvents were obtained from commercial sources and were of the 
highest purity available. 
MCO of HSA 
HSA was dissolved at a final concentration of 25 mM in oxidation buffer (50 mM 
HEPES, N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid buffer, pH 7.4, containing 100 
mM KCl and 10 mM MgCl2). The oxidation mixture was prepared by adding neutral ascorbic 
acid and metal ions (Fe and Cu) to a final concentration of 15 mM and 1 mM, respectively. The 
mixture was incubated for 24 h at 37 °C in a water bath, after which oxidation was terminated by 
addition of EDTA (ethylenediaminetetraacetic acid) to a final concentration of 1 mM. 
HOCl OXIDATION  
HSA (2 mg) was dissolved at a concentration of 2 mg/ mL in HPLC-grade water. 
Oxidation was performed by adding NaOCl to a final concentration of 5 mM. The mixture was 
incubated for 15 min at 37 °C in a water bath. Following the oxidation, HOCl was removed by 
diluting the sample with PBS (phosphate-buffered saline) buffer (pH 7.4) and filtering the 
solution through a Microcon YM-30 filter device. Filtration was accomplished by centrifugation 
of the Microcon assembly at 8000 rpm for about 5 to 10 min. The dilution/centrifugation process 
was repeated four times.  
LABELING MODIFIED PROTEIN 
Labeling of the carbonyl groups of oxidized HSA was performed by reaction with biotin 
hydrazide using an approach based on the method of Yoo and Regnier.274 In summary, the 
oxidized protein samples were mixed with standard, extended-chain, and PEG4-linked biotin 
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hydrazide to a final concentration of 5 mM using a 50 mM stock solution. The samples were 
reincubated at room temperature for 2 h with shaking and then cooled to 0 °C. An equal volume 
of 30 mM sodium cyanoborohydride in PBS buffer was subsequently added to stabilize the 
reaction products. Following the labeling, the HSA samples were precipitated with 20% 
trichloroacetic acid in an ice bath for 1 h, and the excess reagents were removed as a part of the 
supernatant. The pellets were washed three times with ethanol/ethyl acetate (1:1) and then 
dissolved in ammonium bicarbonate buffer in preparation for enzymatic digestion. 
ENZYMATIC DIGESTION 
The labeled HSA samples in 50 mM ammonium bicarbonate buffer at a concentration of 
1 mg/mL were reduced with 30 mM dithiothreitol at 50 °C for 20 min and alkylated with 55 mM 
iodoacetamide at room temperature for 30 min in the dark. The excess of dithiothreitol and 
iodoacetamide were removed using a Microcon YM-30 filter at 8000 g for 15 min. The proteins 
were redissolved in 50 mM ammonium bicarbonate, and subsequently digested with trypsin 
(substrate/enzyme ratio of 40/1, wt/wt) at 37 °C for 24 h. The digestion was terminated by 
adding 0.1% formic acid (120 L). 
QUANTIFICATION OF TOTAL CARBONYLATED PROTEIN LEVEL 
Quantification of the carbonylated proteins was done as described by Levine.275 In this 
protocol, reactive carbonyl groups were converted to the corresponding hydrazone by reaction 
with 10 mM 2,4-dinitrophenyl hydrazine (2,4-DNPH) in 2 M HCl (1:500 protein to 2,4-DNPH 
ratio). The reaction mixture was incubated for 15 min with shaking and the protein mixtures 
were precipitated with trichloroacetic acid (final concentration 15% vol/vol ratio). After 
incubation in an ice bath for 45 min, the precipitate was centrifuged at 13400 rpm for 5 min. The 
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supernatant was discarded and the precipitate was washed 3 times with an ethanol-ethyl acetate 
mixture (1:1 vol/vol ratio). The precipitate was resuspended in 6 M guanidine-HCl solution (pH 
2.3). UV-Vis absorances were taken at the 370 nm and 276 nm. The former corresponds to the 
hydrazone maximum with an estimated molar absorptivity coefficient of 22,000 M-1 cm-1. The 
calculations have been made based on Lambert-Beer Law shown in Equation 2 and Equation 3. 
A276 and A370 are absorbances at 276 nm and 370 nm, respectively. [HSA] and [HSAoxi] are the 
concentrations of HSA and oxidized/labeled HSA. εAbs@276 and εAbs@370 are molar absorption 
coefficients for HSA at 276 nm and 370 nm. ε [HSAoxi]@276nm and ε [HSAoxi]@370nm are molar 
absorption coefficients for oxidized HSA at 276 nm and 370 nm. l is the path length. 
A276=εAbs@276[HSA]l +εAbs@276[HSAoxi]l   Eq. 2 
A370= εAbs@370[HSA]l +εAbs@370[HSAoxi]l   Eq. 3 
ε [HSAoxi]@276nm=9460 M-1cm-1  ε [HSA]@276nm=45800 M-1cm-1 
ε [HSAoxi]@370nm=22000  M-1cm-1 ε [HSA]@370nm=900 M-1cm-1 
 
UV spectra are shown in Figure 28. It is clear that oxidized proteins have higher 
absorbance than the native ones at 370 nm, which indicates carbonylation. The MCO (Fe) 
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Figure 29: UV spectra of oxidized HSA in MCO (Fe). 
 
Table 6: DNPH analysis of native and oxidized HSA samples in MCO (Fe). 







Control 0.612 0.107 1.25 10‐5 4.35 10‐6 0.349 
Sample 1 0.805 0.420 1.37 10‐5 1.85 10‐5 1.348 
 
LC/ESI-MS/MS ANALYSIS 
Liquid chromatography/electrospray ionization-tandem mass spectrometry (LC/ESI-
MS/MS) analysis of digested HSA samples (300 pmol/injection) was performed using a capillary 
HPLC system (Thermo Finnigan, San Jose, CA) connected to an LTQ ion trap mass 
spectrometer (Thermo Finnigan, San Jose, CA) with a nanospray source. Tryptic peptides were 
separated by reverse-phase chromatography on a C18 column (C18 Thermo, 5μm particle size, 
300Å, 100x0.18 mm) with a split flow system. The split is approximately 100:1 with a master 











from the column using two mobile phases, A (0.1% formic acid in water) and B (0.1% formic 
acid in methanol). The gradient started from 2% B, then increased to 15% B over 15 min, then 
increased to 80% B over 70 min, and finally increased to 95% B over 25 min. The eluted 
peptides (singly, doubly, or triply-charged ions) were analyzed using a data-dependent scan 
procedure. To exclude the redundant processing of a few dominant ions in the MS/MS analyses, 
a dynamic exclusion feature was used that only allows a particular m/z value to be processed 
twice in a 2 min time window. The acquired MS/MS spectra were then searched against the 
NCBI non-redundant human protein database (GI: 4502027) using the Finnigan Bioworks v.3.2 
(Sequest) software. The database searching was set to only consider peptides within the mass 
range 500–4000 Da. Up to two missed cleavage sites were allowed, and cysteines were defined 
as modified with carbamidomethylation (+57). To search for oxidized peptides, the differential 
modifications of methionine, histidine, lysine, and arginine were set to +16, +16, +241, and +199 
Da, respectively for standard biotin hydrazide, +16, +16, +354, and +312 Da, for extended-chain 
hydrazide, +16, +16, +488, and +445 Da, for PEG4-linked biotin hydrazide. In order to filter the 
search results the Yates Rule was applied and the Xcorr threshold was set to 1.9, 2.2 and 3.75 for 
+1, +2 and +3 charged peptides, respectively. ΔC was set to 0.1 and the number of top matches 
was set to 1. 
RESULTS  
 
HSA is a 66 kDa protein with 59 lysine and 24 arginine residues in its secreted form. 
HSA contains 609 amino acids (SwissProt P02768). The first 24 amino acids are signal and 
propeptide portions not observed in the transcribed, translated, and transported protein, but are 
present in the gene. HSA was oxidized with MCO conditions and labeled with the three different 
biotin hydrazides. Protein carbonylation followed by reductive labeling with biotin hydrazide 
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results in predictable increases in the masses of the amino acid residues. In the case of lysine, it 
is converted to 2-aminoadipic semialdehyde by oxidation and this causes a loss of 1Da in mass. 
Formation of the hydrazone from standard biotin hydrazide and reduction with NaBH3CN, adds 
242 Da for a net mass shift of 241 Da compared to lysine. In the case of arginine, the oxidation 
and labeling causes a mass shift of 199 Da compared to the starting residue mass. On the other 
hand, extended-chain biotin and PEG4-linked biotin hydrazides give rise to 354 and 488 Da 
mass shifts for lysine, and 312 and 445 Da for arginine, respectively. These altered masses are 
incorporated into the Bioworks program used to automatically interpret the tandem mass spectra 
generated for the peptides from the tryptic digests of the oxidized protein. After tryptic digest, a 
majority of the lysine and arginine residues in HSA were identified in the peptide mixture using 
the Sequest algorithm in the Bioworks program. 
 
ANALYSIS of HSA SUBJECTED TO HOCl OXIDATION  
HSA was oxidized with NaOCl and labeled only with the standard biotin hydrazide. An 
analysis of HSA subjected to HOCl oxidation gave rise to mainly lysine modifications. The 
tyrptic digest data provided 68% sequence coverage for the samples subjected to HOCl. There 
were 13 peptides identified in HOCl oxidized HSA with mass shifts consistent with lysine 
modification. These sites are Lys-65, Lys-75, Lys-198, Lys-214, Lys-257, Lys-402, Lys-438, 
Lys-499, Lys-549, Lys-569, Lys-588, and Lys-597. For example the peptide containing 
biotinylated Lys-257 (AA 249-264) was detected at m/z 632.02 for a triply-charged ion that 
matches the calculated mass of 1896.06 Da for the peptide bearing modification and biotin label 
(Figure 29). The modified lysine represents a missed cleavage point. As part of the peptide 
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identification process, MS/MS fragmentation spectra are used. MS/MS analysis of the precursor 
ion at m/z 632.02 results in a comprehensive set of ions that confirms the sequence of the peptide 
(Figure 30).The 369 Da mass difference (label plus Lys, 241+128) between the y7 and y8 ions as 
well as between the b7 and b8 ions confirms that Lys-257 was modified and contains the biotin 
label. The spectra used for identification of the 12 other modified lysine sites are shown in 
Appendix B. 
 
NaOClsam ple1 #13910 RT: 70.87 AV: 1 SB: 343 52.34-63.45 NL: 2.39E5
F: ITMS + c NSI Full ms 







































1246.67679.39374.58 1372.87 1646.68 1990.281723.47442.75
 
Figure 30: Full scan mass spectrum and the corresponding zoom scan of the peptide containing 
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Figure 31: MS/MS spectrum of the peptide containing AA# 249-264. Parent ion is triply-





ANALYSIS of HSA SUBJECTED TO MCO (Fe2+)  
HSA was oxidized under MCO (Fe2+) conditions and labeled with the three different 
biotin hydrazides. The overall sequence coverage was approximately 88%. One of the 
advantages of using three different labels is that detection sites are confirmed in multiple 
experiments involving different mass shifts, which greatly reduces the possibility of false 
positives due to coincident masses. Table 7 shows the oxidation sites and the spectrum counts 
for the three different labels in three repeats.  
Table 7: Modified sites identified in MCO (Fe2+) oxidation of HSA with biotin hyrazide, 
extended-chain hydrazide and PEG4-linked hydrazide and their spectral counts. Control is not 









R-34 2 4 0 0 
K-97 15 9 6 0 
R-105 1 5 1 0 
R-141 0 3 0 0 
K-161 3 0 0 0 
R-210 0 3 3 0 
K-223 0 8 1 0 
R-233 1 0 0 0 
K-236 1 4 0 0 
K-249 2 6 0 0 
K-257 0 3 0 0 
K-375 0 1 0 0 
K-402 0 2 0 0 
R-469 5 7 1 0 
K-490 5 6 5 0 
K-499 0 0 4 0 
R-496 0 4 0 0 




MCO oxidation of HSA with Fe2+ results in the identification of Arg-34, Lys-97, Arg-
105, Arg-210, Lys-223, Lys-236, Lys-249, Lys-490, Arg-469 and Lys-549 as modification sites. 
These sites were confirmed by at least two labels. For example, Figures 31, 32 and 33 show 
spectra for peptides containing the three different biotin hydrazide labels on oxidized Lys-97 
(AA 89-105). The modified lysine in this peptide was skipped in the tryptic digest and represents 
a missed cleavage point. Figure 31 shows an MS/MS spectrum for the peptide containing 
standard biotin. It was detected at m/z 725.31 for the triply-charged peptide with a mass of 
2175.93 Da. The MS/MS spectra also confirm the modification site. Figure 32 shows an MS/MS 
spectrum for the peptide containing extended-chain biotin labeled Lys-97. It was detected at m/z 
763.24 for the triply-charged peptide with a mass of 2289.72 Da. Figure 33 shows an MS/MS 
spectrum for the peptide containing the PEG4- linked biotin labeled Lys-97 and was detected at 
m/z 807.94 for the triply-charged peptide with a mass of 2423.82 Da. The mass shifts 
corresponding to the labels are observed in the appropriate b and y fragment ions for all of the 
cases. For the sake of the simplicity in Figures 31, 32, and 33 the losses of water or ammonia 
from b and y ions were not annotated in the spectra. Detailed information and spectra for other 








b3 b5 b8 b15b12
y3y7y12
S    L    H    T    L    F    G     D  K*  L    C    T    V    A   T   L    R










Figure 32: MS/MS spectrum of the biotin hydrazide labeled peptide containing AA# 89-105, 
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Figure 33: MS/MS spectrum of the extended-chain biotin labeled peptide containing AA# 89-
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Figure 34: MS/MS spectrum of the PEG4-linked biotin labeled peptide containing AA# 89-105, 










ANALYSIS of HSA SUBJECTED TO MCO (Cu2+) 
HSA was treated under MCO (Cu2+) conditions and labeled with the three different biotin 
hydrazides. The overall sequence coverage was approximately 86%. Table 8 shows the 
oxidation sites and the spectrum counts for the three different labels in three repeats. 
Table 8: Modified sites in MCO (Cu2+) of HSA and labeled with biotin hyrazide, extended-
chain hydrazide and PEG linked hydrazide and their spectral counts. Control is not oxidized and 









K-46 1 0 0 0 
K-97 0 1 2 0 
K-161 4 2 0 0 
R-169 0 1 2 0 
K-198 3 5 2 0 
R-210 0 2 0 0 
K-223 2 6 5 0 
K-236 5 4 1 0 
R-246 0 1 0 0 
K-257 0 7 0 0 
K-375 5 1 0 0 
R-469 1 0 0 0 
K-490 9 7 10 0 
K-549 18 15 5 0 
 
MCO oxidation of HSA with Cu2+ resulted in the identification of Lys-97, Lys-161, Arg-
169, Lys-198, Lys-223, Lys-236, Lys-375, Lys-549, and Lys-490 as modification sites .These 
sites were confirmed by at least two labels. For example Figures 34, 35 and 36 show MS/MS 
spectra for the peptide containing modified Lys-236 (AA 234-242) with three different labels. 
The modified lysine in this peptide was skipped in the tryptic digest and represents a missed 
cleavage point. In Figure 34, the peptide labeled with standard biotin at Lys-236 was detected at 
m/z 631.16 for the doubly-charged peptide with a mass of 1262.32 Da. In Figure 35, the peptide 
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labeled with extended-chain biotin at Lys-236 was detected at m/z 687.61 for the doubly-charged 
peptide with a mass of 1375.22 Da. In Figure 36, the peptide labeled with PEG4-linked biotin at 
Lys-236 was detected at m/z 754.64 for the doubly-charged peptide with a mass of 1509.28 Da. 
The fragmentation patterns are consistent with the identified modification site and the 
appropriate mass shifts corresponding to three different labels were observed. Spectra for other 
modified sites can be found in Appendix B. The overall oxidation sites, confirmed with at least 
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Figure 35: MS/MS spectrum of the standard biotin labeled peptide containing AA# 234-242, 
m/z 631.16. Fragmentation indicates modification at Lys-236. b* and y* represent ammonia loss, 
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Figure 36: MS/MS spectrum of the extended-chain biotin labeled peptide containing AA# 234-
242, m/z 687.61. Fragmentation indicates modification at Lys-236. b* and y* represent ammonia 
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Figure 37: MS/MS spectrum of the PEG4-linked biotin labeled peptide containing AA# 234-
242, m/z 754.64. Fragmentation indicates modification at Lys-236. b* and y* represent ammonia 





MKWVTFISLL FLFSSAYSRG VFRR34DAHKSE VAHRFKDLGE ENFKALVLIA   50 
FAQYLQQCPF EDHVK65LVNEV TEFAK75TCVAD ESAENCDKSL HTLFGDK97LCT  100 
VATLR105ETYGE MADCCAKQEP ERNECFLQHK DDNPNLPRLV RPEVDVMCTA  150 
FHDNEETFLK K161YLYEIARR169H PYFYAPELLF FAKRYKAAFT ECCQAADK198AA  200 
CLLPKLDELR210 DEGK214ASSAKQ RLK223CASLQKF GERAFK236AWAV ARLSQRFPKA  250 
EFAEVSK257LVT DLTKVHTECC HGDLLECADD RADLAKYICE NQDSISSKLK300   300 
ECCEKPLLEK SHCIAEVEND EMPADLPSLA ADFVESKDVC KNYAEAKDVF   350 
LGMFLYEYAR RHPDYSVVLL LRLAK375TYETT LEKCCAAADP HECYAKVFDE   400 
FK402PLVEEPQN LIKQNCELFE QLGEYKFQNA LLVRYTKK438VP QVSTPTLVEV   450 
SRNLGKVGSK CCKHPEAKR469M PCAEDYLSVV LNQLCVLHEK490 TPVSDRVTK499C  500 
CTESLVNRRP CFSALEVDET YVPKEFNAET FTFHADICTL SEKERQIKK549Q   550 
TALVELVKHK PKATKEQLK569A VMDDFAAFVE KCCKADDK588ET CFAEEGK597KLV  600 
AASQAALGL           609 
Figure 38: Sequence of human serum albumin. (SwissProt P02768) Modified lysines and 
arginine sites by MCO (Fe) shown in bold, modified sites by MCO (Cu) are underlined, and 
modified sites by HOCl shown in red italics. Modified sites with both HOCl and MCO (Fe) are 
in bold and red italics. Modified sites with both MCO (Fe and Cu) are bold and underlined. 
Modified sites both HOCl and MCO (Cu) are in red and underlined.
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ANALYSIS OF UBIQUITIN SUBJECTED TO MCO (Fe2+) 
Ubiquitin is approximately a 8.5 kDa protein. Ubiquitin consist of 76 amino acids. It has 
7 lysine and 3 arginine residues. The overall sequence coverage was approximately 92%. 
Treatment of ubiquitin under the MCO (Fe) conditions gave only one oxidation site, which is 
Arg-54 (Figure 38).  
         AA# 
MQIFVKTLTGKTITLEVEPSDTIENVKAKI   31 
QDKEGIPPDQQRLIFAGKQLEDGR54 TLSDYN  61 
IQK63 ESTLHLVLRLRGG      76 
Figure 39: Amino acid sequence of ubiquitin (Swissprot P62990). Arg-54 modified by MCO is 
shown in bold underlined. 
 
Modification of Arg-54 was confirmed with two labels. Figures 39 and 40 show the 
relevant peptide containing the two different biotin hydrazide labels at Arg-54 (AA 49-63). The 
modified arginine in this peptide was skipped in the tryptic digest and represents a missed 
cleavage point. In Figure 39, the peptide containing the standard biotin label at Arg-54 was 
detected at m/z 990.96 for the doubly-charged peptide with a mass of 1981.92 Da. The MS/MS 
spectra confirm the modification site. The 355 Da mass difference between b5 and b*6 (label plus 
Lys, 156+199) and the mass shift between y9 and y11 confirm that Arg-54 was modified and 
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Figure 40: MS/MS spectrum of the standard biotin labeled peptide containing AA# 49-63, m/z 
990.96. Fragmentation indicates modification at Arg-54. b* and y* represent ammonia loss, bo 
and yo represent water loss in the ions. 
 
In Figure 40, the mass spectrum for the peptide containing the extended-chain biotin at 
Arg-54 was detected at m/z 1047.09 for the doubly charged peptide with a mass of 2094.18 Da. 
The MS/MS spectra also confirm the modification site. The 468 Da mass difference between b5 
and b6 (label plus Lys, 312+156) as well as the mass shift between y9 and y11 confirm that Arg-
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Figure 41: MS/MS spectrum of the extended-chain biotin labeled peptide containing AA# 49-
63, m/z 1047.09. Fragmentation indicates modification at Arg-54. b* and y* represent ammonia 











There were 12 peptides identified in HOCl oxidized HSA with mass shifts consistent 
with lysine modification. These sites are Lys-65, Lys-75, Lys-198, Lys-214, Lys-257, Lys-402, 
Lys-438, Lys-499, Lys-549, Lys-569, Lys-588, and Lys-597. A peptide with a mass 
corresponding to peptide residues (301–310) with a modified lysine was also identified. The 
mass shift associated with a biotin-labeled lysine residue is equal to the total masses of a 
leucine/isoleucine and a lysine combined. In HSA, residues 299 and 300 are a leucine and a 
lysine Thus, a peptide with residues (301–310) with a modified lysine and one missed cleavage 
point has the same mass as a peptide containing residues (299–310) with no modifications and 
two missed cleavage points. The MS/MS data on this peptide are not conclusive and do not 
absolutely indicate a lysine modification. 
When examining the crystal structure of the HSA, it was found that all of the HOCl 
active sites are surrounded by acidic residues. Temple et al. reported that the common feature in 
modification sites in the HOCl oxidized protein is the presence of nearby acidic residues.228 In 
the oxidation mechanism, the ammonium ion of the lysine side chain must be converted to a free 
amine by deprotonation. Once the free amine is formed, nucleophilic attack by the oxygen of 
HOCl can take place and the hydroxylamine intermediate can form followed by conversion to an 
imine. Each of these steps would be facilitated by the presence of a nearby acidic residue, which 
serves as a proton acceptor or donor. On the other hand, this type of structural pattern is not 
unique to the observed modification sites and it is not clear what is the driving force to 
differentiate them from other lysine residues that have nearby acidic residues. Surface 
accessibility might also play a role. This can be examined with a simple solvent accessible 
surface area (SASA) calculation for each of the residues. Even though it may not be a perfect 
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measure of the environment, it gives some insight. Side chain and backbone SASAs for lysines 
in HSA are plotted in Figure 41 with data from the GETAREA program 
(http://curie.utmb.edu/getarea.html), Figure 41 shows that many of the HOCl modified sites 
have high accessibility on the side chain. Modification sites were all over the protein sequence 
and HOCl can modify both the residues on the surface as well as residues that are partially 
buried. This suggests that HOCl oxidation is somewhat random.  
In addition to oxidation of lysine, we also observed methionine and histidine oxidation. 
However, mass spectrometry data did not provide evidence to confirm oxidation of arginine to 
glutamic semialdehyde. The absence of arginine modification implies that this process is slower 




Figure 42: SASA in Å2 for the lysines of HSA. Light gray bars are the backbones, and dark gray 
bars are the side chains. Arrows indicate sites that were modified with HOCl. In this graph the 
data are too extensive to include residue numbers, but modified sites are labeled. 
 
SASA calculations showed that most of the MCO modified sites have moderate to low 
accessibility on the side chain (Figures 42 and 43). SASA analysis gives only a crude measure 
of the environment so we have turned to the crystal structure of HSA to get a better 





Figure 43: SASA in Å2 for the lysines of HSA. Light gray bars are the backbones, and dark gray 
bars are the side chains. Red arrows indicate the sites that were modified with MCO (Fe2+). Blue 
arrows indicate the sites that were modified with MCO (Cu2+). White arrows indicate the sites 
that modified with both conditions. In graph the data are too extensive to include residue 





Figure 44 SASA in Å for the arginines of HSA. Light gray bars are the backbones, and dark 
gray bars are the side chains. Red arrows indicate sites that were modified with MCO (Fe2+). 
Blue arrows indicate sites that were modified with MCO (Cu2+). X-axis shows the residue 
numbers. 
 
The Vachet group has extensively studied MCO conditions with copper and investigated 
a number of proteins.276-283 This group and number of others have reported that histidine residues 
could be a binding site for copper and direct oxidation. 278-287 We were expecting that MCO (Cu) 
conditions would result in modification sites that are close to histidine residues. Temple at al. has 
suggested that MCO (Fe) condition could result in modification sites that are near acidic 
residues, which can serve as a metal binding site for iron.228 The crystal structure of HSA shows 
that the modification sites we have identified with MCO (Cu) have at least one histidine residue 
within a 10 Å distance except for Lys-375. It has been reported that Cu (2+) ions bind non-
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specifically to individual nitrogen and oxygen donors on the surface of the albumin. Such 
binding is much weaker and very labile.288 SASA also shows that Lys-375 is on the very surface 
of the HSA and also surrounded by acidic residues (Figure 49). That might be why this site is 
readily oxidized with both MCO and HOCl. All of the modification sites we have identified with 
MCO (Fe) were surrounded by acidic residues where the metal could bind as seen in the 
projections of the crystal structure shown in Appendix B. Human serum albumin is known to 
bind transition metals at the N-terminus. His-27, His-91, His-129, His-170, and His-271 also 
have been reported be metal binding sites for human serum albumin.288-293 In fact, Lys-97, Lys-
161, Lys-169, Arg-169, and Lys-490 modification sites are very close to these reported metal 
binding sites in the protein.  As an example Figure 44 shows Arg-210 and Lys-490.  Arg-210 
was oxidized in MCO (Fe) conditions and is very close to acidic residues such as Asp-207, Asp-
211, Glu-208, and Glu-212, which makes it a good, potential metal binding site. Lys-490 was 
modified in MCO (Cu) conditions and is very close to Glu-110, Asp-131, Asp-132, His-488 and 




Whereas Arg-34, Arg-105, and Lys-249, sites were identified under the MCO (Fe) 
conditions, they were not identified under the MCO (Cu) conditions (Table 7-8). Arg-105 and 
Lys-249 have no histidine residues nearby and are surrounded by acidic residues where the iron 
metal can bind. Arg-34 is the only iron modification site that is close to a histidine residue, but 
where copper modification is not seen. Sequest search results for MCO (Cu) did not show any 
peptides bearing the Arg-34, so it not covered in the sequence. This peptide must be near our 
detection limit so its omission in the MCO (Cu) results may be a sensitivity issue. Lys-549 is 
identified with both MCO conditions. Spectral count data in Table 8 show that Lys-549 has the 
highest number of hits in MCO (Cu). There are a total of 38 from the three labels. In the MCO 
(Fe), this is a minor site with a total of only 9 hits. The opposite trend was observed for Lys-97. 
Lys-97 has the highest number of hits in MCO (Fe), but only a few in MCO (Cu) (Table 7). This 
trend suggests that Lys-549 and Lys-97 are preferential binding sites for copper and iron, 
respectively. The reason behind the preference for Lys-549 with copper is not clear but it is a 
unique microenvironment with a narrow channel. Lys-490 also has numerous hits with MCO 
(Cu) and is located near two histidines including one that is known to bind metals. (Figure 50) 
In the HOCl oxidation, the majority of the lysine residues on the surface were modified 
except for Lys-117, Lys-219, Lys-286, Lys-375, Lys-396, Lys-524, and Lys-581. When looking 
at the search results, the peptides carrying the Lys-117, Lys-286, Lys-375, and Lys-396 sites 
were not covered in the sequence and therefore are unlikely to be identified as modification sites. 
As a result, the greater majority of highly exposed and detected lysines were modified. 
It is surprising that ubiquitin displays a single modification, particularly at an arginine 
site. Out of ten possible sites (7 lysines and 3 arginines) only Arg-54 is identified as a 
modification site. One would expect that relatively small and highly exposed ubiquitin should 
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show less selectivity toward the MCO conditions. However, oxidation may not stop at 
carbonylation and go further in this small protein. It is known that excessive oxidation results in 
different oxidative modifications including cross-linking and cyclization. These modifications 
are highly variable, are not included in our search routine, and would not be detected. Based on 
these initial results, we did not further pursue ubiquitin oxidation. 
CONCLUSION  
 
In this study, specific carbonyl modification sites in HSA and ubiquitin subjected to 
HOCl and MCO were identified. HSA oxidized with HOCl resulted in 13 modification sites. The 
MCO (Cu) condition resulted in 9 modifications whereas the MCO (Fe) condition gave rise to 10 
modification sites. Each of these sites is close to residues that could bind a metal ion. Figure 51 
shows the number of sites that have been identified with the three different conditions. There are 
only two sites that are identified in both HOCl and MCO conditions, showing that these 
processes are fundamentally different in nature. There are 5 sites that have been identified with 
both MCO condition, suggesting that there are some similarities between the two oxidation 
mechanisms; however, each of the MCO conditions had a number of unique sites. Overall, 
Figure 51 shows a remarkably high level of selectivity in these processes. The previous acrolein 
data also support high selectivity. Three of the five major lysine modification sites with acrolein 
(Chapter 2) are on residues not modified by MCO. These results indicate that metal-binding 
must play a role in directing MCO and that different patterns emerge with free, molecular 





Figure 45: Number of sites that have been identified with three different conditions 
 
This study contributes to our understanding how different oxidizers would result in a 
different oxidation patterns. This is consistent with our hypothesis that oxidation patterns are 
potential biomarkers for the active species in oxidative stress. In order to understand the 
mechanism of the selective oxidation and the structural motifs that are prone to carbonylation, 









CHAPTER 4: Quantification of Mitochondrial Protein Changes in Response 




Mitochondria are involved in many cellular processes including energy production, and 
signaling pathways, each of which is very crucial for cell homeostasis.294 Mitochondria have 
multiple copies in a cell and a highly-folded inner-membrane that contains the respiratory chain 
components that generate the proton gradient necessary to drive ATP synthesis. Mitochondria 
can be divided into four compartments: the inner membrane, outer membrane, inter membrane 
space and the matrix. Mitochondria uniquely have their own DNA (mtDNA). Out of 37 genes in 
mtDNA, 13 are translated into proteins that are localized in the inner mitochondrial membrane as 
part of oxidative phosphorylation enzymes (Complex I, III, IV and V).295 The main role of 
mitochondria is ATP synthesis. This is achieved by the sequential transfer of electrons from 
succinate, NADH and other electron rich components to molecular oxygen in a four electron 
reduction to water. Interestingly, mitochondria are also responsible for generating most cellular 
ROS. These ROS are thought to be toxic byproducts of respiratory metabolism.296 It is believed 
that approximately 1-2% of the oxygen consumed during the respiration is partially reduced to 
superoxide radicals, which can be converted to H2O2 and hydroxide radicals as shown in Figure 
52.297 The primary source of ROS in the Electron Transport Chain (ETC) is Complex III. One 
electron reduction of oxygen to superoxide radicals takes place at Complex I and III. Complex 
III produces superoxide radical by auto oxidation of ubisemiquinone formed through the Q cycle. 
Specifically, superoxide radicals can be produced at two sites, Q0 and Q1 within the Complex III. 
The second source of ROS generation in the mitochondria is Complex I, but the specific nature 
of the site and its contribution to ROS production remains unclear.298 While Complex III releases 
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the majority of the superoxide radicals into intermembrane space, Complex I releases the 
superoxide radicals into the matrix.299 Superoxide radicals can be dismuted to hydrogen peroxide 
by superoxide dismutases such as CuZnSOD or MnSOD. Once generated, hydrogen peroxide 
molecules move through the mitochondrial membrane to the cytosol. In the presence of 
glutathione peroxidase (GPX) or catalase, hydrogen peroxide molecules are converted into 
water.300 
 
Figure 46: The mitochondrial respiratory chain is located in the inner membrane IM) and 
composed of four membrane proteins complexes (Complex I-IV). NADH transfers an electron to 
Complex I (NADH-ubiquinone oxireductase). Succinate transfers an electron to Complex II 
(succinate dehydrogenase). Electrons move through CoQ (ubuquinone) to Complex III 
(ubiquinol-cytochrome c oxireductase) and then from Complex III to cytochrome c. Finally, 
electrons move from cytochrome c to Complex IV (cytochrome c oxireductase), which transfers 
four electrons to reduce molecular oxygen to water. 299 
 
During oxidative stress, ROS oxidizes surrounding biomolecules such as DNA, lipids, 
carbohydrates and proteins.301 Proteins are a main target for oxidation and can be oxidized in 
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many different ways.302 Protein carbonylation is believed to be a major form of protein oxidation 
and also a useful measure of protein oxidation.303 While some of these oxidations are reversible, 
others are not and can result in inactivation of the modified protein. Cells have multiple 
mechanisms for neutralizing ROS, repairing damage, or removing damaged proteins.304 When 
antioxidant capacity of the cell is unable to cope with oxidative stress, the amount of oxidized 
protein increases and this can result in cell death. Thus cells also have ways to minimize ROS 
production. For example, sod2 (superoxide dismutase 2) knock-down mice experience a decrease 
in the proteins in electron transport chain.305 And it is also reported that hypoxia can stop and 
reverse the toxic effect seen in sod2 knock-downs in drosophila.306 In fact, a general reaction to 
oxidative stress maybe to down-regulate the electron transport chain to slow the generation of 
ROS. Under some circumstances such as disease, pathogenic attack, or nutrient deficiency, ROS 
production increases. Understanding protein oxidation is critical for understanding the impact of 
oxidative stress. As a source of ROS, mitochondria themselves are vulnerable to oxidative 
damage.  
In order to test our hypotheses that a subset of mitochondrial proteins is susceptible to 
carbonylation and that a response to oxidative stress is down-regulation of the electron transport 
chain proteins, we have investigated mitochondrial proteins from wild-type Caenorhabditis 
elegans raised with and without paraquat exposure. The nematode Caenorhabditis elegans is an 
exceptional model for studying oxidative stress because it has a short life span, a small number 
of cells, a well-established database and the availability of a variety of mutants. C. elegans has 
been employed in many studies and has shown protein carbonyl formation under number of 
conditions including genetic modifications, and chemical oxidant systems.307-311 For example, a 
dose-dependent increase in the level of protein carbonylation has been observed in C elegans 
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treated with paraquat. Treatment of those C. elegans with anti-oxidants then reduced the 
carbonylation level by 30%.312 
C. elegans were raised according to standard protocols and harvested at five days. 
Mitochondria from age-matched groups were isolated.313 This part of the experiment was 
completed in Dr. Jill Bettinger’s lab at the MCV campus of Virginia Commonwealth University. 
From previous studies, it has been found out that 1 mL of nematode yields about 1 mg of 
mitochondrial protein. A five-day timeframe was preferred because of the high survival rate and 
moderate level of carbonyl formation at this point.314 
Oxidation was induced by treating C. elegans with paraquat (1, 1'-dimethyl-4, 4'-
bipyridylium dichloride). Scheme 5 shows how paraquat leads to the formation of superoxide. 
Stimulating oxidative stress by paraquat exposure is a very common technique314-316 L1 worms 
were taken into plates containing 0.1, 0.2, or 0.5 mM of paraquat and allowed to develop to 
adulthood as described by Ishii.308After that, adults were collected. It has been reported that these 










In order to provide a quantitative analysis of carbonylation levels, we have used the 
isobaric tags for relative and absolute quantitation (iTRAQ) technique. Although LC-MS/MS 
analysis has been used for the identification of modification sites in the proteins from complexes 
and cell lysates (qualitative proteomics), until recently the quantitative study of gene expression 
was limited to 2-D gel analyses. On the other hand, an alternative to gel based approach was to 
use of isotope coded affinity tags (ICAT) for quantitative study of gene expression at the 
proteome level.  Recently, a more general approach, ITRAQ, has been developed. The ITRAQ 
method is based on chemically tagging the N-terminus of peptides produced from protein digests 
that have isolated from cells in two different states, such as control and paraquat-exposed in our 
case. The two, labeled samples are then combined, separated by LC, and analysed by tandem 
mass spectrometry. Database searching of the fragmentation data of the peptides allows for the  
identification of the labeled peptides and therefore the corresponding protein. Fragmentation of 
the label attached to peptides also produces a low molecular weight reporter ion that is unique to 
the tag used to label protein mixtures. Measuring the intensity of these reporter ions gives  
relative quantification of the peptides across each of the conditions.  
 In this method, the same amount of protein from native and paraquat-treated animals was 
incubated with biotin hydrazide, denatured with urea, reduced with DDT, and alkylated with 
IAA. After digestion, peptides were labeled with iTRAQ reagents. Once they are labeled with 
iTRAQ reagents, they are ready for LC/MS analysis. iTRAQ reagents are composed of a reporter 
group (based on N-methylpiperazine), a mass balance group (carbonyl), and a peptide-reactive 
group (NHS ester) as shown in Scheme 6. The total mass of reporter and balance components of 
the molecule are kept constant using different isotopes of 13C, 15N, and 18O atoms. Using heavy-
atom isotopes prevents problems that might stem from differential chromatographic separation of 
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deuterated compounds. Masses of the reporter groups range from m/z 114 to 117, while the 
balance group ranges from 28 to 31 Da, so that the total mass remains constant (145 Da) for each 


















Scheme 6: iTRAQ reagent. 
The iTRAQ reagent reacts with a peptide to form an amide linkage with the N-terminus 
or an amino group of lysine. When a doubly or triply-charged iTRAQ-labeled peptide fragments, 
it tends to produce a mixture of b and y ions for sequence identification as well as an a1 ion (the 
piperazine unit), which represents the reporter group. After fragmentation the charge remains in 
the reporter ion and the balance group is lost as a neutral. Four distinct masses stemming from 
the reporter groups appear in the mass spectrum (114–117 Da). The relative intensities of the 
four peaks give the relative concentration of peptides from up to 4 different conditions (Scheme 
7). Tandem mass tag (TMT) is a related technology that also involves isobaric tags. It was used 
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Scheme 7: Labeling with iTRAQ reagents. 
 
METHODS AND MATERIALS  
 
MATERIALS  
Mitochondria samples isolated from C. elegans were prepared by Dr. Jill Bettinger’s lab. 
Extended-chain biotin, SDS, MES buffer, NaBH3CN, IAM, DTT, and PBS buffer were 
purchased from Sigma-Aldrich (St. Louis, MO). The Oxyblot protein oxidation detection kit was 
purchased from Milipore (Billerica, MA). Laemmli loading buffer was obtained from Bio-Rad 
(Hercules, CA). The enhanced chemiluminescence detection kit was purchased from GE 
Healthcare (Pittsburgh, PA). The iTRAQ protein quantification kit was purchased from Applied 
Biosystems (Foster City, CA). Sequencing-grade, modified trypsin was purchased from Promega 
(Madison, WI). Streptavidin beads and the BCA protein assay kit were purchased from Thermo 
Scientific (Rockford, IL). The MCX solid phase extraction columns and Sep-Pak C-18 column 





OXYBLOT ANALYSIS  
Both control and paraquat exposed mitochondrial proteins isolated from C. elegans were 
quantified using the Oxyblot kit according to the manufacturer’s protocol. Both the control and 
paraquat samples (10 μg) were denatured by 12 % SDS to a final concentration to 6% SDS. 
Denatured proteins were derivatized by adding 10 μl of the DNPH solution provided in the kit 
and incubated for 15 min. at room temperature. The control and paraquat samples were 
neutralized by adding 7.5 μl of neutralization solution. After reduction with 2 μl of β-
mercaptoethanol, they were loaded on a 4-20% gradient polyacrylamide gel. The gel was run at 
120 V for an hour. The separated proteins were transferred onto a polyvinylidene difluoride 
(PVDF) membrane by electroblotting. Membranes were blocked in a buffer (50 mM Tris-HCl, 
154 mM NaCl, 0.1% Tween-20, (pH 7.5) containing 5% nonfat dry milk for 1 hour, and 
incubated with a rabbit anti-DNP antibody (1:150) for 1 hour at room temperature. The 
secondary antibody incubation was performed using a horseradish peroxidase (HRP)–conjugated 
anti-rabbit IgG (1:300) for 1 hour at room temperature. The immunoreactivity was visualized by 
enhanced chemiluminescence using commercial reagents (GE Healthcare, Piscataway, NJ). The 
kit used for the oxyblot analysis is sensitive enough to detect femtomole-level amounts of 
dinitrophenyl residues. Treatment of samples with a 2 M HCl solution was used as a negative 






BIOTINYLATION OF PROTEIN CARBONYLS 
Mitochondrial proteins isolated from C. elegans (both control and paraquat exposed) 
were incubated with extended-chain biotin hydrazide at a concentration of 5mM for 1 hour at 
room temperature. First, the mitochondrial membrane was disrupted with SDS at a final 
concentration of 2% while vortexing at room temperature. After centrifugation at 12800 g, the 
insoluble part was discarded and the supernatant was diluted with MES buffer (50 mM, pH 5.5). 
At this point the extended-chain biotin hydrazide was added from a 50 mM stock solution to give 
a final concentration of 5 mM for the second time. The subsequent mixture was incubated for 2 
hours at room temperature with gentle shaking. The hydrazone was stabilized by adding 
NaBH3CN to a final concentration of a 15 mM and incubated at room temperature for an hour. In 
order to prepare for the enrichment protocol, the control and paraquat samples were washed with 
PBS buffer (pH 7.4) using a Microcon filter (3kDa molecular weight cutoff). Protein 
concentrations were determined using a BCA protein assay kit. 
ENRICHMENT OF BIOTINYLATED PROTEINS  
After labeling, biotinylated proteins were enriched using streptavidin beads. The 
enrichment was done according to the manufacturer’s protocol with a slight adjustment. Briefly, 
the same quantity of biotinylated control and paraquat samples (~100 μg) were incubated with 
pre-equilibrated streptavidin beads for an hour at room temperature. The slurry was separated 
using Microcon filters at 4000 g for 2 min. Since the pore size of the filter is smaller than the 
diameter of the beads, all of the non-bound proteins were removed in this process. The 
streptavidin-bound proteins were washed three times with 0.1% SDS in PBS buffer (pH 7.4). 
After that, streptavidin-bound proteins were digested with trypsin.  
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ENZYMATIC DIGESTION  
Streptavidin-bound proteins were resuspended with 6 M urea in 50 mM ammonium 
bicarbonate buffer (pH 8.5). After that, they were reduced with 20 mM dithiothreitol at 37 °C for 
60 min and alkylated with 30 mM iodoacetamide at room temperature for 60 min in the dark. 
The excess of dithiothreitol and iodoacetamide were removed using a Microcon filter (0.22 μm 
pore size) at 4000 g for 2 min. The proteins were washed and redissolved in 50 mM ammonium 
bicarbonate. 100 mM calcium chloride (aq) was added to each tube to bring the Ca2+ 
concentration to circa 1 mM. The samples were digested with trypsin (substrate/enzyme ratio of 
40/1, wt/wt) at 37 °C for 24 h. Digestion was repeated by adding trypsin and incubating for 
second day. Tryptic peptides were collected using Microcon filter (0.22 μm pore size) at 4000 g 
for 2 min. This part was TMT labeled and quantified. Second part, which is streptavidin-bound 
peptides were eluted using 0.1 M glycine (pH 2.8) and were analyzed for identification of the 
modification site. 
iTRAQ LABELING 
The iTRAQ labeling was done according to the manufacturer’s protocol as shown in 
Figure 53. The enriched peptide mixtures of control and paraquat were desalted using MCX 




Figure 47: iTRAQ labeling of control and paraquat exposed proteins. 
 
The dried peptide mixtures of control and paraquat samples were then redissolved in 30μl 
of iTRAQ dissolution buffer. Two of the iTRAQ reagents were chosen for analysis, either 114 
with 116 or 115 with 117. They were dissolved in 70 μl of ethanol separately. Subsequent 
aliquots were added to peptide samples. The resulting solutions were incubated at room 
temperature for 2 hours with gentle shaking. The control and paraquat sample solutions were 
combined and the excess amounts of reagents were removed with Sep-Pak C-18 columns. The 
solution of the labeled control and paraquat sample peptides were dried with a Speed-Vac and 
resuspended in 0.1 % FA for LC-MS/MS analysis. 
TANDEM MASS TAG (TMT) LABELING 
TMT labeling was done according to the manufacturer’s protocol. Briefly, both the 
control and paraquat sample were digested and cleaned up using MCX columns. Both the control 
and paraquat samples were dried in a Sped-Vac and then resuspended in 30 μl of 100 mM TEAB 
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(triethyl ammonium bicarbonate) buffer. TMT labels were dissolved in 41μl of acetonitrile. The 
control was treated with TMT-127 and the paraquat sample was treated with TMT-126 labels 
and incubated for one hour at room temperature. Next, the mixture was quenched with 5% 
hydroxylamine by incubating at room temperature for 15 min. Excess amounts of the reagents 
were cleaned up using Sep-pak (C-18) columns. Finally, mixture was dried in a Sped-Vac and 
redissolved in 0.1 %TFA for LC-MS/MS analysis. 
LC-MS/MS ANALYSIS  
Identification of Carbonylated Proteins 
Liquid chromatography/electrospray ionization-tandem mass spectrometry (LC/ESI-
MS/MS) analysis of both the control and paraquat sample (300 pmol/injection) were performed 
using a capillary HPLC system (ThermoFinnigan, San Jose, CA) connected to an LTQ ion trap 
mass spectrometer (ThermoFinnigan, San Jose, CA) with a nanospray source. Tryptic peptides 
were separated by reverse-phase chromatography on a C18 column (C18 Thermo, 5μm particle 
size, 300Å, 100x0.18 mm) with a split flow system. The split is approximately 100:1 with a 
master flow rate of 50 μl/min (~0.5 μl/min in the analytical column). The digested peptides were 
eluted from the column using two mobile phases, A (0.1% formic acid in water) and B (0.1% 
formic acid in methanol). The gradient started from 2% B, then increased to 15% B over 15 min, 
then increased to 80% B over 70 min, and finally increased to 95% B over 25 min. The eluted 
peptides (singly, doubly, or triply-charged ions) were analyzed using a data-dependent scan 
procedure. To exclude the redundant processing of a few dominant ions in the MS/MS analyses, 
a dynamic exclusion feature was used that only allows a particular m/z value to be processed 
twice in a 2 min time window.  
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iTRAQ and TMT Quantification  
Analyses of iTRAQ and TMT labeled samples were done using Thermo LTQ Orbitrap 
Velos mass spectrometer coupled to a 2-D HPLC system. 1 µL of the iTRAQ and TMT labeled 
solution was injected and the peptides which were not trapped on the strong cation exchange 
(SCX) column were eluted from the column by an acetonitrile/0.1 M formic acid gradient at a 
flow rate of 0.4 µL/min over 60 minutes. At first, the labeled peptides were separated using SCX 
by increasing the concentration of ammonium acetate from 1mM to 1M. Then, the flowthrough 
eight ion exchange fractions were eluted onto the C18 column for further separation by reverse 
phase liquid chromatography. Each ion exchange fraction was analyzed with by an 
acetonitrile/0.1 M formic acid gradient at a flow rate of 0.4 µL/min over 60 minutes.  The 
nanospray ion source was operated at 3.5 kV. The digests were analyzed using the double-play 
capability of the instrument which acquires a full scan mass spectra to determine peptide 
molecular weights and then product ion spectra to determine amino acid sequence in sequential 
scans. A full scan in the range of 300-2000 m/z was performed to get precursor ions, followed by 
ten data-dependent high energy collision dissociation (HCD) MS/MS scans for the most 
abundant precursor ions in the full scan. This mode of analysis produces approximately 100000 
CAD spectra per ion exchange fraction of ions ranging in abundance over several orders of 
magnitude. To exclude the redundant processing of a few dominant ions in the MS/MS analyses, 
a dynamic exclusion feature was used that only allows a particular m/z value to be processed 






Peptide sequences and modifications were identified using Bioworks implementation of 
Sequest (Thermo). The C. elegans proteome database was downloaded from www.wormbase.org. 
Only fully tryptic peptides were considered and up to three missed cleavage sites were allowed. 
Precursor ion mass tolerances were 0.8 Da for the linear ion trap and 15 ppm for the Orbitrap 
measurements. Static mass shifts were applied for carboxyamidomethylated cysteines (+57). 
Dynamic mass shifts were incorporated for extended-chain biotin hyrazide labeled carbonylation 
at lysine (+354), arginine (+312), and proline (+371), as well as methionine oxidation (+16). A 
maximum of four variable modifications were permitted for each peptide. For iTRAQ labeled 
peptides, a static mass shift of +144 Da was added to the peptide N-terminus and lysine residues. 
For TMT labeled peptides, static mass shifts of +225 Da were added to the peptide N-terminus 
and all lysine residues. Sequest results were refined using Scaffold 3 software. 
RESULTS  
 
C. elegans were raised according to standard protocols and mitochondria from age-
matched groups were isolated in the Bettinger lab at MCV. Oxidation was induced by treating C. 
elegans with paraquat, which is a common method for stimulating oxidative stress. Worms were 
taken into plates containing 0.1 mM of paraquat and allowed to develop into adulthood. Adults 
were collected and mitochondrial proteins were isolated via differential centrifugation. Three 
types of analyses were completed (1) Protein carbonyl content for the control and paraquat 
samples was analyzed using an Oxyblot kit. (2) Relative protein levels in both the control and 
paraquat samples were quantified with an iTRAQ quantification scheme. (3), Carbonylated 
proteins were labeled with extended-chain biotin and enriched using streptavidin resin. After the 
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digestion of proteins bound to the resin, the peptides that were released from the resin were 
quantified with a TMT quantification kit.  
OXYBLOT ANALYSIS  
Both control and paraquat exposed mitochondrial proteins isolated from C. elegans were 
quantified using an Oxyblot kit. Carbonyl groups from oxidized amino acid residues are 
derivatized with DNPH and then detected using anti-DNP in conjunction with a secondary 
antibody. Even though it’s a rough measure of oxidation, it is a simple and common way of 
investigating the extent of oxidation. Western blots showed positive blotting for both control and 
paraquat-exposed samples. The signal in paraquat-exposed proteins is higher than the control 
confirming that paraquat exposure induces protein carbonylation. 
iTRAQ QUANTIFICATION 
The program Scaffold 3 was used to quantify iTRAQ-labeled peptides and identify 
proteins and peptides.318,319 Peptide identifications were accepted if they could be established at 
greater than 95.0% probability as specified by the Peptide Prophet scheme. Protein 
identifications were accepted if they could be established at greater than 99.0% probability by 
Protein Prophet and contained at least 2 identified peptides. Proteins that contained similar 
peptides and could not be differentiated based on MS/MS analysis alone were grouped to satisfy 
the principles of parsimony. In the first set, 124 proteins were identified from three different set 
of control and paraquat-exposed samples when applying criteria to give a 0.1% false discovery 




Figure 48: 124 proteins were identified in the first set of samples with a 0.1% false discovery 
rate. There were a total of 6262 spectra 
 
Peptides were quantified using the centroided reporter ion peak intensity. Intra-sample 
channels were normalized based on the median ratio for each channel across all proteins. 
Multiple isobaric tag samples were normalized by comparing the median protein ratios for the 
reference channel. Protein quantitative values were derived from only uniquely assigned 
peptides. The minimum quantitative value for each spectrum was calculated as the 5.0% percent 
of the highest peak.  Protein quantitative ratios were calculated as the median of all peptide 
ratios. Dispersion of the measurements were calculated as the interquartile range around the 
median. Quantitative ratios were Log₂ normalized for final quantitative testing. Figure 55 shows 







Figure 49: Sample MS/MS spectrum to illustrate iTRAQ labeling and reporter ions. Upper panel 
is full CID spectrum and lower panel is expansion of reporter region. 
 
In the second set, there were 170 proteins that were identified from three different set of 
control and paraquat-exposed samples when applying a criteria to give a 0.1% false discovery 





Figure 50: 170 proteins were identified from three different set of control and paraquat-exposed 
samples with a 0.1% false discovery rate. There were a total of 8156 spectra. 
 
After refining the protocols, 434 proteins were identified from three different set of 
control and paraquat-exposed samples when applying criteria to give a 0.1% false discovery rate 
out of 8564 spectra (Figure 57). Because the third set was viewed as the highest quality data 
with by far the greatest number of protein identifications, it was used for further analysis of 
protein levels. The histogram in Figure 58 plots the number of proteins vs. their log2 fold 
changes for proteins under control and paraquat conditions. In general, most proteins did not 
show a large variation in concentration when the animals were treated with paraquat. Ratios over 





Figure 51: 434 proteins were identified from three different set of control and paraquat-exposed 
samples with a 0.1% false discovery rate. There were a total of 8564 spectra. 
 
 
     Log2 fold change 
Figure 52: Number of proteins vs. log2 fold changes for mitochondrial proteins in the third set 
of control and paraquat-exposed samples. 
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Table 9 shows the proteins that were identified in at least 2 samples in the third set and 
their ratios (Paraquat-exposed/Control). The other of proteins can be seen in Appendix C.  
 








CE00078 WBGene00004433 locus:rpl‐21 Ribosomal protein L21   N/A  1.07  1.00 
CE00209 WBGene00010130 locus:vha‐14 Membrane‐associated 
atpase gamma chain   N/A  1.23  1.07 
CE00480 WBGene00011867 locus:chc‐1 Clathrin heavy chain   1.23  1.62  1.15 
CE00664 WBGene00004470 locus:rps‐1 Ribosomal protein S3a 
(human) homolog  N/A  0.81  0.87 
CE00744 WBGene00004417 locus:rpl‐6 Ribosomal protein ML16   1.32  N/A  0.87 
CE00778 WBGene00004435 locus:rpl‐23   1.41  1.41  0.93 
CE00821 WBGene00004483 locus:rps‐14 Ribosomal protein S14   0.93  N/A  0.93 
CE00839 WBGene00000479 locus:cgh‐1 ATP‐dependent RNA 
helicase   N/A  1.32  0.87 
CE00821 WBGene00004483 locus:rps‐14 Ribosomal protein S14   0.93  N/A  0.93 
CE01030 WBGene00004428 locus:rpl‐16 L13P family ribosomal 
protein   N/A  0.93  0.87 
CE01217 WBGene00017125 locus:acdh‐12 Isovaleryl‐CoA 
dehydrogenase   1.23  N/A  1.07 
CE01225 WBGene00017166 locus:aldo‐2 Fructose‐biphosphate 
aldolase   N/A  1.52  1.15 
CE01236 WBGene00003371 locus:mlc‐3   1.15  N/A  1.23 
CE01270 WBGene00001168 locus:eef‐1A.1 Elongation factor 1‐
alpha   1.15  0.71  0.87 
CE01341 WBGene00002083 locus:inf‐1   1.62  1.15  1.07 
CE01380 WBGene00004420 locus:rpl‐9 Ribosomal protein L9   1.62  0.87  0.87 
CE01543 WBGene00004421 locus:rpl‐10 ribosomal protein L10 (QM 
protein)   N/A  0.71  0.87 
CE01810 WBGene00004472 locus:rps‐3 Ribosomal protein S3   N/A  0.81  0.93 
CE01921 WBGene00006727 locus:ubq‐1   1.00  N/A  0.87 
CE01976 WBGene00019061 ATP synthase   1.23  N/A  1.00 
CE02163 WBGene00002267 locus:lec‐4 galactoside binding lectin   N/A  1.32  1.07 
CE02183 WBGene00000114 locus:alh‐8 methylmalonate‐
semialdehyde dehydrogenase   1.41  1.15  1.23 
CE02255 WBGene00004416 locus:rpl‐5 60S ribosomal protein L5   N/A  0.93  0.87 
CE02622 WBGene00002054 locus:ifb‐2 Intermediate filament 
protein   N/A  0.81  0.47 




CE03252 WBGene00001920 locus:his‐46 histone H4   1.00  1.07  1.00 
CE03278 WBGene00004440 locus:rpl‐26 ribosomal protein L26 like   2.00  1.00  1.00 
CE03389 WBGene00001502 locus:ftt‐2 14‐3‐3 protein   N/A  0.71  1.00 
CE03436 WBGene00010317 locus:idh‐1 isocitrate dehydrogenase 1  N/A  0.76  1.15 
CE03684 WBGene00011884 locus:enol‐1 enolase   N/A  1.07  1.23 
CE03921 WBGene00006929 locus:vit‐5   N/A  0.93  0.71 
CE03972 WBGene00003963 locus:pdi‐2 protein disulfide isomerase   0.93  N/A  0.81 
CE04001 WBGene00015803   1.15  N/A  1.07 
CE04187 WBGene00016558 polyketide synthase   N/A  0.71  1.07 
CE04237 WBGene00004471 locus:rps‐2   1.41  0.87  1.00 
CE04424 WBGene00006921 locus:vha‐12 vacuolar ATP synthase 
(strong)   N/A  0.93  1.00 
CE04501 WBGene00001921 locus:his‐47 histone H2A   N/A  1.62  1.00 
CE04561 WBGene00004477 locus:rps‐8 40S ribosomal protein S8   N/A  0.81  0.93 
CE05165 WBGene00001922 locus:his‐48 histone H2B   0.93  1.00  N/A 
CE05441 WBGene00000915 locus:daf‐21 heat shock protein 
(HSP90)   0.93  1.00  0.81 
CE05598 WBGene00004414 locus:rpl‐3 60S ribosomal protein L3   N/A  1.07  0.81 
CE05656 WBGene00008920 locus:eef‐1G elongation factor 1‐
gamma   1.41  N/A  1.00 
CE05747 WBGene00004492 locus:rps‐23 ribosomal protein S23   N/A  1.00  0.93 
CE05849 WBGene00004478 locus:rps‐9 ribosomal protein S9   N/A  0.62  1.00 
CE05860 WBGene00004480 locus:rps‐11 ribosomal protein S11   1.32  N/A  1.00 
CE06050 WBGene00010470 locus:cdr‐4 glutathione S‐transferase   N/A  1.87  1.32 
CE06090 WBGene00010556 locus:rack‐1 guanine nucleotide‐
binding protein   N/A  1.00  0.87 
CE06114 WBGene00010627 yeast protein L8167.9‐like   1.23  0.93  1.07 
CE06253 WBGene00002348 locus:myo‐1 myosin heavy chain   1.15  1.15  1.00 
CE06313 WBGene00004442 locus:rpl‐28 ribsomal protein L28 like   1.15  N/A  0.87 
CE06360 WBGene00004474 locus:rps‐5 40S ribosomal protein S5   N/A  0.81  0.87 
CE06362 WBGene00011480 endoplasmin precursor (GRP94)   N/A  1.00  0.93 
CE06577 WBGene00004476 locus:rps‐7 40S ribosomal protein S7   N/A  1.15  1.00 
CE06652 WBGene00014095 glutamate dehydrogenase   N/A  1.07  1.07 
CE06950 WBGene00006926 locus:vit‐2 vitellogenin   1.00  1.23  0.87 
CE06974 WBGene00000210 locus:asg‐2 ATP synthase   N/A  0.93  1.00 
CE07373 WBGene00004951 locus:spc‐1 spectrin alpha chain   N/A  1.00  0.87 
CE07426 WBGene00019947 locus:htz‐1 histone H2A variant   0.93  1.00  N/A 
CE07537 WBGene00020808 calponin‐like protein   1.00  1.15  1.07 
CE07669 WBGene00004415 locus:rpl‐4 ribosomal protein L1   1.41  0.71  0.93 




CE08034 WBGene00004431 locus:rpl‐19 60S ribosomal protein L19   N/A  0.81  0.87 
CE08177 WBGene00002007 locus:hsp‐3 heat shock protein   1.07  N/A  0.87 
CE08258 WBGene00007646 locus:nkb‐1 sodium\/potassium 
transporting ATPase beta chain   1.15  N/A  1.00 
CE08526 WBGene00004425 locus:rpl‐13 ribosomal protein L13   N/A  1.07  0.87 
CE08852 WBGene00008205 locus:sams‐1 s‐adenosylmethionine 
synthetase   N/A  0.76  0.87 
CE09015 WBGene00016943 locus:acdh‐1 acyl‐CoA   1.74  1.23  1.23 
CE09047 WBGene00004436 locus:rpl‐24.1 60S ribosomal protein 
L24   N/A  0.62  0.93 
CE09163 WBGene00008506 locus:tkt‐1 transketolase  N/A  0.81  1.23 
CE09197 WBGene00006754 locus:unc‐15 paramyosin   1.00  0.87  1.07 
CE09349 WBGene00006789 locus:unc‐54 myosin heavy chain   0.93  1.07  1.07 
CE09650 WBGene00009119 locus:ndk‐1 nucleoside diphosphate 
kinase   N/A  0.81  0.93 
CE09655 WBGene00004408 locus:rla‐0 deoxyribonuclease   1.32  1.00  0.81 
CE09682 WBGene00002005 locus:hsp‐1 HSP‐1 heat shock 70kd 
protein A   1.23  0.93  1.07 
CE09693 WBGene00000371 locus:cco‐1 cytochrome C oxidase   N/A  0.93  1.07 
CE09719 WBGene00000230 locus:atp‐3 ATPase   1.07  1.15  1.07 
CE09866 WBGene00017982 locus:hpo‐18 ATP synthase epsilion 
chain   1.00  N/A  1.15 
CE09945 WBGene00004484 locus:rps‐15 40S ribosomal protein S15   N/A  0.47  0.93 
CE09946 WBGene00009454   1.23  N/A  1.07 
CE10878 WBGene00009952 Thiolases   N/A  1.15  1.32 
CE11024 WBGene00004418 locus:rpl‐7 ribosomal protein   N/A  0.93  0.93 
CE11226 WBGene00018963 locus:ucr‐1 Mitochondrial processing 
protease enhancing protein   N/A  1.00  1.07 
CE11342 WBGene00001581 locus:gfi‐1   1.23  0.87  1.07 
CE11570 WBGene00003964 locus:pdi‐3 protein disulphide 
isomerase ER‐60 precursor like   1.52  1.00  0.93 
CE12148 WBGene00004427 locus:rpl‐15 60S ribosomal protein L15   N/A  0.62  0.87 
CE12358 WBGene00000066 locus:act‐4 actin   0.93  1.07  N/A 
CE12918 WBGene00004485 locus:rps‐16 40S ribosomal protein S16   N/A  1.00  1.00 
CE12920 WBGene00001423 locus:fib‐1 fibrillarin   1.00  1.32  0.93 
CE13431 WBGene00020347 3‐hydroxyacyl‐CoA dehydrogenase   1.23  0.87  1.15 
CE14263 WBGene00006439 locus:ant‐1.1 ADP\/ATP carrier protein   1.07  0.81  1.07 
CE15028 WBGene00006787 locus:unc‐52 UNC‐52 membrane 
proteoglycan   1.15  0.87  N/A 
CE15602 WBGene00007385 locus:atp‐5 ATP synthase D chain   1.07  1.07  1.07 
CE15746 WBGene00003052 locus:lmn‐1 Intermediate filament 




(contains ATP\/GTP binding P‐loop)   1.07  0.81  0.93 
CE16194 WBGene00004302 locus:ran‐1 GTP‐binding protein   N/A  1.23  1.32 
CE16308 WBGene00011156 RNA recognition motif. (aka RRM, RBD, 
or RNP domain)   N/A  0.87  1.07 
CE16463 WBGene00000067 locus:act‐5 Actins   1.15  1.23  1.23 
CE16576 WBGene00002264 locus:lec‐1 galectin   1.00  1.00  1.07 
CE16650 WBGene00004430 locus:rpl‐18 Eukaryotic ribosomal 
protein L18   1.23  1.07  0.93 
CE16905 WBGene00004266 locus:rab‐1 RAS‐related protein   1.23  N/A  1.00 
CE17071 WBGene00002162 locus:isp‐1 ubiquinol‐cytochrome C 
reductase   1.07  1.15  1.15 
CE17154 WBGene00019322 locus:ahcy‐1 S‐adenosylhomocysteine 
hydrolase   N/A  0.62  1.07 
CE17563 WBGene00006529 locus:tba‐2 Tubulin   0.81  1.00  1.00 
CE17720 WBGene00017926 protein_id:AAC19190.1  N/A  1.15  1.07 
CE17730 WBGene00000881 locus:cyn‐5 cyclophillin   N/A  0.76  0.87 
CE17986 WBGene00004424 locus:rpl‐12 Ribosomal protein L11   N/A  1.07  0.87 
CE18478 WBGene00004413 locus:rpl‐2 Ribosomal Proteins L2   N/A  0.62  1.00 
CE18676 WBGene00009688   2.30  1.15  1.23 
CE18826 WBGene00010419 ATP synthase alpha and beta subunits, 
ATP synthase Alpha chain, C terminal   1.15  1.15  1.00 
CE18884 WBGene00004736 locus:sca‐1 E1‐E2 ATPases   1.07  0.81  0.93 
CE19904 WBGene00004496 locus:rps‐27 ribosomal protein   1.62  1.52  1.00 
CE20171 WBGene00012354   1.07  N/A  0.93 
CE20371 WBGene00000883 locus:cyn‐7 Peptidyl‐prolyl cis‐trans 
isomerases   N/A  0.76  1.07 
CE20658 WBGene00006819 locus:unc‐87 calponin   1.07  1.00  1.23 
CE21392 WBGene00004432 locus:rpl‐20 ribosomal protein   1.62  0.87  1.00 
CE21418 WBGene00003989 locus:pfn‐1 Profilins   0.87  N/A  0.87 
CE21562 WBGene00000802 locus:crt‐1 calreticulin precursor   1.74  1.00  0.93 
CE21842 WBGene00004497 locus:rps‐28   N/A  0.81  0.76 
CE22117 WBGene00004456 locus:rpl‐43   1.62  N/A  0.93 
CE22195 WBGene00004429 locus:rpl‐17   N/A  1.07  0.93 
CE22210 WBGene00013025 locus:vha‐13 ATP synthase alpha and 
beta subunits \; ATP synthase ab C terminal   N/A  0.76  1.00 
CE22939 WBGene00022170   N/A  1.00  1.15 
CE23521 WBGene00001564 locus:icl‐1 isocitrate lyase   N/A  1.74  1.87 
CE23530 WBGene00007463 high‐density lipoprotein‐binding 
protein   1.15  1.00  0.93 
CE24222 WBGene00012608 Iron‐containing alcohol 
dehydrogenases   N/A  1.41  1.23 
CE24278 WBGene00004473 locus:rps‐4   1.87  0.93  0.87 
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CE24592 WBGene00004475 locus:rps‐6 40S ribosomal protein S6   N/A  0.93  0.87 
CE24743 WBGene00002266 locus:lec‐3 galactoside‐binding lectin   N/A  1.32  0.87 
CE25005 WBGene00000041 locus:aco‐2 Aconitate hydratase   N/A  1.32  1.23 
CE25552 WBGene00004412 locus:rpl‐1   N/A  1.15  0.87 
CE26244 WBGene00022122 locus:trap‐1   N/A  0.71  0.87 
CE26774 WBGene00021350   N/A  0.81  0.81 
CE26775 WBGene00004014 locus:phb‐1   N/A  1.32  0.87 
CE26817 WBGene00006928 locus:vit‐4   0.81  0.38  0.57 
CE27244 WBGene00002025 locus:hsp‐60   1.74  N/A  1.23 
CE27398 WBGene00004419 locus:rpl‐7A   1.41  1.15  0.93 
CE27514 WBGene00022089   N/A  1.07  1.07 
CE27706 WBGene00001000 locus:dim‐1   1.41  1.00  1.23 
CE27803 WBGene00007708 locus:nola‐3   1.15  1.07  N/A 
CE28594 WBGene00006930 locus:vit‐6 vitellogenin   1.07  N/A  0.93 
CE28782 WBGene00002978 locus:lev‐11   0.87  0.87  1.07 
CE29443 WBGene00019900 Channel Protein   1.23  1.07  1.15 
CE29684 WBGene00016258 locus:vha‐16 vaculolar ATPase   N/A  0.93  0.93 
CE29835 WBGene00004489 locus:rps‐20   N/A  1.15  0.87 
CE29950 WBGene00000229 locus:atp‐2 ATP synthase beta chain   1.15  1.00  1.07 
CE30779 WBGene00004490 locus:rps‐21 Ribosomal protein S21   N/A  0.93  0.93 
CE30781 WBGene00004450 locus:rpl‐36 Ribosomal protein YL39   N/A  0.54  0.93 
CE31619 WBGene00003514 locus:myo‐2 myosin heavy chain C   1.07  0.81  1.00 
CE32361 WBGene00006434 locus:prdx‐2   1.62  N/A  1.32 
CE32894 WBGene00002265 locus:lec‐2 galactoside‐binding lectin   0.93  1.41  1.07 
CE34269 WBGene00003369 locus:mlc‐1   0.76  1.15  1.00 
CE34936 WBGene00003515 locus:myo‐3 myosin heavy chain   1.00  1.15  1.15 
CE35878 WBGene00010015 locus:atad‐3 ATPases associated with 
various cellular activities (AAA)   1.52  1.23  1.23 
CE36725 WBGene00006436 locus:ttn‐1   N/A  2.14  1.15 
CE37112 WBGene00018519 arginine kinase   N/A  1.07  1.07 
CE40325 WBGene00008505   N/A  0.54  1.00 
CE42777 WBGene00009342 locus:fasn‐1 fatty acid synthase   1.52  0.93  1.00 
 
There were 24 mitochondrial proteins that were identified by at least two samples as 
listed in Table 10. A number of inferences can be drawn from the data. First, the mitochondrial 
enrichment is not very effective and many other proteins are present in the samples. Second, the 
paraquat treatment had very little impact on the protein levels. Most had ratios close to 1 and 
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there was no solid evidence of any mitochondrial proteins differing in a statistically significant 
manner from a ratio of 1. 









dehydrogenase   1.23  N/A  1.07 
CE01225 WBGene00017166 locus:aldo‐2 Fructose‐biphosphate 
aldolase   N/A  1.52  1.15 
CE01976 WBGene00019061 ATP synthase   1.23  N/A  1.00 
CE02183 WBGene00000114 locus:alh‐8 methylmalonate‐
semialdehyde dehydrogenase   1.41  1.15  1.23 
CE06652 WBGene00014095 glutamate dehydrogenase   N/A  1.07  1.07 
CE06974 WBGene00000210 locus:asg‐2 ATP synthase   N/A  0.93  1.00 
CE09015 WBGene00016943 locus:acdh‐1 acyl‐CoA   1.74  1.23  1.23 
CE09650 WBGene00009119 locus:ndk‐1 nucleoside diphosphate 
kinase   N/A  0.81  0.93 
CE09693 WBGene00000371 locus:cco‐1 cytochrome C oxidase   N/A  0.93  1.07 
CE09719 WBGene00000230 locus:atp‐3 ATPase   1.07  1.15  1.07 
CE11226 WBGene00018963 locus:ucr‐1 Mitochondrial processing 
protease enhancing protein   N/A  1.00  1.07 
CE13431 WBGene00020347 3‐hydroxyacyl‐CoA dehydrogenase   1.23  0.87  1.15 
CE14263 WBGene00006439 locus:ant‐1.1 ADP\/ATP carrier protein   1.07  0.81  1.07 
CE15602 WBGene00007385 locus:atp‐5 ATP synthase D chain   1.07  1.07  1.07 
CE17071 WBGene00002162 locus:isp‐1 ubiquinol‐cytochrome C 
reductase   1.07  1.15  1.15 
CE18826 WBGene00010419 ATP synthase alpha and beta subunits, 
ATP synthase Alpha chain, C terminal   1.15  1.15  1.00 
CE20171 WBGene00012354   1.07  N/A  0.93 
CE23521 WBGene00001564 locus:icl‐1 isocitrate lyase   N/A  1.74  1.87 
CE24222 WBGene00012608 Iron‐containing alcohol 
dehydrogenases   N/A  1.41  1.23 
CE25005 WBGene00000041 locus:aco‐2 Aconitate hydratase   N/A  1.32  1.23 
CE26775 WBGene00004014 locus:phb‐1   N/A  1.32  0.87 
CE29950 WBGene00000229 locus:atp‐2 ATP synthase beta chain   1.15  1.00  1.07 
CE35878 WBGene00010015 locus:atad‐3 ATPases associated with 
various cellular activities (AAA)   1.52  1.23  1.23 




TMT QUANTIFICATION OF STREPTAVIDIN ENRICHED MITOCHONDRIAL 
PROTEINS 
After biotinylation and streptavidin enrichment, mitochondrial proteins from C. elegans 
were quantified using a TMT analysis of the resulting peptides. The Scaffold program was used 
to validate MS/MS based peptide and protein identifications. Peptide identifications were 
accepted if they could be established at greater than 95.0% probability as specified by the 
Peptide Prophet algorithm. Protein identifications were accepted if they could be established at 
greater than 99.0% probability and contained at least 2 identified peptides. Protein probabilities 
were assigned by the Protein Prophet algorithm. Proteins that contained similar peptides and 
could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles 
of parsimony. Analysis of TMT labeled proteins resulted in the identification of 76 proteins 
using criteria of a 0.1 % false discovery rate. (Figure 59) There were 1525 spectra in the 
analysis. 
 





Table 11 and 12 list all of the proteins that gave TMT quantification data. The results do 
not meet expectations. If paraquat exposure increases the level of carbonylation, large ratios are 
anticipated because we are comparing to background oxidation and in the absence of 
carbonylation in the control, the ratio would go to infinity (instrument and chemical noise 
prevent such ratios). Here the ratios were clustered near 1, suggesting that the control and 
paraquat-treated samples are similar in terms of oxidation. The observed proteins may be due to 
oxidation (i.e., biotinylation and trapped on the streptavidin) or non-specific binding of non-
oxidized proteins on a streptavidin. It is difficult to distinguish between these possibilities, but it 
is clear that paraquat had limited impact on the oxidation levels of the proteins with this protocol. 













































































































































































































































































































































Our objective was to examine the effect of imposed oxidative stress on the carbonylation 
and relative levels of mitochondrial proteins in C. elegans. In the first part of the project, we 
investigated the oxidation level in paraquat-exposed samples as compared to controls using 
Oxyblot . The Oxyblot analysis suggested increased oxidation in the paraquat sample. Next, we 
looked into the impact of oxidative stress on the levels of mitochondrial proteins using iTRAQ 
quantification. After refining the protocols, a large number of proteins were identified, 434. Our 
hypothesis was that under paraquat-imposed oxidative stress, C. elegans would minimize the 
production of ROS by down-regulating the proteins that take part in the electron transport chain 
and up-regulating the proteins that scavenge ROS. When looking at the last set of samples in the 
iTRAQ quantification runs, they contained only 24 proteins that are annotated as mitochondrial 
in the worm database. There were only four mitochondrial proteins where the data suggested a 
possible significant change in protein level. These proteins are fructose-biphosphate aldolase 
(aldo-2, ratio: 1.52), acyl-CoA (acdh-1, ratio: 1.74), isocitrate lyase (icl-1, ratio: 1.87), and 
ATPases (atad-3, ratio: 1.52). Aldo-2, acdh-1, and icl-1 play role in Krebs cycle. Atad-1 takes 
part in complex I in mitochondria. As noted earlier, the statistical significance of these changes is 
marginal. The major result is that for a broad selection of proteins, the paraquat incubation seems 
to have had a modest effect on protein levels. Unlike previous work where the ETC appeared to 
be down-regulated,305 there seems to be little impact here. 
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Despite efforts to increase the number of identified proteins, only a small percentage of 
the proteins identified were from mitochondria. This is partially because the genome database 
does not provide annotations for many proteins and this makes it very difficult to identify the 
location of proteins. Nonetheless, it is clear that the centrifugation protocol used by the Bettinger 
lab led to many non-mitochondrial proteins. Related work in our group has revealed the same 
problem with Drosophila samples. Experience with those samples suggests that a better approach 
is to skip mitochondrial enrichment and analyze all the proteins using a more robust fractionation 
scheme before mass spectrometry. 
In the third phase of the project, we looked for oxidized proteins by tagging them with 
biotin hydrazide and using avidin products to enrich them. We have tried several methods to 
enrich the biotinylated proteins including monomeric avidin beads, streptavidin beads, and 
streptavidin resin. Only the streptavidin resin resulted in detectable signals in mass spectrometry 
for enriched and TMT-labeled peptides. Mitochondrial proteins from C. elegans under control 
and paraquat conditions were biotinylated, streptavidin enriched, digested on the resin, and TMT 
labeled. We have used TMT here because TMT is more cost effective than iTRAQ labels when 
quantifying only 2 samples. The analysis did not pinpoint proteins that are preferentially 
oxidized and suggested little difference between the control and paraquat-treated samples. An 
attempt was also made to identify specific medication sites. The streptavidin-bound peptides, 
which carry the biotin labels, are retained on the beads after digestion. Analysis of streptavidin-
bound peptides after elution from the resin did not result in identification of any oxidation sites. 






C. elegans was raised in standard and paraquat solutions. Mitochondrial proteins were 
isolated from C. elegans. The extent of oxidation was measured by Oxyblot analysis. Oxyblot 
analysis showed an increased level of oxidation. However, this was not reflected in the mass 
spectrometric approach aimed at identifying oxidized proteins. The oxyblot approach is very 
sensitive and changes in signal intensity might reflect very small changes in total carbonylated 
protein levels. There was also little change in protein levels in the mitochondria. Overall, the 
results suggest that the paraquat incubation is not leading to extreme oxidative stress despite 
killing the animals. The samples provided a good testing ground for analytical method 
development, but did not address the biological problem. 
FUTURE DIRECTION 
 
The objective of this project was to identify carbonylated proteins and examine the effect 
of paraquat-induced oxidative stress on the relative levels of mitochondrial proteins in C. 
elegans. The final goal was to identify modification sites by labeling them with a biotin reagent. 
When determining the relative protein levels in mitochondria, our methodology still needs some 
refinement to increase the percentage of mitochondrial proteins. A new fractionation method 
developed for Drosophila is promising. It limits pre-purification, which leads to much larger 
sample sizes and then uses 2-D LC to analyze all of the proteins. Its high efficiency leads to 
more hits for all proteins and increases the number of mitochondrial proteins significantly. The 
other analytical protocols developed here worked well, but the samples proved problematic. The 
paraquat-treated animals did not exhibit exceptional oxidative stress. A number of approaches 
are available to address this issue. One concern is that paraquat levels were too high and rapidly 
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killed individuals. The survivors which were analyzed were then a subset which had ingested 
limited amounts of paraquat. Moving to a protocol based on more chronic exposure could solve 
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MS/MS Spectra of Peptides Containing Cys-58, Lys-186, Lys-286, Lys-375, Lys-
549, Lys-569, His-91, His-170, and His-312.Label 1-5 
C-58 WITH LABEL 1  
RESIDUE #45-65 
PEPTIDE SEQUENCE: ALVLIAFAQYLQQC*PFEDHVK 
Page 1
DTA for scan: ZU023-A, 19900
Precursor ion: 911.29
Mass type: mono
Mod's: (C* +57.02150) (K# +298.40000) (C@ +298.40000) (H^ +298.40000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 A    72.04    55.02    54.03
 L   185.13   168.10   167.12  2660.63  2643.60  2642.62
 V   284.20   267.17   266.19  2547.54  2530.52  2529.53
 L   397.28   380.25   379.27  2448.47  2431.45  2430.46
 I   510.36   493.34   492.35  2335.39  2318.36  2317.38
 A   581.40   564.38   563.39  2222.31  2205.28  2204.30
 F   728.47   711.44   710.46  2151.27  2134.24  2133.26
 A   799.51   782.48   781.50  2004.20  1987.17  1986.19
 Q   927.57   910.54   909.56  1933.16  1916.14  1915.15
 Y  1090.63  1073.60  1072.62  1805.10  1788.08  1787.09
 L  1203.71  1186.69  1185.70  1642.04  1625.01  1624.03
 Q  1331.77  1314.75  1313.76  1528.96  1511.93  1510.95
 Q  1459.83  1442.80  1441.82  1400.90  1383.87  1382.89
 C@  1861.24  1844.21  1843.23  1272.84  1255.81  1254.83
 P  1958.29  1941.27  1940.28   871.43   854.40   853.42
 F  2105.36  2088.33  2087.35   774.38   757.35   756.37
 E  2234.40  2217.38  2216.39   627.31   610.28   609.30
 D  2349.43  2332.40  2331.42   498.27   481.24   480.26
 H  2486.49  2469.46  2468.48   383.24   366.21   365.23
 V  2585.56  2568.53  2567.55   246.18   229.15   228.17
 K   147.11   130.09   129.10








































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 9:56:50 AM
K-186 WITH LABEL 1  
RESIDUE #185-198 
PEPTIDE SEQUENCE: YK*AAFTECCQAADK 
Page 1
DTA for scan: ZU023-A-R2, 10135
Precursor ion: 981.37
Mass type: mono
Mod's: (C* +57.02150) (K# +298.40000) (C@ +298.40000) (H^ +298.40000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 Y   164.07   147.04   146.06
 K#   590.57   573.54   572.56  1798.06  1781.04  1780.05
 A   661.60   644.58   643.59  1371.57  1354.54  1353.56
 A   732.64   715.61   714.63  1300.53  1283.50  1282.52
 F   879.71   862.68   861.70  1229.49  1212.47  1211.48
 T   980.76   963.73   962.75  1082.42  1065.40  1064.41
 E  1109.80  1092.77  1091.79   981.38   964.35   963.37
 C*  1269.83  1252.80  1251.82   852.33   835.31   834.32
 C*  1429.86  1412.83  1411.85   692.30   675.28   674.29
 Q  1557.92  1540.89  1539.91   532.27   515.25   514.26
 A  1628.96  1611.93  1610.94   404.21   387.19   386.20
 A  1699.99  1682.97  1681.98   333.18   316.15   315.17
 D  1815.02  1797.99  1797.01   262.14   245.11   244.13
 K   147.11   130.09   129.10















































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 10:18:37 AM
K-286 WITH LABEL 1  
RESIDUE #282-297 
PEPTIDE SEQUENCE: ADLAK*YICE NQDSISSK 
Page 1
DTA for scan: ZU023-A, 13568
Precursor ion: 748.09
Mass type: mono
Mod's: (C* +57.02150) (K# +298.40000) (C@ +298.40000) (H^ +298.40000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 A    72.04    55.02    54.03
 D   187.07   170.04   169.06  2169.29  2152.26  2151.27
 L   300.16   283.13   282.14  2054.26  2037.23  2036.25
 A   371.19   354.17   353.18  1941.17  1924.15  1923.16
 K#   797.69   780.66   779.68  1870.14  1853.11  1852.13
 Y   960.75   943.72   942.74  1443.64  1426.62  1425.63
 I  1073.83  1056.81  1055.82  1280.58  1263.55  1262.57
 C*  1233.87  1216.84  1215.85  1167.49  1150.47  1149.48
 E  1362.91  1345.88  1344.90  1007.46   990.44   989.45
 N  1476.95  1459.92  1458.94   878.42   861.39   860.41
 Q  1605.01  1587.98  1587.00   764.38   747.35   746.37
 D  1720.04  1703.01  1702.03   636.32   619.29   618.31
 S  1807.07  1790.04  1789.06   521.29   504.27   503.28
 I  1920.15  1903.13  1902.14   434.26   417.23   416.25
 S  2007.18  1990.16  1989.17   321.18   304.15   303.17
 S  2094.22  2077.19  2076.21   234.14   217.12   216.13
 K   147.11   130.09   129.10











































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 10:25:01 AM
K-375 WITH LABEL 1  
RESIDUE #373-383 
PEPTIDE SEQUENCE: LAK*TYETT LEK 
Page 1
DTA for scan: ZU023-A-R2, 10577
Precursor ion: 798.25
Mass type: mono
Mod's: (C* +57.02150) (K# +298.40000) (C@ +298.40000) (H^ +298.40000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 A   185.13   168.10   167.12  1482.02  1464.99  1464.01
 K#   611.62   594.60   593.61  1410.98  1393.96  1392.97
 T   712.67   695.64   694.66   984.49   967.46   966.48
 Y   875.73   858.71   857.72   883.44   866.41   865.43
 E  1004.78   987.75   986.77   720.38   703.35   702.37
 T  1105.82  1088.80  1087.81   591.33   574.31   573.32
 T  1206.87  1189.85  1188.86   490.29   473.26   472.28
 L  1319.96  1302.93  1301.95   389.24   372.21   371.23
 E  1449.00  1431.97  1430.99   276.16   259.13   258.14
 K   147.11   130.09   129.10





















































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 10:31:23 AM
K-549 WITH LABEL 1  
RESIDUE #549-558 
PEPTIDE SEQUENCE: K*Q TALVELVK 
Page 1
DTA for scan: ZU023-A, 12439
Precursor ion: 714.22
Mass type: mono
Mod's: (C* +57.02150) (K# +298.40000) (C@ +298.40000) (H^ +298.40000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 K#   427.50   410.48   409.49
 Q   555.56   538.53   537.55  1000.60   983.58   982.59
 T   656.61   639.58   638.60   872.55   855.52   854.53
 A   727.65   710.62   709.64   771.50   754.47   753.49
 L   840.73   823.70   822.72   700.46   683.43   682.45
 V   939.80   922.77   921.79   587.38   570.35   569.37
 E  1068.84  1051.81  1050.83   488.31   471.28   470.30
 L  1181.92  1164.90  1163.91   359.27   342.24   341.25
 V  1280.99  1263.97  1262.98   246.18   229.15   228.17
 K   147.11   130.09   129.10













































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 10:36:54 AM
K-569 WITH LABEL 1  
RESIDUE #566-591 
PEPTIDE SEQUENCE: EQLK*AVMDDFAAFVEK 
Page 1
DTA for scan: ZU023-A, 20038
Precursor ion: 1070.24
Mass type: mono
Mod's: (C* +57.02150) (K# +298.40000) (C@ +298.40000) (H^ +298.40000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 E   130.05   113.02   112.04
 Q   258.11   241.08   240.10  2010.27  1993.25  1992.26
 L   371.19   354.17   353.18  1882.21  1865.19  1864.20
 K#   797.69   780.66   779.68  1769.13  1752.10  1751.12
 A   868.72   851.70   850.71  1342.63  1325.61  1324.62
 V   967.79   950.77   949.78  1271.60  1254.57  1253.59
 M  1098.83  1081.81  1080.82  1172.53  1155.50  1154.52
 D  1213.86  1196.83  1195.85  1041.49  1024.46  1023.48
 D  1328.89  1311.86  1310.88   926.46   909.44   908.45
 F  1475.96  1458.93  1457.95   811.43   794.41   793.42
 A  1546.99  1529.97  1528.98   664.37   647.34   646.36
 A  1618.03  1601.00  1600.02   593.33   576.30   575.32
 F  1765.10  1748.07  1747.09   522.29   505.27   504.28
 V  1864.17  1847.14  1846.16   375.22   358.20   357.21
 E  1993.21  1976.18  1975.20   276.16   259.13   258.14
 K   147.11   130.09   129.10
















































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 10:39:52 AM
H-91 WITH LABEL 1  
RESIDUE #89-97 
PEPTIDE SEQUENCE: SLH*TLFGDK 
Page 1
DTA for scan: ZU026-A-R, 12651
Precursor ion: 658.34
Mass type: mono
Mod's: (C* +57.02150) (K# +298.40000) (C@ +298.40000) (H^ +298.40000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 S    88.04    71.01    70.03
 L   201.12   184.10   183.11  1228.90  1211.88  1210.89
 H^   636.58   619.56   618.57  1115.82  1098.79  1097.81
 T   737.63   720.60   719.62   680.36   663.33   662.35
 L   850.71   833.69   832.70   579.31   562.29   561.30
 F   997.78   980.76   979.77   466.23   449.20   448.22
 G  1054.80  1037.78  1036.79   319.16   302.13   301.15
 D  1169.83  1152.80  1151.82   262.14   245.11   244.13
 K   147.11   130.09   129.10









































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 11:00:14 AM
H-170 WITH LABEL 1  
RESIDUE #170-183 
PEPTIDE SEQUENCE: H*PYFYAPELLFFAK 
Page 1
DTA for scan: ZU027-A, 19028
Precursor ion: 1022.02
Mass type: mono
Mod's: (C* +57.02150) (K# +298.40000) (C@ +298.40000) (H^ +298.40000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 H^   436.47   419.44   418.46
 P   533.52   516.49   515.51  1605.84  1588.81  1587.82
 Y   696.58   679.56   678.57  1508.78  1491.76  1490.77
 F   843.65   826.62   825.64  1345.72  1328.69  1327.71
 Y  1006.71   989.69   988.70  1198.65  1181.62  1180.64
 A  1077.75  1060.72  1059.74  1035.59  1018.56  1017.58
 P  1174.80  1157.78  1156.79   964.55   947.52   946.54
 E  1303.85  1286.82  1285.84   867.50   850.47   849.49
 L  1416.93  1399.90  1398.92   738.45   721.43   720.44
 L  1530.01  1512.99  1512.00   625.37   608.34   607.36
 F  1677.08  1660.06  1659.07   512.29   495.26   494.28
 F  1824.15  1807.12  1806.14   365.22   348.19   347.21
 A  1895.19  1878.16  1877.18   218.15   201.12   200.14
 K   147.11   130.09   129.10









































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 1:11:16 PM
H-312 WITH LABEL 1  
RESIDUE #311-337 
PEPTIDE SEQUENCE: SH*CIAEVENDEMPADLPSLAADFVESK 
Page 1
DTA for scan: ZU023-A-R2, 19763
Precursor ion: 1092.25
Mass type: mono
Mod's: (C* +57.02150) (K# +298.40000) (C@ +298.40000) (H^ +298.40000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 S    88.04    71.01    70.03
 H^   523.50   506.47   505.49  3185.71  3168.69  3167.70
 C*   683.53   666.50   665.52  2750.25  2733.23  2732.24
 I   796.61   779.59   778.60  2590.22  2573.20  2572.21
 A   867.65   850.62   849.64  2477.14  2460.11  2459.13
 E   996.69   979.67   978.68  2406.10  2389.08  2388.09
 V  1095.76  1078.73  1077.75  2277.06  2260.03  2259.05
 E  1224.80  1207.78  1206.79  2177.99  2160.96  2159.98
 N  1338.85  1321.82  1320.84  2048.95  2031.92  2030.94
 D  1453.87  1436.85  1435.86  1934.91  1917.88  1916.89
 E  1582.92  1565.89  1564.91  1819.88  1802.85  1801.87
 M  1713.96  1696.93  1695.95  1690.84  1673.81  1672.83
 P  1811.01  1793.98  1793.00  1559.80  1542.77  1541.78
 A  1882.05  1865.02  1864.04  1462.74  1445.72  1444.73
 D  1997.07  1980.05  1979.06  1391.71  1374.68  1373.69
 L  2110.16  2093.13  2092.15  1276.68  1259.65  1258.67
 P  2207.21  2190.18  2189.20  1163.59  1146.57  1145.58
 S  2294.24  2277.22  2276.23  1066.54  1049.51  1048.53
 L  2407.33  2390.30  2389.32   979.51   962.48   961.50
 A  2478.36  2461.34  2460.35   866.43   849.40   848.41
 A  2549.40  2532.37  2531.39   795.39   778.36   777.38
 D  2664.43  2647.40  2646.42   724.35   707.32   706.34
 F  2811.50  2794.47  2793.49   609.32   592.30   591.31
 V  2910.56  2893.54  2892.55   462.26   445.23   444.25
 E  3039.61  3022.58  3021.60   363.19   346.16   345.18
 S  3126.64  3109.61  3108.63   234.14   217.12   216.13
 K   147.11   130.09   129.10


















































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 11:36:10 AM
C-58 WITH LABEL 2  
RESIDUE #45-65 
PEPTIDE SEQUENCE: ALVLIA FAQYLQQC*PFEDHVK 
Page 1
DTA for scan: ZU026-B-R, 20429
Precursor ion: 949.50
Mass type: mono
Mod's: (C* +57.02150) (K# +411.50000) (C@ +411.50000) (H^ +411.50000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 A    72.04    55.02    54.03
 L   185.13   168.10   167.12  2773.73  2756.70  2755.72
 V   284.20   267.17   266.19  2660.64  2643.62  2642.63
 L   397.28   380.25   379.27  2561.57  2544.55  2543.56
 I   510.36   493.34   492.35  2448.49  2431.46  2430.48
 A   581.40   564.38   563.39  2335.41  2318.38  2317.40
 F   728.47   711.44   710.46  2264.37  2247.34  2246.36
 A   799.51   782.48   781.50  2117.30  2100.27  2099.29
 Q   927.57   910.54   909.56  2046.26  2029.24  2028.25
 Y  1090.63  1073.60  1072.62  1918.20  1901.18  1900.19
 L  1203.71  1186.69  1185.70  1755.14  1738.11  1737.13
 Q  1331.77  1314.75  1313.76  1642.06  1625.03  1624.05
 Q  1459.83  1442.80  1441.82  1514.00  1496.97  1495.99
 C@  1974.34  1957.31  1956.33  1385.94  1368.91  1367.93
 P  2071.39  2054.37  2053.38   871.43   854.40   853.42
 F  2218.46  2201.43  2200.45   774.38   757.35   756.37
 E  2347.50  2330.48  2329.49   627.31   610.28   609.30
 D  2462.53  2445.50  2444.52   498.27   481.24   480.26
 H  2599.59  2582.56  2581.58   383.24   366.21   365.23
 V  2698.66  2681.63  2680.65   246.18   229.15   228.17
 K   147.11   130.09   129.10








































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 12:02:21 PM
K-186 WITH LABEL 2  
RESIDUE #185-198 
PEPTIDE SEQUENCE: YK*AAFTECCQAADK 
Page 1
DTA for scan: ZU026-B-R2, 10776
Precursor ion: 1037.64
Mass type: mono
Mod's: (C* +57.02150) (K# +411.50000) (C@ +411.50000) (H^ +411.50000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 Y   164.07   147.04   146.06
 K#   703.67   686.64   685.66  1911.16  1894.14  1893.15
 A   774.70   757.68   756.69  1371.57  1354.54  1353.56
 A   845.74   828.71   827.73  1300.53  1283.50  1282.52
 F   992.81   975.78   974.80  1229.49  1212.47  1211.48
 T  1093.86  1076.83  1075.85  1082.42  1065.40  1064.41
 E  1222.90  1205.87  1204.89   981.38   964.35   963.37
 C*  1382.93  1365.90  1364.92   852.33   835.31   834.32
 C*  1542.96  1525.93  1524.95   692.30   675.28   674.29
 Q  1671.02  1653.99  1653.01   532.27   515.25   514.26
 A  1742.06  1725.03  1724.04   404.21   387.19   386.20
 A  1813.09  1796.07  1795.08   333.18   316.15   315.17
 D  1928.12  1911.09  1910.11   262.14   245.11   244.13
 K   147.11   130.09   129.10























































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 12:10:54 PM
K-286 WITH LABEL 2  
RESIDUE #282-297 
PEPTIDE SEQUENCE: ADLAK*YICE NQDSISSK 
Page 1
DTA for scan: ZU026-B-R2, 14150
Precursor ion: 785.75
Mass type: mono
Mod's: (C* +57.02150) (K# +411.50000) (C@ +411.50000) (H^ +411.50000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 A    72.04    55.02    54.03
 D   187.07   170.04   169.06  2282.39  2265.36  2264.37
 L   300.16   283.13   282.14  2167.36  2150.33  2149.35
 A   371.19   354.17   353.18  2054.27  2037.25  2036.26
 K#   910.79   893.76   892.78  1983.24  1966.21  1965.23
 Y  1073.85  1056.82  1055.84  1443.64  1426.62  1425.63
 I  1186.93  1169.91  1168.92  1280.58  1263.55  1262.57
 C*  1346.97  1329.94  1328.95  1167.49  1150.47  1149.48
 E  1476.01  1458.98  1458.00  1007.46   990.44   989.45
 N  1590.05  1573.02  1572.04   878.42   861.39   860.41
 Q  1718.11  1701.08  1700.10   764.38   747.35   746.37
 D  1833.14  1816.11  1815.13   636.32   619.29   618.31
 S  1920.17  1903.14  1902.16   521.29   504.27   503.28
 I  2033.25  2016.23  2015.24   434.26   417.23   416.25
 S  2120.28  2103.26  2102.27   321.18   304.15   303.17
 S  2207.32  2190.29  2189.31   234.14   217.12   216.13
 K   147.11   130.09   129.10














































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 12:17:27 PM
K-375 WITH LABEL 2  
RESIDUE #373-383 
PEPTIDE SEQUENCE: LAK*TYETT LEK 
Page 1
DTA for scan: ZU026-B-R, 11064
Precursor ion: 570.25
Mass type: mono
Mod's: (C* +57.02150) (K# +411.50000) (C@ +411.50000) (H^ +411.50000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 A   185.13   168.10   167.12  1595.12  1578.09  1577.11
 K#   724.72   707.70   706.71  1524.08  1507.06  1506.07
 T   825.77   808.74   807.76   984.49   967.46   966.48
 Y   988.83   971.81   970.82   883.44   866.41   865.43
 E  1117.88  1100.85  1099.87   720.38   703.35   702.37
 T  1218.92  1201.90  1200.91   591.33   574.31   573.32
 T  1319.97  1302.95  1301.96   490.29   473.26   472.28
 L  1433.06  1416.03  1415.05   389.24   372.21   371.23
 E  1562.10  1545.07  1544.09   276.16   259.13   258.14
 K   147.11   130.09   129.10




























































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 12:26:54 PM
K-549 WITH LABEL 2  
RESIDUE #549-558 
PEPTIDE SEQUENCE: K*Q TALVELVK 
Page 1
DTA for scan: ZU026-B, 13314
Precursor ion: 770.40
Mass type: mono
Mod's: (C* +57.02150) (K# +411.50000) (C@ +411.50000) (H^ +411.50000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 K#   540.60   523.58   522.59
 Q   668.66   651.63   650.65  1000.60   983.58   982.59
 T   769.71   752.68   751.70   872.55   855.52   854.53
 A   840.75   823.72   822.74   771.50   754.47   753.49
 L   953.83   936.80   935.82   700.46   683.43   682.45
 V  1052.90  1035.87  1034.89   587.38   570.35   569.37
 E  1181.94  1164.91  1163.93   488.31   471.28   470.30
 L  1295.02  1278.00  1277.01   359.27   342.24   341.25
 V  1394.09  1377.07  1376.08   246.18   229.15   228.17
 K   147.11   130.09   129.10



























































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 12:29:26 PM
K-569 WITH LABEL 2  
RESIDUE #566-591 
PEPTIDE SEQUENCE: EQLK*AVMDDFAAFVEK 
Page 1
DTA for scan: ZU026-B-R2, 20391
Precursor ion: 1126.77
Mass type: mono
Mod's: (C* +57.02150) (K# +411.50000) (C@ +411.50000) (H^ +411.50000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 E   130.05   113.02   112.04
 Q   258.11   241.08   240.10  2123.37  2106.35  2105.36
 L   371.19   354.17   353.18  1995.31  1978.29  1977.30
 K#   910.79   893.76   892.78  1882.23  1865.20  1864.22
 A   981.82   964.80   963.81  1342.63  1325.61  1324.62
 V  1080.89  1063.87  1062.88  1271.60  1254.57  1253.59
 M  1211.93  1194.91  1193.92  1172.53  1155.50  1154.52
 D  1326.96  1309.93  1308.95  1041.49  1024.46  1023.48
 D  1441.99  1424.96  1423.98   926.46   909.44   908.45
 F  1589.06  1572.03  1571.05   811.43   794.41   793.42
 A  1660.09  1643.07  1642.08   664.37   647.34   646.36
 A  1731.13  1714.10  1713.12   593.33   576.30   575.32
 F  1878.20  1861.17  1860.19   522.29   505.27   504.28
 V  1977.27  1960.24  1959.26   375.22   358.20   357.21
 E  2106.31  2089.28  2088.30   276.16   259.13   258.14
 K   147.11   130.09   129.10




















































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 12:33:03 PM
H-91 WITH LABEL 2  
RESIDUE #89-97 
PEPTIDE SEQUENCE: SLH*TLFGDK 
Page 1
DTA for scan: ZU026-B-R2, 13405
Precursor ion: 715.22
Mass type: mono
Mod's: (C* +57.02150) (K# +411.50000) (C@ +411.50000) (H^ +411.50000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 S    88.04    71.01    70.03
 L   201.12   184.10   183.11  1342.00  1324.98  1323.99
 H^   749.68   732.66   731.67  1228.92  1211.89  1210.91
 T   850.73   833.70   832.72   680.36   663.33   662.35
 L   963.81   946.79   945.80   579.31   562.29   561.30
 F  1110.88  1093.86  1092.87   466.23   449.20   448.22
 G  1167.90  1150.88  1149.89   319.16   302.13   301.15
 D  1282.93  1265.90  1264.92   262.14   245.11   244.13
 K   147.11   130.09   129.10












































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 12:36:21 PM
H-170 WITH LABEL 2  
RESIDUE #170-183 
PEPTIDE SEQUENCE: H*PYFYAPELLFFAK 
Page 1
DTA for scan: ZU027-B-R2, 18679
Precursor ion: 1077.94
Mass type: mono
Mod's: (C* +57.02150) (K# +411.50000) (C@ +411.50000) (H^ +411.50000) 
Ion series for charge: +2
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 H^   275.29   266.77   266.28
 P   323.81   315.30   314.81   803.42   794.91   794.42
 Y   405.34   396.83   396.34   754.89   746.38   745.89
 F   478.88   470.37   469.87   673.36   664.85   664.36
 Y   560.41   551.90   551.41   599.83   591.32   590.82
 A   595.93   587.42   586.92   518.30   509.78   509.29
 P   644.46   635.94   635.45   482.78   474.27   473.77
 E   708.98   700.46   699.97   434.25   425.74   425.25
 L   765.52   757.01   756.51   369.73   361.22   360.73
 L   822.06   813.55   813.06   313.19   304.68   304.18
 F   895.60   887.08   886.59   256.65   248.13   247.64
 F   969.13   960.62   960.12   183.11   174.60   174.11
 A  1004.65   996.13   995.64   109.58   101.07   100.57
 K    74.06    65.55    65.05





















































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 1:03:55 PM
H-312 WITH LABEL 2  
RESIDUE #311-337 
PEPTIDE SEQUENCE: SH*CIAEVENDEMPADLPSLAADFVESK 
Page 1
DTA for scan: ZU026-B, 19569
Precursor ion: 1129.48
Mass type: mono
Mod's: (C* +57.02150) (K# +411.50000) (C@ +411.50000) (H^ +411.50000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 S    88.04    71.01    70.03
 H^   636.60   619.57   618.59  3298.81  3281.79  3280.80
 C*   796.63   779.60   778.62  2750.25  2733.23  2732.24
 I   909.71   892.69   891.70  2590.22  2573.20  2572.21
 A   980.75   963.72   962.74  2477.14  2460.11  2459.13
 E  1109.79  1092.77  1091.78  2406.10  2389.08  2388.09
 V  1208.86  1191.83  1190.85  2277.06  2260.03  2259.05
 E  1337.90  1320.88  1319.89  2177.99  2160.96  2159.98
 N  1451.95  1434.92  1433.94  2048.95  2031.92  2030.94
 D  1566.97  1549.95  1548.96  1934.91  1917.88  1916.89
 E  1696.02  1678.99  1678.01  1819.88  1802.85  1801.87
 M  1827.06  1810.03  1809.05  1690.84  1673.81  1672.83
 P  1924.11  1907.08  1906.10  1559.80  1542.77  1541.78
 A  1995.15  1978.12  1977.14  1462.74  1445.72  1444.73
 D  2110.17  2093.15  2092.16  1391.71  1374.68  1373.69
 L  2223.26  2206.23  2205.25  1276.68  1259.65  1258.67
 P  2320.31  2303.28  2302.30  1163.59  1146.57  1145.58
 S  2407.34  2390.32  2389.33  1066.54  1049.51  1048.53
 L  2520.43  2503.40  2502.42   979.51   962.48   961.50
 A  2591.46  2574.44  2573.45   866.43   849.40   848.41
 A  2662.50  2645.47  2644.49   795.39   778.36   777.38
 D  2777.53  2760.50  2759.52   724.35   707.32   706.34
 F  2924.60  2907.57  2906.59   609.32   592.30   591.31
 V  3023.66  3006.64  3005.65   462.26   445.23   444.25
 E  3152.71  3135.68  3134.70   363.19   346.16   345.18
 S  3239.74  3222.71  3221.73   234.14   217.12   216.13
 K   147.11   130.09   129.10




















































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 1:16:49 PM
C-58 WITH LABEL 3  
RESIDUE #45-65 
PEPTIDE SEQUENCE: ALVLIA FAQYLQQC*PFEDHVK 
Page 1
DTA for scan: ZU023-C, 20293
Precursor ion: 994.19
Mass type: mono
Mod's: (C* +57.02150) (K# +545.30000) (C@ +545.30000) (H^ +545.30000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 A    72.04    55.02    54.03
 L   185.13   168.10   167.12  2907.53  2890.50  2889.52
 V   284.20   267.17   266.19  2794.44  2777.42  2776.43
 L   397.28   380.25   379.27  2695.37  2678.35  2677.36
 I   510.36   493.34   492.35  2582.29  2565.26  2564.28
 A   581.40   564.38   563.39  2469.21  2452.18  2451.20
 F   728.47   711.44   710.46  2398.17  2381.14  2380.16
 A   799.51   782.48   781.50  2251.10  2234.07  2233.09
 Q   927.57   910.54   909.56  2180.06  2163.04  2162.05
 Y  1090.63  1073.60  1072.62  2052.00  2034.98  2033.99
 L  1203.71  1186.69  1185.70  1888.94  1871.91  1870.93
 Q  1331.77  1314.75  1313.76  1775.86  1758.83  1757.85
 Q  1459.83  1442.80  1441.82  1647.80  1630.77  1629.79
 C@  2108.14  2091.11  2090.13  1519.74  1502.71  1501.73
 P  2205.19  2188.17  2187.18   871.43   854.40   853.42
 F  2352.26  2335.23  2334.25   774.38   757.35   756.37
 E  2481.30  2464.28  2463.29   627.31   610.28   609.30
 D  2596.33  2579.30  2578.32   498.27   481.24   480.26
 H  2733.39  2716.36  2715.38   383.24   366.21   365.23
 V  2832.46  2815.43  2814.45   246.18   229.15   228.17
 K   147.11   130.09   129.10














































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 2:15:02 PM
K-186 WITH LABEL 3  
RESIDUE #185-198 
PEPTIDE SEQUENCE: YK*AAFTECCQAADK 
Page 1
DTA for scan: ZU023-C-R, 11489
Precursor ion: 1104.73
Mass type: mono
Mod's: (C* +57.02150) (K# +545.30000) (C@ +545.30000) (H^ +545.30000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 Y   164.07   147.04   146.06
 K#   837.47   820.44   819.46  2044.96  2027.94  2026.95
 A   908.50   891.48   890.49  1371.57  1354.54  1353.56
 A   979.54   962.51   961.53  1300.53  1283.50  1282.52
 F  1126.61  1109.58  1108.60  1229.49  1212.47  1211.48
 T  1227.66  1210.63  1209.65  1082.42  1065.40  1064.41
 E  1356.70  1339.67  1338.69   981.38   964.35   963.37
 C*  1516.73  1499.70  1498.72   852.33   835.31   834.32
 C*  1676.76  1659.73  1658.75   692.30   675.28   674.29
 Q  1804.82  1787.79  1786.81   532.27   515.25   514.26
 A  1875.86  1858.83  1857.84   404.21   387.19   386.20
 A  1946.89  1929.87  1928.88   333.18   316.15   315.17
 D  2061.92  2044.89  2043.91   262.14   245.11   244.13
 K   147.11   130.09   129.10




































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 2:18:36 PM
K-286 WITH LABEL 3  
RESIDUE #275-375 
PEPTIDE SEQUENCE: VHTECCHGDLLECADDRADLAK* 
Page 1
DTA for scan: ZU023-C-R, 10523
Precursor ion: 1044.18
Mass type: mono
Mod's: (C* +57.02150) (K# +545.30000) (C@ +545.30000) (H^ +545.30000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 V   100.08    83.05    82.07
 H   237.13   220.11   219.12  3031.35  3014.32  3013.34
 T   338.18   321.16   320.17  2894.29  2877.26  2876.28
 E   467.22   450.20   449.21  2793.24  2776.22  2775.23
 C*   627.26   610.23   609.24  2664.20  2647.17  2646.19
 C*   787.29   770.26   769.28  2504.17  2487.14  2486.16
 H   924.35   907.32   906.33  2344.14  2327.11  2326.13
 G   981.37   964.34   963.36  2207.08  2190.05  2189.07
 D  1096.39  1079.37  1078.38  2150.06  2133.03  2132.05
 L  1209.48  1192.45  1191.47  2035.03  2018.01  2017.02
 L  1322.56  1305.54  1304.55  1921.95  1904.92  1903.94
 E  1451.60  1434.58  1433.59  1808.86  1791.84  1790.85
 C*  1611.63  1594.61  1593.62  1679.82  1662.79  1661.81
 A  1682.67  1665.65  1664.66  1519.79  1502.76  1501.78
 D  1797.70  1780.67  1779.69  1448.75  1431.73  1430.74
 D  1912.73  1895.70  1894.72  1333.73  1316.70  1315.72
 R  2068.83  2051.80  2050.82  1218.70  1201.67  1200.69
 A  2139.86  2122.84  2121.85  1062.60  1045.57  1044.59
 D  2254.89  2237.86  2236.88   991.56   974.53   973.55
 L  2367.98  2350.95  2349.96   876.53   859.51   858.52
 A  2439.01  2421.99  2421.00   763.45   746.42   745.44
 K#   692.41   675.39   674.40













































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 2:29:42 PM
K-375 WITH LABEL 3  
RESIDUE #373-383 
PEPTIDE SEQUENCE: LAK*TYETT LEK 
Page 1
DTA for scan: ZU023-C-R, 11845
Precursor ion: 921.59
Mass type: mono
Mod's: (C* +57.02150) (K# +545.30000) (C@ +545.30000) (H^ +545.30000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 A   185.13   168.10   167.12  1728.92  1711.89  1710.91
 K#   858.52   841.50   840.51  1657.88  1640.86  1639.87
 T   959.57   942.54   941.56   984.49   967.46   966.48
 Y  1122.63  1105.61  1104.62   883.44   866.41   865.43
 E  1251.68  1234.65  1233.67   720.38   703.35   702.37
 T  1352.72  1335.70  1334.71   591.33   574.31   573.32
 T  1453.77  1436.75  1435.76   490.29   473.26   472.28
 L  1566.86  1549.83  1548.85   389.24   372.21   371.23
 E  1695.90  1678.87  1677.89   276.16   259.13   258.14
 K   147.11   130.09   129.10











































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 2:54:09 PM
K-549 WITH LABEL 3  
RESIDUE #549-558 
PEPTIDE SEQUENCE: K*Q TALVELVK 
Page 1
DTA for scan: ZU023-C, 14089
Precursor ion: 837.61
Mass type: mono
Mod's: (C* +57.02150) (K# +545.30000) (C@ +545.30000) (H^ +545.30000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 K#   674.40   657.38   656.39
 Q   802.46   785.43   784.45  1000.60   983.58   982.59
 T   903.51   886.48   885.50   872.55   855.52   854.53
 A   974.55   957.52   956.54   771.50   754.47   753.49
 L  1087.63  1070.60  1069.62   700.46   683.43   682.45
 V  1186.70  1169.67  1168.69   587.38   570.35   569.37
 E  1315.74  1298.71  1297.73   488.31   471.28   470.30
 L  1428.82  1411.80  1410.81   359.27   342.24   341.25
 V  1527.89  1510.87  1509.88   246.18   229.15   228.17
 K   147.11   130.09   129.10

























































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 2:59:46 PM
K-569 WITH LABEL 3  
RESIDUE #566-591 
PEPTIDE SEQUENCE: EQLK*AVMDDFAAFVEK 
Page 1
DTA for scan: ZU023-C-R, 20125
Precursor ion: 1193.95
Mass type: mono
Mod's: (C* +57.02150) (K# +545.30000) (C@ +545.30000) (H^ +545.30000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 E   130.05   113.02   112.04
 Q   258.11   241.08   240.10  2257.17  2240.15  2239.16
 L   371.19   354.17   353.18  2129.11  2112.09  2111.10
 K#  1044.59  1027.56  1026.58  2016.03  1999.00  1998.02
 A  1115.62  1098.60  1097.61  1342.63  1325.61  1324.62
 V  1214.69  1197.67  1196.68  1271.60  1254.57  1253.59
 M  1345.73  1328.71  1327.72  1172.53  1155.50  1154.52
 D  1460.76  1443.73  1442.75  1041.49  1024.46  1023.48
 D  1575.79  1558.76  1557.78   926.46   909.44   908.45
 F  1722.86  1705.83  1704.85   811.43   794.41   793.42
 A  1793.89  1776.87  1775.88   664.37   647.34   646.36
 A  1864.93  1847.90  1846.92   593.33   576.30   575.32
 F  2012.00  1994.97  1993.99   522.29   505.27   504.28
 V  2111.07  2094.04  2093.06   375.22   358.20   357.21
 E  2240.11  2223.08  2222.10   276.16   259.13   258.14
 K   147.11   130.09   129.10














































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 2:57:58 PM
H-91 WITH LABEL 3  
RESIDUE #89-97 
PEPTIDE SEQUENCE: SLH*TLFGDK 
Page 1
DTA for scan: ZU026-C-R2, 13420
Precursor ion: 782.14
Mass type: mono
Mod's: (C* +57.02150) (K# +545.30000) (C@ +545.30000) (H^ +545.30000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 S    88.04    71.01    70.03
 L   201.12   184.10   183.11  1475.80  1458.78  1457.79
 H^   883.48   866.46   865.47  1362.72  1345.69  1344.71
 T   984.53   967.50   966.52   680.36   663.33   662.35
 L  1097.61  1080.59  1079.60   579.31   562.29   561.30
 F  1244.68  1227.66  1226.67   466.23   449.20   448.22
 G  1301.70  1284.68  1283.69   319.16   302.13   301.15
 D  1416.73  1399.70  1398.72   262.14   245.11   244.13
 K   147.11   130.09   129.10





















































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 3:18:50 PM
H-170 WITH LABEL 3  
RESIDUE #170-183 
PEPTIDE SEQUENCE: H*PYFYAPELLFFAK 
Page 1
DTA for scan: ZU027-C-R2, 19057
Precursor ion: 1145.35
Mass type: mono
Mod's: (C* +57.02150) (K# +545.30000) (C@ +545.30000) (H^ +545.30000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 H^   683.37   666.34   665.36
 P   780.42   763.39   762.41  1605.84  1588.81  1587.82
 Y   943.48   926.46   925.47  1508.78  1491.76  1490.77
 F  1090.55  1073.52  1072.54  1345.72  1328.69  1327.71
 Y  1253.61  1236.59  1235.60  1198.65  1181.62  1180.64
 A  1324.65  1307.62  1306.64  1035.59  1018.56  1017.58
 P  1421.70  1404.68  1403.69   964.55   947.52   946.54
 E  1550.75  1533.72  1532.74   867.50   850.47   849.49
 L  1663.83  1646.80  1645.82   738.45   721.43   720.44
 L  1776.91  1759.89  1758.90   625.37   608.34   607.36
 F  1923.98  1906.96  1905.97   512.29   495.26   494.28
 F  2071.05  2054.02  2053.04   365.22   348.19   347.21
 A  2142.09  2125.06  2124.08   218.15   201.12   200.14
 K   147.11   130.09   129.10















































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 1:57:32 PM
C-58 WITH LABEL 4  
RESIDUE #45-65 
PEPTIDE SEQUENCE: ALVLIA FAQYLQQC*PFEDHVK 
Page 1
DTA for scan: ZU067-D, 20066
Precursor ion: 897.37
Mass type: avg
Mod's: (C* +57.05130) (K# +254.31000) (R@ +254.31000) (H^ +254.31000) (C~ +254.31000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 A    72.09    55.06    54.07
 L   185.24   168.21   167.23  2618.07  2601.04  2600.06
 V   284.38   267.34   266.36  2504.91  2487.88  2486.90
 L   397.53   380.50   379.52  2405.78  2388.75  2387.77
 I   510.69   493.66   492.68  2292.62  2275.59  2274.61
 A   581.77   564.74   563.75  2179.47  2162.44  2161.45
 F   728.94   711.91   710.93  2108.39  2091.36  2090.37
 A   800.02   782.99   782.01  1961.21  1944.18  1943.20
 Q   928.15   911.12   910.14  1890.14  1873.10  1872.12
 Y  1091.33  1074.30  1073.31  1762.01  1744.97  1743.99
 L  1204.49  1187.45  1186.47  1598.83  1581.80  1580.82
 Q  1332.62  1315.58  1314.60  1485.67  1468.64  1467.66
 Q  1460.74  1443.71  1442.73  1357.54  1340.51  1339.53
 C~  1818.20  1801.17  1800.18  1229.41  1212.38  1211.40
 P  1915.31  1898.28  1897.30   871.96   854.93   853.94
 F  2062.49  2045.46  2044.47   774.84   757.81   756.83
 E  2191.60  2174.57  2173.59   627.67   610.64   609.65
 D  2306.69  2289.66  2288.68   498.55   481.52   480.54
 H  2443.83  2426.80  2425.82   383.47   366.44   365.45
 V  2542.96  2525.93  2524.95   246.33   229.30   228.31
 K   147.20   130.17   129.18













































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 4:25:28 PM
K-186 WITH LABEL 4  
RESIDUE #185-198 
PEPTIDE SEQUENCE: YK*AAFTECCQAADK 
Page 1
DTA for scan: ZU067-D-R2, 12658
Precursor ion: 640.08
Mass type: avg
Mod's: (C* +57.05130) (K# +254.31000) (R@ +254.31000) (H^ +254.31000) (C~ +254.31000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 Y   164.18   147.15   146.17
 K#   546.66   529.63   528.65  1754.99  1737.96  1736.98
 A   617.74   600.71   599.73  1372.51  1355.48  1354.49
 A   688.82   671.79   670.81  1301.43  1284.40  1283.42
 F   836.00   818.97   817.98  1230.35  1213.32  1212.34
 T   937.10   920.07   919.08  1083.18  1066.15  1065.16
 E  1066.21  1049.18  1048.20   982.07   965.04   964.06
 C*  1226.41  1209.38  1208.39   852.96   835.93   834.94
 C*  1386.60  1369.57  1368.59   692.76   675.73   674.75
 Q  1514.73  1497.70  1496.72   532.57   515.54   514.55
 A  1585.81  1568.78  1567.80   404.44   387.41   386.42
 A  1656.89  1639.86  1638.88   333.36   316.33   315.35
 D  1771.98  1754.95  1753.96   262.28   245.25   244.27
 K   147.20   130.17   129.18











































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 4:29:29 PM
K-286 WITH LABEL 4  
RESIDUE #282-297 
PEPTIDE SEQUENCE: ADLAK*YICE NQDSISSK 
Page 1
DTA for scan: ZU067-D, 14635
Precursor ion: 733.70
Mass type: avg
Mod's: (C* +57.05130) (K# +254.31000) (R@ +254.31000) (H^ +254.31000) (C~ +254.31000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 A    72.09    55.06    54.07
 D   187.17   170.14   169.16  2126.36  2109.33  2108.34
 L   300.33   283.30   282.32  2011.27  1994.24  1993.25
 A   371.41   354.38   353.39  1898.11  1881.08  1880.10
 K#   753.89   736.86   735.88  1827.03  1810.00  1809.02
 Y   917.07   900.04   899.05  1444.55  1427.52  1426.53
 I  1030.23  1013.19  1012.21  1281.38  1264.34  1263.36
 C*  1190.42  1173.39  1172.40  1168.22  1151.19  1150.20
 E  1319.53  1302.50  1301.52  1008.02   990.99   990.01
 N  1433.64  1416.61  1415.62   878.91   861.88   860.89
 Q  1561.77  1544.74  1543.75   764.80   747.77   746.79
 D  1676.86  1659.82  1658.84   636.67   619.64   618.66
 S  1763.93  1746.90  1745.92   521.59   504.56   503.57
 I  1877.09  1860.06  1859.08   434.51   417.48   416.49
 S  1964.17  1947.14  1946.15   321.35   304.32   303.34
 S  2051.25  2034.22  2033.23   234.27   217.24   216.26
 K   147.20   130.17   129.18























































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 4:35:08 PM
K-375 WITH LABEL 4  
RESIDUE #373-383 
PEPTIDE SEQUENCE: LAK*TYETT LEK 
Page 1
DTA for scan: ZU067-D, 13026
Precursor ion: 518.22
Mass type: avg
Mod's: (C* +57.05130) (K# +254.31000) (R@ +254.31000) (H^ +254.31000) (C~ +254.31000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.17    97.14    96.15
 A   185.24   168.21   167.23  1438.63  1421.60  1420.62
 K#   567.73   550.70   549.71  1367.55  1350.52  1349.54
 T   668.83   651.80   650.82   985.07   968.04   967.05
 Y   832.01   814.97   813.99   883.97   866.94   865.95
 E   961.12   944.09   943.10   720.79   703.76   702.78
 T  1062.22  1045.19  1044.21   591.68   574.65   573.66
 T  1163.33  1146.30  1145.31   490.57   473.54   472.56
 L  1276.49  1259.46  1258.47   389.47   372.44   371.45
 E  1405.60  1388.57  1387.59   276.31   259.28   258.29
 K   147.20   130.17   129.18










































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 4:40:35 PM
K-549 WITH LABEL 4  
RESIDUE #549-558 
PEPTIDE SEQUENCE: K*QTALVELVK 
Page 1
DTA for scan: ZU070-D-R4, 14368
Precursor ion: 692.51
Mass type: avg
Mod's: (C* +57.05130) (K# +254.31000) (R@ +254.31000) (H^ +254.31000) (C~ +254.31000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 K#   383.49   366.46   365.47
 Q   511.62   494.59   493.60  1001.20   984.17   983.19
 T   612.72   595.69   594.71   873.07   856.04   855.06
 A   683.80   666.77   665.79   771.97   754.94   753.95
 L   796.96   779.93   778.95   700.89   683.86   682.87
 V   896.09   879.06   878.08   587.73   570.70   569.72
 E  1025.21  1008.18  1007.19   488.60   471.57   470.58
 L  1138.37  1121.33  1120.35   359.49   342.45   341.47
 V  1237.50  1220.47  1219.48   246.33   229.30   228.31
 K   147.20   130.17   129.18













































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 4:47:24 PM
K-569 WITH LABEL 4  
RESIDUE #566-591 
PEPTIDE SEQUENCE: EQLK*AVMDDFAAFVEK 
Page 1
DTA for scan: ZU070-D_110418133618, 19806
Precursor ion: 699.85
Mass type: avg
Mod's: (C* +57.05130) (K# +254.31000) (R@ +254.31000) (H^ +254.31000) (C~ +254.31000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 E   130.12   113.09   112.11
 Q   258.25   241.22   240.24  1967.30  1950.27  1949.29
 L   371.41   354.38   353.39  1839.17  1822.14  1821.16
 K#   753.89   736.86   735.88  1726.01  1708.98  1708.00
 A   824.97   807.94   806.96  1343.53  1326.50  1325.51
 V   924.10   907.07   906.09  1272.45  1255.42  1254.44
 M  1055.30  1038.27  1037.28  1173.32  1156.29  1155.31
 D  1170.39  1153.36  1152.37  1042.12  1025.09  1024.11
 D  1285.48  1268.44  1267.46   927.04   910.00   909.02
 F  1432.65  1415.62  1414.63   811.95   794.92   793.93
 A  1503.73  1486.70  1485.71   664.77   647.74   646.76
 A  1574.81  1557.78  1556.79   593.69   576.66   575.68
 F  1721.98  1704.95  1703.97   522.62   505.59   504.60
 V  1821.11  1804.08  1803.10   375.44   358.41   357.43
 E  1950.23  1933.20  1932.21   276.31   259.28   258.29
 K   147.20   130.17   129.18















































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 4:49:53 PM
H-91 WITH LABEL 4  
RESIDUE #89-97 
PEPTIDE SEQUENCE: SLH*TLFGDK 
Page 1
DTA for scan: ZU070-D, 15411
Precursor ion: 636.88
Mass type: avg
Mod's: (C* +57.05130) (K# +254.31000) (R@ +254.31000) (H^ +254.31000) (C~ +254.31000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 S    88.09    71.05    70.07
 L   201.24   184.21   183.23  1185.38  1168.35  1167.37
 H^   592.69   575.66   574.68  1072.22  1055.19  1054.21
 T   693.80   676.77   675.78   680.77   663.74   662.76
 L   806.96   789.93   788.94   579.67   562.64   561.65
 F   954.13   937.10   936.12   466.51   449.48   448.49
 G  1011.18   994.15   993.17   319.34   302.30   301.32
 D  1126.27  1109.24  1108.25   262.28   245.25   244.27
 K   147.20   130.17   129.18
























































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 4:53:32 PM
H-170 WITH LABEL 4  
RESIDUE #169-183 
PEPTIDE SEQUENCE: RH*PYFYAPELLFFAK 
Page 1
DTA for scan: ZU032-D-R2, 20966
Precursor ion: 1078.01
Mass type: mono
Mod's: (C* +57.02150) (K# +254.31000) (C@ +254.31000) (H^ +254.31000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 R   157.11   140.08   139.10
 H^   548.48   531.45   530.47  1997.20  1980.18  1979.19
 P   645.53   628.50   627.52  1605.84  1588.81  1587.82
 Y   808.59   791.57   790.58  1508.78  1491.76  1490.77
 F   955.66   938.64   937.65  1345.72  1328.69  1327.71
 Y  1118.73  1101.70  1100.71  1198.65  1181.62  1180.64
 A  1189.76  1172.74  1171.75  1035.59  1018.56  1017.58
 P  1286.82  1269.79  1268.80   964.55   947.52   946.54
 E  1415.86  1398.83  1397.85   867.50   850.47   849.49
 L  1528.94  1511.92  1510.93   738.45   721.43   720.44
 L  1642.03  1625.00  1624.02   625.37   608.34   607.36
 F  1789.09  1772.07  1771.08   512.29   495.26   494.28
 F  1936.16  1919.14  1918.15   365.22   348.19   347.21
 A  2007.20  1990.17  1989.19   218.15   201.12   200.14
 K   147.11   130.09   129.10















































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 5:15:10 PM
H-312 WITH LABEL 4  
RESIDUE #311-337 
PEPTIDE SEQUENCE: SH*CIAEVENDEMPADLPSLAADFVESK 
Page 1
DTA for scan: ZU070-D-R2, 18912
Precursor ion: 1077.63
Mass type: avg
Mod's: (C* +57.05130) (K# +254.31000) (R@ +254.31000) (H^ +254.31000) (C~ +254.31000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 S    88.09    71.05    70.07
 H^   479.53   462.50   461.52  3143.47  3126.44  3125.46
 C*   639.73   622.70   621.71  2752.02  2734.99  2734.01
 I   752.89   735.86   734.87  2591.83  2574.80  2573.81
 A   823.97   806.94   805.95  2478.67  2461.64  2460.66
 E   953.08   936.05   935.07  2407.59  2390.56  2389.58
 V  1052.21  1035.18  1034.20  2278.48  2261.45  2260.46
 E  1181.33  1164.30  1163.31  2179.35  2162.32  2161.33
 N  1295.43  1278.40  1277.41  2050.23  2033.20  2032.22
 D  1410.52  1393.49  1392.50  1936.13  1919.10  1918.11
 E  1539.63  1522.60  1521.62  1821.04  1804.01  1803.03
 M  1670.83  1653.80  1652.81  1691.93  1674.90  1673.91
 P  1767.95  1750.91  1749.93  1560.73  1543.70  1542.71
 A  1839.02  1821.99  1821.01  1463.61  1446.58  1445.60
 D  1954.11  1937.08  1936.10  1392.54  1375.51  1374.52
 L  2067.27  2050.24  2049.25  1277.45  1260.42  1259.43
 P  2164.39  2147.35  2146.37  1164.29  1147.26  1146.27
 S  2251.46  2234.43  2233.45  1067.17  1050.14  1049.16
 L  2364.62  2347.59  2346.61   980.10   963.07   962.08
 A  2435.70  2418.67  2417.68   866.94   849.91   848.92
 A  2506.78  2489.75  2488.76   795.86   778.83   777.84
 D  2621.87  2604.84  2603.85   724.78   707.75   706.77
 F  2769.04  2752.01  2751.02   609.69   592.66   591.68
 V  2868.17  2851.14  2850.16   462.52   445.49   444.50
 E  2997.29  2980.26  2979.27   363.39   346.36   345.37
 S  3084.36  3067.33  3066.35   234.27   217.24   216.26
 K   147.20   130.17   129.18






































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 4:57:00 PM
C-58 WITH LABEL 5  
RESIDUE #31-65 
PEPTIDE SEQUENCE: VAHRFKDLGEENFKALVLIAFAQYLQQC*PFEDHVK 
Page 1
DTA for scan: ZU067-E-R, 22803
Precursor ion: 1318.91
Mass type: avg
Mod's: (C* +57.05130) (K# +310.42000) (R@ +310.42000) (H^ +310.42000) (C~ +310.42000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 F   148.18   131.15   130.17
 K   276.36   259.32   258.34  3806.41  3789.38  3788.40
 D   391.44   374.41   373.43  3678.24  3661.21  3660.22
 L   504.60   487.57   486.59  3563.15  3546.12  3545.14
 G   561.65   544.62   543.64  3449.99  3432.96  3431.98
 E   690.77   673.74   672.75  3392.94  3375.91  3374.93
 E   819.88   802.85   801.87  3263.83  3246.80  3245.81
 N   933.98   916.95   915.97  3134.71  3117.68  3116.70
 F  1081.16  1064.13  1063.14  3020.61  3003.58  3002.59
 K  1209.33  1192.30  1191.32  2873.43  2856.40  2855.42
 A  1280.41  1263.38  1262.40  2745.26  2728.23  2727.25
 L  1393.57  1376.54  1375.55  2674.18  2657.15  2656.17
 V  1492.70  1475.67  1474.69  2561.02  2543.99  2543.01
 L  1605.86  1588.83  1587.84  2461.89  2444.86  2443.88
 I  1719.02  1701.99  1701.00  2348.73  2331.70  2330.72
 A  1790.10  1773.06  1772.08  2235.58  2218.55  2217.56
 F  1937.27  1920.24  1919.25  2164.50  2147.47  2146.48
 A  2008.35  1991.32  1990.33  2017.32  2000.29  1999.31
 Q  2136.48  2119.45  2118.46  1946.25  1929.21  1928.23
 Y  2299.65  2282.62  2281.64  1818.12  1801.08  1800.10
 L  2412.81  2395.78  2394.79  1654.94  1637.91  1636.93
 Q  2540.94  2523.91  2522.92  1541.78  1524.75  1523.77
 Q  2669.07  2652.04  2651.05  1413.65  1396.62  1395.64
 C~  3082.63  3065.60  3064.62  1285.52  1268.49  1267.51
 P  3179.75  3162.72  3161.73   871.96   854.93   853.94
 F  3326.92  3309.89  3308.91   774.84   757.81   756.83
 E  3456.04  3439.01  3438.02   627.67   610.64   609.65
 D  3571.13  3554.10  3553.11   498.55   481.52   480.54
 H  3708.27  3691.24  3690.25   383.47   366.44   365.45
 V  3807.40  3790.37  3789.38   246.33   229.30   228.31
 K   147.20   130.17   129.18




























































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 6:15:26 PM
K-186 WITH LABEL 5  
RESIDUE #185-198 
PEPTIDE SEQUENCE: YK*AAFTECCQAADK 
Page 1
DTA for scan: ZU070-E, 17055
Precursor ion: 658.87
Mass type: avg
Mod's: (C* +57.05130) (K# +310.42000) (R@ +310.42000) (H^ +310.42000) (C~ +310.42000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 Y   164.18   147.15   146.17
 K#   602.77   585.74   584.76  1811.10  1794.07  1793.09
 A   673.85   656.82   655.84  1372.51  1355.48  1354.49
 A   744.93   727.90   726.92  1301.43  1284.40  1283.42
 F   892.11   875.08   874.09  1230.35  1213.32  1212.34
 T   993.21   976.18   975.19  1083.18  1066.15  1065.16
 E  1122.32  1105.29  1104.31   982.07   965.04   964.06
 C*  1282.52  1265.49  1264.50   852.96   835.93   834.94
 C*  1442.71  1425.68  1424.70   692.76   675.73   674.75
 Q  1570.84  1553.81  1552.83   532.57   515.54   514.55
 A  1641.92  1624.89  1623.91   404.44   387.41   386.42
 A  1713.00  1695.97  1694.99   333.36   316.33   315.35
 D  1828.09  1811.06  1810.07   262.28   245.25   244.27
 K   147.20   130.17   129.18

























































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 6:38:51 PM
K-286 WITH LABEL 5  
RESIDUE #282-297 
PEPTIDE SEQUENCE: ADLAK*YICENQDSISSK 
Page 1
DTA for scan: ZU067-E_110414174521, 18396
Precursor ion: 752.33
Mass type: avg
Mod's: (C* +57.05130) (K# +310.42000) (R@ +310.42000) (H^ +310.42000) (C~ +310.42000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 A    72.09    55.06    54.07
 D   187.17   170.14   169.16  2182.47  2165.44  2164.45
 L   300.33   283.30   282.32  2067.38  2050.35  2049.36
 A   371.41   354.38   353.39  1954.22  1937.19  1936.21
 K#   810.00   792.97   791.99  1883.14  1866.11  1865.13
 Y   973.18   956.15   955.16  1444.55  1427.52  1426.53
 I  1086.34  1069.30  1068.32  1281.38  1264.34  1263.36
 C*  1246.53  1229.50  1228.51  1168.22  1151.19  1150.20
 E  1375.64  1358.61  1357.63  1008.02   990.99   990.01
 N  1489.75  1472.72  1471.73   878.91   861.88   860.89
 Q  1617.88  1600.85  1599.86   764.80   747.77   746.79
 D  1732.97  1715.93  1714.95   636.67   619.64   618.66
 S  1820.04  1803.01  1802.03   521.59   504.56   503.57
 I  1933.20  1916.17  1915.19   434.51   417.48   416.49
 S  2020.28  2003.25  2002.26   321.35   304.32   303.34
 S  2107.36  2090.33  2089.34   234.27   217.24   216.26
 K   147.20   130.17   129.18


























































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 6:24:43 PM
K-375 WITH LABEL 5  
RESIDUE #373-383 
PEPTIDE SEQUENCE: LAK*TYETTLEK 
Page 1
DTA for scan: ZU067-E_110414174521, 17215
Precursor ion: 805.39
Mass type: avg
Mod's: (C* +57.05130) (K# +310.42000) (R@ +310.42000) (H^ +310.42000) (C~ +310.42000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.17    97.14    96.15
 A   185.24   168.21   167.23  1494.74  1477.71  1476.73
 K#   623.84   606.81   605.82  1423.66  1406.63  1405.65
 T   724.94   707.91   706.93   985.07   968.04   967.05
 Y   888.12   871.08   870.10   883.97   866.94   865.95
 E  1017.23  1000.20   999.21   720.79   703.76   702.78
 T  1118.33  1101.30  1100.32   591.68   574.65   573.66
 T  1219.44  1202.41  1201.42   490.57   473.54   472.56
 L  1332.60  1315.57  1314.58   389.47   372.44   371.45
 E  1461.71  1444.68  1443.70   276.31   259.28   258.29
 K   147.20   130.17   129.18







































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 6:43:51 PM
K-549 WITH LABEL 5  
RESIDUE #549-558 
PEPTIDE SEQUENCE: K*QTALVELVK 
Page 1
DTA for scan: ZU067-E-R2, 18823
Precursor ion: 720.52
Mass type: avg
Mod's: (C* +57.05130) (K# +310.42000) (R@ +310.42000) (H^ +310.42000) (C~ +310.42000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 K#   439.60   422.57   421.58
 Q   567.73   550.70   549.71  1001.20   984.17   983.19
 T   668.83   651.80   650.82   873.07   856.04   855.06
 A   739.91   722.88   721.90   771.97   754.94   753.95
 L   853.07   836.04   835.06   700.89   683.86   682.87
 V   952.20   935.17   934.19   587.73   570.70   569.72
 E  1081.32  1064.29  1063.30   488.60   471.57   470.58
 L  1194.48  1177.44  1176.46   359.49   342.45   341.47
 V  1293.61  1276.58  1275.59   246.33   229.30   228.31
 K   147.20   130.17   129.18













































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 6:32:09 PM
MODIFIED K-569 WITH LABEL 5  
RESIDUE #563-591 
PEPTIDE SEQUENCE: ATKEQLK*AVMDDFAAFVEK 
Page 1
DTA for scan: ZU067-E-R, 21326
Precursor ion: 818.31
Mass type: avg
Mod's: (C* +57.05130) (K# +310.42000) (R@ +310.42000) (H^ +310.42000) (C~ +310.42000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 A    72.09    55.06    54.07
 T   173.19   156.16   155.17  2381.80  2364.77  2363.79
 K   301.36   284.33   283.35  2280.70  2263.67  2262.68
 E   430.48   413.45   412.46  2152.53  2135.50  2134.51
 Q   558.61   541.58   540.59  2023.41  2006.38  2005.40
 L   671.77   654.73   653.75  1895.28  1878.25  1877.27
 K#  1110.36  1093.33  1092.34  1782.12  1765.09  1764.11
 A  1181.44  1164.41  1163.42  1343.53  1326.50  1325.51
 V  1280.57  1263.54  1262.55  1272.45  1255.42  1254.44
 M  1411.77  1394.73  1393.75  1173.32  1156.29  1155.31
 D  1526.85  1509.82  1508.84  1042.12  1025.09  1024.11
 D  1641.94  1624.91  1623.93   927.04   910.00   909.02
 F  1789.12  1772.09  1771.10   811.95   794.92   793.93
 A  1860.19  1843.16  1842.18   664.77   647.74   646.76
 A  1931.27  1914.24  1913.26   593.69   576.66   575.68
 F  2078.45  2061.42  2060.43   522.62   505.59   504.60
 V  2177.58  2160.55  2159.56   375.44   358.41   357.43
 E  2306.69  2289.66  2288.68   276.31   259.28   258.29
 K   147.20   130.17   129.18









































































































BioworksBrowser rev. 3.3.1 SP1 1/22/2012 6:27:28 PM
H-91 WITH LABEL 5  
RESIDUE #89-97 
PEPTIDE SEQUENCE: SLH*TLFGDK 
Page 1
DTA for scan: ZU067-E-R, 20231
Precursor ion: 664.89
Mass type: avg
Mod's: (C* +57.05130) (K# +310.42000) (R@ +310.42000) (H^ +310.42000) (C~ +310.42000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 S    88.09    71.05    70.07
 L   201.24   184.21   183.23  1241.49  1224.46  1223.48
 H^   648.80   631.77   630.79  1128.33  1111.30  1110.32
 T   749.91   732.88   731.89   680.77   663.74   662.76
 L   863.07   846.04   845.05   579.67   562.64   561.65
 F  1010.24   993.21   992.23   466.51   449.48   448.49
 G  1067.29  1050.26  1049.28   319.34   302.30   301.32
 D  1182.38  1165.35  1164.36   262.28   245.25   244.27
 K   147.20   130.17   129.18
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H-170 WITH LABEL 5  
RESIDUE #169-183 
PEPTIDE SEQUENCE: RH*PYFYAPELLFFAK 
Page 1
DTA for scan: ZU032-E-R, 22886
Precursor ion: 1104.85
Mass type: mono
Mod's: (C* +57.02150) (K# +310.42000) (C@ +310.42000) (H^ +310.42000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 R   157.11   140.08   139.10
 H^   604.59   587.56   586.58  2053.31  2036.29  2035.30
 P   701.64   684.61   683.63  1605.84  1588.81  1587.82
 Y   864.70   847.68   846.69  1508.78  1491.76  1490.77
 F  1011.77   994.75   993.76  1345.72  1328.69  1327.71
 Y  1174.84  1157.81  1156.82  1198.65  1181.62  1180.64
 A  1245.87  1228.85  1227.86  1035.59  1018.56  1017.58
 P  1342.93  1325.90  1324.91   964.55   947.52   946.54
 E  1471.97  1454.94  1453.96   867.50   850.47   849.49
 L  1585.05  1568.03  1567.04   738.45   721.43   720.44
 L  1698.14  1681.11  1680.13   625.37   608.34   607.36
 F  1845.20  1828.18  1827.19   512.29   495.26   494.28
 F  1992.27  1975.25  1974.26   365.22   348.19   347.21
 A  2063.31  2046.28  2045.30   218.15   201.12   200.14
 K   147.11   130.09   129.10
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H-312 WITH LABEL 5  
RESIDUE #311-337 
PEPTIDE SEQUENCE: SH*CIAEVENDEMPADLPSLAADFVESK 
Page 1
DTA for scan: ZU034-E-R, 23842
Precursor ion: 1095.41
Mass type: mono
Mod's: (C* +57.02150) (K# +310.42000) (C@ +310.42000) (H^ +310.42000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 S    88.04    71.01    70.03
 H^   535.52   518.49   517.51  3197.73  3180.71  3179.72
 C*   695.55   678.52   677.54  2750.25  2733.23  2732.24
 I   808.63   791.61   790.62  2590.22  2573.20  2572.21
 A   879.67   862.64   861.66  2477.14  2460.11  2459.13
 E  1008.71   991.69   990.70  2406.10  2389.08  2388.09
 V  1107.78  1090.75  1089.77  2277.06  2260.03  2259.05
 E  1236.82  1219.80  1218.81  2177.99  2160.96  2159.98
 N  1350.87  1333.84  1332.86  2048.95  2031.92  2030.94
 D  1465.89  1448.87  1447.88  1934.91  1917.88  1916.89
 E  1594.94  1577.91  1576.93  1819.88  1802.85  1801.87
 M  1725.98  1708.95  1707.97  1690.84  1673.81  1672.83
 P  1823.03  1806.00  1805.02  1559.80  1542.77  1541.78
 A  1894.07  1877.04  1876.06  1462.74  1445.72  1444.73
 D  2009.09  1992.07  1991.08  1391.71  1374.68  1373.69
 L  2122.18  2105.15  2104.17  1276.68  1259.65  1258.67
 P  2219.23  2202.20  2201.22  1163.59  1146.57  1145.58
 S  2306.26  2289.24  2288.25  1066.54  1049.51  1048.53
 L  2419.35  2402.32  2401.34   979.51   962.48   961.50
 A  2490.38  2473.36  2472.37   866.43   849.40   848.41
 A  2561.42  2544.39  2543.41   795.39   778.36   777.38
 D  2676.45  2659.42  2658.44   724.35   707.32   706.34
 F  2823.52  2806.49  2805.51   609.32   592.30   591.31
 V  2922.58  2905.56  2904.57   462.26   445.23   444.25
 E  3051.63  3034.60  3033.62   363.19   346.16   345.18
 S  3138.66  3121.63  3120.65   234.14   217.12   216.13
 K   147.11   130.09   129.10
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APPENDIX B 
CHAPTER 3 
MS/MS Spectra of Modified Peptides in MCO (Fe), MCO (Cu), and HOCl modification. 
 
R-34 MODIFIED WITH MCO (Fe2+) AND LABELED WITH STANDARD BIOTIN 
HYRAZIDE  
AA#29-36 SEVAHRFK  
M/Z =587.08 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU028-B1-R2, 9570
Precursor ion: 587.08
Mass type: mono
Mod's: (C* +57.02150) (K# +241.00000) (R@ +199.00000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 S    88.04    71.01    70.03
 E   217.08   200.06   199.07  1085.49  1068.46  1067.48
 V   316.15   299.12   298.14   956.45   939.42   938.44
 A   387.19   370.16   369.18   857.38   840.35   839.37
 H   524.25   507.22   506.24   786.34   769.31   768.33
 R@   879.35   862.32   861.34   649.28   632.26   631.27
 F  1026.42  1009.39  1008.41   294.18   277.15   276.17
 K   147.11   130.09   129.10
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K-97 MODIFIED WITH MCO (Fe2+) AND LABELED WITH STANDARD BIOTIN 
HYRAZIDE  
AA#89-105 SLHTLFGDKLCTVATLR 
M/Z =725.31 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU028-B1-R2, 18332
Precursor ion: 725.31
Mass type: mono
Mod's: (C* +57.02150) (K# +241.00000) (R@ +199.00000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 S    88.04    71.01    70.03
 L   201.12   184.10   183.11  2086.01  2068.98  2067.99
 H   338.18   321.16   320.17  1972.92  1955.89  1954.91
 T   439.23   422.20   421.22  1835.86  1818.84  1817.85
 L   552.31   535.29   534.30  1734.81  1717.79  1716.80
 F   699.38   682.36   681.37  1621.73  1604.70  1603.72
 G   756.40   739.38   738.39  1474.66  1457.64  1456.65
 D   871.43   854.40   853.42  1417.64  1400.61  1399.63
 K#  1240.53  1223.50  1222.52  1302.61  1285.59  1284.60
 L  1353.61  1336.58  1335.60   933.52   916.49   915.51
 C*  1513.64  1496.61  1495.63   820.43   803.41   802.42
 T  1614.69  1597.66  1596.68   660.40   643.38   642.39
 V  1713.76  1696.73  1695.75   559.36   542.33   541.35
 A  1784.79  1767.77  1766.78   460.29   443.26   442.28
 T  1885.84  1868.81  1867.83   389.25   372.22   371.24
 L  1998.93  1981.90  1980.91   288.20   271.18   270.19
 R   175.12   158.09   157.11
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R-105 MODIFIED WITH MCO (Fe2+) AND LABELED WITH STANDARD BIOTIN 
HYRAZIDE  
AA#98-117 LCTVATLRETYGEMADCCAKR 
M/Z =850.63 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU028-B1-R2, 16390
Precursor ion: 850.63
Mass type: mono
Mod's: (C* +57.02150) (K# +241.00000) (R@ +199.00000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L    86.10   114.09    97.06    96.08
 C*   246.13   274.12   257.10   256.11  2434.95  2417.92  2416.94
 T   347.17   375.17   358.14   357.16  2274.92  2257.89  2256.91
 V   446.24   474.24   457.21   456.23  2173.87  2156.85  2155.86
 A   517.28   545.28   528.25   527.26  2074.80  2057.78  2056.79
 T   618.33   646.32   629.30   628.31  2003.77  1986.74  1985.76
 L   731.41   759.41   742.38   741.40  1902.72  1885.69  1884.71
 R@  1086.51  1114.51  1097.48  1096.50  1789.63  1772.61  1771.62
 E  1215.56  1243.55  1226.52  1225.54  1434.53  1417.51  1416.52
 T  1316.60  1344.60  1327.57  1326.59  1305.49  1288.46  1287.48
 Y  1479.67  1507.66  1490.64  1489.65  1204.44  1187.42  1186.43
 G  1536.69  1564.68  1547.66  1546.67  1041.38  1024.35  1023.37
 E  1665.73  1693.73  1676.70  1675.72   984.36   967.33   966.35
 M  1796.77  1824.77  1807.74  1806.76   855.32   838.29   837.31
 A  1867.81  1895.80  1878.78  1877.79   724.28   707.25   706.26
 D  1982.84  2010.83  1993.80  1992.82   653.24   636.21   635.23
 C*  2142.87  2170.86  2153.83  2152.85   538.21   521.18   520.20
 C*  2302.90  2330.89  2313.87  2312.88   378.18   361.15   360.17
 A  2373.93  2401.93  2384.90  2383.92   218.15   201.12   200.14
 K   147.11   130.09   129.10
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K-161 MODIFIED WITH MCO (Fe2+) AND LABELED WITH STANDARD BIOTIN 
HYRAZIDE  
AA#161-168 KYLYEIAR  
M/Z =649.66 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU028-B1-R2, 12990
Precursor ion: 649.66
Mass type: mono
Mod's: (C* +57.02150) (K# +241.00000) (R@ +199.00000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 K#   370.10   353.08   352.09
 Y   533.17   516.14   515.16   927.49   910.47   909.48
 L   646.25   629.22   628.24   764.43   747.40   746.42
 Y   809.31   792.29   791.30   651.35   634.32   633.34
 E   938.36   921.33   920.34   488.28   471.26   470.27
 I  1051.44  1034.41  1033.43   359.24   342.21   341.23
 A  1122.48  1105.45  1104.47   246.16   229.13   228.15
 R   175.12   158.09   157.11
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R-233 MODIFIED WITH MCO (Fe2+) AND LABELED WITH STANDARD BIOTIN 
HYRAZIDE  
AA#230-236 FGERAF 
M/Z =527.64 (+2 CHARGED) 
 
Page 1




Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 F   148.08   131.05   130.07
 G   205.10   188.07   187.09   707.38   690.36   689.37
 E   334.14   317.11   316.13   650.36   633.34   632.35
 R@   490.24   473.21   472.23   521.32   504.29   503.31
 A   561.28   544.25   543.27   365.22   348.19   347.21
 F   708.35   691.32   690.34   294.18   277.15   276.17
 K   147.11   130.09   129.10
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K-236 MODIFIED WITH MCO(Fe2+) AND LABELED WITH STANDARD BIOTIN 
HYRAZIDE  
AA#234-242 AFKAWAVAR 
M/Z =630.96 (+2 CHARGED) 
Page 1




Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 A    72.04    55.02    54.03
 F   219.11   202.09   201.10   948.54   931.51   930.53
 K#   347.21   330.18   329.20   801.47   784.45   783.46
 A   418.24   401.22   400.23   673.38   656.35   655.37
 W   604.32   587.30   586.31   602.34   585.31   584.33
 A   675.36   658.33   657.35   416.26   399.24   398.25
 V   774.43   757.40   756.42   345.22   328.20   327.21
 A   845.47   828.44   827.46   246.16   229.13   228.15
 R   175.12   158.09   157.11
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R-469 MODIFIED WITH MCO (Fe2+) AND LABELED WITH STANDARD BIOTIN 
HYRAZIDE  
AA#469-490 RMPCAEDYLSVVLNQLCVLHEK  
M/Z =958.7 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU028-B1-R2, 21034
Precursor ion: 958.70
Mass type: mono
Mod's: (C* +57.02150) (K# +241.00000) (R@ +199.00000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 R@   356.11   339.08   338.10
 M   487.15   470.12   469.14  2518.21  2501.19  2500.20
 P   584.20   567.18   566.19  2387.17  2370.15  2369.16
 C*   744.23   727.21   726.22  2290.12  2273.09  2272.11
 A   815.27   798.24   797.26  2130.09  2113.06  2112.08
 E   944.31   927.29   926.30  2059.05  2042.03  2041.04
 D  1059.34  1042.31  1041.33  1930.01  1912.98  1912.00
 Y  1222.40  1205.38  1204.39  1814.98  1797.96  1796.97
 L  1335.49  1318.46  1317.48  1651.92  1634.89  1633.91
 S  1422.52  1405.49  1404.51  1538.84  1521.81  1520.83
 V  1521.59  1504.56  1503.58  1451.80  1434.78  1433.79
 V  1620.66  1603.63  1602.64  1352.74  1335.71  1334.72
 L  1733.74  1716.71  1715.73  1253.67  1236.64  1235.66
 N  1847.78  1830.76  1829.77  1140.58  1123.56  1122.57
 Q  1975.84  1958.81  1957.83  1026.54  1009.51  1008.53
 L  2088.92  2071.90  2070.91   898.48   881.45   880.47
 C*  2248.96  2231.93  2230.94   785.40   768.37   767.39
 V  2348.02  2331.00  2330.01   625.37   608.34   607.36
 L  2461.11  2444.08  2443.10   526.30   509.27   508.29
 H  2598.17  2581.14  2580.16   413.21   396.19   395.20
 E  2727.21  2710.18  2709.20   276.16   259.13   258.14
 K   147.11   130.09   129.10
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K-490 MODIFIED WITH MCO (Fe2+) AND LABELED WITH STANDARD BIOTIN 
HYRAZIDE  
AA#470-490 MPCAEDYLSVVLNQLCVLHEK  
M/Z =925.58 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU028-B1-R2, 19792
Precursor ion: 925.58
Mass type: mono
Mod's: (C* +57.02150) (K# +241.00000) (R@ +199.00000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 M   132.05   115.02   114.04
 P   229.10   212.07   211.09  2644.17  2627.15  2626.16
 C*   389.13   372.10   371.12  2547.12  2530.09  2529.11
 A   460.17   443.14   442.16  2387.09  2370.06  2369.08
 E   589.21   572.18   571.20  2316.05  2299.03  2298.04
 D   704.24   687.21   686.23  2187.01  2169.98  2169.00
 Y   867.30   850.27   849.29  2071.98  2054.96  2053.97
 L   980.39   963.36   962.37  1908.92  1891.89  1890.91
 S  1067.42  1050.39  1049.41  1795.84  1778.81  1777.83
 V  1166.49  1149.46  1148.48  1708.80  1691.78  1690.79
 V  1265.55  1248.53  1247.54  1609.74  1592.71  1591.72
 L  1378.64  1361.61  1360.63  1510.67  1493.64  1492.66
 N  1492.68  1475.65  1474.67  1397.58  1380.56  1379.57
 Q  1620.74  1603.71  1602.73  1283.54  1266.51  1265.53
 L  1733.82  1716.80  1715.81  1155.48  1138.45  1137.47
 C*  1893.85  1876.83  1875.84  1042.40  1025.37  1024.39
 V  1992.92  1975.90  1974.91   882.37   865.34   864.36
 L  2106.01  2088.98  2088.00   783.30   766.27   765.29
 H^  2259.07  2242.04  2241.06   670.21   653.19   652.20
 E  2388.11  2371.08  2370.10   517.16   500.13   499.14
 K#   388.11   371.09   370.10
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K-549 MODIFIED WITH MCO (Fe2+) AND LABELED WITH STANDARD BIOTIN 
HYRAZIDE  
AA#549-558 KQTALVELVK  
M/Z =685.82 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU028-B1-R2, 13595
Precursor ion: 685.82
Mass type: mono
Mod's: (C* +57.02150) (K# +241.00000) (R@ +199.00000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 K#   370.10   353.08   352.09
 Q   498.16   481.13   480.15  1000.60   983.58   982.59
 T   599.21   582.18   581.20   872.55   855.52   854.53
 A   670.25   653.22   652.24   771.50   754.47   753.49
 L   783.33   766.30   765.32   700.46   683.43   682.45
 V   882.40   865.37   864.39   587.38   570.35   569.37
 E  1011.44   994.41   993.43   488.31   471.28   470.30
 L  1124.52  1107.50  1106.51   359.27   342.24   341.25
 V  1223.59  1206.57  1205.58   246.18   229.15   228.17
 K   147.11   130.09   129.10
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R-34 MODIFIED WITH MCO (Fe2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#29-36 SEVAHRFK  
M/Z =643.72 (+2CHARGED) 
 
Page 1
DTA for scan: ZU028-B2-R, 10054
Precursor ion: 643.72
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 S    88.04    71.01    70.03
 E   217.08   200.06   199.07  1198.65  1181.62  1180.64
 V   316.15   299.12   298.14  1069.61  1052.58  1051.60
 A   387.19   370.16   369.18   970.54   953.51   952.53
 H   524.25   507.22   506.24   899.50   882.47   881.49
 R@   992.51   975.48   974.50   762.44   745.42   744.43
 F  1139.58  1122.55  1121.57   294.18   277.15   276.17
 K   147.11   130.09   129.10
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K-97 MODIFIED WITH MCO (Fe2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#89-105 SLHTLFGDKLCTVATLR  
M/Z =763.24 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU028-B2-R, 18423
Precursor ion: 763.24
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 S    88.04    71.01    70.03
 L   201.12   184.10   183.11  2199.17  2182.14  2181.15
 H   338.18   321.16   320.17  2086.08  2069.05  2068.07
 T   439.23   422.20   421.22  1949.02  1932.00  1931.01
 L   552.31   535.29   534.30  1847.97  1830.95  1829.96
 F   699.38   682.36   681.37  1734.89  1717.86  1716.88
 G   756.40   739.38   738.39  1587.82  1570.80  1569.81
 D   871.43   854.40   853.42  1530.80  1513.77  1512.79
 K#  1353.69  1336.66  1335.68  1415.77  1398.75  1397.76
 L  1466.77  1449.74  1448.76   933.52   916.49   915.51
 C*  1626.80  1609.77  1608.79   820.43   803.41   802.42
 T  1727.85  1710.82  1709.84   660.40   643.38   642.39
 V  1826.92  1809.89  1808.91   559.36   542.33   541.35
 A  1897.95  1880.93  1879.94   460.29   443.26   442.28
 T  1999.00  1981.97  1980.99   389.25   372.22   371.24
 L  2112.09  2095.06  2094.07   288.20   271.18   270.19
 R   175.12   158.09   157.11








































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 5:34:23 PM
R-105 MODIFIED WITH MCO (Fe2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#98-117 LCTVATLRETYGEMADCCAK  
M/Z =1331.58 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU028-B2-R, 16770
Precursor ion: 1331.58
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 C*   274.12   257.10   256.11  2548.11  2531.08  2530.10
 T   375.17   358.14   357.16  2388.08  2371.05  2370.07
 V   474.24   457.21   456.23  2287.03  2270.01  2269.02
 A   545.28   528.25   527.26  2187.96  2170.94  2169.95
 T   646.32   629.30   628.31  2116.93  2099.90  2098.92
 L   759.41   742.38   741.40  2015.88  1998.85  1997.87
 R@  1227.67  1210.64  1209.66  1902.79  1885.77  1884.78
 E  1356.71  1339.68  1338.70  1434.53  1417.51  1416.52
 T  1457.76  1440.73  1439.75  1305.49  1288.46  1287.48
 Y  1620.82  1603.80  1602.81  1204.44  1187.42  1186.43
 G  1677.84  1660.82  1659.83  1041.38  1024.35  1023.37
 E  1806.89  1789.86  1788.88   984.36   967.33   966.35
 M  1937.93  1920.90  1919.92   855.32   838.29   837.31
 A  2008.96  1991.94  1990.95   724.28   707.25   706.26
 D  2123.99  2106.96  2105.98   653.24   636.21   635.23
 C*  2284.02  2266.99  2266.01   538.21   521.18   520.20
 C*  2444.05  2427.03  2426.04   378.18   361.15   360.17
 A  2515.09  2498.06  2497.08   218.15   201.12   200.14
 K   147.11   130.09   129.10



















































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 5:00:47 PM
R-141 MODIFIED WITH MCO (Fe2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#139-160 LVRPEVDVMCTAFHDNEETFLK  
M/Z =988.76 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU028-B2-R, 18545
Precursor ion: 988.76
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 V   213.16   196.13   195.15  2849.34  2832.31  2831.33
 R@   681.42   664.39   663.41  2750.27  2733.24  2732.26
 P   778.47   761.45   760.46  2282.01  2264.98  2264.00
 E   907.52   890.49   889.51  2184.96  2167.93  2166.95
 V  1006.58   989.56   988.57  2055.92  2038.89  2037.90
 D  1121.61  1104.59  1103.60  1956.85  1939.82  1938.84
 V  1220.68  1203.65  1202.67  1841.82  1824.79  1823.81
 M  1351.72  1334.69  1333.71  1742.75  1725.72  1724.74
 C*  1511.75  1494.72  1493.74  1611.71  1594.68  1593.70
 T  1612.80  1595.77  1594.79  1451.68  1434.65  1433.67
 A  1683.84  1666.81  1665.83  1350.63  1333.61  1332.62
 F  1830.90  1813.88  1812.89  1279.60  1262.57  1261.58
 H  1967.96  1950.94  1949.95  1132.53  1115.50  1114.52
 D  2082.99  2065.96  2064.98   995.47   978.44   977.46
 N  2197.03  2180.01  2179.02   880.44   863.41   862.43
 E  2326.08  2309.05  2308.07   766.40   749.37   748.39
 E  2455.12  2438.09  2437.11   637.36   620.33   619.34
 T  2556.17  2539.14  2538.16   508.31   491.29   490.30
 F  2703.23  2686.21  2685.22   407.27   390.24   389.25
 L  2816.32  2799.29  2798.31   260.20   243.17   242.19
 K   147.11   130.09   129.10



































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 5:15:27 PM
R-210 MODIFIED WITH MCO (Fe2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#206-214 LDELRDEGK 
M/Z =693.59 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU028-B2-R, 11092
Precursor ion: 693.59
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 D   229.12   212.09   211.11  1273.62  1256.59  1255.61
 E   358.16   341.13   340.15  1158.59  1141.57  1140.58
 L   471.24   454.22   453.23  1029.55  1012.52  1011.54
 R@   939.51   922.48   921.50   916.46   899.44   898.45
 D  1054.53  1037.51  1036.52   448.20   431.18   430.19
 E  1183.58  1166.55  1165.57   333.18   316.15   315.17
 G  1240.60  1223.57  1222.59   204.13   187.11   186.12
 K   147.11   130.09   129.10







































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 5:04:03 PM
K-223 MODIFIED WITH MCO (Fe2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#222-229 LKCASLQK  
M/Z =651.44 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU028-B2-R, 10630
Precursor ion: 651.44
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 K#   596.35   579.32   578.34  1188.61  1171.58  1170.60
 C*   756.38   739.35   738.37   706.36   689.33   688.34
 A   827.41   810.39   809.40   546.32   529.30   528.31
 S   914.45   897.42   896.44   475.29   458.26   457.28
 L  1027.53  1010.50  1009.52   388.26   371.23   370.24
 Q  1155.59  1138.56  1137.58   275.17   258.14   257.16
 K   147.11   130.09   129.10



































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 5:06:49 PM
K-236 MODIFIED WITH MCO (Fe2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#234-242 AFKAWAVAR 
M/Z =687.56 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU028-B2-R2, 13439
Precursor ion: 687.56
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 A    72.04    55.02    54.03
 F   219.11   202.09   201.10  1302.70  1285.67  1284.69
 K#   701.37   684.34   683.36  1155.63  1138.61  1137.62
 A   772.40   755.38   754.39   673.38   656.35   655.37
 W   958.48   941.46   940.47   602.34   585.31   584.33
 A  1029.52  1012.49  1011.51   416.26   399.24   398.25
 V  1128.59  1111.56  1110.58   345.22   328.20   327.21
 A  1199.63  1182.60  1181.62   246.16   229.13   228.15
 R   175.12   158.09   157.11




































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 4:53:20 PM
K-300 MODIFIED WITH MCO (Fe2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#299-310 LKECCEKPLLEK  
M/Z =634.81 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU028-B2-R, 11277
Precursor ion: 634.81
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 K#   596.35   579.32   578.34  1787.87  1770.85  1769.86
 E   725.39   708.36   707.38  1305.62  1288.59  1287.61
 C*   885.42   868.39   867.41  1176.58  1159.55  1158.56
 C*  1045.45  1028.42  1027.44  1016.54   999.52   998.53
 E  1174.49  1157.47  1156.48   856.51   839.49   838.50
 K  1302.59  1285.56  1284.58   727.47   710.44   709.46
 P  1399.64  1382.61  1381.63   599.38   582.35   581.37
 L  1512.72  1495.70  1494.71   502.32   485.30   484.31
 L  1625.81  1608.78  1607.80   389.24   372.21   371.23
 E  1754.85  1737.82  1736.84   276.16   259.13   258.14
 K   147.11   130.09   129.10

















































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 5:09:21 PM
K-337 MODIFIED WITH MCO (Fe2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#311-337 SHCIAEVENDEMPADLPSLAADFVESK  
M/Z =1110.6 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU028-B2, 19282
Precursor ion: 1110.60
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 S    88.04    71.01    70.03
 H   225.10   208.07   207.09  3241.47  3224.45  3223.46
 C*   385.13   368.10   367.12  3104.41  3087.39  3086.40
 I   498.21   481.19   480.20  2944.38  2927.36  2926.37
 A   569.25   552.22   551.24  2831.30  2814.27  2813.29
 E   698.29   681.27   680.28  2760.26  2743.24  2742.25
 V   797.36   780.33   779.35  2631.22  2614.19  2613.21
 E   926.40   909.38   908.39  2532.15  2515.12  2514.14
 N  1040.45  1023.42  1022.44  2403.11  2386.08  2385.10
 D  1155.47  1138.45  1137.46  2289.07  2272.04  2271.05
 E  1284.52  1267.49  1266.51  2174.04  2157.01  2156.03
 M  1415.56  1398.53  1397.55  2045.00  2027.97  2026.99
 P  1512.61  1495.58  1494.60  1913.96  1896.93  1895.94
 A  1583.65  1566.62  1565.64  1816.90  1799.88  1798.89
 D  1698.67  1681.65  1680.66  1745.87  1728.84  1727.85
 L  1811.76  1794.73  1793.75  1630.84  1613.81  1612.83
 P  1908.81  1891.78  1890.80  1517.75  1500.73  1499.74
 S  1995.84  1978.82  1977.83  1420.70  1403.67  1402.69
 L  2108.93  2091.90  2090.92  1333.67  1316.64  1315.66
 A  2179.96  2162.94  2161.95  1220.59  1203.56  1202.57
 A  2251.00  2233.97  2232.99  1149.55  1132.52  1131.54
 D  2366.03  2349.00  2348.02  1078.51  1061.48  1060.50
 F  2513.10  2496.07  2495.09   963.48   946.46   945.47
 V  2612.16  2595.14  2594.15   816.42   799.39   798.41
 E  2741.21  2724.18  2723.20   717.35   700.32   699.34
 S  2828.24  2811.21  2810.23   588.30   571.28   570.29
 K#   501.27   484.25   483.26























































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 5:29:39 PM
K-375 MODIFIED WITH MCO (Fe2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#373-383 LAKTYETTLEK  
M/Z =826.08 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU028-B2-R, 12434
Precursor ion: 826.08
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 A   185.13   168.10   167.12  1537.78  1520.75  1519.77
 K#   667.38   650.36   649.37  1466.74  1449.72  1448.73
 T   768.43   751.40   750.42   984.49   967.46   966.48
 Y   931.49   914.47   913.48   883.44   866.41   865.43
 E  1060.54  1043.51  1042.53   720.38   703.35   702.37
 T  1161.58  1144.56  1143.57   591.33   574.31   573.32
 T  1262.63  1245.61  1244.62   490.29   473.26   472.28
 L  1375.72  1358.69  1357.71   389.24   372.21   371.23
 E  1504.76  1487.73  1486.75   276.16   259.13   258.14
 K   147.11   130.09   129.10












































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 4:58:37 PM
K-402 MODIFIED WITH MCO (Fe2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#397-413 VFDEFKPLVEEPQNLIK  
M/Z =1200.44 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU028-B2-R2, 19170
Precursor ion: 1200.44
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 V   100.08    83.05    82.07
 F   247.14   230.12   229.13  2300.19  2283.16  2282.18
 D   362.17   345.14   344.16  2153.12  2136.09  2135.11
 E   491.21   474.19   473.20  2038.09  2021.07  2020.08
 F   638.28   621.26   620.27  1909.05  1892.02  1891.04
 K#  1120.54  1103.51  1102.53  1761.98  1744.95  1743.97
 P  1217.59  1200.56  1199.58  1279.73  1262.70  1261.72
 L  1330.67  1313.65  1312.66  1182.67  1165.65  1164.66
 V  1429.74  1412.72  1411.73  1069.59  1052.56  1051.58
 E  1558.78  1541.76  1540.77   970.52   953.49   952.51
 E  1687.83  1670.80  1669.82   841.48   824.45   823.47
 P  1784.88  1767.85  1766.87   712.44   695.41   694.42
 Q  1912.94  1895.91  1894.93   615.38   598.36   597.37
 N  2026.98  2009.96  2008.97   487.32   470.30   469.31
 L  2140.07  2123.04  2122.06   373.28   356.25   355.27
 I  2253.15  2236.12  2235.14   260.20   243.17   242.19
 K   147.11   130.09   129.10

































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 6:12:21 PM
R-469 MODIFIED WITH MCO (Fe2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#469-490 RMPCAEDYLSVVLNQLCVLHEK  
M/Z =996.4 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU028-B2-R, 21355
Precursor ion: 996.40
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 R@   469.27   452.24   451.26
 M   600.31   583.28   582.30  2518.21  2501.19  2500.20
 P   697.36   680.34   679.35  2387.17  2370.15  2369.16
 C*   857.39   840.37   839.38  2290.12  2273.09  2272.11
 A   928.43   911.40   910.42  2130.09  2113.06  2112.08
 E  1057.47  1040.45  1039.46  2059.05  2042.03  2041.04
 D  1172.50  1155.47  1154.49  1930.01  1912.98  1912.00
 Y  1335.56  1318.54  1317.55  1814.98  1797.96  1796.97
 L  1448.65  1431.62  1430.64  1651.92  1634.89  1633.91
 S  1535.68  1518.65  1517.67  1538.84  1521.81  1520.83
 V  1634.75  1617.72  1616.74  1451.80  1434.78  1433.79
 V  1733.82  1716.79  1715.80  1352.74  1335.71  1334.72
 L  1846.90  1829.87  1828.89  1253.67  1236.64  1235.66
 N  1960.94  1943.92  1942.93  1140.58  1123.56  1122.57
 Q  2089.00  2071.97  2070.99  1026.54  1009.51  1008.53
 L  2202.08  2185.06  2184.07   898.48   881.45   880.47
 C*  2362.12  2345.09  2344.10   785.40   768.37   767.39
 V  2461.18  2444.16  2443.17   625.37   608.34   607.36
 L  2574.27  2557.24  2556.26   526.30   509.27   508.29
 H  2711.33  2694.30  2693.32   413.21   396.19   395.20
 E  2840.37  2823.34  2822.36   276.16   259.13   258.14
 K   147.11   130.09   129.10



































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 5:23:51 PM
K-490 MODIFIED WITH MCO (Fe2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#470-490 MPCAEDYLSVVLNQLCVLHEK  
M/Z =963.74 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU028-B2-R, 19764
Precursor ion: 963.74
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 M   132.05   115.02   114.04
 P   229.10   212.07   211.09  2757.33  2740.31  2739.32
 C*   389.13   372.10   371.12  2660.28  2643.25  2642.27
 A   460.17   443.14   442.16  2500.25  2483.22  2482.24
 E   589.21   572.18   571.20  2429.21  2412.19  2411.20
 D   704.24   687.21   686.23  2300.17  2283.14  2282.16
 Y   867.30   850.27   849.29  2185.14  2168.12  2167.13
 L   980.39   963.36   962.37  2022.08  2005.05  2004.07
 S  1067.42  1050.39  1049.41  1909.00  1891.97  1890.99
 V  1166.49  1149.46  1148.48  1821.96  1804.94  1803.95
 V  1265.55  1248.53  1247.54  1722.90  1705.87  1704.88
 L  1378.64  1361.61  1360.63  1623.83  1606.80  1605.82
 N  1492.68  1475.65  1474.67  1510.74  1493.72  1492.73
 Q  1620.74  1603.71  1602.73  1396.70  1379.67  1378.69
 L  1733.82  1716.80  1715.81  1268.64  1251.61  1250.63
 C*  1893.85  1876.83  1875.84  1155.56  1138.53  1137.55
 V  1992.92  1975.90  1974.91   995.53   978.50   977.52
 L  2106.01  2088.98  2088.00   896.46   879.43   878.45
 H^  2259.07  2242.04  2241.06   783.37   766.35   765.36
 E  2388.11  2371.08  2370.10   630.32   613.29   612.30
 K#   501.27   484.25   483.26





































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 5:17:40 PM
R-496 MODIFIED WITH MCO (Fe2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#491-499 TPVSDRVTK  
M/Z =658.22 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU028-B2-R, 10276
Precursor ion: 658.22
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 T   102.05    85.03    84.04
 P   199.11   182.08   181.10  1213.67  1196.64  1195.66
 V   298.18   281.15   280.17  1116.62  1099.59  1098.61
 S   385.21   368.18   367.20  1017.55  1000.52   999.54
 D   500.24   483.21   482.22   930.52   913.49   912.51
 R@   968.50   951.47   950.49   815.49   798.46   797.48
 V  1067.56  1050.54  1049.55   347.23   330.20   329.22
 T  1168.61  1151.59  1150.60   248.16   231.13   230.15
 K   147.11   130.09   129.10












































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 6:10:15 PM
K-549 MODIFIED WITH MCO (Fe2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#549-558 KQTALVELVK  
M/Z =742.27 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU028-B2, 14141
Precursor ion: 742.27
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 K#   483.26   466.24   465.25
 Q   611.32   594.29   593.31  1000.60   983.58   982.59
 T   712.37   695.34   694.36   872.55   855.52   854.53
 A   783.41   766.38   765.40   771.50   754.47   753.49
 L   896.49   879.46   878.48   700.46   683.43   682.45
 V   995.56   978.53   977.55   587.38   570.35   569.37
 E  1124.60  1107.57  1106.59   488.31   471.28   470.30
 L  1237.68  1220.66  1219.67   359.27   342.24   341.25
 V  1336.75  1319.73  1318.74   246.18   229.15   228.17
 K   147.11   130.09   129.10




















































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 4:56:56 PM
K-97 MODIFIED WITH MCO (Fe2+) AND LABELED WITH PEG4 LINKED BIOTIN 
HYRAZIDE  
AA#89-105 SLHTLFGDKLCTVATLR 
M/Z =807.94 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU028-B3-R2, 18446
Precursor ion: 807.94
Mass type: mono
Mod's: (C* +57.02150) (K# +487.92000) (R@ +445.92000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 S    88.04    71.01    70.03
 L   201.12   184.10   183.11  2332.93  2315.90  2314.91
 H   338.18   321.16   320.17  2219.84  2202.81  2201.83
 T   439.23   422.20   421.22  2082.78  2065.76  2064.77
 L   552.31   535.29   534.30  1981.73  1964.71  1963.72
 F   699.38   682.36   681.37  1868.65  1851.62  1850.64
 G   756.40   739.38   738.39  1721.58  1704.56  1703.57
 D   871.43   854.40   853.42  1664.56  1647.53  1646.55
 K#  1487.45  1470.42  1469.44  1549.53  1532.51  1531.52
 L  1600.53  1583.50  1582.52   933.52   916.49   915.51
 C*  1760.56  1743.53  1742.55   820.43   803.41   802.42
 T  1861.61  1844.58  1843.60   660.40   643.38   642.39
 V  1960.68  1943.65  1942.67   559.36   542.33   541.35
 A  2031.71  2014.69  2013.70   460.29   443.26   442.28
 T  2132.76  2115.73  2114.75   389.25   372.22   371.24
 L  2245.85  2228.82  2227.83   288.20   271.18   270.19
 R   175.12   158.09   157.11









































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 6:28:41 PM
R-105 MODIFIED WITH MCO (Fe2+) AND LABELED WITH PEG4 LINKED BIOTIN 
HYRAZIDE  
AA#98-117 LCTVATLRETYGEMADCCAK  
M/Z =932.97 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU028-B3, 16604
Precursor ion: 932.97
Mass type: mono
Mod's: (C* +57.02150) (K# +487.92000) (R@ +445.92000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 C*   274.12   257.10   256.11  2681.87  2664.84  2663.86
 T   375.17   358.14   357.16  2521.84  2504.81  2503.83
 V   474.24   457.21   456.23  2420.79  2403.77  2402.78
 A   545.28   528.25   527.26  2321.72  2304.70  2303.71
 T   646.32   629.30   628.31  2250.69  2233.66  2232.68
 L   759.41   742.38   741.40  2149.64  2132.61  2131.63
 R@  1361.43  1344.40  1343.42  2036.55  2019.53  2018.54
 E  1490.47  1473.44  1472.46  1434.53  1417.51  1416.52
 T  1591.52  1574.49  1573.51  1305.49  1288.46  1287.48
 Y  1754.58  1737.56  1736.57  1204.44  1187.42  1186.43
 G  1811.60  1794.58  1793.59  1041.38  1024.35  1023.37
 E  1940.65  1923.62  1922.64   984.36   967.33   966.35
 M  2071.69  2054.66  2053.68   855.32   838.29   837.31
 A  2142.72  2125.70  2124.71   724.28   707.25   706.26
 D  2257.75  2240.72  2239.74   653.24   636.21   635.23
 C*  2417.78  2400.75  2399.77   538.21   521.18   520.20
 C*  2577.81  2560.79  2559.80   378.18   361.15   360.17
 A  2648.85  2631.82  2630.84   218.15   201.12   200.14
 K   147.11   130.09   129.10












































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 6:16:46 PM
R-210 MODIFIED WITH MCO (Fe2+) AND LABELED WITH PEG4 LINKED BIOTIN 
HYRAZIDE  
AA#206-214 LDELRDEGK  
M/Z =761.7 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU028-B3-R, 11652
Precursor ion: 761.70
Mass type: mono
Mod's: (C* +57.02150) (K# +487.92000) (R@ +445.92000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 D   229.12   212.09   211.11  1407.38  1390.35  1389.37
 E   358.16   341.13   340.15  1292.35  1275.33  1274.34
 L   471.24   454.22   453.23  1163.31  1146.28  1145.30
 R@  1073.27  1056.24  1055.26  1050.22  1033.20  1032.21
 D  1188.29  1171.27  1170.28   448.20   431.18   430.19
 E  1317.34  1300.31  1299.33   333.18   316.15   315.17
 G  1374.36  1357.33  1356.35   204.13   187.11   186.12
 K   147.11   130.09   129.10


































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 6:20:17 PM
K-223 MODIFIED WITH MCO (Fe2+) AND LABELED WITH PEG4 LINKED 
BIOTIN HYRAZIDE  
AA#222-229 LKCASLQK 
M/Z =718.41 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU028-B3-R2, 11055
Precursor ion: 718.41
Mass type: mono
Mod's: (C* +57.02150) (K# +487.92000) (R@ +445.92000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 K#   730.11   713.08   712.10  1322.37  1305.34  1304.36
 C*   890.14   873.11   872.13   706.36   689.33   688.34
 A   961.17   944.15   943.16   546.32   529.30   528.31
 S  1048.21  1031.18  1030.20   475.29   458.26   457.28
 L  1161.29  1144.26  1143.28   388.26   371.23   370.24
 Q  1289.35  1272.32  1271.34   275.17   258.14   257.16
 K   147.11   130.09   129.10































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 6:21:59 PM
R-469 MODIFIED WITH MCO (Fe2+) AND LABELED WITH PEG4 LINKED BIOTIN 
HYRAZIDE  
AA#469-490 RMPCAEDYLSVVLNQLCVLHEK  
M/Z =1041.26 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU028-B3, 21299
Precursor ion: 1041.26
Mass type: mono
Mod's: (C* +57.02150) (K# +487.92000) (R@ +445.92000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 R@   603.03   586.00   585.02
 M   734.07   717.04   716.06  2518.21  2501.19  2500.20
 P   831.12   814.10   813.11  2387.17  2370.15  2369.16
 C*   991.15   974.13   973.14  2290.12  2273.09  2272.11
 A  1062.19  1045.16  1044.18  2130.09  2113.06  2112.08
 E  1191.23  1174.21  1173.22  2059.05  2042.03  2041.04
 D  1306.26  1289.23  1288.25  1930.01  1912.98  1912.00
 Y  1469.32  1452.30  1451.31  1814.98  1797.96  1796.97
 L  1582.41  1565.38  1564.40  1651.92  1634.89  1633.91
 S  1669.44  1652.41  1651.43  1538.84  1521.81  1520.83
 V  1768.51  1751.48  1750.50  1451.80  1434.78  1433.79
 V  1867.58  1850.55  1849.56  1352.74  1335.71  1334.72
 L  1980.66  1963.63  1962.65  1253.67  1236.64  1235.66
 N  2094.70  2077.68  2076.69  1140.58  1123.56  1122.57
 Q  2222.76  2205.73  2204.75  1026.54  1009.51  1008.53
 L  2335.84  2318.82  2317.83   898.48   881.45   880.47
 C*  2495.88  2478.85  2477.86   785.40   768.37   767.39
 V  2594.94  2577.92  2576.93   625.37   608.34   607.36
 L  2708.03  2691.00  2690.02   526.30   509.27   508.29
 H  2845.09  2828.06  2827.08   413.21   396.19   395.20
 E  2974.13  2957.10  2956.12   276.16   259.13   258.14
 K   147.11   130.09   129.10












































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 6:26:27 PM
K-490 MODIFIED WITH MCO (Fe2+) AND LABELED WITH PEG4 LINKED 
BIOTIN HYRAZIDE  
AA#470-490 MPCAEDYLSVVLNQLCVLHEK 
M/Z =1008.48 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU028-B3-R, 19804
Precursor ion: 1008.48
Mass type: mono
Mod's: (C* +57.02150) (K# +487.92000) (R@ +445.92000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 M   132.05   115.02   114.04
 P   229.10   212.07   211.09  2891.09  2874.07  2873.08
 C*   389.13   372.10   371.12  2794.04  2777.01  2776.03
 A   460.17   443.14   442.16  2634.01  2616.98  2616.00
 E   589.21   572.18   571.20  2562.97  2545.95  2544.96
 D   704.24   687.21   686.23  2433.93  2416.90  2415.92
 Y   867.30   850.27   849.29  2318.90  2301.88  2300.89
 L   980.39   963.36   962.37  2155.84  2138.81  2137.83
 S  1067.42  1050.39  1049.41  2042.76  2025.73  2024.75
 V  1166.49  1149.46  1148.48  1955.72  1938.70  1937.71
 V  1265.55  1248.53  1247.54  1856.66  1839.63  1838.64
 L  1378.64  1361.61  1360.63  1757.59  1740.56  1739.58
 N  1492.68  1475.65  1474.67  1644.50  1627.48  1626.49
 Q  1620.74  1603.71  1602.73  1530.46  1513.43  1512.45
 L  1733.82  1716.80  1715.81  1402.40  1385.37  1384.39
 C*  1893.85  1876.83  1875.84  1289.32  1272.29  1271.31
 V  1992.92  1975.90  1974.91  1129.29  1112.26  1111.28
 L  2106.01  2088.98  2088.00  1030.22  1013.19  1012.21
 H^  2259.07  2242.04  2241.06   917.13   900.11   899.12
 E  2388.11  2371.08  2370.10   764.08   747.05   746.06
 K#   635.03   618.01   617.02











































































































BioworksBrowser rev. 3.3.1 SP1 3/3/2012 6:24:40 PM
K-36 MODIFIED WITH MCO (Cu2+) AND LABELED WITH STANDARD BIOTIN 
HYRAZIDE  
AA#35-44 FKDLGEENFK 
M/Z =735.2 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU024-C1, 12817
Precursor ion: 735.20
Mass type: mono
Mod's: (C* +57.02150) (K# +241.00000) (R@ +199.00000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 F   148.08   131.05   130.07
 K#   517.17   500.14   499.16  1320.54  1303.51  1302.53
 D   632.20   615.17   614.19   951.44   934.42   933.43
 L   745.28   728.26   727.27   836.41   819.39   818.40
 G   802.30   785.28   784.29   723.33   706.30   705.32
 E   931.35   914.32   913.34   666.31   649.28   648.30
 E  1060.39  1043.36  1042.38   537.27   520.24   519.26
 N  1174.43  1157.40  1156.42   408.22   391.20   390.21
 F  1321.50  1304.47  1303.49   294.18   277.15   276.17
 K   147.11   130.09   129.10



































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 9:24:53 PM
K-161 MODIFIED WITH MCO (Cu2+) AND LABELED WITH STANDARD BIOTIN 
HYRAZIDE  
AA#161-168 KYLYEIAR 
M/Z =649.64 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU024-C1-R2, 12551
Precursor ion: 649.64
Mass type: mono
Mod's: (C* +57.02150) (K# +241.00000) (R@ +199.00000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 K#   370.10   353.08   352.09
 Y   533.17   516.14   515.16   927.49   910.47   909.48
 L   646.25   629.22   628.24   764.43   747.40   746.42
 Y   809.31   792.29   791.30   651.35   634.32   633.34
 E   938.36   921.33   920.34   488.28   471.26   470.27
 I  1051.44  1034.41  1033.43   359.24   342.21   341.23
 A  1122.48  1105.45  1104.47   246.16   229.13   228.15
 R   175.12   158.09   157.11










































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 9:28:54 PM
K-198 MODIFIED WITH MCO (Cu2+) AND LABELED WITH STANDARD BIOTIN 
HYRAZIDE  
AA#187-205 AAFTECCQAADKAACLL 
M/Z =789.69 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU024-C1-R2, 16143
Precursor ion: 789.69
Mass type: mono
Mod's: (C* +57.02150) (K# +241.00000) (R@ +199.00000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 A    72.04    55.02    54.03
 A   143.08   126.05   125.07  2294.95  2277.92  2276.94
 F   290.15   273.12   272.14  2223.91  2206.89  2205.90
 T   391.20   374.17   373.19  2076.84  2059.82  2058.83
 E   520.24   503.21   502.23  1975.80  1958.77  1957.79
 C*   680.27   663.24   662.26  1846.75  1829.73  1828.74
 C*   840.30   823.28   822.29  1686.72  1669.70  1668.71
 Q   968.36   951.33   950.35  1526.69  1509.67  1508.68
 A  1039.40  1022.37  1021.39  1398.63  1381.61  1380.62
 A  1110.43  1093.41  1092.42  1327.60  1310.57  1309.59
 D  1225.46  1208.43  1207.45  1256.56  1239.53  1238.55
 K#  1594.56  1577.53  1576.55  1141.53  1124.51  1123.52
 A  1665.59  1648.57  1647.58   772.44   755.41   754.43
 A  1736.63  1719.60  1718.62   701.40   684.37   683.39
 C*  1896.66  1879.63  1878.65   630.36   613.34   612.35
 L  2009.75  1992.72  1991.73   470.33   453.31   452.32
 L  2122.83  2105.80  2104.82   357.25   340.22   339.24
 P  2219.88  2202.86  2201.87   244.17   227.14   226.16
 K   147.11   130.09   129.10













































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 9:25:58 PM
K-223 MODIFIED WITH MCO (Cu2+) AND LABELED WITH STANDARD BIOTIN 
HYRAZIDE  
AA#222-229 LKCASLQK 
M/Z =595.61 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU024-C1, 9687
Precursor ion: 595.61
Mass type: mono
Mod's: (C* +57.02150) (K# +241.00000) (R@ +199.00000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 K#   483.19   466.16   465.18  1075.45  1058.42  1057.44
 C*   643.22   626.19   625.21   706.36   689.33   688.34
 A   714.25   697.23   696.24   546.32   529.30   528.31
 S   801.29   784.26   783.28   475.29   458.26   457.28
 L   914.37   897.34   896.36   388.26   371.23   370.24
 Q  1042.43  1025.40  1024.42   275.17   258.14   257.16
 K   147.11   130.09   129.10



































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 9:33:21 PM
K-236 MODIFIED WITH MCO (Cu2+) AND LABELED WITH STANDARD BIOTIN 
HYRAZIDE  
AA#234-242 AFKAWAVAR 
M/Z =631.16 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU024-C1-R, 12708
Precursor ion: 631.16
Mass type: mono
Mod's: (C* +57.02150) (K# +241.00000) (R@ +199.00000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 A    72.04    55.02    54.03
 F   219.11   202.09   201.10  1189.54  1172.51  1171.53
 K#   588.21   571.18   570.20  1042.47  1025.45  1024.46
 A   659.24   642.22   641.23   673.38   656.35   655.37
 W   845.32   828.30   827.31   602.34   585.31   584.33
 A   916.36   899.33   898.35   416.26   399.24   398.25
 V  1015.43   998.40   997.42   345.22   328.20   327.21
 A  1086.47  1069.44  1068.46   246.16   229.13   228.15
 R   175.12   158.09   157.11

































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 9:25:24 PM
K-375 MODIFIED WITH MCO (Cu2+) AND LABELED WITH STANDARD BIOTIN 
HYRAZIDE  
AA#373-383 LAKTYETTLEK 
M/Z =769.7 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU024-C1, 11251
Precursor ion: 769.70
Mass type: mono
Mod's: (C* +57.02150) (K# +241.00000) (R@ +199.00000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 A   185.13   168.10   167.12  1424.62  1407.59  1406.61
 K#   554.22   537.20   536.21  1353.58  1336.56  1335.57
 T   655.27   638.24   637.26   984.49   967.46   966.48
 Y   818.33   801.31   800.32   883.44   866.41   865.43
 E   947.38   930.35   929.37   720.38   703.35   702.37
 T  1048.42  1031.40  1030.41   591.33   574.31   573.32
 T  1149.47  1132.45  1131.46   490.29   473.26   472.28
 L  1262.56  1245.53  1244.55   389.24   372.21   371.23
 E  1391.60  1374.57  1373.59   276.16   259.13   258.14
 K   147.11   130.09   129.10














































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 9:31:13 PM
R-469 MODIFIED WITH MCO (Cu2+) AND LABELED WITH STANDARD BIOTIN 
HYRAZIDE  
AA#464-490 HPEAKRMPCAEDYLSVVLNQLCVLHEK 
M/Z =1146.38 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU024-C1, 19589
Precursor ion: 1146.38
Mass type: mono
Mod's: (C* +57.02150) (K# +241.00000) (R@ +199.00000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 H   138.07   121.04   120.06
 P   235.12   218.09   217.11  3298.54  3281.52  3280.53
 E   364.16   347.13   346.15  3201.49  3184.46  3183.48
 A   435.20   418.17   417.19  3072.45  3055.42  3054.44
 K   563.29   546.27   545.28  3001.41  2984.38  2983.40
 R@   918.39   901.37   900.38  2873.32  2856.29  2855.30
 M  1049.44  1032.41  1031.42  2518.21  2501.19  2500.20
 P  1146.49  1129.46  1128.48  2387.17  2370.15  2369.16
 C*  1306.52  1289.49  1288.51  2290.12  2273.09  2272.11
 A  1377.56  1360.53  1359.55  2130.09  2113.06  2112.08
 E  1506.60  1489.57  1488.59  2059.05  2042.03  2041.04
 D  1621.63  1604.60  1603.61  1930.01  1912.98  1912.00
 Y  1784.69  1767.66  1766.68  1814.98  1797.96  1796.97
 L  1897.77  1880.75  1879.76  1651.92  1634.89  1633.91
 S  1984.80  1967.78  1966.79  1538.84  1521.81  1520.83
 V  2083.87  2066.85  2065.86  1451.80  1434.78  1433.79
 V  2182.94  2165.92  2164.93  1352.74  1335.71  1334.72
 L  2296.03  2279.00  2278.02  1253.67  1236.64  1235.66
 N  2410.07  2393.04  2392.06  1140.58  1123.56  1122.57
 Q  2538.13  2521.10  2520.12  1026.54  1009.51  1008.53
 L  2651.21  2634.18  2633.20   898.48   881.45   880.47
 C*  2811.24  2794.22  2793.23   785.40   768.37   767.39
 V  2910.31  2893.28  2892.30   625.37   608.34   607.36
 L  3023.39  3006.37  3005.38   526.30   509.27   508.29
 H  3160.45  3143.43  3142.44   413.21   396.19   395.20
 E  3289.50  3272.47  3271.49   276.16   259.13   258.14
 K   147.11   130.09   129.10







































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 9:22:17 PM
K-490 MODIFIED WITH MCO (Cu2+) AND LABELED WITH STANDARD BIOTIN 
HYRAZIDE  
AA#470-490 MPCAEDYLSVVLNQLCVLHEK 
M/Z =926.19 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU024-C1-R2, 19376
Precursor ion: 926.05
Mass type: mono
Mod's: (C* +57.02150) (K# +241.00000) (R@ +199.00000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 M   132.05   115.02   114.04
 P   229.10   212.07   211.09  2644.17  2627.15  2626.16
 C*   389.13   372.10   371.12  2547.12  2530.09  2529.11
 A   460.17   443.14   442.16  2387.09  2370.06  2369.08
 E   589.21   572.18   571.20  2316.05  2299.03  2298.04
 D   704.24   687.21   686.23  2187.01  2169.98  2169.00
 Y   867.30   850.27   849.29  2071.98  2054.96  2053.97
 L   980.39   963.36   962.37  1908.92  1891.89  1890.91
 S  1067.42  1050.39  1049.41  1795.84  1778.81  1777.83
 V  1166.49  1149.46  1148.48  1708.80  1691.78  1690.79
 V  1265.55  1248.53  1247.54  1609.74  1592.71  1591.72
 L  1378.64  1361.61  1360.63  1510.67  1493.64  1492.66
 N  1492.68  1475.65  1474.67  1397.58  1380.56  1379.57
 Q  1620.74  1603.71  1602.73  1283.54  1266.51  1265.53
 L  1733.82  1716.80  1715.81  1155.48  1138.45  1137.47
 C*  1893.85  1876.83  1875.84  1042.40  1025.37  1024.39
 V  1992.92  1975.90  1974.91   882.37   865.34   864.36
 L  2106.01  2088.98  2088.00   783.30   766.27   765.29
 H^  2259.07  2242.04  2241.06   670.21   653.19   652.20
 E  2388.11  2371.08  2370.10   517.16   500.13   499.14
 K#   388.11   371.09   370.10









































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 10:42:12 PM
K-549 MODIFIED WITH MCO (Cu2+) AND LABELED WITH STANDARD BIOTIN 
HYRAZIDE  
AA#549-558 KQTALVELVK 
M/Z =685.53 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU024-C1, 13412
Precursor ion: 685.53
Mass type: mono
Mod's: (C* +57.02150) (K# +241.00000) (R@ +199.00000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 K#   370.10   353.08   352.09
 Q   498.16   481.13   480.15  1000.60   983.58   982.59
 T   599.21   582.18   581.20   872.55   855.52   854.53
 A   670.25   653.22   652.24   771.50   754.47   753.49
 L   783.33   766.30   765.32   700.46   683.43   682.45
 V   882.40   865.37   864.39   587.38   570.35   569.37
 E  1011.44   994.41   993.43   488.31   471.28   470.30
 L  1124.52  1107.50  1106.51   359.27   342.24   341.25
 V  1223.59  1206.57  1205.58   246.18   229.15   228.17
 K   147.11   130.09   129.10

















































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 9:20:58 PM
K-97 MODIFIED WITH MCO (Cu2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA# 89-105 SLHTLFGDKLCTVATLR 
M/Z =763.26 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU024-C2-R, 17683
Precursor ion: 763.26
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 S    88.04    71.01    70.03
 L   201.12   184.10   183.11  2199.17  2182.14  2181.15
 H   338.18   321.16   320.17  2086.08  2069.05  2068.07
 T   439.23   422.20   421.22  1949.02  1932.00  1931.01
 L   552.31   535.29   534.30  1847.97  1830.95  1829.96
 F   699.38   682.36   681.37  1734.89  1717.86  1716.88
 G   756.40   739.38   738.39  1587.82  1570.80  1569.81
 D   871.43   854.40   853.42  1530.80  1513.77  1512.79
 K#  1353.69  1336.66  1335.68  1415.77  1398.75  1397.76
 L  1466.77  1449.74  1448.76   933.52   916.49   915.51
 C*  1626.80  1609.77  1608.79   820.43   803.41   802.42
 T  1727.85  1710.82  1709.84   660.40   643.38   642.39
 V  1826.92  1809.89  1808.91   559.36   542.33   541.35
 A  1897.95  1880.93  1879.94   460.29   443.26   442.28
 T  1999.00  1981.97  1980.99   389.25   372.22   371.24
 L  2112.09  2095.06  2094.07   288.20   271.18   270.19
 R   175.12   158.09   157.11






































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 10:47:47 PM
K-161 MODIFIED WITH MCO (Cu2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#161-168 KYLYEIAR 
M/Z =705.77 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU024-C2-R, 12926
Precursor ion: 705.77
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 K#   483.26   466.24   465.25
 Y   646.33   629.30   628.32   927.49   910.47   909.48
 L   759.41   742.38   741.40   764.43   747.40   746.42
 Y   922.47   905.45   904.46   651.35   634.32   633.34
 E  1051.52  1034.49  1033.50   488.28   471.26   470.27
 I  1164.60  1147.57  1146.59   359.24   342.21   341.23
 A  1235.64  1218.61  1217.63   246.16   229.13   228.15
 R   175.12   158.09   157.11














































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 10:20:09 PM
R-169 MODIFIED WITH MCO (Cu2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA# 169-183 RHPYFYAPELLFFAK 
M/Z =738.3 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU024-C2, 17861
Precursor ion: 738.30
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 R@   469.27   452.24   451.26
 H   606.33   589.30   588.32  1742.89  1725.87  1724.88
 P   703.38   686.35   685.37  1605.84  1588.81  1587.82
 Y   866.44   849.42   848.43  1508.78  1491.76  1490.77
 F  1013.51   996.49   995.50  1345.72  1328.69  1327.71
 Y  1176.58  1159.55  1158.56  1198.65  1181.62  1180.64
 A  1247.61  1230.59  1229.60  1035.59  1018.56  1017.58
 P  1344.67  1327.64  1326.65   964.55   947.52   946.54
 E  1473.71  1456.68  1455.70   867.50   850.47   849.49
 L  1586.79  1569.77  1568.78   738.45   721.43   720.44
 L  1699.88  1682.85  1681.87   625.37   608.34   607.36
 F  1846.94  1829.92  1828.93   512.29   495.26   494.28
 F  1994.01  1976.99  1976.00   365.22   348.19   347.21
 A  2065.05  2048.02  2047.04   218.15   201.12   200.14
 K   147.11   130.09   129.10

















































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 10:46:01 PM
R-210 MODIFIED WITH MCO (Cu2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA# 206-214 LDELRDEGK 
M/Z =694.48 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU024-C2-R, 10796
Precursor ion: 694.48
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 D   229.12   212.09   211.11  1273.62  1256.59  1255.61
 E   358.16   341.13   340.15  1158.59  1141.57  1140.58
 L   471.24   454.22   453.23  1029.55  1012.52  1011.54
 R@   939.51   922.48   921.50   916.46   899.44   898.45
 D  1054.53  1037.51  1036.52   448.20   431.18   430.19
 E  1183.58  1166.55  1165.57   333.18   316.15   315.17
 G  1240.60  1223.57  1222.59   204.13   187.11   186.12
 K   147.11   130.09   129.10













































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 10:28:15 PM
K-223 MODIFIED WITH MCO (Cu2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#222-229 LKCASLQK 
M/Z =651.41 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU024-C2-R2, 10361
Precursor ion: 651.41
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 K#   596.35   579.32   578.34  1188.61  1171.58  1170.60
 C*   756.38   739.35   738.37   706.36   689.33   688.34
 A   827.41   810.39   809.40   546.32   529.30   528.31
 S   914.45   897.42   896.44   475.29   458.26   457.28
 L  1027.53  1010.50  1009.52   388.26   371.23   370.24
 Q  1155.59  1138.56  1137.58   275.17   258.14   257.16
 K   147.11   130.09   129.10


































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 10:32:49 PM
K-236 MODIFIED WITH MCO (Cu2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA# 234-242 AFKAWAVAR 
M/Z =687.61 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU024-C2-R2, 13124
Precursor ion: 687.61
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 A    72.04    55.02    54.03
 F   219.11   202.09   201.10  1302.70  1285.67  1284.69
 K#   701.37   684.34   683.36  1155.63  1138.61  1137.62
 A   772.40   755.38   754.39   673.38   656.35   655.37
 W   958.48   941.46   940.47   602.34   585.31   584.33
 A  1029.52  1012.49  1011.51   416.26   399.24   398.25
 V  1128.59  1111.56  1110.58   345.22   328.20   327.21
 A  1199.63  1182.60  1181.62   246.16   229.13   228.15
 R   175.12   158.09   157.11







































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 10:03:50 PM
R-246 MODIFIED WITH MCO (Cu2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#243-249 LSQRFPK 
M/Z =594.41 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU024-C2, 11078
Precursor ion: 594.41
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 S   201.12   184.10   183.11  1074.59  1057.56  1056.58
 Q   329.18   312.16   311.17   987.55   970.53   969.54
 R@   797.44   780.42   779.43   859.50   842.47   841.48
 F   944.51   927.48   926.50   391.23   374.21   373.22
 P  1041.56  1024.54  1023.55   244.17   227.14   226.16
 K   147.11   130.09   129.10








































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 10:35:43 PM
K-257 MODIFIED WITH MCO (Cu2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#250-264 AEFAEVSKLVTDLTK 
M/Z =1003.24 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU024-C2-R, 19238
Precursor ion: 1003.24
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 A    72.04    55.02    54.03
 E   201.09   184.06   183.08  1934.02  1916.99  1916.01
 F   348.16   331.13   330.14  1804.98  1787.95  1786.96
 A   419.19   402.17   401.18  1657.91  1640.88  1639.90
 E   548.24   531.21   530.22  1586.87  1569.84  1568.86
 V   647.30   630.28   629.29  1457.83  1440.80  1439.82
 S   734.34   717.31   716.32  1358.76  1341.73  1340.75
 K#  1216.59  1199.56  1198.58  1271.73  1254.70  1253.72
 L  1329.67  1312.65  1311.66   789.47   772.45   771.46
 V  1428.74  1411.72  1410.73   676.39   659.36   658.38
 T  1529.79  1512.76  1511.78   577.32   560.29   559.31
 D  1644.82  1627.79  1626.81   476.27   459.24   458.26
 L  1757.90  1740.88  1739.89   361.24   344.22   343.23
 T  1858.95  1841.92  1840.94   248.16   231.13   230.15
 K   147.11   130.09   129.10





































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 9:56:47 PM
K-375 MODIFIED WITH MCO (Cu2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA#373-383 LAKTYETTLEK 
M/Z =826.48 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU024-C2-R, 11905
Precursor ion: 826.48
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 A   185.13   168.10   167.12  1537.78  1520.75  1519.77
 K#   667.38   650.36   649.37  1466.74  1449.72  1448.73
 T   768.43   751.40   750.42   984.49   967.46   966.48
 Y   931.49   914.47   913.48   883.44   866.41   865.43
 E  1060.54  1043.51  1042.53   720.38   703.35   702.37
 T  1161.58  1144.56  1143.57   591.33   574.31   573.32
 T  1262.63  1245.61  1244.62   490.29   473.26   472.28
 L  1375.72  1358.69  1357.71   389.24   372.21   371.23
 E  1504.76  1487.73  1486.75   276.16   259.13   258.14
 K   147.11   130.09   129.10











































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 10:25:22 PM
K-490 MODIFIED WITH MCO (Cu2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA# 470-490 MPCAEDYLSVVLNQLCVLHEK 
M/Z =964.04 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU024-C2-R, 19288
Precursor ion: 964.04
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 M   132.05   115.02   114.04
 P   229.10   212.07   211.09  2757.33  2740.31  2739.32
 C*   389.13   372.10   371.12  2660.28  2643.25  2642.27
 A   460.17   443.14   442.16  2500.25  2483.22  2482.24
 E   589.21   572.18   571.20  2429.21  2412.19  2411.20
 D   704.24   687.21   686.23  2300.17  2283.14  2282.16
 Y   867.30   850.27   849.29  2185.14  2168.12  2167.13
 L   980.39   963.36   962.37  2022.08  2005.05  2004.07
 S  1067.42  1050.39  1049.41  1909.00  1891.97  1890.99
 V  1166.49  1149.46  1148.48  1821.96  1804.94  1803.95
 V  1265.55  1248.53  1247.54  1722.90  1705.87  1704.88
 L  1378.64  1361.61  1360.63  1623.83  1606.80  1605.82
 N  1492.68  1475.65  1474.67  1510.74  1493.72  1492.73
 Q  1620.74  1603.71  1602.73  1396.70  1379.67  1378.69
 L  1733.82  1716.80  1715.81  1268.64  1251.61  1250.63
 C*  1893.85  1876.83  1875.84  1155.56  1138.53  1137.55
 V  1992.92  1975.90  1974.91   995.53   978.50   977.52
 L  2106.01  2088.98  2088.00   896.46   879.43   878.45
 H^  2259.07  2242.04  2241.06   783.37   766.35   765.36
 E  2388.11  2371.08  2370.10   630.32   613.29   612.30
 K#   501.27   484.25   483.26












































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 10:42:37 PM
K-549 MODIFIED WITH MCO (Cu2+) AND LABELED WITH EXTENDED CHAIN 
BIOTIN HYRAZIDE  
AA# 549-558 KQTALVELVK 
M/Z =742.5 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU024-C2-R2, 14018
Precursor ion: 742.50
Mass type: mono
Mod's: (C* +57.02150) (K# +354.16000) (R@ +312.16000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 K#   483.26   466.24   465.25
 Q   611.32   594.29   593.31  1000.60   983.58   982.59
 T   712.37   695.34   694.36   872.55   855.52   854.53
 A   783.41   766.38   765.40   771.50   754.47   753.49
 L   896.49   879.46   878.48   700.46   683.43   682.45
 V   995.56   978.53   977.55   587.38   570.35   569.37
 E  1124.60  1107.57  1106.59   488.31   471.28   470.30
 L  1237.68  1220.66  1219.67   359.27   342.24   341.25
 V  1336.75  1319.73  1318.74   246.18   229.15   228.17
 K   147.11   130.09   129.10






















































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 10:11:47 PM
R-169 MODIFIED WITH MCO (Cu2+) AND LABELED WITH PEG4 LINKED 
BIOTIN HYRAZIDE  
AA# 169-183 RHPYFYAPELLFFAK 
M/Z =782.62 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU024-C3-R2, 17962
Precursor ion: 782.62
Mass type: mono
Mod's: (C* +57.02150) (K# +487.92000) (R@ +445.92000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 R@   603.03   586.00   585.02
 H   740.09   723.06   722.08  1742.89  1725.87  1724.88
 P   837.14   820.11   819.13  1605.84  1588.81  1587.82
 Y  1000.20   983.18   982.19  1508.78  1491.76  1490.77
 F  1147.27  1130.25  1129.26  1345.72  1328.69  1327.71
 Y  1310.34  1293.31  1292.32  1198.65  1181.62  1180.64
 A  1381.37  1364.35  1363.36  1035.59  1018.56  1017.58
 P  1478.43  1461.40  1460.41   964.55   947.52   946.54
 E  1607.47  1590.44  1589.46   867.50   850.47   849.49
 L  1720.55  1703.53  1702.54   738.45   721.43   720.44
 L  1833.64  1816.61  1815.63   625.37   608.34   607.36
 F  1980.70  1963.68  1962.69   512.29   495.26   494.28
 F  2127.77  2110.75  2109.76   365.22   348.19   347.21
 A  2198.81  2181.78  2180.80   218.15   201.12   200.14
 K   147.11   130.09   129.10


































































































BioworksBrowser rev. 3.3.1 SP1 3/1/2012 11:15:22 PM
K-198 MODIFIED WITH MCO (Cu2+) AND LABELED WITH PEG4 LINKED 
BIOTIN HYRAZIDE  
AA# 187-205 AAFTECCQAADKAACLLPK 
M/Z =871.9 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU024-C3-R, 16578
Precursor ion: 871.90
Mass type: mono
Mod's: (C* +57.02150) (K# +487.92000) (R@ +445.92000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 A    72.04    55.02    54.03
 A   143.08   126.05   125.07  2541.87  2524.84  2523.86
 F   290.15   273.12   272.14  2470.83  2453.81  2452.82
 T   391.20   374.17   373.19  2323.76  2306.74  2305.75
 E   520.24   503.21   502.23  2222.72  2205.69  2204.71
 C*   680.27   663.24   662.26  2093.67  2076.65  2075.66
 C*   840.30   823.28   822.29  1933.64  1916.62  1915.63
 Q   968.36   951.33   950.35  1773.61  1756.59  1755.60
 A  1039.40  1022.37  1021.39  1645.55  1628.53  1627.54
 A  1110.43  1093.41  1092.42  1574.52  1557.49  1556.51
 D  1225.46  1208.43  1207.45  1503.48  1486.45  1485.47
 K#  1841.48  1824.45  1823.47  1388.45  1371.43  1370.44
 A  1912.51  1895.49  1894.50   772.44   755.41   754.43
 A  1983.55  1966.52  1965.54   701.40   684.37   683.39
 C*  2143.58  2126.55  2125.57   630.36   613.34   612.35
 L  2256.67  2239.64  2238.65   470.33   453.31   452.32
 L  2369.75  2352.72  2351.74   357.25   340.22   339.24
 P  2466.80  2449.78  2448.79   244.17   227.14   226.16
 K   147.11   130.09   129.10
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K-223 MODIFIED WITH MCO (Cu2+) AND LABELED WITH PEG4 LINKED 
BIOTIN HYRAZIDE  
AA# 222-229 LKCASLQK 
M/Z =718.54 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU024-C3-R2, 10811
Precursor ion: 718.54
Mass type: mono
Mod's: (C* +57.02150) (K# +487.92000) (R@ +445.92000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 L   114.09    97.06    96.08
 K#   730.11   713.08   712.10  1322.37  1305.34  1304.36
 C*   890.14   873.11   872.13   706.36   689.33   688.34
 A   961.17   944.15   943.16   546.32   529.30   528.31
 S  1048.21  1031.18  1030.20   475.29   458.26   457.28
 L  1161.29  1144.26  1143.28   388.26   371.23   370.24
 Q  1289.35  1272.32  1271.34   275.17   258.14   257.16
 K   147.11   130.09   129.10
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K-236 MODIFIED WITH MCO (Cu2+) AND LABELED WITH PEG4 LINKED 
BIOTIN HYRAZIDE  
AA# 234-242 AFKAWAVAR 
M/Z =754.64 (+2 CHARGED) 
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DTA for scan: ZU024-C3-R2, 13313
Precursor ion: 754.64
Mass type: mono
Mod's: (C* +57.02150) (K# +487.92000) (R@ +445.92000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 A    72.04    55.02    54.03
 F   219.11   202.09   201.10  1436.46  1419.43  1418.45
 K#   835.13   818.10   817.12  1289.39  1272.37  1271.38
 A   906.16   889.14   888.15   673.38   656.35   655.37
 W  1092.24  1075.22  1074.23   602.34   585.31   584.33
 A  1163.28  1146.25  1145.27   416.26   399.24   398.25
 V  1262.35  1245.32  1244.34   345.22   328.20   327.21
 A  1333.39  1316.36  1315.38   246.16   229.13   228.15
 R   175.12   158.09   157.11
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K-490 MODIFIED WITH MCO (Cu2+) AND LABELED WITH PEG4 LINKED 
BIOTIN HYRAZIDE  
AA# 470-490 MPCAEDYLSVVLNQLCVLHEK 
M/Z =1008.6 (+3 CHARGED) 
 
Page 1
DTA for scan: ZU024-C3-R, 19377
Precursor ion: 1008.60
Mass type: mono
Mod's: (C* +57.02150) (K# +487.92000) (R@ +445.92000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 M   132.05   115.02   114.04
 P   229.10   212.07   211.09  2891.09  2874.07  2873.08
 C*   389.13   372.10   371.12  2794.04  2777.01  2776.03
 A   460.17   443.14   442.16  2634.01  2616.98  2616.00
 E   589.21   572.18   571.20  2562.97  2545.95  2544.96
 D   704.24   687.21   686.23  2433.93  2416.90  2415.92
 Y   867.30   850.27   849.29  2318.90  2301.88  2300.89
 L   980.39   963.36   962.37  2155.84  2138.81  2137.83
 S  1067.42  1050.39  1049.41  2042.76  2025.73  2024.75
 V  1166.49  1149.46  1148.48  1955.72  1938.70  1937.71
 V  1265.55  1248.53  1247.54  1856.66  1839.63  1838.64
 L  1378.64  1361.61  1360.63  1757.59  1740.56  1739.58
 N  1492.68  1475.65  1474.67  1644.50  1627.48  1626.49
 Q  1620.74  1603.71  1602.73  1530.46  1513.43  1512.45
 L  1733.82  1716.80  1715.81  1402.40  1385.37  1384.39
 C*  1893.85  1876.83  1875.84  1289.32  1272.29  1271.31
 V  1992.92  1975.90  1974.91  1129.29  1112.26  1111.28
 L  2106.01  2088.98  2088.00  1030.22  1013.19  1012.21
 H^  2259.07  2242.04  2241.06   917.13   900.11   899.12
 E  2388.11  2371.08  2370.10   764.08   747.05   746.06
 K#   635.03   618.01   617.02
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K-549 MODIFIED WITH MCO (Cu2+) AND LABELED WITH PEG4 LINKED 
BIOTIN HYRAZIDE  
AA# 549-558 KQTALVELVK 
M/Z =809.35 (+2 CHARGED) 
 
Page 1
DTA for scan: ZU024-C3-R, 14575
Precursor ion: 809.35
Mass type: mono
Mod's: (C* +57.02150) (K# +487.92000) (R@ +445.92000) (H^ +16.00000) 
Ion series for charge: +1
AA   A ions     B ions     B* ions    Bo ions     C ions    Y ions    Y* ions    Yo ions    Z ions
---------------------------------------------------------------------------------------------------
 K#   617.02   600.00   599.01
 Q   745.08   728.05   727.07  1000.60   983.58   982.59
 T   846.13   829.10   828.12   872.55   855.52   854.53
 A   917.17   900.14   899.16   771.50   754.47   753.49
 L  1030.25  1013.22  1012.24   700.46   683.43   682.45
 V  1129.32  1112.29  1111.31   587.38   570.35   569.37
 E  1258.36  1241.33  1240.35   488.31   471.28   470.30
 L  1371.44  1354.42  1353.43   359.27   342.24   341.25
 V  1470.51  1453.49  1452.50   246.18   229.15   228.17
 K   147.11   130.09   129.10
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CRYSTAL STRUCTURES OF HSA WITH MCO MODIFICATION SITES  
 
Figure 1: Arg-34 and Lys-97 modification sites with MCO. Residues of interest within a 10 Å 
radius of the modification site are labeled in the figure. Red colors represent acidic residues 
whereas, blue ones represent basic residues. Gray ones are the neutral residues. 
 
 
Figure 2: Arg-105 and Lys-161 modification sites with MCO. Residues of interest within a 10 Å 
radius of the modification site are labeled in the figure. Red colors represent acidic residues 
whereas, blue ones represent basic residues. Gray ones are the neutral residues. 
  
Figure 3: Arg-169 and Lys-198 modification sites with MCO. Residues of interest within a 10 Å 
radius of the modification site are labeled in the figure. Red colors represent acidic residues 
whereas, blue ones represent basic residues. Gray ones are the neutral residues. 
 
 
Figure 4: Arg-210 and Lys-223 modification sites with MCO. Residues of interest within a 10 Å 
radius of the modification site are labeled in the figure. Red colors represent acidic residues 
whereas, blue ones represent basic residues. Gray ones are the neutral residues. 
 
 Figure 5: Lys-236 and Lys-249 modification sites with MCO. Residues of interest within a 10 Å 
radius of the modification site are labeled in the figure. Red colors represent acidic residues 
whereas, blue ones represent basic residues. Gray ones are the neutral residues. 
 
 
Figure 6: Lys-375 and Arg-469 modification sites with MCO. Residues of interest within a 10 Å 
radius of the modification site are labeled in the figure. Red colors represent acidic residues 
whereas, blue ones represent basic residues. Gray ones are the neutral residues. 
 
  
Figure 7: Lys-490 and Lys-549 modification sites with MCO. Residues of interest within a 10 Å 
radius of the modification site are labeled in the figure. Red colors represent acidic residues 
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Table 1: iTRAQ labeled proteins in the first sample in the first set. 
Identified Proteins  Mw Ratio 










CE05165 WBGene00001922 locus:his-48 histone H2B status:Confirmed 
UniProt:Q27876 protein_id:CAA97413.1 
14 kDa 0.41 





CE06652 WBGene00014095 glutamate dehydrogenase status:Confirmed 
UniProt:Q23621 protein_id:CAA98074.1 
59 kDa 0.57 
CE03253 WBGene00001919 locus:his-45 histone H3 status:Confirmed 
UniProt:P08898 protein_id:CAA97411.1 
15 kDa 0.62 
CE27244 WBGene00002025 locus:hsp-60 status:Confirmed 60 kDa 0.66 





CE02183 WBGene00000114 locus:alh-8 methylmalonate-semialdehyde 
dehydrogenase status:Confirmed UniProt:P52713 protein_id:CAA88946.1 
56 kDa 0.66 
CE04501 WBGene00001921 locus:his-47 histone H2A status:Confirmed 
UniProt:P09588 protein_id:CAA97414.1 
13 kDa 0.66 





CE25005 WBGene00000041 locus:aco-2 Aconitate hydratase status:Confirmed 
UniProt:P34455 protein_id:AAA28050.2 
84 kDa 0.76 
CE02255 WBGene00004416 locus:rpl-5 60S ribosomal protein L5 status:Confirmed 
UniProt:P49405 protein_id:CAA90251.1 
33 kDa 0.87 
CE16463 WBGene00000067 locus:act-5 Actins status:Confirmed UniProt:O45815 
protein_id:CAB05817.1 
42 kDa 0.87 
CE05347 WBGene00007880 NADH-ubiquinone oxidoreductase 13 KD-B subunit 
status:Confirmed UniProt:Q18359 protein_id:CAA92789.1 
17 kDa 0.87 
CE01921 WBGene00006727 locus:ubq-1 status:Confirmed UniProt:P0CG71 
protein_id:AAC46525.1 
94 kDa 0.87 
CE16576 WBGene00002264 locus:lec-1 galectin status:Partially_confirmed 
UniProt:P36573 protein_id:CAB04959.1 
32 kDa 0.93 
CE24278 WBGene00004473 locus:rps-4 status:Confirmed UniProt:Q9N3X2 
protein_id:AAF60569.1 
29 kDa 0.93 
CE09349 WBGene00006789 locus:unc-54 myosin heavy chain 




CE31083 WBGene00020950 dihydrolipoamide succinyltransferase status:Confirmed 
UniProt:O45148 protein_id:AAC04462.2 
50 kDa 1.00 
CE07721 WBGene00001137 locus:eat-6 Na(+)\/K(+) ATPase alpha subunit 




CE18826 WBGene00010419 ATP synthase alpha and beta subunits, ATP synthase 
Alpha chain, C terminal status:Confirmed UniProt:Q9XXK1 protein_id:CAA19429.1 
58 kDa 1.07 
CE12358 WBGene00000066 locus:act-4 actin status:Confirmed UniProt:P10986 
protein_id:AAB04575.1 
42 kDa 1.07 
CE06313 WBGene00004442 locus:rpl-28 ribsomal protein L28 like status:Confirmed 
UniProt:Q21930 protein_id:CAA99898.1 
14 kDa 1.07 
CE09682 WBGene00002005 locus:hsp-1 HSP-1 heat shock 70kd protein A 
status:Confirmed UniProt:P09446 protein_id:CAB02319.1 
70 kDa 1.07 
CE01270 WBGene00001168 locus:eef-1A.1 Elongation factor 1-alpha 
status:Confirmed UniProt:P53013 protein_id:AAA81688.1 
51 kDa 1.15 
CE17071 WBGene00002162 locus:isp-1 ubiquinol-cytochrome C reductase 
status:Confirmed UniProt:O44512 protein_id:AAB92071.1 
30 kDa 1.15 
CE09719 WBGene00000230 locus:atp-3 ATPase status:Confirmed UniProt:P91283 
protein_id:AAB37654.1 
22 kDa 1.15 
CE29950 WBGene00000229 locus:atp-2 ATP synthase beta chain status:Confirmed 
UniProt:P46561 protein_id:AAA19068.2 
58 kDa 1.23 
CE29443 WBGene00019900 Channel Protein status:Confirmed UniProt:Q21752 
protein_id:AAB00622.2 
30 kDa 1.23 
CE14263 WBGene00006439 locus:ant-1.1 ADP\/ATP carrier protein 
status:Confirmed UniProt:O45865 protein_id:CAB04874.1 
33 kDa 1.23 
CE27514 WBGene00022089 status:Confirmed UniProt:Q95XJ0 
protein_id:AAK68562.1 
32 kDa 1.23 
CE03574 WBGene00011273 ATP synthase complex f subunit like protein 
status:Confirmed UniProt:Q22021 protein_id:CAA91350.1 
19 kDa 1.23 
CE15602 WBGene00007385 locus:atp-5 ATP synthase D chain status:Confirmed 
UniProt:Q17763 protein_id:CAA99772.1 
22 kDa 1.23 
CE18676 WBGene00009688 status:Confirmed UniProt:Q9XU97 
protein_id:CAB05509.1 
9 kDa 1.32 
CE09162 WBGene00008505 phosphate carrier protein precursor status:Confirmed 
UniProt:P40614 protein_id:CAA97430.1 
37 kDa 1.41 
CE11226 WBGene00018963 locus:ucr-1 Mitochondrial processing protease 
enhancing protein status:Confirmed UniProt:P98080 protein_id:AAB52679.1 
52 kDa 1.41 
CE01976 WBGene00019061 ATP synthase status:Confirmed UniProt:Q09544 
protein_id:AAC46699.1 
17 kDa 1.52 
CE09946 WBGene00009454 status:Confirmed UniProt:P90860 
protein_id:CAB03069.1 
20 kDa 1.52 
CE03454 WBGene00010485 locus:ant-1.3 ADP\/ATP carrier protein 
status:Confirmed UniProt:Q21103 protein_id:CAA92472.1 
34 kDa 1.74 






Table 2: iTRAQ labeled proteins in the second sample in the first set. 
Identified Proteins  Mw Ratio 





CE03921 WBGene00006929 locus:vit-5 status:Confirmed UniProt:P06125 186 0.50 
protein_id:AAA83587.1 kDa 










CE29950 WBGene00000229 locus:atp-2 ATP synthase beta chain status:Confirmed 
UniProt:P46561 protein_id:AAA19068.2 
58 kDa 0.93 
CE01976 WBGene00019061 ATP synthase status:Confirmed UniProt:Q09544 
protein_id:AAC46699.1 
17 kDa 0.93 
CE26775 WBGene00004014 locus:phb-1 status:Confirmed UniProt:Q9BKU4 
protein_id:AAK27865.1 
30 kDa 0.93 





CE21562 WBGene00000802 locus:crt-1 calreticulin precursor status:Confirmed 
UniProt:P27798 protein_id:AAD14746.1 
46 kDa 1.00 
CE15602 WBGene00007385 locus:atp-5 ATP synthase D chain status:Confirmed 
UniProt:Q17763 protein_id:CAA99772.1 
22 kDa 1.00 
CE02183 WBGene00000114 locus:alh-8 methylmalonate-semialdehyde 
dehydrogenase status:Confirmed UniProt:P52713 protein_id:CAA88946.1 
56 kDa 1.00 
CE35351 WBGene00010965 cytochrome oxidase subunit II 
status:Partially_confirmed 
27 kDa 1.00 
CE16463 WBGene00000067 locus:act-5 Actins status:Confirmed UniProt:O45815 
protein_id:CAB05817.1 
42 kDa 1.00 
CE11226 WBGene00018963 locus:ucr-1 Mitochondrial processing protease 
enhancing protein status:Confirmed UniProt:P98080 protein_id:AAB52679.1 
52 kDa 1.00 
CE09162 WBGene00008505 phosphate carrier protein precursor status:Confirmed 
UniProt:P40614 protein_id:CAA97430.1 
37 kDa 1.07 
CE08526 WBGene00004425 locus:rpl-13 ribosomal protein L13 status:Confirmed 
UniProt:P91128 protein_id:AAB42322.1 
24 kDa 1.07 
CE14263 WBGene00006439 locus:ant-1.1 ADP\/ATP carrier protein 
status:Confirmed UniProt:O45865 protein_id:CAB04874.1 
33 kDa 1.15 
CE29443 WBGene00019900 Channel Protein status:Confirmed UniProt:Q21752 
protein_id:AAB00622.2 
30 kDa 1.15 
CE06652 WBGene00014095 glutamate dehydrogenase status:Confirmed 
UniProt:Q23621 protein_id:CAA98074.1 
59 kDa 1.15 
CE17069 WBGene00018361 status:Confirmed UniProt:O44509 
protein_id:AAB92069.1 
21 kDa 1.15 
CE19904 WBGene00004496 locus:rps-27 ribosomal protein status:Confirmed 
UniProt:Q9TXP0 protein_id:AAC69219.1 
9 kDa 1.15 
CE09512 WBGene00003162 locus:mdh-2 malate dehydrogenase status:Confirmed 
UniProt:O02640 protein_id:AAB53985.1 
35 kDa 1.15 





CE07669 WBGene00004415 locus:rpl-4 ribosomal protein L1 status:Confirmed 
UniProt:O02056 protein_id:AAC24253.1 
39 kDa 1.15 
CE18826 WBGene00010419 ATP synthase alpha and beta subunits, ATP synthase 58 kDa 1.23 
Alpha chain, C terminal status:Confirmed UniProt:Q9XXK1 protein_id:CAA19429.1 
CE03454 WBGene00010485 locus:ant-1.3 ADP\/ATP carrier protein 
status:Confirmed UniProt:Q21103 protein_id:CAA92472.1 
34 kDa 1.23 
CE16650 WBGene00004430 locus:rpl-18 Eukaryotic ribosomal protein L18 
status:Confirmed UniProt:O45946 protein_id:CAA16387.1 
21 kDa 1.23 
CE22589 WBGene00013238 locus:trap-4 status:Confirmed UniProt:Q9U238 
protein_id:CAB60502.1 
17 kDa 1.23 
CE08258 WBGene00007646 locus:nkb-1 sodium\/potassium transporting ATPase 
beta chain status:Confirmed UniProt:Q93235 protein_id:CAB02752.1 
37 kDa 1.23 
CE07244 WBGene00002008 locus:hsp-4 heat shock protein 
status:Partially_confirmed UniProt:P20163 protein_id:AAC71123.1 
72 kDa 1.23 
CE18478 WBGene00004413 locus:rpl-2 Ribosomal Proteins L2 status:Confirmed 
UniProt:Q9XVF7 protein_id:CAB03792.1 
28 kDa 1.23 
CE01270 WBGene00001168 locus:eef-1A.1 Elongation factor 1-alpha 
status:Confirmed UniProt:P53013 protein_id:AAA81688.1 
51 kDa 1.32 
CE12358 WBGene00000066 locus:act-4 actin status:Confirmed UniProt:P10986 
protein_id:AAB04575.1 
42 kDa 1.32 
CE27244 WBGene00002025 locus:hsp-60 status:Confirmed 60 kDa 1.32 
CE11570 WBGene00003964 locus:pdi-3 protein disulphide isomerase ER-60 
precursor like status:Confirmed UniProt:O17908 protein_id:CAB07480.1 
55 kDa 1.32 
CE17071 WBGene00002162 locus:isp-1 ubiquinol-cytochrome C reductase 
status:Confirmed UniProt:O44512 protein_id:AAB92071.1 
30 kDa 1.32 
CE00744 WBGene00004417 locus:rpl-6 Ribosomal protein ML16 status:Confirmed 
UniProt:P47991 protein_id:AAK29850.1 
24 kDa 1.32 
CE17986 WBGene00004424 locus:rpl-12 Ribosomal protein L11 status:Confirmed 
UniProt:P61866 protein_id:CAB05226.1 
18 kDa 1.32 
CE11024 WBGene00004418 locus:rpl-7 ribosomal protein status:Confirmed 
UniProt:O01802 protein_id:AAB54165.1 
28 kDa 1.32 
CE05656 WBGene00008920 locus:eef-1G elongation factor 1-gamma 
status:Confirmed UniProt:P54412 protein_id:CAA96631.1 
44 kDa 1.32 
CE05721 WBGene00004439 locus:rpl-25.2 60S ribosomal protein status:Confirmed 
UniProt:Q20647 protein_id:CAA99858.1 
16 kDa 1.32 
CE05860 WBGene00004480 locus:rps-11 ribosomal protein S11 status:Confirmed 
UniProt:Q20206 protein_id:CAA97792.1 
18 kDa 1.32 
CE09866 WBGene00017982 locus:hpo-18 ATP synthase epsilion chain 
status:Confirmed UniProt:O16298 protein_id:AAB65352.1 
6 kDa 1.32 
CE27514 WBGene00022089 status:Confirmed UniProt:Q95XJ0 
protein_id:AAK68562.1 
32 kDa 1.41 
CE09946 WBGene00009454 status:Confirmed UniProt:P90860 
protein_id:CAB03069.1 
20 kDa 1.41 
CE24592 WBGene00004475 locus:rps-6 40S ribosomal protein S6 status:Confirmed 
UniProt:Q9NEN6 protein_id:CAB81996.1 
28 kDa 1.41 
CE04237 WBGene00004471 locus:rps-2 status:Confirmed UniProt:P51403 
protein_id:AAF99899.1 
29 kDa 1.41 
CE01380 WBGene00004420 locus:rpl-9 Ribosomal protein L9 status:Confirmed 
UniProt:Q95Y90 protein_id:AAK84469.1 
22 kDa 1.41 
CE03972 WBGene00003963 locus:pdi-2 protein disulfide isomerase 
status:Confirmed UniProt:Q17770 protein_id:AAK39152.1 
55 kDa 1.52 
CE08631 WBGene00002010 locus:hsp-6 heat shock 70 protein 
status:Partially_confirmed UniProt:P11141 protein_id:AAB42371.1 
71 kDa 1.52 
CE27398 WBGene00004419 locus:rpl-7A status:Confirmed UniProt:Q966C6 
protein_id:AAK84600.1 
30 kDa 1.52 
CE05598 WBGene00004414 locus:rpl-3 60S ribosomal protein L3 status:Confirmed 
UniProt:P50880 protein_id:CAA91277.1 
46 kDa 1.52 
CE01810 WBGene00004472 locus:rps-3 Ribosomal protein S3 status:Confirmed 
UniProt:P48152 protein_id:AAF99870.1 
27 kDa 1.52 
CE01030 WBGene00004428 locus:rpl-16 L13P family ribosomal protein 
status:Confirmed UniProt:Q27389 protein_id:CAA86515.1 
23 kDa 1.52 
CE21392 WBGene00004432 locus:rpl-20 ribosomal protein status:Confirmed 
UniProt:O44480 protein_id:AAB92041.2 
21 kDa 1.52 
CE22210 WBGene00013025 locus:vha-13 ATP synthase alpha and beta subunits \; 
ATP synthase ab C terminal status:Confirmed UniProt:Q9XW92 
protein_id:CAA22076.1 
66 kDa 1.52 
CE25005 WBGene00000041 locus:aco-2 Aconitate hydratase status:Confirmed 
UniProt:P34455 protein_id:AAA28050.2 
84 kDa 1.52 
CE00513 WBGene00000833 locus:cts-1 Citrate synthase status:Confirmed 
UniProt:P34575 protein_id:CAA83004.1 
52 kDa 1.52 
CE08034 WBGene00004431 locus:rpl-19 60S ribosomal protein L19 status:Confirmed 
UniProt:O02639 protein_id:AAB53979.1 
24 kDa 1.52 
CE08177 WBGene00002007 locus:hsp-3 heat shock protein status:Confirmed 
UniProt:P27420 protein_id:AAB52671.1 
73 kDa 1.62 
CE00854 WBGene00004469 locus:rps-0 40S ribosomal protein status:Confirmed 
UniProt:P46769 protein_id:CAA86061.1 
31 kDa 1.62 
CE06313 WBGene00004442 locus:rpl-28 ribsomal protein L28 like status:Confirmed 
UniProt:Q21930 protein_id:CAA99898.1 
14 kDa 1.62 
CE16576 WBGene00002264 locus:lec-1 galectin status:Partially_confirmed 
UniProt:P36573 protein_id:CAB04959.1 
32 kDa 1.62 
CE24278 WBGene00004473 locus:rps-4 status:Confirmed UniProt:Q9N3X2 
protein_id:AAF60569.1 
29 kDa 1.62 
CE01921 WBGene00006727 locus:ubq-1 status:Confirmed UniProt:P0CG71 
protein_id:AAC46525.1 
94 kDa 1.62 
CE07721 WBGene00001137 locus:eat-6 Na(+)\/K(+) ATPase alpha subunit 




CE15900 WBGene00001167 locus:eef-2 Elongation factor Tu family (contains 
ATP\/GTP binding P-loop) status:Confirmed UniProt:P29691 protein_id:CAB02985.1 
95 kDa 1.62 
CE20509 WBGene00000198 locus:art-1 status:Confirmed UniProt:Q9N5Y2 
protein_id:AAF39753.1 
35 kDa 1.74 
decoy_15677 67 kDa 1.74 
CE16769 WBGene00015037 status:Partially_confirmed UniProt:O45063 
protein_id:AAC02565.1 
79 kDa 1.74 
CE02255 WBGene00004416 locus:rpl-5 60S ribosomal protein L5 status:Confirmed 
UniProt:P49405 protein_id:CAA90251.1 
33 kDa 1.87 
CE06360 WBGene00004474 locus:rps-5 40S ribosomal protein S5 status:Confirmed 
UniProt:P49041 protein_id:CAA92971.1 
23 kDa 1.87 
CE00078 WBGene00004433 locus:rpl-21 Ribosomal protein L21 status:Confirmed 
UniProt:P34334 protein_id:AAA27951.1 
18 kDa 1.87 
CE00821 WBGene00004483 locus:rps-14 Ribosomal protein S14 status:Confirmed 
UniProt:P48150 protein_id:AAC48301.1 
16 kDa 1.87 
CE09682 WBGene00002005 locus:hsp-1 HSP-1 heat shock 70kd protein A 
status:Confirmed UniProt:P09446 protein_id:CAB02319.1 
70 kDa 2.00 
 
 
Table 3: iTRAQ labeled proteins in the third sample in the first set. 
Identified Proteins  Mw Ratio 















CE02183 WBGene00000114 locus:alh-8 methylmalonate-semialdehyde 
dehydrogenase status:Confirmed UniProt:P52713 protein_id:CAA88946.1 
56 kDa 0.76 





CE01976 WBGene00019061 ATP synthase status:Confirmed UniProt:Q09544 
protein_id:AAC46699.1 
17 kDa 0.81 
CE27242 WBGene00021248 status:Confirmed UniProt:Q965Q1 
protein_id:AAK84584.1 
12 kDa 0.81 
CE35351 WBGene00010965 cytochrome oxidase subunit II 
status:Partially_confirmed 
27 kDa 0.81 
CE16463 WBGene00000067 locus:act-5 Actins status:Confirmed UniProt:O45815 
protein_id:CAB05817.1 
42 kDa 0.81 
CE06233 WBGene00011015 status:Confirmed UniProt:Q21732 
protein_id:CAA98960.1 
12 kDa 0.87 
CE29950 WBGene00000229 locus:atp-2 ATP synthase beta chain status:Confirmed 
UniProt:P46561 protein_id:AAA19068.2 
58 kDa 0.93 
CE26775 WBGene00004014 locus:phb-1 status:Confirmed UniProt:Q9BKU4 
protein_id:AAK27865.1 
30 kDa 0.93 
CE32507 WBGene00012166 locus:nuo-6 status:Confirmed UniProt:Q23098 
protein_id:CAA95851.2 
20 kDa 0.93 
CE05656 WBGene00008920 locus:eef-1G elongation factor 1-gamma 
status:Confirmed UniProt:P54412 protein_id:CAA96631.1 
44 kDa 0.93 
CE06652 WBGene00014095 glutamate dehydrogenase status:Confirmed 
UniProt:Q23621 protein_id:CAA98074.1 
59 kDa 1.00 
CE09162 WBGene00008505 phosphate carrier protein precursor status:Confirmed 37 kDa 1.00 
UniProt:P40614 protein_id:CAA97430.1 
CE11226 WBGene00018963 locus:ucr-1 Mitochondrial processing protease 
enhancing protein status:Confirmed UniProt:P98080 protein_id:AAB52679.1 
52 kDa 1.00 
CE15602 WBGene00007385 locus:atp-5 ATP synthase D chain status:Confirmed 
UniProt:Q17763 protein_id:CAA99772.1 
22 kDa 1.00 
CE16792 WBGene00015248 locus:mai-2 ATPase inhibitor status:Confirmed 
UniProt:O44441 protein_id:AAB92010.1 
12 kDa 1.00 
CE14263 WBGene00006439 locus:ant-1.1 ADP\/ATP carrier protein 
status:Confirmed UniProt:O45865 protein_id:CAB04874.1 
33 kDa 1.07 
CE09512 WBGene00003162 locus:mdh-2 malate dehydrogenase status:Confirmed 
UniProt:O02640 protein_id:AAB53985.1 
35 kDa 1.07 
CE21562 WBGene00000802 locus:crt-1 calreticulin precursor status:Confirmed 
UniProt:P27798 protein_id:AAD14746.1 
46 kDa 1.07 
CE09866 WBGene00017982 locus:hpo-18 ATP synthase epsilion chain 
status:Confirmed UniProt:O16298 protein_id:AAB65352.1 
6 kDa 1.07 
CE24926 WBGene00009187 electron transfer flavoprotein alpha-subunit 
status:Confirmed UniProt:Q93615 protein_id:CAB61027.1 
34 kDa 1.07 
CE09946 WBGene00009454 status:Confirmed UniProt:P90860 
protein_id:CAB03069.1 
20 kDa 1.15 
CE00318 WBGene00001155 locus:ech-6 Enoyl-CoA hydratase status:Confirmed 
UniProt:P34559 protein_id:CAA81594.1 
31 kDa 1.15 
CE09015 WBGene00016943 locus:acdh-1 acyl-CoA dehydrogenase status:Confirmed 
UniProt:Q966M3 protein_id:AAK68275.1 
47 kDa 1.15 





CE20171 WBGene00012354 status:Confirmed UniProt:Q9U329 
protein_id:CAB63334.1 
20 kDa 1.15 
CE21147 WBGene00020181 ubiquinol-cytochrome c reductase complex subunit 
status:Confirmed UniProt:Q9N5E4 protein_id:AAF39958.1 
15 kDa 1.15 
CE40718 WBGene00004015 locus:phb-2 Prohibitin status:Confirmed UniProt:P50093 
protein_id:AAA68353.2 
33 kDa 1.15 
CE18826 WBGene00010419 ATP synthase alpha and beta subunits, ATP synthase 
Alpha chain, C terminal status:Confirmed UniProt:Q9XXK1 protein_id:CAA19429.1 
58 kDa 1.23 
CE29443 WBGene00019900 Channel Protein status:Confirmed UniProt:Q21752 
protein_id:AAB00622.2 
30 kDa 1.23 
CE27514 WBGene00022089 status:Confirmed UniProt:Q95XJ0 
protein_id:AAK68562.1 
32 kDa 1.23 
CE12358 WBGene00000066 locus:act-4 actin status:Confirmed UniProt:P10986 
protein_id:AAB04575.1 
42 kDa 1.23 





CE02733 WBGene00018271 Serine carboxypeptidase status:Confirmed 
UniProt:P52717 protein_id:AAC46812.1 
54 kDa 1.23 
CE16968 WBGene00017121 locus:cyc-2.1 cytochrome C status:Confirmed 
UniProt:P19974 protein_id:AAB92035.1 
12 kDa 1.23 
CE09719 WBGene00000230 locus:atp-3 ATPase status:Confirmed UniProt:P91283 22 kDa 1.23 
protein_id:AAB37654.1 
CE21933 WBGene00021562 locus:nuo-5 NADH-ubiquinone reductase 
status:Confirmed UniProt:Q9N4Y8 protein_id:AAF60575.1 
79 kDa 1.23 
CE32326 WBGene00016630 status:Confirmed UniProt:Q18599 
protein_id:AAN63431.1 
51 kDa 1.23 
CE09597 WBGene00009082 dihyrolipoamide acetyltransferase component 
(pyruvate dehydrogenase complex) status:Confirmed UniProt:Q19749 
protein_id:CAB01163.1 
53 kDa 1.23 
CE35878 WBGene00010015 locus:atad-3 ATPases associated with various cellular 
activities (AAA) status:Confirmed UniProt:Q20748 protein_id:CAA88471.2 
67 kDa 1.23 
CE27244 WBGene00002025 locus:hsp-60 status:Confirmed 60 kDa 1.32 
CE08631 WBGene00002010 locus:hsp-6 heat shock 70 protein 
status:Partially_confirmed UniProt:P11141 protein_id:AAB42371.1 
71 kDa 1.32 
CE00513 WBGene00000833 locus:cts-1 Citrate synthase status:Confirmed 
UniProt:P34575 protein_id:CAA83004.1 
52 kDa 1.32 
CE07016 WBGene00000207 locus:asb-2 ATP synthase B chain status:Confirmed 
UniProt:Q19126 protein_id:AAA96210.1 
35 kDa 1.32 
CE08526 WBGene00004425 locus:rpl-13 ribosomal protein L13 status:Confirmed 
UniProt:P91128 protein_id:AAB42322.1 
24 kDa 1.32 
CE10878 WBGene00009952 Thiolases status:Confirmed UniProt:O45552 
protein_id:CAB04455.2 
41 kDa 1.32 
CE41652 WBGene00018395 status:Confirmed UniProt:O02093 
protein_id:AAC71129.3 
37 kDa 1.32 
CE03454 WBGene00010485 locus:ant-1.3 ADP\/ATP carrier protein 
status:Confirmed UniProt:Q21103 protein_id:CAA92472.1 
34 kDa 1.41 
CE03972 WBGene00003963 locus:pdi-2 protein disulfide isomerase 
status:Confirmed UniProt:Q17770 protein_id:AAK39152.1 
55 kDa 1.41 
CE25005 WBGene00000041 locus:aco-2 Aconitate hydratase status:Confirmed 
UniProt:P34455 protein_id:AAA28050.2 
84 kDa 1.41 
CE17071 WBGene00002162 locus:isp-1 ubiquinol-cytochrome C reductase 
status:Confirmed UniProt:O44512 protein_id:AAB92071.1 
30 kDa 1.41 
CE17069 WBGene00018361 status:Confirmed UniProt:O44509 
protein_id:AAB92069.1 
21 kDa 1.41 
CE08950 WBGene00008262 locus:ril-1 status:Confirmed UniProt:O17694 
protein_id:CAB03983.1 
16 kDa 1.41 
CE19904 WBGene00004496 locus:rps-27 ribosomal protein status:Confirmed 
UniProt:Q9TXP0 protein_id:AAC69219.1 
9 kDa 1.41 
CE22210 WBGene00013025 locus:vha-13 ATP synthase alpha and beta subunits \; 
ATP synthase ab C terminal status:Confirmed UniProt:Q9XW92 
protein_id:CAA22076.1 
66 kDa 1.41 
CE05227 WBGene00007350 succinyl-CoA synthetase status:Confirmed 
UniProt:P53596 protein_id:CAA94107.1 
34 kDa 1.41 
CE09693 WBGene00000371 locus:cco-1 cytochrome C oxidase status:Confirmed 
UniProt:P90849 protein_id:CAB03002.1 
15 kDa 1.41 
CE03917 WBGene00015391 locus:sdha-1 succinate dehydrogenase flavoprotein 
subunit status:Confirmed UniProt:Q09508 protein_id:AAB37034.1 
70 kDa 1.41 
CE22589 WBGene00013238 locus:trap-4 status:Confirmed UniProt:Q9U238 
protein_id:CAB60502.1 
17 kDa 1.52 
CE18478 WBGene00004413 locus:rpl-2 Ribosomal Proteins L2 status:Confirmed 
UniProt:Q9XVF7 protein_id:CAB03792.1 
28 kDa 1.52 
CE01270 WBGene00001168 locus:eef-1A.1 Elongation factor 1-alpha 
status:Confirmed UniProt:P53013 protein_id:AAA81688.1 
51 kDa 1.62 
CE11570 WBGene00003964 locus:pdi-3 protein disulphide isomerase ER-60 
precursor like status:Confirmed UniProt:O17908 protein_id:CAB07480.1 
55 kDa 1.62 
CE08177 WBGene00002007 locus:hsp-3 heat shock protein status:Confirmed 
UniProt:P27420 protein_id:AAB52671.1 
73 kDa 1.62 
CE16576 WBGene00002264 locus:lec-1 galectin status:Partially_confirmed 
UniProt:P36573 protein_id:CAB04959.1 
32 kDa 1.62 
CE31083 WBGene00020950 dihydrolipoamide succinyltransferase status:Confirmed 
UniProt:O45148 protein_id:AAC04462.2 
50 kDa 1.62 
CE12920 WBGene00001423 locus:fib-1 fibrillarin status:Confirmed UniProt:Q22053 
protein_id:CAB01657.1 
36 kDa 1.62 
CE24222 WBGene00012608 Iron-containing alcohol dehydrogenases 
status:Confirmed UniProt:Q9U2M4 protein_id:CAA21631.2 
51 kDa 1.62 
CE18676 WBGene00009688 status:Confirmed UniProt:Q9XU97 
protein_id:CAB05509.1 
9 kDa 1.74 
CE13431 WBGene00020347 3-hydroxyacyl-CoA dehydrogenase status:Confirmed 
UniProt:Q9GYT0 protein_id:AAK21462.1 
85 kDa 1.74 
CE00657 WBGene00011110 locus:prdx-3 Mer5 (mouse) status:Confirmed 
UniProt:Q21824 protein_id:CAA83619.1 
25 kDa 1.74 
CE16650 WBGene00004430 locus:rpl-18 Eukaryotic ribosomal protein L18 
status:Confirmed UniProt:O45946 protein_id:CAA16387.1 
21 kDa 1.74 
CE16769 WBGene00015037 status:Partially_confirmed UniProt:O45063 
protein_id:AAC02565.1 
79 kDa 1.74 
CE01643 WBGene00011510 pyruvate dehydrogenase E1 alpha subunit 
status:Confirmed UniProt:P52899 protein_id:CAA87793.1 
44 kDa 1.74 
CE23962 WBGene00011679 locus:ucr-2.2 ubiquinol-cytochrome c reductase 
complex core protein 2 status:Confirmed UniProt:Q22370 protein_id:CAA96675.2 
44 kDa 1.74 
CE07669 WBGene00004415 locus:rpl-4 ribosomal protein L1 status:Confirmed 
UniProt:O02056 protein_id:AAC24253.1 
39 kDa 1.74 
CE31971 WBGene00010794 dihydrolipoamide dehydrogenase status:Confirmed 
UniProt:O17953 protein_id:CAB05249.2 
53 kDa 1.87 
CE00897 WBGene00003962 locus:pdi-1 protein disulfide isomerase 
status:Confirmed UniProt:Q17967 protein_id:CAA85491.1 
53 kDa 1.87 
CE15900 WBGene00001167 locus:eef-2 Elongation factor Tu family (contains 
ATP\/GTP binding P-loop) status:Confirmed UniProt:P29691 protein_id:CAB02985.1 
95 kDa 2.00 
CE05514 WBGene00000869 locus:cyc-1 cytochrome C1, heme protein 
status:Confirmed UniProt:Q18853 protein_id:CAA99820.1 
31 kDa 2.00 
CE17986 WBGene00004424 locus:rpl-12 Ribosomal protein L11 status:Confirmed 
UniProt:P61866 protein_id:CAB05226.1 
18 kDa 2.00 
CE09349 WBGene00006789 locus:unc-54 myosin heavy chain 




CE05860 WBGene00004480 locus:rps-11 ribosomal protein S11 status:Confirmed 
UniProt:Q20206 protein_id:CAA97792.1 
18 kDa 2.00 
CE01380 WBGene00004420 locus:rpl-9 Ribosomal protein L9 status:Confirmed 
UniProt:Q95Y90 protein_id:AAK84469.1 
22 kDa 2.14 
CE05598 WBGene00004414 locus:rpl-3 60S ribosomal protein L3 status:Confirmed 
UniProt:P50880 protein_id:CAA91277.1 
46 kDa 2.14 
CE07721 WBGene00001137 locus:eat-6 Na(+)\/K(+) ATPase alpha subunit 




CE08034 WBGene00004431 locus:rpl-19 60S ribosomal protein L19 status:Confirmed 
UniProt:O02639 protein_id:AAB53979.1 
24 kDa 2.14 
CE09682 WBGene00002005 locus:hsp-1 HSP-1 heat shock 70kd protein A 
status:Confirmed UniProt:P09446 protein_id:CAB02319.1 
70 kDa 2.14 
CE27398 WBGene00004419 locus:rpl-7A status:Confirmed UniProt:Q966C6 
protein_id:AAK84600.1 
30 kDa 2.30 
CE00744 WBGene00004417 locus:rpl-6 Ribosomal protein ML16 status:Confirmed 
UniProt:P47991 protein_id:AAK29850.1 
24 kDa 2.30 
CE00854 WBGene00004469 locus:rps-0 40S ribosomal protein status:Confirmed 
UniProt:P46769 protein_id:CAA86061.1 
31 kDa 2.30 
CE04237 WBGene00004471 locus:rps-2 status:Confirmed UniProt:P51403 
protein_id:AAF99899.1 
29 kDa 2.30 
CE24278 WBGene00004473 locus:rps-4 status:Confirmed UniProt:Q9N3X2 
protein_id:AAF60569.1 
29 kDa 2.46 
CE06313 WBGene00004442 locus:rpl-28 ribsomal protein L28 like status:Confirmed 
UniProt:Q21930 protein_id:CAA99898.1 
14 kDa 2.46 
CE21392 WBGene00004432 locus:rpl-20 ribosomal protein status:Confirmed 
UniProt:O44480 protein_id:AAB92041.2 
21 kDa 2.46 










CE06360 WBGene00004474 locus:rps-5 40S ribosomal protein S5 status:Confirmed 
UniProt:P49041 protein_id:CAA92971.1 
23 kDa 2.46 
CE02255 WBGene00004416 locus:rpl-5 60S ribosomal protein L5 status:Confirmed 
UniProt:P49405 protein_id:CAA90251.1 
33 kDa 3.48 
CE20168 WBGene00004445 locus:rpl-31 Ribosomal protein L31e status:Confirmed 
UniProt:Q9U332 protein_id:CAB63331.1 
14 kDa 4.00 
 
 
Table 4: iTRAQ labeled proteins in the fourth sample in the second set. 
Identified Proteins  Mw Ratio 
CE05493 WBGene00004451 locus:rpl-37 60S ribosomal protein L37 status:Confirmed 
UniProt:P49622 protein_id:CAB00854.1 
10 kDa 0.54 
CE01976 WBGene00019061 ATP synthase status:Confirmed UniProt:Q09544 17 kDa 0.62 
protein_id:AAC46699.1 
CE08034 WBGene00004431 locus:rpl-19 60S ribosomal protein L19 status:Confirmed 
UniProt:O02639 protein_id:AAB53979.1 
24 kDa 0.62 
CE12148 WBGene00004427 locus:rpl-15 60S ribosomal protein L15 status:Confirmed 
UniProt:P91374 protein_id:AAC24397.1 
24 kDa 0.62 
CE28340 WBGene00010139 Leucine Rich Repeat (2 copies) (2 domains) 
status:Confirmed UniProt:Q95ZS5 protein_id:CAC42304.1 
49 kDa 0.62 
CE07669 WBGene00004415 locus:rpl-4 ribosomal protein L1 status:Confirmed 
UniProt:O02056 protein_id:AAC24253.1 
39 kDa 0.66 
CE21392 WBGene00004432 locus:rpl-20 ribosomal protein status:Confirmed 
UniProt:O44480 protein_id:AAB92041.2 
21 kDa 0.66 
CE04362 WBGene00004447 locus:rpl-33 60s ribosomal protein L35A 
status:Confirmed UniProt:P49180 protein_id:AAA82422.1 
14 kDa 0.66 
CE06878 WBGene00004499 locus:rps-30 ribosomal protein\/ubiquitin-like protein 
status:Confirmed UniProt:Q18231 protein_id:AAB37076.1 
14 kDa 0.66 
CE26244 WBGene00022122 locus:trap-1 status:Confirmed UniProt:Q95XT5 
protein_id:AAK66027.1 
29 kDa 0.66 
CE20168 WBGene00004445 locus:rpl-31 Ribosomal protein L31e status:Confirmed 
UniProt:Q9U332 protein_id:CAB63331.1 
14 kDa 0.71 
CE04561 WBGene00004477 locus:rps-8 40S ribosomal protein S8 status:Confirmed 
UniProt:P48156 protein_id:AAA81485.1 
24 kDa 0.71 
CE05860 WBGene00004480 locus:rps-11 ribosomal protein S11 status:Confirmed 
UniProt:Q20206 protein_id:CAA97792.1 
18 kDa 0.71 
CE01543 WBGene00004421 locus:rpl-10 ribosomal protein L10 (QM protein) 
status:Confirmed UniProt:Q09533 protein_id:CAA88308.1 
25 kDa 0.71 
CE01030 WBGene00004428 locus:rpl-16 L13P family ribosomal protein 
status:Confirmed UniProt:Q27389 protein_id:CAA86515.1 
23 kDa 0.71 
CE11254 WBGene00006924 locus:vig-1 status:Confirmed UniProt:O16646 
protein_id:AAB66119.1 
40 kDa 0.71 
CE18884 WBGene00004736 locus:sca-1 E1-E2 ATPases status:Confirmed 
UniProt:Q9XTG6 protein_id:CAB07262.1 
116 kDa 0.71 
CE17943 WBGene00019097 status:Confirmed UniProt:O61880 
protein_id:AAC17663.1 
18 kDa 0.71 
CE12918 WBGene00004485 locus:rps-16 40S ribosomal protein S16 
status:Confirmed UniProt:Q22054 protein_id:CAB01658.1 
16 kDa 0.71 
CE18478 WBGene00004413 locus:rpl-2 Ribosomal Proteins L2 status:Confirmed 
UniProt:Q9XVF7 protein_id:CAB03792.1 
28 kDa 0.76 
CE04237 WBGene00004471 locus:rps-2 status:Confirmed UniProt:P51403 
protein_id:AAF99899.1 
29 kDa 0.76 
CE05656 WBGene00008920 locus:eef-1G elongation factor 1-gamma 
status:Confirmed UniProt:P54412 protein_id:CAA96631.1 
44 kDa 0.76 
CE00450 WBGene00004449 locus:rpl-35 60S ribosomal protein L35 status:Confirmed 
UniProt:P34662 protein_id:AAA28216.1 
14 kDa 0.76 
CE11570 WBGene00003964 locus:pdi-3 protein disulphide isomerase ER-60 
precursor like status:Confirmed UniProt:O17908 protein_id:CAB07480.1 
55 kDa 0.76 
CE03972 WBGene00003963 locus:pdi-2 protein disulfide isomerase 55 kDa 0.76 
status:Confirmed UniProt:Q17770 protein_id:AAK39152.1 
CE09047 WBGene00004436 locus:rpl-24.1 60S ribosomal protein L24 
status:Confirmed UniProt:O01868 protein_id:AAK18907.1 
18 kDa 0.76 
CE40718 WBGene00004015 locus:phb-2 Prohibitin status:Confirmed 
UniProt:P50093 protein_id:AAA68353.2 
33 kDa 0.76 
CE15602 WBGene00007385 locus:atp-5 ATP synthase D chain status:Confirmed 
UniProt:Q17763 protein_id:CAA99772.1 
22 kDa 0.76 
CE00078 WBGene00004433 locus:rpl-21 Ribosomal protein L21 status:Confirmed 
UniProt:P34334 protein_id:AAA27951.1 
18 kDa 0.76 
CE00854 WBGene00004469 locus:rps-0 40S ribosomal protein status:Confirmed 
UniProt:P46769 protein_id:CAA86061.1 
31 kDa 0.76 
CE01270 WBGene00001168 locus:eef-1A.1 Elongation factor 1-alpha 
status:Confirmed UniProt:P53013 protein_id:AAA81688.1 
51 kDa 0.81 
CE27398 WBGene00004419 locus:rpl-7A status:Confirmed UniProt:Q966C6 
protein_id:AAK84600.1 
30 kDa 0.81 
CE11024 WBGene00004418 locus:rpl-7 ribosomal protein status:Confirmed 
UniProt:O01802 protein_id:AAB54165.1 
28 kDa 0.81 
CE30781 WBGene00004450 locus:rpl-36 Ribosomal protein YL39 status:Confirmed 
UniProt:P49181 protein_id:AAC48295.2 
12 kDa 0.81 
CE16650 WBGene00004430 locus:rpl-18 Eukaryotic ribosomal protein L18 
status:Confirmed UniProt:O45946 protein_id:CAA16387.1 
21 kDa 0.81 
CE05721 WBGene00004439 locus:rpl-25.2 60S ribosomal protein status:Confirmed 
UniProt:Q20647 protein_id:CAA99858.1 
16 kDa 0.81 
CE26896 WBGene00004481 locus:rps-12 status:Confirmed UniProt:P49196 
protein_id:AAK20077.1 
15 kDa 0.81 
CE11342 WBGene00001581 locus:gfi-1 status:Partially_confirmed UniProt:Q94246 
protein_id:AAB09166.1 
227 kDa 0.81 
CE06090 WBGene00010556 locus:rack-1 guanine nucleotide-binding protein 
status:Confirmed UniProt:Q21215 protein_id:CAA93514.1 
36 kDa 0.81 
CE22117 WBGene00004456 locus:rpl-43 status:Confirmed UniProt:Q9U2A8 
protein_id:CAB54440.1 
10 kDa 0.81 
CE17691 WBGene00017719 status:Confirmed UniProt:Q9GZE9 
protein_id:AAF99915.1 
47 kDa 0.81 
CE01568 WBGene00001686 locus:gpd-4 glyceraldehyde 3-phosphate 
dehydrogenase 4 status:Confirmed UniProt:P17331 protein_id:CAA88697.1 
36 kDa 0.81 
CE04424 WBGene00006921 locus:vha-12 vacuolar ATP synthase (strong) 
status:Confirmed UniProt:Q19626 protein_id:AAA82311.1 
55 kDa 0.81 
CE12358 WBGene00000066 locus:act-4 actin status:Confirmed UniProt:P10986 
protein_id:AAB04575.1 
42 kDa 0.87 
CE05165 WBGene00001922 locus:his-48 histone H2B status:Confirmed 
UniProt:Q27876 protein_id:CAA97413.1 
14 kDa 0.87 
CE20900 WBGene00006927 locus:vit-3 status:Partially_confirmed UniProt:Q9N4J2 
protein_id:AAK09075.1 
187 kDa 0.87 
CE06950 WBGene00006926 locus:vit-2 vitellogenin status:Confirmed 
UniProt:P05690 protein_id:AAA98720.1 
188 kDa 0.87 
CE09682 WBGene00002005 locus:hsp-1 HSP-1 heat shock 70kd protein A 70 kDa 0.87 
status:Confirmed UniProt:P09446 protein_id:CAB02319.1 
CE05598 WBGene00004414 locus:rpl-3 60S ribosomal protein L3 status:Confirmed 
UniProt:P50880 protein_id:CAA91277.1 
46 kDa 0.87 
CE19904 WBGene00004496 locus:rps-27 ribosomal protein status:Confirmed 
UniProt:Q9TXP0 protein_id:AAC69219.1 
9 kDa 0.87 
CE03278 WBGene00004440 locus:rpl-26 ribosomal protein L26 like status:Confirmed 
UniProt:Q19869 protein_id:CAA92674.1 
16 kDa 0.87 
CE00744 WBGene00004417 locus:rpl-6 Ribosomal protein ML16 status:Confirmed 
UniProt:P47991 protein_id:AAK29850.1 
24 kDa 0.87 
CE07721 WBGene00001137 locus:eat-6 Na(+)\/K(+) ATPase alpha subunit 
status:Confirmed UniProt:P90735 protein_id:CAB02694.1 
111 kDa 0.87 
CE08526 WBGene00004425 locus:rpl-13 ribosomal protein L13 status:Confirmed 
UniProt:P91128 protein_id:AAB42322.1 
24 kDa 0.87 
CE06114 WBGene00010627 yeast protein L8167.9-like status:Confirmed 
UniProt:Q21276 protein_id:CAA94897.1 
55 kDa 0.87 
CE00778 WBGene00004435 locus:rpl-23 status:Confirmed UniProt:P48158 
protein_id:AAK18857.1 
15 kDa 0.87 
CE23530 WBGene00007463 high-density lipoprotein-binding protein 
status:Confirmed UniProt:Q17832 protein_id:CAA91144.2 
134 kDa 0.87 
CE06652 WBGene00014095 glutamate dehydrogenase status:Confirmed 
UniProt:Q23621 protein_id:CAA98074.1 
59 kDa 0.87 
CE14265 WBGene00012094 ubiquinol-cytochrome c reductase complexn 11 KD 
protein status:Confirmed UniProt:O45864 protein_id:CAB04873.1 
9 kDa 0.87 
CE01380 WBGene00004420 locus:rpl-9 Ribosomal protein L9 status:Confirmed 
UniProt:Q95Y90 protein_id:AAK84469.1 
22 kDa 0.87 
CE14263 WBGene00006439 locus:ant-1.1 ADP\/ATP carrier protein 
status:Confirmed UniProt:O45865 protein_id:CAB04874.1 
33 kDa 0.93 
CE28594 WBGene00006930 locus:vit-6 vitellogenin status:Partially_confirmed 
UniProt:P18948 protein_id:AAC04423.2 
193 kDa 0.93 
CE29950 WBGene00000229 locus:atp-2 ATP synthase beta chain status:Confirmed 
UniProt:P46561 protein_id:AAA19068.2 
58 kDa 0.93 
CE29443 WBGene00019900 Channel Protein status:Confirmed UniProt:Q21752 
protein_id:AAB00622.2 
30 kDa 0.93 
CE00913 WBGene00006537 locus:tbb-2 beta tubulin status:Confirmed 
UniProt:P52275 protein_id:CAA84648.1 
50 kDa 0.93 
CE09197 WBGene00006754 locus:unc-15 paramyosin status:Confirmed 
UniProt:P10567 protein_id:CAB01965.1 
101 kDa 0.93 
CE06313 WBGene00004442 locus:rpl-28 ribsomal protein L28 like status:Confirmed 
UniProt:Q21930 protein_id:CAA99898.1 
14 kDa 0.93 
CE18676 WBGene00009688 status:Confirmed UniProt:Q9XU97 
protein_id:CAB05509.1 
9 kDa 0.93 
CE24278 WBGene00004473 locus:rps-4 status:Confirmed UniProt:Q9N3X2 
protein_id:AAF60569.1 
29 kDa 0.93 
CE17563 WBGene00006529 locus:tba-2 Tubulin status:Confirmed UniProt:P34690 
protein_id:CAB16856.1 
50 kDa 0.93 
CE08177 WBGene00002007 locus:hsp-3 heat shock protein status:Confirmed 73 kDa 0.93 
UniProt:P27420 protein_id:AAB52671.1 
CE19381 WBGene00004441 locus:rpl-27 60S ribosomal protein L27 status:Confirmed 
UniProt:P91914 protein_id:AAK68266.1 
16 kDa 0.93 
CE21562 WBGene00000802 locus:crt-1 calreticulin precursor status:Confirmed 
UniProt:P27798 protein_id:AAD14746.1 
46 kDa 0.93 
CE05747 WBGene00004492 locus:rps-23 ribosomal protein S23 status:Confirmed 
UniProt:Q19877 protein_id:CAA94601.1 
16 kDa 0.93 
CE04009 WBGene00004482 locus:rps-13 40S ribosomal protein S13 
status:Confirmed UniProt:P51404 protein_id:AAB47594.1 
17 kDa 0.93 
CE34936 WBGene00003515 locus:myo-3 myosin heavy chain 
status:Partially_confirmed UniProt:P12844 protein_id:CAB01576.2 
226 kDa 0.93 
CE29330 WBGene00002265 locus:lec-2 galactoside-binding lectin status:Confirmed 
UniProt:Q9GNP7 protein_id:CAC70097.1 
31 kDa 0.93 
CE02183 WBGene00000114 locus:alh-8 methylmalonate-semialdehyde 
dehydrogenase status:Confirmed UniProt:P52713 protein_id:CAA88946.1 
56 kDa 0.93 
CE22210 WBGene00013025 locus:vha-13 ATP synthase alpha and beta subunits \; 
ATP synthase ab C terminal status:Confirmed UniProt:Q9XW92 
protein_id:CAA22076.1 
66 kDa 0.93 
CE05514 WBGene00000869 locus:cyc-1 cytochrome C1, heme protein 
status:Confirmed UniProt:Q18853 protein_id:CAA99820.1 
31 kDa 0.93 
CE33017 WBGene00006759 locus:unc-22 Fibronectin type III domain (31 domains), 
IG (immunoglobulin) superfamily (18 domains), calcium\/calmodulin dependent 
protein kinase status:Partially_confirmed UniProt:Q23551 protein_id:CAA98081.2 
754 kDa 0.93 
CE32361 WBGene00006434 locus:prdx-2 status:Confirmed UniProt:Q8IG31 
protein_id:AAN63412.1 
22 kDa 0.93 
CE09650 WBGene00009119 locus:ndk-1 nucleoside diphosphate kinase 
status:Confirmed UniProt:Q93576 protein_id:CAB02101.1 
17 kDa 0.93 
CE12920 WBGene00001423 locus:fib-1 fibrillarin status:Confirmed UniProt:Q22053 
protein_id:CAB01657.1 
36 kDa 0.93 
CE09072 WBGene00004258 locus:pyc-1 pyruvate carboxylase status:Confirmed 
UniProt:O17732 protein_id:CAB02872.1 
129 kDa 0.93 
CE02777 WBGene00004438 locus:rpl-25.1 Ribosomal protein L23 status:Confirmed 
UniProt:P48162 protein_id:AAA81728.1 
17 kDa 0.93 
CE35878 WBGene00010015 locus:atad-3 ATPases associated with various cellular 
activities (AAA) status:Confirmed UniProt:Q20748 protein_id:CAA88471.2 
67 kDa 0.93 
CE17939 WBGene00003795 locus:npp-9 Nucleoporin status:Confirmed 
UniProt:Q21021 protein_id:CAA84330.1 
93 kDa 0.93 
CE11006 WBGene00004274 locus:rab-11.1 RAS-related protein status:Confirmed 
UniProt:O01803 protein_id:AAB54158.1 
23 kDa 0.93 
CE09349 WBGene00006789 locus:unc-54 myosin heavy chain 
status:Partially_confirmed UniProt:P02566 protein_id:CAB05505.1 
225 kDa 1.00 
CE18826 WBGene00010419 ATP synthase alpha and beta subunits, ATP synthase 
Alpha chain, C terminal status:Confirmed UniProt:Q9XXK1 protein_id:CAA19429.1 
58 kDa 1.00 
CE15900 WBGene00001167 locus:eef-2 Elongation factor Tu family (contains 
ATP\/GTP binding P-loop) status:Confirmed UniProt:P29691 protein_id:CAB02985.1 
95 kDa 1.00 
CE00821 WBGene00004483 locus:rps-14 Ribosomal protein S14 status:Confirmed 16 kDa 1.00 
UniProt:P48150 protein_id:AAC48301.1 
CE02255 WBGene00004416 locus:rpl-5 60S ribosomal protein L5 status:Confirmed 
UniProt:P49405 protein_id:CAA90251.1 
33 kDa 1.00 
CE27514 WBGene00022089 status:Confirmed UniProt:Q95XJ0 
protein_id:AAK68562.1 
32 kDa 1.00 
CE06360 WBGene00004474 locus:rps-5 40S ribosomal protein S5 status:Confirmed 
UniProt:P49041 protein_id:CAA92971.1 
23 kDa 1.00 
CE34313 WBGene00006587 locus:tnt-2 status:Confirmed UniProt:Q7Z072 
protein_id:AAP68941.1 
49 kDa 1.00 
CE09946 WBGene00009454 status:Confirmed UniProt:P90860 
protein_id:CAB03069.1 
20 kDa 1.00 
CE02193 WBGene00003903 locus:pab-2 poly-adenylate binding protein 
status:Confirmed UniProt:Q19579 protein_id:CAA90444.1 
76 kDa 1.00 
CE31619 WBGene00003514 locus:myo-2 myosin heavy chain C status:Confirmed 
UniProt:P12845 protein_id:CAA92197.2 
223 kDa 1.00 
CE24592 WBGene00004475 locus:rps-6 40S ribosomal protein S6 status:Confirmed 
UniProt:Q9NEN6 protein_id:CAB81996.1 
28 kDa 1.00 
CE08852 WBGene00008205 locus:sams-1 s-adenosylmethionine synthetase 
status:Confirmed UniProt:O17680 protein_id:CAB03975.1 
44 kDa 1.00 
CE20485 WBGene00004452 locus:rpl-38 status:Confirmed UniProt:O17570 
protein_id:CAB03853.1 
8 kDa 1.00 
CE09866 WBGene00017982 locus:hpo-18 ATP synthase epsilion chain 
status:Confirmed UniProt:O16298 protein_id:AAB65352.1 
6 kDa 1.00 
CE06577 WBGene00004476 locus:rps-7 40S ribosomal protein S7 status:Confirmed 
UniProt:Q23312 protein_id:CAB00058.1 
22 kDa 1.00 
CE01236 WBGene00003371 locus:mlc-3 status:Confirmed UniProt:P53014 
protein_id:AAA50701.1 
17 kDa 1.07 
CE16463 WBGene00000067 locus:act-5 Actins status:Confirmed UniProt:O45815 
protein_id:CAB05817.1 
42 kDa 1.07 
CE07537 WBGene00020808 calponin-like protein status:Confirmed UniProt:Q23050 
protein_id:AAB04989.1 
44 kDa 1.07 
CE28782 WBGene00002978 locus:lev-11 status:Confirmed UniProt:Q22866 
protein_id:CAC70114.1 
33 kDa 1.07 
CE34269 WBGene00003369 locus:mlc-1 status:Confirmed UniProt:P19625 
protein_id:AAK09070.2 
19 kDa 1.07 
CE04038 WBGene00001000 locus:dim-1 status:Confirmed UniProt:Q18066 
protein_id:AAP31442.1 
36 kDa 1.07 
CE17071 WBGene00002162 locus:isp-1 ubiquinol-cytochrome C reductase 
status:Confirmed UniProt:O44512 protein_id:AAB92071.1 
30 kDa 1.07 
CE06253 WBGene00002348 locus:myo-1 myosin heavy chain status:Confirmed 
UniProt:P02567 protein_id:CAA95848.1 
223 kDa 1.07 
CE17986 WBGene00004424 locus:rpl-12 Ribosomal protein L11 status:Confirmed 
UniProt:P61866 protein_id:CAB05226.1 
18 kDa 1.07 
CE20171 WBGene00012354 status:Confirmed UniProt:Q9U329 
protein_id:CAB63334.1 
20 kDa 1.07 
CE13431 WBGene00020347 3-hydroxyacyl-CoA dehydrogenase status:Confirmed 85 kDa 1.07 
UniProt:Q9GYT0 protein_id:AAK21462.1 
CE09945 WBGene00004484 locus:rps-15 40S ribosomal protein S15 
status:Confirmed UniProt:Q9XVP0 protein_id:CAB03065.1 
17 kDa 1.07 
CE17154 WBGene00019322 locus:ahcy-1 S-adenosylhomocysteine hydrolase 
status:Confirmed UniProt:P27604 protein_id:AAB97565.1 
48 kDa 1.07 
CE09015 WBGene00016943 locus:acdh-1 acyl-CoA dehydrogenase status:Confirmed 
UniProt:Q966M3 protein_id:AAK68275.1 
47 kDa 1.07 
CE27244 WBGene00002025 locus:hsp-60 status:Confirmed 60 kDa 1.07 
CE22589 WBGene00013238 locus:trap-4 status:Confirmed UniProt:Q9U238 
protein_id:CAB60502.1 
17 kDa 1.07 
CE04501 WBGene00001921 locus:his-47 histone H2A status:Confirmed 
UniProt:P09588 protein_id:CAA97414.1 
13 kDa 1.15 
CE20658 WBGene00006819 locus:unc-87 calponin status:Confirmed UniProt:P37806 
protein_id:AAC78234.1 
63 kDa 1.15 
CE03253 WBGene00001919 locus:his-45 histone H3 status:Confirmed 
UniProt:P08898 protein_id:CAA97411.1 
15 kDa 1.15 
CE06200 WBGene00003920 locus:par-5 14-3-3 protein status:Confirmed 
UniProt:P41932 protein_id:CAA98138.1 
28 kDa 1.15 
CE00513 WBGene00000833 locus:cts-1 Citrate synthase status:Confirmed 
UniProt:P34575 protein_id:CAA83004.1 
52 kDa 1.15 
CE02163 WBGene00002267 locus:lec-4 galactoside binding lectin status:Confirmed 
UniProt:Q18625 protein_id:CAA88850.1 
32 kDa 1.15 
CE08260 WBGene00003172 locus:mec-8 mecanosensory gene mec-8 
status:Confirmed UniProt:Q19018 protein_id:CAB03111.1 
33 kDa 1.15 
CE25552 WBGene00004412 locus:rpl-1 status:Confirmed UniProt:Q9N4I4 
protein_id:AAF36008.1 
24 kDa 1.15 
CE16576 WBGene00002264 locus:lec-1 galectin status:Partially_confirmed 
UniProt:P36573 protein_id:CAB04959.1 
32 kDa 1.23 
CE01921 WBGene00006727 locus:ubq-1 status:Confirmed UniProt:P0CG71 
protein_id:AAC46525.1 
94 kDa 1.23 
CE25005 WBGene00000041 locus:aco-2 Aconitate hydratase status:Confirmed 
UniProt:P34455 protein_id:AAA28050.2 
84 kDa 1.23 
CE17720 WBGene00017926 status:Confirmed UniProt:O76367 
protein_id:AAC19190.1 
10 kDa 1.23 
CE08631 WBGene00002010 locus:hsp-6 heat shock 70 protein 
status:Partially_confirmed UniProt:P11141 protein_id:AAB42371.1 
71 kDa 1.32 
CE23521 WBGene00001564 locus:icl-1 isocitrate lyase status:Confirmed 
UniProt:Q10663 protein_id:AAB71278.2 
109 kDa 1.41 
 
Table 5 iTRAQ labeled proteins in the fifth sample in the second set. 
Identified Proteins  Mw Ratio 
CE27361 WBGene00015761 status:Confirmed UniProt:O44671 
protein_id:AAB94265.2 
60 kDa 0.50 
CE02777 WBGene00004438 locus:rpl-25.1 Ribosomal protein L23 status:Confirmed 17 kDa 0.57 
UniProt:P48162 protein_id:AAA81728.1 
CE40119 WBGene00004493 locus:rps-24 ribosomal protein status:Confirmed 
UniProt:Q1XFY9 protein_id:ABD94090.1 
15 kDa 0.57 
CE26774 WBGene00021350 status:Confirmed UniProt:Q9BKU5 
protein_id:AAK27870.1 
16 kDa 0.57 
CE11024 WBGene00004418 locus:rpl-7 ribosomal protein status:Confirmed 
UniProt:O01802 protein_id:AAB54165.1 
28 kDa 0.62 
CE17720 WBGene00017926 status:Confirmed UniProt:O76367 
protein_id:AAC19190.1 
10 kDa 0.62 
CE20900 WBGene00006927 locus:vit-3 status:Partially_confirmed UniProt:Q9N4J2 
protein_id:AAK09075.1 
187 kDa 0.66 
CE05493 WBGene00004451 locus:rpl-37 60S ribosomal protein L37 status:Confirmed 
UniProt:P49622 protein_id:CAB00854.1 
10 kDa 0.71 
CE07669 WBGene00004415 locus:rpl-4 ribosomal protein L1 status:Confirmed 
UniProt:O02056 protein_id:AAC24253.1 
39 kDa 0.76 
CE11570 WBGene00003964 locus:pdi-3 protein disulphide isomerase ER-60 
precursor like status:Confirmed UniProt:O17908 protein_id:CAB07480.1 
55 kDa 0.76 
CE04424 WBGene00006921 locus:vha-12 vacuolar ATP synthase (strong) 
status:Confirmed UniProt:Q19626 protein_id:AAA82311.1 
55 kDa 0.76 
CE03921 WBGene00006929 locus:vit-5 status:Confirmed UniProt:P06125 
protein_id:AAA83587.1 
186 kDa 0.76 
CE16905 WBGene00004266 locus:rab-1 RAS-related protein status:Confirmed 
UniProt:Q9UAQ6 protein_id:AAC69218.1 
23 kDa 0.76 
CE18478 WBGene00004413 locus:rpl-2 Ribosomal Proteins L2 status:Confirmed 
UniProt:Q9XVF7 protein_id:CAB03792.1 
28 kDa 0.81 
CE04561 WBGene00004477 locus:rps-8 40S ribosomal protein S8 status:Confirmed 
UniProt:P48156 protein_id:AAA81485.1 
24 kDa 0.81 
CE20168 WBGene00004445 locus:rpl-31 Ribosomal protein L31e status:Confirmed 
UniProt:Q9U332 protein_id:CAB63331.1 
14 kDa 0.81 
CE03278 WBGene00004440 locus:rpl-26 ribosomal protein L26 like status:Confirmed 
UniProt:Q19869 protein_id:CAA92674.1 
16 kDa 0.81 
CE21392 WBGene00004432 locus:rpl-20 ribosomal protein status:Confirmed 
UniProt:O44480 protein_id:AAB92041.2 
21 kDa 0.81 
CE05860 WBGene00004480 locus:rps-11 ribosomal protein S11 status:Confirmed 
UniProt:Q20206 protein_id:CAA97792.1 
18 kDa 0.81 
CE12148 WBGene00004427 locus:rpl-15 60S ribosomal protein L15 status:Confirmed 
UniProt:P91374 protein_id:AAC24397.1 
24 kDa 0.81 
CE04237 WBGene00004471 locus:rps-2 status:Confirmed UniProt:P51403 
protein_id:AAF99899.1 
29 kDa 0.81 
CE30781 WBGene00004450 locus:rpl-36 Ribosomal protein YL39 status:Confirmed 
UniProt:P49181 protein_id:AAC48295.2 
12 kDa 0.81 
CE01976 WBGene00019061 ATP synthase status:Confirmed UniProt:Q09544 
protein_id:AAC46699.1 
17 kDa 0.81 
CE22195 WBGene00004429 locus:rpl-17 status:Confirmed UniProt:Q9BL19 
protein_id:AAK29902.1 
22 kDa 0.81 
CE03972 WBGene00003963 locus:pdi-2 protein disulfide isomerase 55 kDa 0.81 
status:Confirmed UniProt:Q17770 protein_id:AAK39152.1 
CE01270 WBGene00001168 locus:eef-1A.1 Elongation factor 1-alpha 
status:Confirmed UniProt:P53013 protein_id:AAA81688.1 
51 kDa 0.87 
CE06950 WBGene00006926 locus:vit-2 vitellogenin status:Confirmed 
UniProt:P05690 protein_id:AAA98720.1 
188 kDa 0.87 
CE28594 WBGene00006930 locus:vit-6 vitellogenin status:Partially_confirmed 
UniProt:P18948 protein_id:AAC04423.2 
193 kDa 0.87 
CE05721 WBGene00004439 locus:rpl-25.2 60S ribosomal protein status:Confirmed 
UniProt:Q20647 protein_id:CAA99858.1 
16 kDa 0.87 
CE01543 WBGene00004421 locus:rpl-10 ribosomal protein L10 (QM protein) 
status:Confirmed UniProt:Q09533 protein_id:CAA88308.1 
25 kDa 0.87 
CE06090 WBGene00010556 locus:rack-1 guanine nucleotide-binding protein 
status:Confirmed UniProt:Q21215 protein_id:CAA93514.1 
36 kDa 0.87 
CE06114 WBGene00010627 yeast protein L8167.9-like status:Confirmed 
UniProt:Q21276 protein_id:CAA94897.1 
55 kDa 0.87 
CE19904 WBGene00004496 locus:rps-27 ribosomal protein status:Confirmed 
UniProt:Q9TXP0 protein_id:AAC69219.1 
9 kDa 0.87 
CE18884 WBGene00004736 locus:sca-1 E1-E2 ATPases status:Confirmed 
UniProt:Q9XTG6 protein_id:CAB07262.1 
116 kDa 0.87 
CE00078 WBGene00004433 locus:rpl-21 Ribosomal protein L21 status:Confirmed 
UniProt:P34334 protein_id:AAA27951.1 
18 kDa 0.87 
CE31847 WBGene00006780 locus:unc-44 AO13 ankyrin status:Partially_confirmed 
UniProt:Q17490 protein_id:AAA93447.2 
775 kDa 0.87 
CE21417 WBGene00001427 locus:fkb-2 FKBP-type peptidyl-prolyl cis-trans 
isomerases status:Confirmed UniProt:Q9U2Q8 protein_id:CAA22330.1 
12 kDa 0.87 
CE11254 WBGene00006924 locus:vig-1 status:Confirmed UniProt:O16646 
protein_id:AAB66119.1 
40 kDa 0.87 
CE29443 WBGene00019900 Channel Protein status:Confirmed UniProt:Q21752 
protein_id:AAB00622.2 
30 kDa 0.93 
CE05598 WBGene00004414 locus:rpl-3 60S ribosomal protein L3 status:Confirmed 
UniProt:P50880 protein_id:CAA91277.1 
46 kDa 0.93 
CE09682 WBGene00002005 locus:hsp-1 HSP-1 heat shock 70kd protein A 
status:Confirmed UniProt:P09446 protein_id:CAB02319.1 
70 kDa 0.93 
CE27398 WBGene00004419 locus:rpl-7A status:Confirmed UniProt:Q966C6 
protein_id:AAK84600.1 
30 kDa 0.93 
CE18676 WBGene00009688 status:Confirmed UniProt:Q9XU97 
protein_id:CAB05509.1 
9 kDa 0.93 
CE08526 WBGene00004425 locus:rpl-13 ribosomal protein L13 status:Confirmed 
UniProt:P91128 protein_id:AAB42322.1 
24 kDa 0.93 
CE15900 WBGene00001167 locus:eef-2 Elongation factor Tu family (contains 
ATP\/GTP binding P-loop) status:Confirmed UniProt:P29691 protein_id:CAB02985.1 
95 kDa 0.93 
CE27514 WBGene00022089 status:Confirmed UniProt:Q95XJ0 
protein_id:AAK68562.1 
32 kDa 0.93 
CE01030 WBGene00004428 locus:rpl-16 L13P family ribosomal protein 
status:Confirmed UniProt:Q27389 protein_id:CAA86515.1 
23 kDa 0.93 
CE01810 WBGene00004472 locus:rps-3 Ribosomal protein S3 status:Confirmed 27 kDa 0.93 
UniProt:P48152 protein_id:AAF99870.1 
CE32639 WBGene00009267 locus:usp-48 ubiquitin carboxyl-termianl hydrolase 
status:Confirmed UniProt:Q93371 protein_id:CAB03026.2 
144 kDa 0.93 
CE09162 WBGene00008505 phosphate carrier protein precursor status:Confirmed 
UniProt:P40614 protein_id:CAA97430.1 
37 kDa 0.93 
CE11342 WBGene00001581 locus:gfi-1 status:Partially_confirmed UniProt:Q94246 
protein_id:AAB09166.1 
227 kDa 0.93 
CE17691 WBGene00017719 status:Confirmed UniProt:Q9GZE9 
protein_id:AAF99915.1 
47 kDa 0.93 
CE42777 WBGene00009342 locus:fasn-1 fatty acid synthase 
status:Partially_confirmed UniProt:P91871 protein_id:CAB04244.2 
289 kDa 0.93 
CE09693 WBGene00000371 locus:cco-1 cytochrome C oxidase status:Confirmed 
UniProt:P90849 protein_id:CAB03002.1 
15 kDa 0.93 
CE26244 WBGene00022122 locus:trap-1 status:Confirmed UniProt:Q95XT5 
protein_id:AAK66027.1 
29 kDa 0.93 
CE06652 WBGene00014095 glutamate dehydrogenase status:Confirmed 
UniProt:Q23621 protein_id:CAA98074.1 
59 kDa 0.93 
CE30639 WBGene00002891 locus:let-767 status:Confirmed UniProt:Q09517 
protein_id:AAA64333.2 
34 kDa 0.93 
CE24441 WBGene00021832 status:Confirmed UniProt:Q9N3E8 
protein_id:AAF60766.1 
63 kDa 0.93 
CE15898 WBGene00009126 locus:pyk-1 Pyruvate kinase status:Confirmed 
UniProt:O17836 protein_id:CAB02984.1 
61 kDa 0.93 
CE01052 WBGene00001086 locus:dpy-27 chromosome segregation protein (SMC-1) 
status:Partially_confirmed UniProt:P48996 protein_id:CAA84669.1 
170 kDa 0.93 
CE12358 WBGene00000066 locus:act-4 actin status:Confirmed UniProt:P10986 
protein_id:AAB04575.1 
42 kDa 1.00 
CE18826 WBGene00010419 ATP synthase alpha and beta subunits, ATP synthase 
Alpha chain, C terminal status:Confirmed UniProt:Q9XXK1 protein_id:CAA19429.1 
58 kDa 1.00 
CE29950 WBGene00000229 locus:atp-2 ATP synthase beta chain status:Confirmed 
UniProt:P46561 protein_id:AAA19068.2 
58 kDa 1.00 
CE00913 WBGene00006537 locus:tbb-2 beta tubulin status:Confirmed 
UniProt:P52275 protein_id:CAA84648.1 
50 kDa 1.00 
CE19381 WBGene00004441 locus:rpl-27 60S ribosomal protein L27 status:Confirmed 
UniProt:P91914 protein_id:AAK68266.1 
16 kDa 1.00 
CE00744 WBGene00004417 locus:rpl-6 Ribosomal protein ML16 status:Confirmed 
UniProt:P47991 protein_id:AAK29850.1 
24 kDa 1.00 
CE05747 WBGene00004492 locus:rps-23 ribosomal protein S23 status:Confirmed 
UniProt:Q19877 protein_id:CAA94601.1 
16 kDa 1.00 
CE15602 WBGene00007385 locus:atp-5 ATP synthase D chain status:Confirmed 
UniProt:Q17763 protein_id:CAA99772.1 
22 kDa 1.00 
CE05514 WBGene00000869 locus:cyc-1 cytochrome C1, heme protein 
status:Confirmed UniProt:Q18853 protein_id:CAA99820.1 
31 kDa 1.00 
CE04009 WBGene00004482 locus:rps-13 40S ribosomal protein S13 
status:Confirmed UniProt:P51404 protein_id:AAB47594.1 
17 kDa 1.00 
CE09946 WBGene00009454 status:Confirmed UniProt:P90860 20 kDa 1.00 
protein_id:CAB03069.1 
CE26896 WBGene00004481 locus:rps-12 status:Confirmed UniProt:P49196 
protein_id:AAK20077.1 
15 kDa 1.00 
CE32361 WBGene00006434 locus:prdx-2 status:Confirmed UniProt:Q8IG31 
protein_id:AAN63412.1 
22 kDa 1.00 
CE14956 WBGene00004487 locus:rps-18 ribosomal protein S13 status:Confirmed 
UniProt:O18240 protein_id:CAB16517.1 
18 kDa 1.00 
CE35878 WBGene00010015 locus:atad-3 ATPases associated with various cellular 
activities (AAA) status:Confirmed UniProt:Q20748 protein_id:CAA88471.2 
67 kDa 1.00 
CE22117 WBGene00004456 locus:rpl-43 status:Confirmed UniProt:Q9U2A8 
protein_id:CAB54440.1 
10 kDa 1.00 
CE09047 WBGene00004436 locus:rpl-24.1 60S ribosomal protein L24 
status:Confirmed UniProt:O01868 protein_id:AAK18907.1 
18 kDa 1.00 
CE04861 WBGene00002238 locus:kars-1 lysyl-tRNA synthetase status:Confirmed 
UniProt:Q22099 protein_id:AAA82396.1 
65 kDa 1.00 
CE03709 WBGene00004446 locus:rpl-32 60S ribosomal protein L32 status:Confirmed 
UniProt:Q22716 protein_id:CAA92757.1 
16 kDa 1.00 
CE29312 WBGene00018152 locus:acs-4 status:Confirmed UniProt:Q20121 
protein_id:AAC48292.3 
81 kDa 1.00 
CE14263 WBGene00006439 locus:ant-1.1 ADP\/ATP carrier protein 
status:Confirmed UniProt:O45865 protein_id:CAB04874.1 
33 kDa 1.07 
CE16463 WBGene00000067 locus:act-5 Actins status:Confirmed UniProt:O45815 
protein_id:CAB05817.1 
42 kDa 1.07 
CE09197 WBGene00006754 locus:unc-15 paramyosin status:Confirmed 
UniProt:P10567 protein_id:CAB01965.1 
101 kDa 1.07 
CE05656 WBGene00008920 locus:eef-1G elongation factor 1-gamma 
status:Confirmed UniProt:P54412 protein_id:CAA96631.1 
44 kDa 1.07 
CE06313 WBGene00004442 locus:rpl-28 ribsomal protein L28 like status:Confirmed 
UniProt:Q21930 protein_id:CAA99898.1 
14 kDa 1.07 
CE00664 WBGene00004470 locus:rps-1 Ribosomal protein S3a (human) homolog. 
status:Confirmed UniProt:P48154 protein_id:CAA83605.1 
29 kDa 1.07 
CE17563 WBGene00006529 locus:tba-2 Tubulin status:Confirmed UniProt:P34690 
protein_id:CAB16856.1 
50 kDa 1.07 
CE21562 WBGene00000802 locus:crt-1 calreticulin precursor status:Confirmed 
UniProt:P27798 protein_id:AAD14746.1 
46 kDa 1.07 
CE20658 WBGene00006819 locus:unc-87 calponin status:Confirmed UniProt:P37806 
protein_id:AAC78234.1 
63 kDa 1.07 
CE16650 WBGene00004430 locus:rpl-18 Eukaryotic ribosomal protein L18 
status:Confirmed UniProt:O45946 protein_id:CAA16387.1 
21 kDa 1.07 
CE08034 WBGene00004431 locus:rpl-19 60S ribosomal protein L19 status:Confirmed 
UniProt:O02639 protein_id:AAB53979.1 
24 kDa 1.07 
CE08177 WBGene00002007 locus:hsp-3 heat shock protein status:Confirmed 
UniProt:P27420 protein_id:AAB52671.1 
73 kDa 1.07 
CE24592 WBGene00004475 locus:rps-6 40S ribosomal protein S6 status:Confirmed 
UniProt:Q9NEN6 protein_id:CAB81996.1 
28 kDa 1.07 
CE11854 WBGene00002070 locus:ile-1 P58 protein like status:Confirmed 55 kDa 1.07 
UniProt:P90913 protein_id:CAB03169.1 
CE00778 WBGene00004435 locus:rpl-23 status:Confirmed UniProt:P48158 
protein_id:AAK18857.1 
15 kDa 1.07 
CE09719 WBGene00000230 locus:atp-3 ATPase status:Confirmed UniProt:P91283 
protein_id:AAB37654.1 
22 kDa 1.07 
CE03389 WBGene00001502 locus:ftt-2 14-3-3 protein status:Confirmed 
UniProt:Q20655 protein_id:CAA91474.1 
28 kDa 1.07 
CE20412 WBGene00003902 locus:pab-1 RNA recognition motif. (aka RRM, RBD, or 
RNP domain) \; Poly-adenylate binding protein, unique domain. status:Confirmed 
UniProt:Q9U302 protein_id:CAA21572.1 
72 kDa 1.07 
CE06360 WBGene00004474 locus:rps-5 40S ribosomal protein S5 status:Confirmed 
UniProt:P49041 protein_id:CAA92971.1 
23 kDa 1.07 
CE20485 WBGene00004452 locus:rpl-38 status:Confirmed UniProt:O17570 
protein_id:CAB03853.1 
8 kDa 1.07 
CE02183 WBGene00000114 locus:alh-8 methylmalonate-semialdehyde 
dehydrogenase status:Confirmed UniProt:P52713 protein_id:CAA88946.1 
56 kDa 1.07 
CE05165 WBGene00001922 locus:his-48 histone H2B status:Confirmed 
UniProt:Q27876 protein_id:CAA97413.1 
14 kDa 1.15 
CE01236 WBGene00003371 locus:mlc-3 status:Confirmed UniProt:P53014 
protein_id:AAA50701.1 
17 kDa 1.15 
CE04501 WBGene00001921 locus:his-47 histone H2A status:Confirmed 
UniProt:P09588 protein_id:CAA97414.1 
13 kDa 1.15 
CE23530 WBGene00007463 high-density lipoprotein-binding protein 
status:Confirmed UniProt:Q17832 protein_id:CAA91144.2 
134 kDa 1.15 
CE07721 WBGene00001137 locus:eat-6 Na(+)\/K(+) ATPase alpha subunit 
status:Confirmed UniProt:P90735 protein_id:CAB02694.1 
111 kDa 1.15 
CE24278 WBGene00004473 locus:rps-4 status:Confirmed UniProt:Q9N3X2 
protein_id:AAF60569.1 
29 kDa 1.15 
CE04362 WBGene00004447 locus:rpl-33 60s ribosomal protein L35A 
status:Confirmed UniProt:P49180 protein_id:AAA82422.1 
14 kDa 1.15 
CE17071 WBGene00002162 locus:isp-1 ubiquinol-cytochrome C reductase 
status:Confirmed UniProt:O44512 protein_id:AAB92071.1 
30 kDa 1.15 
CE06253 WBGene00002348 locus:myo-1 myosin heavy chain status:Confirmed 
UniProt:P02567 protein_id:CAA95848.1 
223 kDa 1.15 
CE32894 WBGene00002265 locus:lec-2 galactoside-binding lectin status:Confirmed 
UniProt:Q20684 protein_id:CAA91327.2 
132 kDa 1.15 
CE17986 WBGene00004424 locus:rpl-12 Ribosomal protein L11 status:Confirmed 
UniProt:P61866 protein_id:CAB05226.1 
18 kDa 1.15 
CE08258 WBGene00007646 locus:nkb-1 sodium\/potassium transporting ATPase 
beta chain status:Confirmed UniProt:Q93235 protein_id:CAB02752.1 
37 kDa 1.15 
C.Elegans ? 1.15 
CE22210 WBGene00013025 locus:vha-13 ATP synthase alpha and beta subunits \; 
ATP synthase ab C terminal status:Confirmed UniProt:Q9XW92 
protein_id:CAA22076.1 
66 kDa 1.15 
CE27322 WBGene00007000 locus:tufm-1 status:Confirmed UniProt:Q19072 
protein_id:AAK29979.1 
55 kDa 1.15 
CE42983 WBGene00002845 locus:let-711 status:Partially_confirmed 
UniProt:Q20937 protein_id:AAA21168.2 
282 kDa 1.15 
CE09349 WBGene00006789 locus:unc-54 myosin heavy chain 
status:Partially_confirmed UniProt:P02566 protein_id:CAB05505.1 
225 kDa 1.23 
CE28782 WBGene00002978 locus:lev-11 status:Confirmed UniProt:Q22866 
protein_id:CAC70114.1 
33 kDa 1.23 
CE31619 WBGene00003514 locus:myo-2 myosin heavy chain C status:Confirmed 
UniProt:P12845 protein_id:CAA92197.2 
223 kDa 1.23 
CE01341 WBGene00002083 locus:inf-1 status:Confirmed UniProt:P27639 
protein_id:AAA21170.1 
45 kDa 1.23 
CE12920 WBGene00001423 locus:fib-1 fibrillarin status:Confirmed UniProt:Q22053 
protein_id:CAB01657.1 
36 kDa 1.23 
CE23521 WBGene00001564 locus:icl-1 isocitrate lyase status:Confirmed 
UniProt:Q10663 protein_id:AAB71278.2 
109 kDa 1.23 
CE09650 WBGene00009119 locus:ndk-1 nucleoside diphosphate kinase 
status:Confirmed UniProt:Q93576 protein_id:CAB02101.1 
17 kDa 1.23 
CE07537 WBGene00020808 calponin-like protein status:Confirmed UniProt:Q23050 
protein_id:AAB04989.1 
44 kDa 1.32 
CE16576 WBGene00002264 locus:lec-1 galectin status:Partially_confirmed 
UniProt:P36573 protein_id:CAB04959.1 
32 kDa 1.32 
CE02255 WBGene00004416 locus:rpl-5 60S ribosomal protein L5 status:Confirmed 
UniProt:P49405 protein_id:CAA90251.1 
33 kDa 1.32 
CE34269 WBGene00003369 locus:mlc-1 status:Confirmed UniProt:P19625 
protein_id:AAK09070.2 
19 kDa 1.32 
CE01921 WBGene00006727 locus:ubq-1 status:Confirmed UniProt:P0CG71 
protein_id:AAC46525.1 
94 kDa 1.32 
CE34936 WBGene00003515 locus:myo-3 myosin heavy chain 
status:Partially_confirmed UniProt:P12844 protein_id:CAB01576.2 
226 kDa 1.32 
CE14064 WBGene00020732 status:Partially_confirmed UniProt:O17339 
protein_id:AAB71257.1 
101 kDa 1.32 
CE01943 WBGene00001945 locus:his-71 Histone H3 status:Confirmed 
UniProt:Q10453 protein_id:AAB04902.1 
15 kDa 1.41 
CE25005 WBGene00000041 locus:aco-2 Aconitate hydratase status:Confirmed 
UniProt:P34455 protein_id:AAA28050.2 
84 kDa 1.52 
CE05219 WBGene00007310 status:Partially_confirmed UniProt:Q17634 
protein_id:CAA94679.1 
59 kDa 1.52 
CE26076 WBGene00000498 locus:chk-1 status:Confirmed UniProt:Q9N3Z3 
protein_id:AAF59485.2 




Table 6: iTRAQ labeled proteins in the sixth sample in the second set. 
Identified Proteins Mw Ratio 
CE24592 WBGene00004475 locus:rps-6 40S ribosomal protein S6 status:Confirmed 
UniProt:Q9NEN6 protein_id:CAB81996.1 
28 kDa 0.33 
CE04009 WBGene00004482 locus:rps-13 40S ribosomal protein S13 
status:Confirmed UniProt:P51404 protein_id:AAB47594.1 
17 kDa 0.44 
CE14956 WBGene00004487 locus:rps-18 ribosomal protein S13 status:Confirmed 
UniProt:O18240 protein_id:CAB16517.1 
18 kDa 0.44 
CE19381 WBGene00004441 locus:rpl-27 60S ribosomal protein L27 status:Confirmed 
UniProt:P91914 protein_id:AAK68266.1 
16 kDa 0.54 
CE21562 WBGene00000802 locus:crt-1 calreticulin precursor status:Confirmed 
UniProt:P27798 protein_id:AAD14746.1 
46 kDa 0.62 
CE03253 WBGene00001919 locus:his-45 histone H3 status:Confirmed 
UniProt:P08898 protein_id:CAA97411.1 
15 kDa 0.66 
CE00744 WBGene00004417 locus:rpl-6 Ribosomal protein ML16 status:Confirmed 
UniProt:P47991 protein_id:AAK29850.1 
24 kDa 0.66 





CE06652 WBGene00014095 glutamate dehydrogenase status:Confirmed 
UniProt:Q23621 protein_id:CAA98074.1 
59 kDa 0.71 
CE12920 WBGene00001423 locus:fib-1 fibrillarin status:Confirmed UniProt:Q22053 
protein_id:CAB01657.1 
36 kDa 0.71 
CE05656 WBGene00008920 locus:eef-1G elongation factor 1-gamma 
status:Confirmed UniProt:P54412 protein_id:CAA96631.1 
44 kDa 0.76 
CE07537 WBGene00020808 calponin-like protein status:Confirmed UniProt:Q23050 
protein_id:AAB04989.1 
44 kDa 0.81 
CE05860 WBGene00004480 locus:rps-11 ribosomal protein S11 status:Confirmed 
UniProt:Q20206 protein_id:CAA97792.1 
18 kDa 0.81 
CE07721 WBGene00001137 locus:eat-6 Na(+)\/K(+) ATPase alpha subunit 
status:Confirmed UniProt:P90735 protein_id:CAB02694.1 
111 kDa 0.81 
CE12148 WBGene00004427 locus:rpl-15 60S ribosomal protein L15 status:Confirmed 
UniProt:P91374 protein_id:AAC24397.1 
24 kDa 0.81 
CE16576 WBGene00002264 locus:lec-1 galectin status:Partially_confirmed 
UniProt:P36573 protein_id:CAB04959.1 
32 kDa 0.87 
CE06950 WBGene00006926 locus:vit-2 vitellogenin status:Confirmed 
UniProt:P05690 protein_id:AAA98720.1 
188 kDa 0.87 
CE09197 WBGene00006754 locus:unc-15 paramyosin status:Confirmed 
UniProt:P10567 protein_id:CAB01965.1 
101 kDa 0.87 
CE06114 WBGene00010627 yeast protein L8167.9-like status:Confirmed 
UniProt:Q21276 protein_id:CAA94897.1 
55 kDa 0.87 
CE17071 WBGene00002162 locus:isp-1 ubiquinol-cytochrome C reductase 
status:Confirmed UniProt:O44512 protein_id:AAB92071.1 
30 kDa 0.87 
CE30781 WBGene00004450 locus:rpl-36 Ribosomal protein YL39 status:Confirmed 
UniProt:P49181 protein_id:AAC48295.2 
12 kDa 0.87 
CE22117 WBGene00004456 locus:rpl-43 status:Confirmed UniProt:Q9U2A8 10 kDa 0.87 
protein_id:CAB54440.1 
CE32361 WBGene00006434 locus:prdx-2 status:Confirmed UniProt:Q8IG31 
protein_id:AAN63412.1 
22 kDa 0.87 
CE14263 WBGene00006439 locus:ant-1.1 ADP\/ATP carrier protein 
status:Confirmed UniProt:O45865 protein_id:CAB04874.1 
33 kDa 0.93 
CE29443 WBGene00019900 Channel Protein status:Confirmed UniProt:Q21752 
protein_id:AAB00622.2 
30 kDa 0.93 
CE01236 WBGene00003371 locus:mlc-3 status:Confirmed UniProt:P53014 
protein_id:AAA50701.1 
17 kDa 0.93 
CE18478 WBGene00004413 locus:rpl-2 Ribosomal Proteins L2 status:Confirmed 
UniProt:Q9XVF7 protein_id:CAB03792.1 
28 kDa 0.93 
CE05165 WBGene00001922 locus:his-48 histone H2B status:Confirmed 
UniProt:Q27876 protein_id:CAA97413.1 
14 kDa 0.93 
CE27398 WBGene00004419 locus:rpl-7A status:Confirmed UniProt:Q966C6 
protein_id:AAK84600.1 
30 kDa 0.93 
CE20658 WBGene00006819 locus:unc-87 calponin status:Confirmed UniProt:P37806 
protein_id:AAC78234.1 
63 kDa 0.93 
CE09946 WBGene00009454 status:Confirmed UniProt:P90860 
protein_id:CAB03069.1 
20 kDa 0.93 
CE31619 WBGene00003514 locus:myo-2 myosin heavy chain C status:Confirmed 
UniProt:P12845 protein_id:CAA92197.2 
223 kDa 0.93 
CE18884 WBGene00004736 locus:sca-1 E1-E2 ATPases status:Confirmed 
UniProt:Q9XTG6 protein_id:CAB07262.1 
116 kDa 0.93 
CE24278 WBGene00004473 locus:rps-4 status:Confirmed UniProt:Q9N3X2 
protein_id:AAF60569.1 
29 kDa 0.93 
CE29330 WBGene00002265 locus:lec-2 galactoside-binding lectin status:Confirmed 
UniProt:Q9GNP7 protein_id:CAC70097.1 
31 kDa 0.93 
CE42660 WBGene00044989 status:Partially_confirmed UniProt:Q09EE4 
protein_id:CAL44977.2 
168 kDa 0.93 
CE22210 WBGene00013025 locus:vha-13 ATP synthase alpha and beta subunits \; 
ATP synthase ab C terminal status:Confirmed UniProt:Q9XW92 
protein_id:CAA22076.1 
66 kDa 0.93 
CE26948 WBGene00004486 locus:rps-17 40S ribosomal protein S17 
status:Confirmed UniProt:O01692 protein_id:AAG00017.2 
15 kDa 0.93 
CE18826 WBGene00010419 ATP synthase alpha and beta subunits, ATP synthase 
Alpha chain, C terminal status:Confirmed UniProt:Q9XXK1 protein_id:CAA19429.1 
58 kDa 1.00 
CE19904 WBGene00004496 locus:rps-27 ribosomal protein status:Confirmed 
UniProt:Q9TXP0 protein_id:AAC69219.1 
9 kDa 1.00 
CE07669 WBGene00004415 locus:rpl-4 ribosomal protein L1 status:Confirmed 
UniProt:O02056 protein_id:AAC24253.1 
39 kDa 1.00 
CE21392 WBGene00004432 locus:rpl-20 ribosomal protein status:Confirmed 
UniProt:O44480 protein_id:AAB92041.2 
21 kDa 1.00 
CE08526 WBGene00004425 locus:rpl-13 ribosomal protein L13 status:Confirmed 
UniProt:P91128 protein_id:AAB42322.1 
24 kDa 1.00 
CE15602 WBGene00007385 locus:atp-5 ATP synthase D chain status:Confirmed 
UniProt:Q17763 protein_id:CAA99772.1 
22 kDa 1.00 
CE01270 WBGene00001168 locus:eef-1A.1 Elongation factor 1-alpha 
status:Confirmed UniProt:P53013 protein_id:AAA81688.1 
51 kDa 1.07 
CE16463 WBGene00000067 locus:act-5 Actins status:Confirmed UniProt:O45815 
protein_id:CAB05817.1 
42 kDa 1.07 
CE29950 WBGene00000229 locus:atp-2 ATP synthase beta chain status:Confirmed 
UniProt:P46561 protein_id:AAA19068.2 
58 kDa 1.07 
CE28594 WBGene00006930 locus:vit-6 vitellogenin status:Partially_confirmed 
UniProt:P18948 protein_id:AAC04423.2 
193 kDa 1.07 
CE00913 WBGene00006537 locus:tbb-2 beta tubulin status:Confirmed 
UniProt:P52275 protein_id:CAA84648.1 
50 kDa 1.07 
CE34269 WBGene00003369 locus:mlc-1 status:Confirmed UniProt:P19625 
protein_id:AAK09070.2 
19 kDa 1.07 
CE05598 WBGene00004414 locus:rpl-3 60S ribosomal protein L3 status:Confirmed 
UniProt:P50880 protein_id:CAA91277.1 
46 kDa 1.07 
CE03278 WBGene00004440 locus:rpl-26 ribosomal protein L26 like status:Confirmed 
UniProt:Q19869 protein_id:CAA92674.1 
16 kDa 1.07 
CE26817 WBGene00006928 locus:vit-4 status:Partially_confirmed UniProt:P18947 
protein_id:AAK09074.1 
186 kDa 1.07 
CE08177 WBGene00002007 locus:hsp-3 heat shock protein status:Confirmed 
UniProt:P27420 protein_id:AAB52671.1 
73 kDa 1.07 
CE11570 WBGene00003964 locus:pdi-3 protein disulphide isomerase ER-60 
precursor like status:Confirmed UniProt:O17908 protein_id:CAB07480.1 
55 kDa 1.07 
CE06313 WBGene00004442 locus:rpl-28 ribsomal protein L28 like status:Confirmed 
UniProt:Q21930 protein_id:CAA99898.1 
14 kDa 1.07 
CE03972 WBGene00003963 locus:pdi-2 protein disulfide isomerase 
status:Confirmed UniProt:Q17770 protein_id:AAK39152.1 
55 kDa 1.07 
CE09650 WBGene00009119 locus:ndk-1 nucleoside diphosphate kinase 
status:Confirmed UniProt:Q93576 protein_id:CAB02101.1 
17 kDa 1.07 
CE04362 WBGene00004447 locus:rpl-33 60s ribosomal protein L35A 
status:Confirmed UniProt:P49180 protein_id:AAA82422.1 
14 kDa 1.07 
CE04561 WBGene00004477 locus:rps-8 40S ribosomal protein S8 status:Confirmed 
UniProt:P48156 protein_id:AAA81485.1 
24 kDa 1.15 
CE23530 WBGene00007463 high-density lipoprotein-binding protein 
status:Confirmed UniProt:Q17832 protein_id:CAA91144.2 
134 kDa 1.15 
CE08258 WBGene00007646 locus:nkb-1 sodium\/potassium transporting ATPase 
beta chain status:Confirmed UniProt:Q93235 protein_id:CAB02752.1 
37 kDa 1.15 
CE12358 WBGene00000066 locus:act-4 actin status:Confirmed UniProt:P10986 
protein_id:AAB04575.1 
42 kDa 1.23 
CE09349 WBGene00006789 locus:unc-54 myosin heavy chain 
status:Partially_confirmed UniProt:P02566 protein_id:CAB05505.1 
225 kDa 1.23 
CE28782 WBGene00002978 locus:lev-11 status:Confirmed UniProt:Q22866 
protein_id:CAC70114.1 
33 kDa 1.23 
CE04237 WBGene00004471 locus:rps-2 status:Confirmed UniProt:P51403 
protein_id:AAF99899.1 
29 kDa 1.23 
CE15900 WBGene00001167 locus:eef-2 Elongation factor Tu family (contains 
ATP\/GTP binding P-loop) status:Confirmed UniProt:P29691 protein_id:CAB02985.1 
95 kDa 1.23 
CE04038 WBGene00001000 locus:dim-1 status:Confirmed UniProt:Q18066 
protein_id:AAP31442.1 
36 kDa 1.23 
CE04501 WBGene00001921 locus:his-47 histone H2A status:Confirmed 
UniProt:P09588 protein_id:CAA97414.1 
13 kDa 1.32 
CE21417 WBGene00001427 locus:fkb-2 FKBP-type peptidyl-prolyl cis-trans 
isomerases status:Confirmed UniProt:Q9U2Q8 protein_id:CAA22330.1 
12 kDa 1.32 
CE18676 WBGene00009688 status:Confirmed UniProt:Q9XU97 
protein_id:CAB05509.1 
9 kDa 1.41 
CE04994 WBGene00003495 locus:mup-2 troponin T-like protein status:Confirmed 
UniProt:Q27371 protein_id:AAA83615.1 
47 kDa 1.41 
CE09682 WBGene00002005 locus:hsp-1 HSP-1 heat shock 70kd protein A 
status:Confirmed UniProt:P09446 protein_id:CAB02319.1 
70 kDa 1.62 
CE06253 WBGene00002348 locus:myo-1 myosin heavy chain status:Confirmed 
UniProt:P02567 protein_id:CAA95848.1 
223 kDa 1.62 
CE20168 WBGene00004445 locus:rpl-31 Ribosomal protein L31e status:Confirmed 
UniProt:Q9U332 protein_id:CAB63331.1 
14 kDa 1.62 
CE01341 WBGene00002083 locus:inf-1 status:Confirmed UniProt:P27639 
protein_id:AAA21170.1 
45 kDa 1.62 
CE14265 WBGene00012094 ubiquinol-cytochrome c reductase complexn 11 KD 
protein status:Confirmed UniProt:O45864 protein_id:CAB04873.1 
9 kDa 1.74 
CE01976 WBGene00019061 ATP synthase status:Confirmed UniProt:Q09544 
protein_id:AAC46699.1 
17 kDa 1.87 
CE37468 WBGene00006534 locus:tba-8 tubulin alpha chain 
status:Partially_confirmed UniProt:P52274 protein_id:CAA85497.2 
50 kDa 1.87 
CE16905 WBGene00004266 locus:rab-1 RAS-related protein status:Confirmed 
UniProt:Q9UAQ6 protein_id:AAC69218.1 
23 kDa 2.00 
CE34936 WBGene00003515 locus:myo-3 myosin heavy chain 
status:Partially_confirmed UniProt:P12844 protein_id:CAB01576.2 
226 kDa 2.14 
 
 
Table 7: iTRAQ labeled proteins in the seventh sample in the third set. 
Identified Proteins Mw Ratio 
CE34269 WBGene00003369 locus:mlc-1 status:Confirmed UniProt:P19625 
protein_id:AAK09070.2 
19 kDa 0.76 
CE26817 WBGene00006928 locus:vit-4 status:Partially_confirmed UniProt:P18947 
protein_id:AAK09074.1 
186 kDa 0.81 
CE17563 WBGene00006529 locus:tba-2 Tubulin status:Confirmed UniProt:P34690 
protein_id:CAB16856.1 
50 kDa 0.81 
CE28782 WBGene00002978 locus:lev-11 status:Confirmed UniProt:Q22866 
protein_id:CAC70114.1 
33 kDa 0.87 
CE21418 WBGene00003989 locus:pfn-1 Profilins status:Confirmed UniProt:Q9XW16 
protein_id:CAA22318.1 
14 kDa 0.87 
CE09349 WBGene00006789 locus:unc-54 myosin heavy chain 225 kDa 0.93 
status:Partially_confirmed UniProt:P02566 protein_id:CAB05505.1 
CE12358 WBGene00000066 locus:act-4 actin status:Confirmed UniProt:P10986 
protein_id:AAB04575.1 
42 kDa 0.93 
CE05165 WBGene00001922 locus:his-48 histone H2B status:Confirmed 
UniProt:Q27876 protein_id:CAA97413.1 
14 kDa 0.93 
CE07426 WBGene00019947 locus:htz-1 histone H2A variant status:Confirmed 
UniProt:Q27511 protein_id:AAC48074.1 
15 kDa 0.93 
CE32894 WBGene00002265 locus:lec-2 galactoside-binding lectin status:Confirmed 
UniProt:Q20684 protein_id:CAA91327.2 
132 kDa 0.93 
CE03972 WBGene00003963 locus:pdi-2 protein disulfide isomerase 
status:Confirmed UniProt:Q17770 protein_id:AAK39152.1 
55 kDa 0.93 
CE05441 WBGene00000915 locus:daf-21 heat shock protein (HSP90) 
status:Confirmed UniProt:Q18688 protein_id:CAA99793.1 
80 kDa 0.93 
CE00821 WBGene00004483 locus:rps-14 Ribosomal protein S14 status:Confirmed 
UniProt:P48150 protein_id:AAC48301.1 
16 kDa 0.93 
CE06950 WBGene00006926 locus:vit-2 vitellogenin status:Confirmed 
UniProt:P05690 protein_id:AAA98720.1 
188 kDa 1.00 
CE07537 WBGene00020808 calponin-like protein status:Confirmed UniProt:Q23050 
protein_id:AAB04989.1 
44 kDa 1.00 
CE09197 WBGene00006754 locus:unc-15 paramyosin status:Confirmed 
UniProt:P10567 protein_id:CAB01965.1 
101 kDa 1.00 
CE16576 WBGene00002264 locus:lec-1 galectin status:Partially_confirmed 
UniProt:P36573 protein_id:CAB04959.1 
32 kDa 1.00 
CE34936 WBGene00003515 locus:myo-3 myosin heavy chain 
status:Partially_confirmed UniProt:P12844 protein_id:CAB01576.2 
226 kDa 1.00 
CE07721 WBGene00001137 locus:eat-6 Na(+)\/K(+) ATPase alpha subunit 
status:Confirmed UniProt:P90735 protein_id:CAB02694.1 
111 kDa 1.00 
CE03252 WBGene00001920 locus:his-46 histone H4 status:Predicted 
UniProt:P62784 protein_id:CAA97407.1 
11 kDa 1.00 
CE12920 WBGene00001423 locus:fib-1 fibrillarin status:Confirmed UniProt:Q22053 
protein_id:CAB01657.1 
36 kDa 1.00 
CE01921 WBGene00006727 locus:ubq-1 status:Confirmed UniProt:P0CG71 
protein_id:AAC46525.1 
94 kDa 1.00 
CE09866 WBGene00017982 locus:hpo-18 ATP synthase epsilion chain 
status:Confirmed UniProt:O16298 protein_id:AAB65352.1 
6 kDa 1.00 
CE14263 WBGene00006439 locus:ant-1.1 ADP\/ATP carrier protein 
status:Confirmed UniProt:O45865 protein_id:CAB04874.1 
33 kDa 1.07 
CE28594 WBGene00006930 locus:vit-6 vitellogenin status:Partially_confirmed 
UniProt:P18948 protein_id:AAC04423.2 
193 kDa 1.07 
CE31619 WBGene00003514 locus:myo-2 myosin heavy chain C status:Confirmed 
UniProt:P12845 protein_id:CAA92197.2 
223 kDa 1.07 
CE00913 WBGene00006537 locus:tbb-2 beta tubulin status:Confirmed 
UniProt:P52275 protein_id:CAA84648.1 
50 kDa 1.07 
CE15900 WBGene00001167 locus:eef-2 Elongation factor Tu family (contains 
ATP\/GTP binding P-loop) status:Confirmed UniProt:P29691 protein_id:CAB02985.1 
95 kDa 1.07 
CE17071 WBGene00002162 locus:isp-1 ubiquinol-cytochrome C reductase 30 kDa 1.07 
status:Confirmed UniProt:O44512 protein_id:AAB92071.1 
CE08177 WBGene00002007 locus:hsp-3 heat shock protein status:Confirmed 
UniProt:P27420 protein_id:AAB52671.1 
73 kDa 1.07 
CE20658 WBGene00006819 locus:unc-87 calponin status:Confirmed UniProt:P37806 
protein_id:AAC78234.1 
63 kDa 1.07 
CE15602 WBGene00007385 locus:atp-5 ATP synthase D chain status:Confirmed 
UniProt:Q17763 protein_id:CAA99772.1 
22 kDa 1.07 
CE09719 WBGene00000230 locus:atp-3 ATPase status:Confirmed UniProt:P91283 
protein_id:AAB37654.1 
22 kDa 1.07 
CE20171 WBGene00012354 status:Confirmed UniProt:Q9U329 
protein_id:CAB63334.1 
20 kDa 1.07 
CE18884 WBGene00004736 locus:sca-1 E1-E2 ATPases status:Confirmed 
UniProt:Q9XTG6 protein_id:CAB07262.1 
116 kDa 1.07 
CE01270 WBGene00001168 locus:eef-1A.1 Elongation factor 1-alpha 
status:Confirmed UniProt:P53013 protein_id:AAA81688.1 
51 kDa 1.15 
CE29950 WBGene00000229 locus:atp-2 ATP synthase beta chain status:Confirmed 
UniProt:P46561 protein_id:AAA19068.2 
58 kDa 1.15 
CE18826 WBGene00010419 ATP synthase alpha and beta subunits, ATP synthase 
Alpha chain, C terminal status:Confirmed UniProt:Q9XXK1 protein_id:CAA19429.1 
58 kDa 1.15 
CE06253 WBGene00002348 locus:myo-1 myosin heavy chain status:Confirmed 
UniProt:P02567 protein_id:CAA95848.1 
223 kDa 1.15 
CE01236 WBGene00003371 locus:mlc-3 status:Confirmed UniProt:P53014 
protein_id:AAA50701.1 
17 kDa 1.15 
CE16463 WBGene00000067 locus:act-5 Actins status:Confirmed UniProt:O45815 
protein_id:CAB05817.1 
42 kDa 1.15 
CE23530 WBGene00007463 high-density lipoprotein-binding protein 
status:Confirmed UniProt:Q17832 protein_id:CAA91144.2 
134 kDa 1.15 
CE15028 WBGene00006787 locus:unc-52 UNC-52 membrane proteoglycan 
status:Partially_confirmed UniProt:Q06561 protein_id:CAB07706.1 
271 kDa 1.15 
CE08258 WBGene00007646 locus:nkb-1 sodium\/potassium transporting ATPase 
beta chain status:Confirmed UniProt:Q93235 protein_id:CAB02752.1 
37 kDa 1.15 
CE04001 WBGene00015803 status:Confirmed UniProt:Q18032 
protein_id:AAB52666.1 
15 kDa 1.15 
CE06200 WBGene00003920 locus:par-5 14-3-3 protein status:Confirmed 
UniProt:P41932 protein_id:CAA98138.1 
28 kDa 1.15 
CE06313 WBGene00004442 locus:rpl-28 ribsomal protein L28 like status:Confirmed 
UniProt:Q21930 protein_id:CAA99898.1 
14 kDa 1.15 
CE05528 WBGene00008377 status:Confirmed UniProt:Q18943 
protein_id:CAA98435.1 
21 kDa 1.15 
CE06702 WBGene00006780 locus:unc-44 status:Confirmed UniProt:Q17489 
protein_id:AAA93443.1 
223 kDa 1.15 
CE27803 WBGene00007708 locus:nola-3 status:Confirmed UniProt:Q9XVR8 
protein_id:CAB02768.2 
8 kDa 1.15 
CE29443 WBGene00019900 Channel Protein status:Confirmed UniProt:Q21752 
protein_id:AAB00622.2 
30 kDa 1.23 
CE09682 WBGene00002005 locus:hsp-1 HSP-1 heat shock 70kd protein A 70 kDa 1.23 
status:Confirmed UniProt:P09446 protein_id:CAB02319.1 
CE01976 WBGene00019061 ATP synthase status:Confirmed UniProt:Q09544 
protein_id:AAC46699.1 
17 kDa 1.23 
CE00480 WBGene00011867 locus:chc-1 Clathrin heavy chain 
status:Partially_confirmed UniProt:P34574 protein_id:CAA83003.1 
192 kDa 1.23 
CE16905 WBGene00004266 locus:rab-1 RAS-related protein status:Confirmed 
UniProt:Q9UAQ6 protein_id:AAC69218.1 
23 kDa 1.23 
CE06114 WBGene00010627 yeast protein L8167.9-like status:Confirmed 
UniProt:Q21276 protein_id:CAA94897.1 
55 kDa 1.23 
CE20412 WBGene00003902 locus:pab-1 RNA recognition motif. (aka RRM, RBD, or 
RNP domain) \; Poly-adenylate binding protein, unique domain. status:Confirmed 
UniProt:Q9U302 protein_id:CAA21572.1 
72 kDa 1.23 
CE09946 WBGene00009454 status:Confirmed UniProt:P90860 
protein_id:CAB03069.1 
20 kDa 1.23 
CE13431 WBGene00020347 3-hydroxyacyl-CoA dehydrogenase status:Confirmed 
UniProt:Q9GYT0 protein_id:AAK21462.1 
85 kDa 1.23 
CE11342 WBGene00001581 locus:gfi-1 status:Partially_confirmed UniProt:Q94246 
protein_id:AAB09166.1 
227 kDa 1.23 
CE01217 WBGene00017125 locus:acdh-12 Isovaleryl-CoA dehydrogenase 
status:Confirmed UniProt:Q19057 protein_id:AAA68357.1 
66 kDa 1.23 
CE16650 WBGene00004430 locus:rpl-18 Eukaryotic ribosomal protein L18 
status:Confirmed UniProt:O45946 protein_id:CAA16387.1 
21 kDa 1.23 
CE09162 WBGene00008505 phosphate carrier protein precursor status:Confirmed 
UniProt:P40614 protein_id:CAA97430.1 
37 kDa 1.32 
CE05860 WBGene00004480 locus:rps-11 ribosomal protein S11 status:Confirmed 
UniProt:Q20206 protein_id:CAA97792.1 
18 kDa 1.32 
CE09655 WBGene00004408 locus:rla-0 deoxyribonuclease status:Confirmed 
UniProt:Q93572 protein_id:CAB02098.1 
34 kDa 1.32 
CE00744 WBGene00004417 locus:rpl-6 Ribosomal protein ML16 status:Confirmed 
UniProt:P47991 protein_id:AAK29850.1 
24 kDa 1.32 
CE14064 WBGene00020732 status:Partially_confirmed UniProt:O17339 
protein_id:AAB71257.1 
101 kDa 1.32 
CE05656 WBGene00008920 locus:eef-1G elongation factor 1-gamma 
status:Confirmed UniProt:P54412 protein_id:CAA96631.1 
44 kDa 1.41 
CE07669 WBGene00004415 locus:rpl-4 ribosomal protein L1 status:Confirmed 
UniProt:O02056 protein_id:AAC24253.1 
39 kDa 1.41 
CE27398 WBGene00004419 locus:rpl-7A status:Confirmed UniProt:Q966C6 
protein_id:AAK84600.1 
30 kDa 1.41 
CE27706 WBGene00001000 locus:dim-1 status:Confirmed UniProt:Q18066 
protein_id:AAC69011.2 
72 kDa 1.41 
CE02183 WBGene00000114 locus:alh-8 methylmalonate-semialdehyde 
dehydrogenase status:Confirmed UniProt:P52713 protein_id:CAA88946.1 
56 kDa 1.41 
CE00778 WBGene00004435 locus:rpl-23 status:Confirmed UniProt:P48158 
protein_id:AAK18857.1 
15 kDa 1.41 
CE04237 WBGene00004471 locus:rps-2 status:Confirmed UniProt:P51403 
protein_id:AAF99899.1 
29 kDa 1.41 
CE15746 WBGene00003052 locus:lmn-1 Intermediate filament proteins (2 domains) 
status:Confirmed UniProt:Q21443 protein_id:CAB09411.1 
64 kDa 1.41 
CE11570 WBGene00003964 locus:pdi-3 protein disulphide isomerase ER-60 
precursor like status:Confirmed UniProt:O17908 protein_id:CAB07480.1 
55 kDa 1.52 
CE35878 WBGene00010015 locus:atad-3 ATPases associated with various cellular 
activities (AAA) status:Confirmed UniProt:Q20748 protein_id:CAA88471.2 
67 kDa 1.52 
CE42777 WBGene00009342 locus:fasn-1 fatty acid synthase 
status:Partially_confirmed UniProt:P91871 protein_id:CAB04244.2 
289 kDa 1.52 
CE19904 WBGene00004496 locus:rps-27 ribosomal protein status:Confirmed 
UniProt:Q9TXP0 protein_id:AAC69219.1 
9 kDa 1.62 
CE21392 WBGene00004432 locus:rpl-20 ribosomal protein status:Confirmed 
UniProt:O44480 protein_id:AAB92041.2 
21 kDa 1.62 
CE01341 WBGene00002083 locus:inf-1 status:Confirmed UniProt:P27639 
protein_id:AAA21170.1 
45 kDa 1.62 
CE22117 WBGene00004456 locus:rpl-43 status:Confirmed UniProt:Q9U2A8 
protein_id:CAB54440.1 
10 kDa 1.62 
CE32361 WBGene00006434 locus:prdx-2 status:Confirmed UniProt:Q8IG31 
protein_id:AAN63412.1 
22 kDa 1.62 
CE01380 WBGene00004420 locus:rpl-9 Ribosomal protein L9 status:Confirmed 
UniProt:Q95Y90 protein_id:AAK84469.1 
22 kDa 1.62 
CE09015 WBGene00016943 locus:acdh-1 acyl-CoA dehydrogenase status:Confirmed 
UniProt:Q966M3 protein_id:AAK68275.1 
47 kDa 1.74 
CE27244 WBGene00002025 locus:hsp-60 status:Confirmed 60 kDa 1.74 
CE21562 WBGene00000802 locus:crt-1 calreticulin precursor status:Confirmed 
UniProt:P27798 protein_id:AAD14746.1 
46 kDa 1.74 
CE24278 WBGene00004473 locus:rps-4 status:Confirmed UniProt:Q9N3X2 
protein_id:AAF60569.1 
29 kDa 1.87 
CE03278 WBGene00004440 locus:rpl-26 ribosomal protein L26 like status:Confirmed 
UniProt:Q19869 protein_id:CAA92674.1 
16 kDa 2.00 
CE18676 WBGene00009688 status:Confirmed UniProt:Q9XU97 
protein_id:CAB05509.1 
9 kDa 2.30 
 
Table 8: iTRAQ labeled proteins in the eighth sample in the third set. 
Quant View:Identified Proteins  Mw Ratio 
CE16757 WBGene00014193 locus:nhr-247 Ligand-binding domain of nuclear 
hormone receptors, Zinc finger, C4 type (two domains) status:Partially_confirmed 
UniProt:O45987 protein_id:CAB03504.1 
39 kDa 0.20 





CE09945 WBGene00004484 locus:rps-15 40S ribosomal protein S15 
status:Confirmed UniProt:Q9XVP0 protein_id:CAB03065.1 
17 kDa 0.47 
CE03473 WBGene00010705 locus:cyp-14A1 cytochrome p450 
status:Partially_confirmed UniProt:Q27506 protein_id:CAA90616.1 
57 kDa 0.50 
CE40325 WBGene00008505 status:Confirmed UniProt:Q0PDK0 42 kDa 0.54 
protein_id:CAL22703.1 
CE30781 WBGene00004450 locus:rpl-36 Ribosomal protein YL39 status:Confirmed 
UniProt:P49181 protein_id:AAC48295.2 
12 kDa 0.54 
CE09620 WBGene00017765 aminomethytransferase status:Confirmed 
UniProt:Q22968 protein_id:AAB37080.1 
44 kDa 0.54 





CE17154 WBGene00019322 locus:ahcy-1 S-adenosylhomocysteine hydrolase 
status:Confirmed UniProt:P27604 protein_id:AAB97565.1 
48 kDa 0.62 
CE33018 WBGene00006759 locus:unc-22 Fibronectin type III domain (31 domains), 
IG (immunoglobulin) superfamily (18 domains), calcium\/calmodulin dependent 




CE07033 WBGene00004423 locus:rpl-11.2 ribosomal protein status:Confirmed 
UniProt:Q19162 protein_id:AAA83599.1 
23 kDa 0.62 
CE22493 WBGene00002269 locus:lec-6 status:Confirmed UniProt:Q9N384 
protein_id:AAF60785.1 
16 kDa 0.62 
CE05849 WBGene00004478 locus:rps-9 ribosomal protein S9 status:Confirmed 
UniProt:Q20228 protein_id:CAA93262.1 
22 kDa 0.62 
CE12148 WBGene00004427 locus:rpl-15 60S ribosomal protein L15 
status:Confirmed UniProt:P91374 protein_id:AAC24397.1 
24 kDa 0.62 
CE18478 WBGene00004413 locus:rpl-2 Ribosomal Proteins L2 status:Confirmed 
UniProt:Q9XVF7 protein_id:CAB03792.1 
28 kDa 0.62 
CE09047 WBGene00004436 locus:rpl-24.1 60S ribosomal protein L24 
status:Confirmed UniProt:O01868 protein_id:AAK18907.1 
18 kDa 0.62 
CE01643 WBGene00011510 pyruvate dehydrogenase E1 alpha subunit 
status:Confirmed UniProt:P52899 protein_id:CAA87793.1 
44 kDa 0.66 
CE11776 WBGene00019433 locus:acdh-3 acyl-CoA dehydrogenase status:Confirmed 
UniProt:O44549 protein_id:AAK21433.1 
46 kDa 0.66 
CE05019 WBGene00020795 cleavage stimulation factor status:Predicted 
UniProt:Q22777 protein_id:AAA82464.1 
26 kDa 0.66 
CE01543 WBGene00004421 locus:rpl-10 ribosomal protein L10 (QM protein) 
status:Confirmed UniProt:Q09533 protein_id:CAA88308.1 
25 kDa 0.71 
CE01270 WBGene00001168 locus:eef-1A.1 Elongation factor 1-alpha 
status:Confirmed UniProt:P53013 protein_id:AAA81688.1 
51 kDa 0.71 
CE07669 WBGene00004415 locus:rpl-4 ribosomal protein L1 status:Confirmed 
UniProt:O02056 protein_id:AAC24253.1 
39 kDa 0.71 
CE03389 WBGene00001502 locus:ftt-2 14-3-3 protein status:Confirmed 
UniProt:Q20655 protein_id:CAA91474.1 
28 kDa 0.71 
CE17145 WBGene00019176 status:Partially_confirmed UniProt:O44520 
protein_id:AAB93487.1 
28 kDa 0.71 










CE06364 WBGene00011481 locus:imp-2 Yeast YKK0 like status:Confirmed 
UniProt:P49049 protein_id:CAA92975.1 
53 kDa 0.71 





CE05839 WBGene00000822 locus:csq-1 calsequestrin like status:Confirmed 
UniProt:Q20203 protein_id:CAA93667.1 
48 kDa 0.71 
CE29634 WBGene00002268 locus:lec-5 status:Confirmed UniProt:Q23426 
protein_id:AAC71097.2 
35 kDa 0.71 
CE05443 WBGene00006836 locus:unc-112 mitogen inducible MIG-2 protein like 
status:Confirmed UniProt:Q18685 protein_id:CAA99790.1 
82 kDa 0.71 





CE26244 WBGene00022122 locus:trap-1 status:Confirmed UniProt:Q95XT5 
protein_id:AAK66027.1 
29 kDa 0.71 
CE22210 WBGene00013025 locus:vha-13 ATP synthase alpha and beta subunits \; 
ATP synthase ab C terminal status:Confirmed UniProt:Q9XW92 
protein_id:CAA22076.1 
66 kDa 0.76 
CE20371 WBGene00000883 locus:cyn-7 Peptidyl-prolyl cis-trans isomerases 
status:Confirmed UniProt:P52015 protein_id:CAA21760.1 
18 kDa 0.76 
CE17730 WBGene00000881 locus:cyn-5 cyclophillin status:Confirmed 
UniProt:P52013 protein_id:CAB07192.1 
22 kDa 0.76 





CE30438 WBGene00017065 status:Confirmed UniProt:P91194 
protein_id:AAB42224.2 
41 kDa 0.76 
CE07269 WBGene00018701 locus:pccb-1 propionyl-CoA carboxylase beta 
status:Confirmed UniProt:Q20676 protein_id:AAB54030.1 
58 kDa 0.76 
CE08852 WBGene00008205 locus:sams-1 s-adenosylmethionine synthetase 
status:Confirmed UniProt:O17680 protein_id:CAB03975.1 
44 kDa 0.76 
CE03436 WBGene00010317 locus:idh-1 isocitrate dehydrogenase status:Confirmed 
UniProt:Q21032 protein_id:CAA92778.1 
46 kDa 0.76 
CE28759 WBGene00044061 locus:tbc-12 status:Partially_confirmed UniProt:Q21928 
protein_id:AAA83513.2 
70 kDa 0.76 
CE28255 WBGene00020391 locus:cct-7 status:Confirmed UniProt:Q9TZS5 
protein_id:AAC19232.2 
58 kDa 0.76 





CE20298 WBGene00013129 status:Partially_confirmed UniProt:Q9U255 
protein_id:CAB63391.1 
94 kDa 0.76 
CE04561 WBGene00004477 locus:rps-8 40S ribosomal protein S8 status:Confirmed 
UniProt:P48156 protein_id:AAA81485.1 
24 kDa 0.81 
CE15900 WBGene00001167 locus:eef-2 Elongation factor Tu family (contains 
ATP\/GTP binding P-loop) status:Confirmed UniProt:P29691 protein_id:CAB02985.1 
95 kDa 0.81 
CE14263 WBGene00006439 locus:ant-1.1 ADP\/ATP carrier protein 
status:Confirmed UniProt:O45865 protein_id:CAB04874.1 
33 kDa 0.81 
CE02622 WBGene00002054 locus:ifb-2 Intermediate filament protein 
status:Confirmed UniProt:Q19286 protein_id:AAA93405.1 
62 kDa 0.81 
CE08034 WBGene00004431 locus:rpl-19 60S ribosomal protein L19 24 kDa 0.81 
status:Confirmed UniProt:O02639 protein_id:AAB53979.1 
CE06360 WBGene00004474 locus:rps-5 40S ribosomal protein S5 status:Confirmed 
UniProt:P49041 protein_id:CAA92971.1 
23 kDa 0.81 
CE01810 WBGene00004472 locus:rps-3 Ribosomal protein S3 status:Confirmed 
UniProt:P48152 protein_id:AAF99870.1 
27 kDa 0.81 





CE24926 WBGene00009187 electron transfer flavoprotein alpha-subunit 
status:Confirmed UniProt:Q93615 protein_id:CAB61027.1 
34 kDa 0.81 
CE09597 WBGene00009082 dihyrolipoamide acetyltransferase component 
(pyruvate dehydrogenase complex) status:Confirmed UniProt:Q19749 
protein_id:CAB01163.1 
53 kDa 0.81 





CE43309 WBGene00000396 locus:cdh-4 Approximately 25 cadherin-repeats, 3 EGF 





CE21842 WBGene00004497 locus:rps-28 status:Confirmed UniProt:Q95Y04 
protein_id:AAK68479.1 
7 kDa 0.81 
CE09163 WBGene00008506 locus:tkt-1 transketolase status:Confirmed 
UniProt:O17759 protein_id:CAB02889.1 
66 kDa 0.81 
CE00664 WBGene00004470 locus:rps-1 Ribosomal protein S3a (human) homolog. 
status:Confirmed UniProt:P48154 protein_id:CAA83605.1 
29 kDa 0.81 
CE30249 WBGene00015971 locus:swsn-2.2 status:Confirmed UniProt:O02101 
protein_id:AAB52943.2 
52 kDa 0.81 
CE09650 WBGene00009119 locus:ndk-1 nucleoside diphosphate kinase 
status:Confirmed UniProt:Q93576 protein_id:CAB02101.1 
17 kDa 0.81 





CE11095 WBGene00010070 Zinc-binding metalloprotease 




CE01523 WBGene00002067 locus:ifp-1 intermediate filament protein 
status:Confirmed UniProt:Q09501 protein_id:CAA87328.1 
89 kDa 0.81 
CE35071 WBGene00005810 locus:srw-63 7TM chemoreceptor, srw family 
status:Predicted UniProt:Q9U2P2 protein_id:CAA19493.2 
46 kDa 0.81 
CE26774 WBGene00021350 status:Confirmed UniProt:Q9BKU5 
protein_id:AAK27870.1 
16 kDa 0.81 
CE02404 WBGene00006918 locus:vha-9 H+-transporting ATPase status:Confirmed 
UniProt:Q23680 protein_id:CAA88888.1 
13 kDa 0.81 










CE37406 WBGene00020417 locus:nuo-2 NADH-ubiquinone oxidoredutase 30 kd 
subunit status:Confirmed UniProt:O01602 protein_id:AAB52474.2 
51 kDa 0.81 
CE40345 WBGene00007154 dynein status:Partially_confirmed UniProt:P90736 322 0.81 
protein_id:CAB03163.2 kDa 
CE12368 WBGene00019760 locus:calu-1 calcium binding protein status:Confirmed 
UniProt:Q23017 protein_id:AAB04578.1 
36 kDa 0.81 
CE02319 WBGene00000377 locus:cct-1 T-complex protein status:Confirmed 
UniProt:P41988 protein_id:CAA91308.1 
59 kDa 0.81 





CE28782 WBGene00002978 locus:lev-11 status:Confirmed UniProt:Q22866 
protein_id:CAC70114.1 
33 kDa 0.87 





CE15028 WBGene00006787 locus:unc-52 UNC-52 membrane proteoglycan 




CE16308 WBGene00011156 RNA recognition motif. (aka RRM, RBD, or RNP domain) 
status:Confirmed UniProt:O45713 protein_id:CAB03237.1 
9 kDa 0.87 
CE31204 WBGene00002056 locus:ifc-2 intermediate filament proteim A 




CE02618 WBGene00002053 locus:ifb-1 Intermediate filament protein 
status:Confirmed UniProt:Q19289 protein_id:AAA93408.1 
64 kDa 0.87 
CE02733 WBGene00018271 Serine carboxypeptidase status:Confirmed 
UniProt:P52717 protein_id:AAC46812.1 
54 kDa 0.87 
CE01380 WBGene00004420 locus:rpl-9 Ribosomal protein L9 status:Confirmed 
UniProt:Q95Y90 protein_id:AAK84469.1 
22 kDa 0.87 
CE04237 WBGene00004471 locus:rps-2 status:Confirmed UniProt:P51403 
protein_id:AAF99899.1 
29 kDa 0.87 
CE03351 WBGene00009812 succinate-CoA ligase status:Confirmed UniProt:P53588 
protein_id:CAA91981.1 
47 kDa 0.87 










CE30426 WBGene00006820 locus:unc-89 immunoglobin-like protein 














CE13431 WBGene00020347 3-hydroxyacyl-CoA dehydrogenase status:Confirmed 
UniProt:Q9GYT0 protein_id:AAK21462.1 
85 kDa 0.87 
CE36971 WBGene00007207 Zinc finger, C3HC4 type (RING finger) status:Confirmed 
UniProt:Q17532 protein_id:CAA97769.2 
68 kDa 0.87 
CE21392 WBGene00004432 locus:rpl-20 ribosomal protein status:Confirmed 
UniProt:O44480 protein_id:AAB92041.2 
21 kDa 0.87 
CE28600 WBGene00003009 locus:lin-23 Transducin beta chain status:Confirmed 
UniProt:Q09990 protein_id:AAA68258.2 
76 kDa 0.87 
CE31083 WBGene00020950 dihydrolipoamide succinyltransferase status:Confirmed 50 kDa 0.87 
UniProt:O45148 protein_id:AAC04462.2 
CE43252 WBGene00009844 locus:cwp-5 status:Partially_confirmed UniProt:B6VQ87 
protein_id:CAR97835.1 
73 kDa 0.87 
CE32571 WBGene00003961 locus:pct-1 status:Confirmed UniProt:Q8I7M8 
protein_id:AAN84880.1 
76 kDa 0.87 
CE00689 WBGene00017301 Enoyl-CoA hydratase status:Confirmed UniProt:Q19278 
protein_id:AAA50696.1 
43 kDa 0.87 
CE31179 WBGene00018719 status:Partially_confirmed UniProt:O17398 
protein_id:AAB71316.3 
99 kDa 0.87 
CE24278 WBGene00004473 locus:rps-4 status:Confirmed UniProt:Q9N3X2 
protein_id:AAF60569.1 
29 kDa 0.93 
CE04424 WBGene00006921 locus:vha-12 vacuolar ATP synthase (strong) 
status:Confirmed UniProt:Q19626 protein_id:AAA82311.1 
55 kDa 0.93 





CE02255 WBGene00004416 locus:rpl-5 60S ribosomal protein L5 status:Confirmed 
UniProt:P49405 protein_id:CAA90251.1 
33 kDa 0.93 





CE09682 WBGene00002005 locus:hsp-1 HSP-1 heat shock 70kd protein A 
status:Confirmed UniProt:P09446 protein_id:CAB02319.1 
70 kDa 0.93 
CE09693 WBGene00000371 locus:cco-1 cytochrome C oxidase status:Confirmed 
UniProt:P90849 protein_id:CAB03002.1 
15 kDa 0.93 
CE00513 WBGene00000833 locus:cts-1 Citrate synthase status:Confirmed 
UniProt:P34575 protein_id:CAA83004.1 
52 kDa 0.93 










CE01030 WBGene00004428 locus:rpl-16 L13P family ribosomal protein 
status:Confirmed UniProt:Q27389 protein_id:CAA86515.1 
23 kDa 0.93 
CE03917 WBGene00015391 locus:sdha-1 succinate dehydrogenase flavoprotein 
subunit status:Confirmed UniProt:Q09508 protein_id:AAB37034.1 
70 kDa 0.93 
CE11024 WBGene00004418 locus:rpl-7 ribosomal protein status:Confirmed 
UniProt:O01802 protein_id:AAB54165.1 
28 kDa 0.93 
CE42777 WBGene00009342 locus:fasn-1 fatty acid synthase 




CE04451 WBGene00017864 locus:pcca-1 Propionyl-coA carboxylase alpha chain 
precursor status:Confirmed UniProt:Q19842 protein_id:AAA93384.1 
80 kDa 0.93 
CE06114 WBGene00010627 yeast protein L8167.9-like status:Confirmed 
UniProt:Q21276 protein_id:CAA94897.1 
55 kDa 0.93 
CE06974 WBGene00000210 locus:asg-2 ATP synthase status:Confirmed 
UniProt:Q18803 protein_id:AAC48276.1 
15 kDa 0.93 





CE24592 WBGene00004475 locus:rps-6 40S ribosomal protein S6 status:Confirmed 28 kDa 0.93 
UniProt:Q9NEN6 protein_id:CAB81996.1 
CE05311 WBGene00001648 locus:goa-1 guanine nucleotide-binding protein 
status:Confirmed UniProt:P51875 protein_id:CAA96595.1 
40 kDa 0.93 
CE12728 WBGene00011232 phosphoenolpyruvate carboxykinase status:Confirmed 
UniProt:O02286 protein_id:CAB05600.1 
73 kDa 0.93 
CE22127 WBGene00012983 locus:men-1 status:Partially_confirmed 
UniProt:Q9U296 protein_id:CAB54452.1 
70 kDa 0.93 
CE30779 WBGene00004490 locus:rps-21 Ribosomal protein S21 status:Confirmed 
UniProt:P49197 protein_id:AAC48297.2 
10 kDa 0.93 





CE29684 WBGene00016258 locus:vha-16 vaculolar ATPase status:Confirmed 
UniProt:Q95YD5 protein_id:AAK85455.2 
40 kDa 0.93 





CE20087 WBGene00006585 locus:tni-3 Troponin status:Confirmed UniProt:Q9XUN9 
protein_id:CAB04737.1 
30 kDa 0.93 
CE19362 WBGene00006917 locus:vha-8 ATPase status:Confirmed UniProt:Q95X44 
protein_id:AAK67210.1 
26 kDa 0.93 
CE06987 WBGene00004788 locus:sft-4 status:Confirmed UniProt:Q18864 
protein_id:AAB00591.1 
32 kDa 0.93 
CE40009 WBGene00003061 locus:lpd-5 status:Confirmed UniProt:Q9N4L8 
protein_id:AAF40003.2 
20 kDa 0.93 
CE31880 WBGene00002123 locus:inx-1 status:Confirmed UniProt:Q17394 
protein_id:AAN71842.1 
50 kDa 0.93 
CE07241 WBGene00018393 locus:msra-1 status:Confirmed UniProt:O02089 
protein_id:AAC71122.1 
24 kDa 0.93 
CE32696 WBGene00019682 status:Confirmed UniProt:P34528 
protein_id:AAN65310.1 
57 kDa 0.93 
CE30707 WBGene00003475 locus:mtm-1 myotubularin-like protein 
status:Partially_confirmed UniProt:Q9N589 protein_id:AAF60423.3 
68 kDa 0.93 





CE22115 WBGene00004010 locus:pha-1 DNA-binding protein pha-1 
status:Confirmed UniProt:Q27242 protein_id:CAA21655.1 
57 kDa 0.93 
CE28923 WBGene00017829 ankyrin and desmoplakin repeat regions 
status:Confirmed UniProt:Q19822 protein_id:AAK93849.3 
28 kDa 0.93 
CE03918 WBGene00015428 status:Partially_confirmed UniProt:Q11192 
protein_id:AAA82330.1 
14 kDa 0.93 
CE03411 WBGene00010052 acyl-CoA dehydrogenase status:Confirmed 
UniProt:Q20772 protein_id:CAA91333.1 
45 kDa 0.93 
CE30223 WBGene00001804 locus:gur-3 status:Confirmed UniProt:O18280 
protein_id:CAA90343.3 
51 kDa 0.93 
CE05165 WBGene00001922 locus:his-48 histone H2B status:Confirmed 
UniProt:Q27876 protein_id:CAA97413.1 
14 kDa 1.00 
CE29950 WBGene00000229 locus:atp-2 ATP synthase beta chain status:Confirmed 58 kDa 1.00 
UniProt:P46561 protein_id:AAA19068.2 
CE16576 WBGene00002264 locus:lec-1 galectin status:Partially_confirmed 
UniProt:P36573 protein_id:CAB04959.1 
32 kDa 1.00 
CE06090 WBGene00010556 locus:rack-1 guanine nucleotide-binding protein 
status:Confirmed UniProt:Q21215 protein_id:CAA93514.1 
36 kDa 1.00 
CE20658 WBGene00006819 locus:unc-87 calponin status:Confirmed UniProt:P37806 
protein_id:AAC78234.1 
63 kDa 1.00 
CE23530 WBGene00007463 high-density lipoprotein-binding protein 




CE05441 WBGene00000915 locus:daf-21 heat shock protein (HSP90) 
status:Confirmed UniProt:Q18688 protein_id:CAA99793.1 
80 kDa 1.00 





CE11226 WBGene00018963 locus:ucr-1 Mitochondrial processing protease 
enhancing protein status:Confirmed UniProt:P98080 protein_id:AAB52679.1 
52 kDa 1.00 
CE17563 WBGene00006529 locus:tba-2 Tubulin status:Confirmed UniProt:P34690 
protein_id:CAB16856.1 
50 kDa 1.00 
CE03278 WBGene00004440 locus:rpl-26 ribosomal protein L26 like 
status:Confirmed UniProt:Q19869 protein_id:CAA92674.1 
16 kDa 1.00 
CE27706 WBGene00001000 locus:dim-1 status:Confirmed UniProt:Q18066 
protein_id:AAC69011.2 
72 kDa 1.00 
CE21562 WBGene00000802 locus:crt-1 calreticulin precursor status:Confirmed 
UniProt:P27798 protein_id:AAD14746.1 
46 kDa 1.00 
CE07373 WBGene00004951 locus:spc-1 spectrin alpha chain 




CE07426 WBGene00019947 locus:htz-1 histone H2A variant status:Confirmed 
UniProt:Q27511 protein_id:AAC48074.1 
15 kDa 1.00 
CE22939 WBGene00022170 status:Confirmed UniProt:Q9BL34 
protein_id:AAK29974.1 
15 kDa 1.00 















CE06362 WBGene00011480 endoplasmin precursor (GRP94) status:Confirmed 
UniProt:Q22235 protein_id:CAA92973.1 
? 1.00 





CE09655 WBGene00004408 locus:rla-0 deoxyribonuclease status:Confirmed 
UniProt:Q93572 protein_id:CAB02098.1 
34 kDa 1.00 
CE05747 WBGene00004492 locus:rps-23 ribosomal protein S23 status:Confirmed 
UniProt:Q19877 protein_id:CAA94601.1 
16 kDa 1.00 





CE02132 WBGene00003831 locus:nuo-1 NADH-ubiquinone oxidoreductase 52 kDa 1.00 
status:Confirmed UniProt:Q17880 protein_id:CAA90435.1 
CE05514 WBGene00000869 locus:cyc-1 cytochrome C1, heme protein 
status:Confirmed UniProt:Q18853 protein_id:CAA99820.1 
31 kDa 1.00 
CE14944 WBGene00001558 locus:gdi-1 GDI-1 GDP dissociation inhibitor 
status:Confirmed UniProt:Q21449 protein_id:CAB16511.1 
50 kDa 1.00 
CE31733 WBGene00002978 locus:lev-11 status:Partially_confirmed UniProt:Q27249 
protein_id:CAD45604.1 
30 kDa 1.00 
CE18785 WBGene00010260 ATP-dependent helicase (DEAD box) status:Confirmed 
UniProt:Q9XUW5 protein_id:CAB04518.1 
60 kDa 1.00 
CE11570 WBGene00003964 locus:pdi-3 protein disulphide isomerase ER-60 
precursor like status:Confirmed UniProt:O17908 protein_id:CAB07480.1 
55 kDa 1.00 
CE29955 WBGene00017217 Zinc finger protein status:Partially_confirmed 
UniProt:Q09531 protein_id:AAL38955.1 
58 kDa 1.00 
CE29774 WBGene00017734 electron transfer flavoprotein beta status:Confirmed 
UniProt:Q9TXI4 protein_id:AAD03129.2 
28 kDa 1.00 
CE17138 WBGene00019052 status:Predicted UniProt:O44172 
protein_id:AAB88357.1 
20 kDa 1.00 
CE11464 WBGene00010326 NADH ubiquinone oxidoreductase status:Confirmed 
UniProt:Q93831 protein_id:CAB01876.1 
31 kDa 1.00 
CE12918 WBGene00004485 locus:rps-16 40S ribosomal protein S16 
status:Confirmed UniProt:Q22054 protein_id:CAB01658.1 
16 kDa 1.00 
CE41153 WBGene00011328 Copper\/zinc superoxide dismutases (SODC) 









CE02197 WBGene00001230 locus:eif-3.G RNA binding protein status:Confirmed 
UniProt:Q19706 protein_id:CAA90354.1 
29 kDa 1.00 
CE24451 WBGene00006888 locus:vbh-1 helicase status:Confirmed UniProt:Q9N3F4 
protein_id:AAF60764.1 
69 kDa 1.00 
CE09349 WBGene00006789 locus:unc-54 myosin heavy chain 




CE12358 WBGene00000066 locus:act-4 actin status:Confirmed UniProt:P10986 
protein_id:AAB04575.1 
42 kDa 1.07 
CE06652 WBGene00014095 glutamate dehydrogenase status:Confirmed 
UniProt:Q23621 protein_id:CAA98074.1 
59 kDa 1.07 
CE27514 WBGene00022089 status:Confirmed UniProt:Q95XJ0 
protein_id:AAK68562.1 
32 kDa 1.07 
CE15602 WBGene00007385 locus:atp-5 ATP synthase D chain status:Confirmed 
UniProt:Q17763 protein_id:CAA99772.1 
22 kDa 1.07 
CE29443 WBGene00019900 Channel Protein status:Confirmed UniProt:Q21752 
protein_id:AAB00622.2 
30 kDa 1.07 
CE07721 WBGene00001137 locus:eat-6 Na(+)\/K(+) ATPase alpha subunit 




CE03252 WBGene00001920 locus:his-46 histone H4 status:Predicted 
UniProt:P62784 protein_id:CAA97407.1 
11 kDa 1.07 
CE05598 WBGene00004414 locus:rpl-3 60S ribosomal protein L3 status:Confirmed 46 kDa 1.07 
UniProt:P50880 protein_id:CAA91277.1 





CE31971 WBGene00010794 dihydrolipoamide dehydrogenase status:Confirmed 
UniProt:O17953 protein_id:CAB05249.2 
53 kDa 1.07 
CE08526 WBGene00004425 locus:rpl-13 ribosomal protein L13 status:Confirmed 
UniProt:P91128 protein_id:AAB42322.1 
24 kDa 1.07 
CE00078 WBGene00004433 locus:rpl-21 Ribosomal protein L21 status:Confirmed 
UniProt:P34334 protein_id:AAA27951.1 
18 kDa 1.07 
CE38657 WBGene00002244 locus:laf-1 status:Confirmed UniProt:Q4W5R4 
protein_id:AAY43989.1 
70 kDa 1.07 
CE41581 WBGene00004855 locus:sma-1 spectrin beta chain 




CE16650 WBGene00004430 locus:rpl-18 Eukaryotic ribosomal protein L18 
status:Confirmed UniProt:O45946 protein_id:CAA16387.1 
21 kDa 1.07 
CE37112 WBGene00018519 arginine kinase status:Confirmed UniProt:Q10454 
protein_id:AAB37022.2 
44 kDa 1.07 
CE31507 WBGene00002050 locus:ifa-1 intermediate filament protein 
status:Confirmed UniProt:P90901 protein_id:CAD44129.1 
66 kDa 1.07 
CE17986 WBGene00004424 locus:rpl-12 Ribosomal protein L11 status:Confirmed 
UniProt:P61866 protein_id:CAB05226.1 
18 kDa 1.07 
CE42184 WBGene00002025 locus:hsp-60 status:Confirmed 40 kDa 1.07 
CE22195 WBGene00004429 locus:rpl-17 status:Confirmed UniProt:Q9BL19 
protein_id:AAK29902.1 
22 kDa 1.07 
CE22940 WBGene00022169 status:Confirmed UniProt:Q9BL33 
protein_id:AAK29975.1 
16 kDa 1.07 





CE03684 WBGene00011884 locus:enol-1 enolase status:Confirmed UniProt:Q27527 
protein_id:CAA92692.1 
47 kDa 1.07 
CE39447 WBGene00001330 locus:eps-8 status:Confirmed UniProt:O18250 
protein_id:CAB16527.3 
99 kDa 1.07 
CE43076 WBGene00007100 status:Confirmed UniProt:Q17425 
protein_id:CAA94882.2 
65 kDa 1.07 





CE32507 WBGene00012166 locus:nuo-6 status:Confirmed UniProt:Q23098 
protein_id:CAA95851.2 
20 kDa 1.07 
CE18354 WBGene00003485 locus:mua-6 intermediate filament protein 
status:Confirmed UniProt:O02365 protein_id:CAB03486.1 
67 kDa 1.07 
CE27803 WBGene00007708 locus:nola-3 status:Confirmed UniProt:Q9XVR8 
protein_id:CAB02768.2 
8 kDa 1.07 
CE06835 WBGene00015802 kynureninase status:Confirmed UniProt:Q18026 
protein_id:AAB52668.1 
54 kDa 1.07 
CE40923 WBGene00003719 locus:nhr-129 status:Confirmed UniProt:A5JYV3 
protein_id:CAN86585.1 
46 kDa 1.07 





CE28610 WBGene00019713 locus:pqn-52 status:Confirmed UniProt:Q95ZL6 
protein_id:AAK77613.1 
28 kDa 1.07 
CE00832 WBGene00020636 Mitochondrial complex I 23K chain status:Confirmed 
UniProt:Q22619 protein_id:AAA50662.1 
24 kDa 1.07 
CE19180 WBGene00004735 locus:sbp-1 Helix-loop-helix DNA-binding domain 




CE20307 WBGene00013193 status:Confirmed UniProt:Q9XWI7 
protein_id:CAA21680.1 
55 kDa 1.07 
CE17464 WBGene00016062 status:Confirmed UniProt:O76387 
protein_id:AAC19215.1 
34 kDa 1.07 















CE18826 WBGene00010419 ATP synthase alpha and beta subunits, ATP synthase 
Alpha chain, C terminal status:Confirmed UniProt:Q9XXK1 protein_id:CAA19429.1 
58 kDa 1.15 
CE07537 WBGene00020808 calponin-like protein status:Confirmed UniProt:Q23050 
protein_id:AAB04989.1 
44 kDa 1.15 
CE18676 WBGene00009688 status:Confirmed UniProt:Q9XU97 
protein_id:CAB05509.1 
9 kDa 1.15 
CE34936 WBGene00003515 locus:myo-3 myosin heavy chain 




CE02183 WBGene00000114 locus:alh-8 methylmalonate-semialdehyde 
dehydrogenase status:Confirmed UniProt:P52713 protein_id:CAA88946.1 
56 kDa 1.15 
CE02626 WBGene00006626 locus:tsn-1 human 100 kDa activator protein 









CE06577 WBGene00004476 locus:rps-7 40S ribosomal protein S7 status:Confirmed 
UniProt:Q23312 protein_id:CAB00058.1 
22 kDa 1.15 





CE10878 WBGene00009952 Thiolases status:Confirmed UniProt:O45552 
protein_id:CAB04455.2 
41 kDa 1.15 
CE29809 WBGene00000107 locus:alh-1 Aldehyde dehydrogenase 2 
status:Confirmed UniProt:Q20780 protein_id:AAA20615.3 
55 kDa 1.15 
CE30647 WBGene00000381 locus:cct-6 status:Partially_confirmed UniProt:Q8MYQ9 
protein_id:AAM22058.1 
48 kDa 1.15 
CE16333 WBGene00000776 locus:cpl-1 cathepsin-like protease status:Confirmed 
UniProt:O45734 protein_id:CAB07275.1 
38 kDa 1.15 
CE29835 WBGene00004489 locus:rps-20 status:Confirmed UniProt:Q8WQA8 
protein_id:CAD21665.1 
13 kDa 1.15 
CE27398 WBGene00004419 locus:rpl-7A status:Confirmed UniProt:Q966C6 
protein_id:AAK84600.1 
30 kDa 1.15 
CE01341 WBGene00002083 locus:inf-1 status:Confirmed UniProt:P27639 
protein_id:AAA21170.1 
45 kDa 1.15 
CE34018 WBGene00009664 isocitrate dehydrogenase status:Confirmed 
UniProt:Q93714 protein_id:CAB02111.2 
38 kDa 1.15 





CE15746 WBGene00003052 locus:lmn-1 Intermediate filament proteins (2 domains) 
status:Confirmed UniProt:Q21443 protein_id:CAB09411.1 
64 kDa 1.15 
CE34269 WBGene00003369 locus:mlc-1 status:Confirmed UniProt:P19625 
protein_id:AAK09070.2 
19 kDa 1.15 
CE09719 WBGene00000230 locus:atp-3 ATPase status:Confirmed UniProt:P91283 
protein_id:AAB37654.1 
22 kDa 1.15 
CE17720 WBGene00017926 status:Confirmed UniProt:O76367 
protein_id:AAC19190.1 
10 kDa 1.15 
CE20851 WBGene00018783 status:Partially_confirmed UniProt:Q9N4K2 
protein_id:AAF35961.1 
82 kDa 1.15 
CE25552 WBGene00004412 locus:rpl-1 status:Confirmed UniProt:Q9N4I4 
protein_id:AAF36008.1 
24 kDa 1.15 
CE30346 WBGene00004706 locus:rsr-1 status:Partially_confirmed UniProt:O62185 
protein_id:CAB04214.3 
68 kDa 1.15 
CE17071 WBGene00002162 locus:isp-1 ubiquinol-cytochrome C reductase 
status:Confirmed UniProt:O44512 protein_id:AAB92071.1 
30 kDa 1.15 
CE18253 WBGene00004062 locus:pmp-5 ABC transporter status:Confirmed 
UniProt:O76414 protein_id:AAC19238.1 
69 kDa 1.15 
CE11190 WBGene00018890 RNA helicase status:Confirmed UniProt:P91340 
protein_id:AAB37806.1 
85 kDa 1.15 





CE18258 WBGene00020520 status:Predicted UniProt:O17031 
protein_id:AAB69974.1 
34 kDa 1.15 
CE26776 WBGene00021868 status:Confirmed UniProt:Q9BMU4 
protein_id:AAK68527.1 
65 kDa 1.15 










CE09015 WBGene00016943 locus:acdh-1 acyl-CoA dehydrogenase status:Confirmed 
UniProt:Q966M3 protein_id:AAK68275.1 
47 kDa 1.23 
CE16463 WBGene00000067 locus:act-5 Actins status:Confirmed UniProt:O45815 
protein_id:CAB05817.1 
42 kDa 1.23 
CE16194 WBGene00004302 locus:ran-1 GTP-binding protein status:Confirmed 
UniProt:O17915 protein_id:CAB07240.1 
24 kDa 1.23 
CE00234 WBGene00004269 locus:rab-6.1 Rab6 (ras protein) status:Confirmed 
UniProt:P34213 protein_id:CAA77590.1 
23 kDa 1.23 
CE05529 WBGene00008378 status:Confirmed UniProt:Q18947 
protein_id:CAA98439.1 
34 kDa 1.23 





CE00209 WBGene00010130 locus:vha-14 Membrane-associated atpase gamma 
chain status:Confirmed UniProt:P34462 protein_id:CAA81600.1 
29 kDa 1.23 
CE03762 WBGene00004699 locus:rsp-2 pre-mRNA splicing factor like protein 
status:Confirmed UniProt:Q23120 protein_id:CAA91394.1 
32 kDa 1.23 
CE16195 WBGene00010478 centromere\/microtubule binding protein 
status:Confirmed UniProt:O17919 protein_id:CAB07244.1 
50 kDa 1.23 
CE35878 WBGene00010015 locus:atad-3 ATPases associated with various cellular 
activities (AAA) status:Confirmed UniProt:Q20748 protein_id:CAA88471.2 
67 kDa 1.23 
CE11854 WBGene00002070 locus:ile-1 P58 protein like status:Confirmed 
UniProt:P90913 protein_id:CAB03169.1 
55 kDa 1.23 





CE31244 WBGene00020732 status:Partially_confirmed UniProt:Q8MXJ1 
protein_id:AAM69068.1 
98 kDa 1.23 





CE29829 WBGene00006586 locus:tni-4 troponin status:Confirmed UniProt:O44572 
protein_id:AAB94188.2 
23 kDa 1.23 
CE06846 WBGene00003097 locus:lys-8 status:Confirmed UniProt:Q09975 
protein_id:AAB93455.1 
31 kDa 1.23 
CE00848 WBGene00003253 locus:mig-22 status:Confirmed UniProt:P45895 
protein_id:AAA50619.1 
91 kDa 1.23 
CE01426 WBGene00021061 status:Partially_confirmed UniProt:Q23206 
protein_id:AAK29861.1 
55 kDa 1.23 
CE33350 WBGene00022645 status:Confirmed UniProt:O61875 
protein_id:AAG45577.2 
42 kDa 1.23 
CE26775 WBGene00004014 locus:phb-1 status:Confirmed UniProt:Q9BKU4 
protein_id:AAK27865.1 
30 kDa 1.32 
CE24743 WBGene00002266 locus:lec-3 galactoside-binding lectin status:Confirmed 
UniProt:Q09581 protein_id:CAA88570.2 
34 kDa 1.32 
CE12920 WBGene00001423 locus:fib-1 fibrillarin status:Confirmed UniProt:Q22053 
protein_id:CAB01657.1 
36 kDa 1.32 
C.Elegans ? 1.32 
CE16197 WBGene00006536 locus:tbb-1 tubulin beta-chain status:Confirmed 
UniProt:O17921 protein_id:CAB07246.1 
50 kDa 1.32 
CE13465 WBGene00020379 status:Confirmed UniProt:O02155 
protein_id:AAB53007.1 
36 kDa 1.32 
CE25005 WBGene00000041 locus:aco-2 Aconitate hydratase status:Confirmed 
UniProt:P34455 protein_id:AAA28050.2 
84 kDa 1.32 
CE02163 WBGene00002267 locus:lec-4 galactoside binding lectin status:Confirmed 
UniProt:Q18625 protein_id:CAA88850.1 
32 kDa 1.32 
CE31165 WBGene00001187 locus:egl-19 status:Confirmed UniProt:Q8MQA1 213 1.32 
protein_id:AAM75372.1 kDa 





CE00839 WBGene00000479 locus:cgh-1 ATP-dependent RNA helicase 
status:Confirmed UniProt:Q95YF3 protein_id:AAK85443.1 
49 kDa 1.32 
CE11546 WBGene00010336 acyl-CoA oxidase I status:Partially_confirmed 
UniProt:Q93839 protein_id:CAB03158.1 
75 kDa 1.32 
CE15898 WBGene00009126 locus:pyk-1 Pyruvate kinase status:Confirmed 
UniProt:O17836 protein_id:CAB02984.1 
61 kDa 1.32 










CE41311 WBGene00008694 nir like gene involved in denitrification 









CE31743 WBGene00000376 locus:ccr-4 alcohol dehydrogenase transcription 
effector like status:Confirmed UniProt:Q9U1P5 protein_id:CAB54511.2 
69 kDa 1.32 
CE01361 WBGene00019401 locus:nuo-4 NADH dehydrogenase status:Confirmed 
UniProt:Q21233 protein_id:AAA62532.1 
51 kDa 1.32 
CE27322 WBGene00007000 locus:tufm-1 status:Confirmed UniProt:Q19072 
protein_id:AAK29979.1 
55 kDa 1.32 
CE27647 WBGene00015413 pyruvate dehydrogenase status:Confirmed 
UniProt:O44451 protein_id:AAB92024.2 
38 kDa 1.32 





CE21197 WBGene00001061 locus:dpl-1 transcription factor DP-1 status:Confirmed 
UniProt:Q22703 protein_id:CAA92699.1 
68 kDa 1.32 
CE03812 WBGene00000040 locus:aco-1 iron-responsive element-binding like 
protein status:Confirmed UniProt:Q23500 protein_id:CAA91491.1 
97 kDa 1.32 
CE24222 WBGene00012608 Iron-containing alcohol dehydrogenases 
status:Confirmed UniProt:Q9U2M4 protein_id:CAA21631.2 
51 kDa 1.41 





CE00778 WBGene00004435 locus:rpl-23 status:Confirmed UniProt:P48158 
protein_id:AAK18857.1 
15 kDa 1.41 
CE02465 WBGene00015624 status:Partially_confirmed UniProt:Q17847 
protein_id:AAA68803.1 
38 kDa 1.41 
CE03287 WBGene00004874 locus:smc-4 chromosome segregation protein 




CE03574 WBGene00011273 ATP synthase complex f subunit like protein 
status:Confirmed UniProt:Q22021 protein_id:CAA91350.1 
19 kDa 1.41 
CE06184 WBGene00010785 locus:top-2 DNA topoisomerase II 




CE04861 WBGene00002238 locus:kars-1 lysyl-tRNA synthetase status:Confirmed 65 kDa 1.41 
UniProt:Q22099 protein_id:AAA82396.1 





CE25143 WBGene00004298 locus:rad-54 SNF2 and others N-terminal domain 
status:Partially_confirmed UniProt:Q9XW40 protein_id:CAB63308.1 
92 kDa 1.41 
CE41093 WBGene00022822 status:Confirmed UniProt:Q23604 
protein_id:AAB52655.3 
17 kDa 1.41 
CE36102 WBGene00003835 locus:nxf-2 status:Partially_confirmed UniProt:Q9XVS8 
protein_id:CAB02733.2 
46 kDa 1.41 





CE01431 WBGene00003588 locus:nex-1 status:Confirmed UniProt:Q27864 
protein_id:AAB52702.1 
36 kDa 1.52 
CE19904 WBGene00004496 locus:rps-27 ribosomal protein status:Confirmed 
UniProt:Q9TXP0 protein_id:AAC69219.1 
9 kDa 1.52 
CE09895 WBGene00018002 status:Partially_confirmed UniProt:O44773 
protein_id:AAB96694.1 
51 kDa 1.52 
CE44008 WBGene00022337 status:Partially_confirmed UniProt:Q2AAB5 
protein_id:ABD63207.2 
38 kDa 1.52 





CE34087 WBGene00003887 locus:osm-7 status:Partially_confirmed UniProt:O45750 
protein_id:CAB03294.2 
73 kDa 1.52 
CE26832 WBGene00003799 locus:npp-13 status:Partially_confirmed 
UniProt:Q9BKT9 protein_id:AAK27866.1 
88 kDa 1.52 
CE01225 WBGene00017166 locus:aldo-2 Fructose-biphosphate aldolase 
status:Confirmed UniProt:P46563 protein_id:AAC46646.1 
39 kDa 1.52 





CE04501 WBGene00001921 locus:his-47 histone H2A status:Confirmed 
UniProt:P09588 protein_id:CAA97414.1 
13 kDa 1.62 
CE40718 WBGene00004015 locus:phb-2 Prohibitin status:Confirmed 
UniProt:P50093 protein_id:AAA68353.2 
33 kDa 1.62 
CE00480 WBGene00011867 locus:chc-1 Clathrin heavy chain 




CE44292 WBGene00003796 locus:npp-10 nucleoporin \; DNA-directed RNA 
























CE27167 WBGene00009920 locus:abts-1 anion exchange protein status:Confirmed 125 1.74 
UniProt:Q20642 protein_id:CAA99853.3 kDa 
CE06050 WBGene00010470 locus:cdr-4 glutathione S-transferase status:Confirmed 
UniProt:Q21099 protein_id:CAA99876.1 
32 kDa 1.87 
CE34601 WBGene00020972 status:Partially_confirmed UniProt:Q23141 
protein_id:AAC24437.2 
94 kDa 1.87 





CE30165 WBGene00020317 locus:pdf-1 status:Confirmed UniProt:Q8WQD1 
protein_id:AAL56619.1 
20 kDa 2.14 
CE30738 WBGene00016816 status:Confirmed UniProt:Q22924 
protein_id:AAB04881.2 
54 kDa 2.46 





CE32386 WBGene00000485 locus:che-3 dynein heavy chain 




CE05497 WBGene00008296 locus:cdr-2 glutathione S-transferase status:Confirmed 
UniProt:Q18831 protein_id:CAA99803.1 
32 kDa 3.25 
CE22611 WBGene00013252 status:Partially_confirmed UniProt:Q9NA85 
protein_id:CAB55012.1 
84 kDa 3.25 
CE17420 WBGene00003994 locus:pgl-3 status:Confirmed UniProt:O61920 
protein_id:AAC17755.1 




Table 9: iTRAQ labeled proteins in the nineth sample in the third set. 
Identified Proteins  Mw Ratio 








































CE14954 WBGene00013311 protein transport protein SEC61 alpha subunit 




CE26774 WBGene00021350 status:Confirmed UniProt:Q9BKU5 protein_id:AAK27870.1 16 
kDa 
0.81 

























CE03880 WBGene00015168 locus:tag-320 protein disulfide-isomerase 



















CE07721 WBGene00001137 locus:eat-6 Na(+)\/K(+) ATPase alpha subunit 
























CE06090 WBGene00010556 locus:rack-1 guanine nucleotide-binding protein 





























CE00664 WBGene00004470 locus:rps-1 Ribosomal protein S3a (human) homolog. 









CE01543 WBGene00004421 locus:rpl-10 ribosomal protein L10 (QM protein) 



















CE01030 WBGene00004428 locus:rpl-16 L13P family ribosomal protein 









CE02626 WBGene00006626 locus:tsn-1 human 100 kDa activator protein 


































CE06290 WBGene00006911 locus:vha-2 Vacuolar ATP synthase subunit 



















CE31264 WBGene00022500 locus:lfi-1 probable myofibrillar protein 







































CE08852 WBGene00008205 locus:sams-1 s-adenosylmethionine synthetase 
























CE15900 WBGene00001167 locus:eef-2 Elongation factor Tu family (contains ATP\/GTP 




CE16650 WBGene00004430 locus:rpl-18 Eukaryotic ribosomal protein L18 


































CE11570 WBGene00003964 locus:pdi-3 protein disulphide isomerase ER-60 precursor 










































































CE20171 WBGene00012354 status:Confirmed UniProt:Q9U329 protein_id:CAB63334.1 20 
kDa 
0.93 




















CE06362 WBGene00011480 endoplasmin precursor (GRP94) status:Confirmed 
UniProt:Q22235 protein_id:CAA92973.1 
? 0.93 
CE09650 WBGene00009119 locus:ndk-1 nucleoside diphosphate kinase 



















CE06007 WBGene00003415 locus:mars-1 methionyl-tRNA synthetase 




CE20547 WBGene00006794 locus:unc-60 actin depolymerizing factor 














CE18826 WBGene00010419 ATP synthase alpha and beta subunits, ATP synthase Alpha 





































































CE40325 WBGene00008505 status:Confirmed UniProt:Q0PDK0 protein_id:CAL22703.1 42 
kDa 
1.00 













































CE22210 WBGene00013025 locus:vha-13 ATP synthase alpha and beta subunits \; ATP 



















CE08258 WBGene00007646 locus:nkb-1 sodium\/potassium transporting ATPase beta 




CE04424 WBGene00006921 locus:vha-12 vacuolar ATP synthase (strong) 



















CE22740 WBGene00022042 status:Confirmed UniProt:Q86S66 protein_id:AAF60854.1 22 
kDa 
1.00 





CE00863 WBGene00000170 locus:aqp-2 glycerol uptake facilitator protein 









CE17691 WBGene00017719 status:Confirmed UniProt:Q9GZE9 protein_id:AAF99915.1 47 
kDa 
1.00 
CE06878 WBGene00004499 locus:rps-30 ribosomal protein\/ubiquitin-like protein 














CE04306 WBGene00017075 status:Confirmed UniProt:Q19007 protein_id:AAA81494.1 36 
kDa 
1.00 










CE37787 WBGene00002064 locus:iff-1 Initiation factor 5A status:Confirmed 
UniProt:P34563 protein_id:CAA81597.2 
? 1.00 















CE14106 WBGene00003798 locus:npp-12 integral membrane protein 




CE09349 WBGene00006789 locus:unc-54 myosin heavy chain 



















CE09682 WBGene00002005 locus:hsp-1 HSP-1 heat shock 70kd protein A 
























CE17154 WBGene00019322 locus:ahcy-1 S-adenosylhomocysteine hydrolase 





























CE09946 WBGene00009454 status:Confirmed UniProt:P90860 protein_id:CAB03069.1 20 
kDa 
1.07 





CE27514 WBGene00022089 status:Confirmed UniProt:Q95XJ0 protein_id:AAK68562.1 32 
kDa 
1.07 















CE20371 WBGene00000883 locus:cyn-7 Peptidyl-prolyl cis-trans isomerases 




CE02193 WBGene00003903 locus:pab-2 poly-adenylate binding protein 




CE18356 WBGene00002135 locus:inx-13 membrane protein\; probably a channel 














CE35351 WBGene00010965 cytochrome oxidase subunit II status:Partially_confirmed 27 
kDa 
1.07 
CE16308 WBGene00011156 RNA recognition motif. (aka RRM, RBD, or RNP domain) 









CE17720 WBGene00017926 status:Confirmed UniProt:O76367 protein_id:AAC19190.1 10 
kDa 
1.07 




















CE04001 WBGene00015803 status:Confirmed UniProt:Q18032 protein_id:AAB52666.1 15 
kDa 
1.07 
CE00209 WBGene00010130 locus:vha-14 Membrane-associated atpase gamma chain 









CE27850 WBGene00016636 status:Confirmed UniProt:O44145 protein_id:AAB88324.2 22 
kDa 
1.07 
CE01217 WBGene00017125 locus:acdh-12 Isovaleryl-CoA dehydrogenase 




CE11226 WBGene00018963 locus:ucr-1 Mitochondrial processing protease enhancing 
























CE34936 WBGene00003515 locus:myo-3 myosin heavy chain 




CE17071 WBGene00002162 locus:isp-1 ubiquinol-cytochrome C reductase 









CE00480 WBGene00011867 locus:chc-1 Clathrin heavy chain 





























CE01225 WBGene00017166 locus:aldo-2 Fructose-biphosphate aldolase 




CE09866 WBGene00017982 locus:hpo-18 ATP synthase epsilion chain 









CE22939 WBGene00022170 status:Confirmed UniProt:Q9BL34 protein_id:AAK29974.1 15 
kDa 
1.15 










CE18676 WBGene00009688 status:Confirmed UniProt:Q9XU97 protein_id:CAB05509.1 9 
kDa 
1.23 















CE02183 WBGene00000114 locus:alh-8 methylmalonate-semialdehyde dehydrogenase 









CE27244 WBGene00002025 locus:hsp-60 status:Confirmed 60 
kDa 
1.23 
CE35878 WBGene00010015 locus:atad-3 ATPases associated with various cellular 














CE01320 WBGene00018953 status:Confirmed UniProt:Q20869 protein_id:AAK18965.1 112 
kDa 
1.23 








































CE01568 WBGene00001686 locus:gpd-4 glyceraldehyde 3-phosphate dehydrogenase 4 














CE08631 WBGene00002010 locus:hsp-6 heat shock 70 protein 









CE23521 WBGene00001564 locus:icl-1 isocitrate lyase status:Confirmed 
UniProt:Q10663 protein_id:AAB71278.2 
109 
kDa 
1.87 
 
